

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number  
WO 02/059148 A2

(51) International Patent Classification: C07K 14/195

[AT/AT]: Arnoldgasse 27/4/27, A-1210 Vienna (AT).  
TEMPELMAIER, Brigitte [AT/AT]: Messenhausergasse  
10/20, A-1030 Vienna (AT).

(21) International Application Number: PCT/EP02/00546

(22) International Filing Date: 21 January 2002 (21.01.2002)

(74) Agents: SONN, Helmut et al.; Riemergasse 14, A-1010  
Wien (AT).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
A 130/01 26 January 2001 (26.01.2001) AT(71) Applicant (for all designated States except US): CISTEM  
BIOTECHNOLOGIES GMBH [AT/AT]: Rennweg 95b,  
A-1030 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MEINKE, Andreas  
[DE/AT]; Pieltgasse 26/1, A-3013 Pressbaum (AT).  
NAGY, Eszter [HU/AT]; Taborstrasse 9/15, A-1020  
Vienna (AT). VON AHSEN, Uwe [DE/AT]; Shmalzhof-  
gasse 22/25 A-1060 Vienna (AT). KLADE, Christoph  
[AT/AT]; Gröbmühlgasse 1B, A-2700 Wr. Neustadt  
(AT). HENICS, Tamas [HU/AT]; Taborstrasse 9/15,  
A-1020 Vienna (AT). ZAUNER, Wolfgang [AT/AT];  
Parkgasse 13/22, A-1030 Vienna (AT). MINH, Duc,  
Bui [VN/AT]; Rudolf Zeller Gasse 70/6/9, A-1230 Vi-  
enna (AT). VYTYVTSKA, Oresta [UA/AT]; Leystrasse  
110/1/2, A-1200 Vienna (AT). ETZ, Hildegard [AT/AT];  
Lortzinggasse 1/21, A-1140 Vienna (AT). DRYLA,  
Agnieszka [PL/AT]; Pragerstrasse 43-47/2/15, A-1210  
Vienna (AT). WEICHART, Thomas [AT/AT]; Hinter-  
holz 10, A-3071 Böheimkirchen (AT). HAFNER, Martin(81) Designated States (national): AE, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, PQ, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

## Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

## Published:

— without international search report and to be republished  
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(54) Title: A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC  
PATHOGEN(57) Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a  
specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a  
given type of animal or for humans, which is characterized by the following steps: - providing an antibody preparation from a plasma  
pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,  
tumor, allergen or tissue or host prone to autoimmunity, providing at least one expression library of said specific pathogen, tumor,  
allergen or tissue or host prone to autoimmunity, screening said at least one expression library with said antibody preparation, -  
identifying antigens which bind in said screening to antibodies in said antibody preparation, screening the identified antigens with  
individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen  
or tissue or host prone to autoimmunity, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and  
which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual  
sera and - optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens  
by chemical or recombinant methods.

WO 02/059148 A2

A method for identification, isolation and production of antigens  
to a specific pathogen

The invention relates to a method for identification, isolation and production of antigens to a specific pathogen as well as new antigens suitable for use in a vaccine for a given type of animal or for humans.

Vaccines can save more lives (and resources) than any other medical intervention. Owing to world-wide vaccination programmes the incidence of many fatal diseases has been decreased drastically. Although this notion is valid for a whole panel of diseases, e.g. diphtheria, pertussis, measles and tetanus, there are no effective vaccines for numerous infectious disease including most viral infections, such as HIV, HCV, CMV and many others. There are also no effective vaccines for other diseases, infectious or non-infectious, claiming the lives of millions of patients per year including malaria or cancer. In addition, the rapid emergence of antibiotic-resistant bacteria and microorganisms calls for alternative treatments with vaccines being a logical choice. Finally, the great need for vaccines is also illustrated by the fact that infectious diseases, rather than cardiovascular disorders or cancer or injuries remain the largest cause of death and disability in the world.

Several established vaccines consist of live attenuated organisms where the risk of reversion to the virulent wild-type strain exists. In particular in immunocompromised hosts this can be a live threatening scenario. Alternatively, vaccines are administered as a combination of pathogen-derived antigens together with compounds that induce or enhance immune responses against these antigens (these compounds are commonly termed adjuvant), since these subunit vaccines on their own are generally not effective.

Whilst there is no doubt that the above vaccines are valuable medical treatments, there is the disadvantage that, due to their complexity, severe side effects can be evoked, e.g. to antigens that are contained in the vaccine that display cross-reactivity with molecules expressed by cells of vaccinated individuals. In addition, existing requirements from regulatory authorities, e.g.

the World Health Organization (WHO), the Food and Drug Administration (FDA), and their European counterparts, for exact specification of vaccine composition and mechanisms of induction of immunity, are difficult to meet.

Some widely used vaccines are whole cell-vaccines (attenuated bacteria or viruses (e.g. Bacille Calmette-Guerin (BCG) (tuberculosis), Measles, Mumps, Rubella, Oral Polio Vaccine (Sabin), killed bacteria or viruses (e.g. Pertussis, Inactivated polio vaccine (Salk)), subunit-vaccines (e.g. Toxoid (Diphtheria, Tetanus)), Capsular polysaccharide (H. influenzae type B), Yeast recombinant subunit (Hepatitis B surface protein).

A vaccine can contain a whole variety of different antigens. Examples of antigens are whole-killed organisms such as inactivated viruses or bacteria, fungi, protozoa or even cancer cells. Antigens may also consist of subfractions of these organisms/tissues, of proteins, or, in their most simple form, of peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system necessary. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Antigen presenting cells belong to the innate immune system, which has evolved as a first line host defence that limits infection early after exposure to microorganisms. Cells of the innate immune system recognize patterns or relatively non-specific structures expressed on their targets rather than more sophisticated, specific structures which are recognized by the adaptive immune system. Examples of cells of the innate immune system are macrophages and dendritic cells but also granulocytes (e.g. neutrophils), natural killer cells and others. By contrast, cells of the adaptive immune system recognize specific, antigenic structures, including peptides, in the case of T-cells and peptides as well as three-dimensional structures in the case of B-cells. The adaptive immune system is much more specific and sophisticated than the innate immune system and improves upon repeated exposure to a given pathogen/antigen. Phylogenetically, the innate immune system is much older and can be found already in very primitive organisms. Nevertheless, the innate immune system is critical during the initial phase of antigenic exposure since, in addition to containing pathogens, cells of the innate immune system, i.e. APCs, prime cells of the adaptive immune system and thus trigger specific immune responses leading to clearance of the intruders. In sum, cells of the innate immune system and in particular APCs play a critical role during the induction phase of immune responses by a) containing infections by means of a primitive pattern recognition system and b) priming cells of the adaptive immune system leading to specific immune responses and memory resulting in clearance of intruding pathogens or of other targets. These mechanisms may also be important to clear or contain tumor cells.

The antigens used for such vaccines have often been selected by chance or by easiness of availability. There is a demand to identify efficient antigens for a given pathogen or - preferably - an almost complete set of all antigens of a given pathogen which are practically (clinically) relevant. Such antigens may be preferred antigen candidates in a vaccine.

It is therefore an object of the present invention to comply with these demands and to provide a method with which such antigens may be provided and with which a practically complete set of an-



tigens of e.g. a given pathogen may be identified with a given serum as antibody source. Such a method should also be suitable for rapidly changing pathogens which evolve a fast resistance against common drugs or vaccines. The method should also be applicable to identify and isolate tumor antigens, allergens, auto-immune antigens.

Therefore, the present invention provides a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, especially from a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, said method being characterized by the following steps:

- providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity,
- providing at least one expression library of said specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity,
- screening said at least one expression library with said antibody preparation,
- identifying antigens which bind in said screening to antibodies in said antibody preparation,
- screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
- identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

This method is also suitable in general for identifying a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen with given sera as antibody sources, if at

least three different expression libraries are screened in a pathogen/antigen identification programme using the method according to the present invention. The present invention therefore also relates to a method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:

- providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
- providing at least three different expression libraries of said specific pathogen,
- screening said at least three different expression libraries with said antibody preparation,
- identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody preparation,
- screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- repeating said screening and identification steps at least once,
- comparing the identified hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the identified hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- further repeating said screening and identification steps, if at least 5 % of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by

chemical or recombinant methods.

The method according to the present invention mainly consists of three essential parts, namely 1. identifying hyperimmune serum sources containing specific antibodies against a given pathogen, 2. screening of suitable expression libraries with a suitable antibody preparation wherein candidate antigens (or antigenic fragments of such antigens) are selected, and - 3. in a second screening round, wherein the hyperimmune serum-reactive antigens are identified by their ability to bind to a relevant portion of individual antibody preparations from individual sera in order to show that these antigens are practically relevant and not only hyperimmune serum-reactive, but also widely immunogenic (i.e. that a lot of individual sera react with a given antigen). With the present method it is possible to provide a set of antigens of a given pathogen which is practically complete with respect to the chosen pathogen and the chosen serum. Therefore, a bias with respect to "wrong" antigen candidates or an incomplete set of antigens of a given pathogen is excluded by the present method.

Completeness of the antigen set of a given pathogen within the meaning of the present invention is, of course, dependent on the completeness of the expression libraries used in the present method and on the quality and size of serum collections (number of individual plasmas/sera) tested, both with respect to representability of the library and usefulness of the expression system. Therefore, preferred embodiments of the present method are characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.

A serum collection used in the present invention should be tested against a panel of known antigenic compounds of a given pathogen, such as polysaccharide, lipid and proteinaceous components of the cell wall, cell membranes and cytoplasm, as well as secreted products. Preferably, three distinct serum collections are used: 1. With very stable antibody repertoire: normal adults, clinically healthy people, who overcome previous encounters or currently carriers of e.g. a given pathogen without acute disease and symptoms, 2. With antibodies induced acutely by the presence

of the pathogenic organism: patients with acute disease with different manifestations (e.g. *S. aureus* sepsis or wound infection, etc.), 3. With no specific antibodies at all (as negative controls): 5-8 months old babies who lost the maternally transmitted immunoglobulins 5-6 months after birth. Sera have to react with multiple pathogen-specific antigens in order to consider hyperimmune for a given pathogen (bacteria, fungus, worm or otherwise), and for that relevant in the screening method according to the present invention.

In the antigen identification programme for identifying a complete set of antigens according to the present invention, it is preferred that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome. It has been observed that although all expression libraries may be complete, using only one or two expression libraries in an antigen identification programme will not lead to a complete set of antigens due to preferential expression properties of each of the different expression libraries. While it is therefore possible to obtain hyperimmune serum-reactive antigens by using only one or two different expression libraries, this might in many cases not finally result in the identification of a complete set of hyperimmune serum-reactive antigens. Of course, the term "complete" according to the present invention does not indicate a theoretical maximum but is indeed a practical completeness, i.e. that at least 95% of the practically relevant antigens or antigenic determinants have been identified of a given pathogen. The practical relevance is thereby defined by the occurrence of antibodies against given antigens in the patient population.

According to the present invention also serum pools or plasma fractions or other pooled antibody containing body fluids are "plasma pools".

An expression library as used in the present invention should at least allow expression of all potential antigens, e.g. all surface proteins of a given pathogen. With the expression libraries according to the present invention, at least one set of potential antigens of a given pathogen is provided, this set being prefera-

bly the complete theoretical complement of (poly-)peptides encoded by the pathogen's genome (i.e. genomic libraries as described in Example 2) and expressed either in a recombinant host (see Example 3) or in vitro (see Example 4). This set of potential antigens can also be a protein preparation, in the case of extracellular pathogens preferably a protein preparation containing surface proteins of said pathogen obtained from said pathogen grown under defined physiological conditions (see Example 5). While the genomic approach has the potential to contain the complete set of antigens, the latter one has the advantage to contain the proteins in their naturally state i.e. including for instance post-translational modifications or processed forms of these proteins, not obvious from the DNA sequence. These or any other sets of potential antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity are hereafter referred to as "expression library". Expression libraries of very different kinds may be applied in the course of the present invention. Suitable examples are given in e.g. Ausubel et al., 1994. Especially preferred are expression libraries representing a display of the genetic set of a pathogen in recombinant form such as in vitro translation techniques, e.g. ribosomal display, or prokaryotic expression systems, e.g. bacterial surface expression libraries or which resemble specific physiological expression states of a given pathogen in a given physiological state, such as a proteome.

Ribosome display is an established method in recombinant DNA technology, which is applicable for each specific pathogen for the sake of the present invention (Schaffitzel et al, 1999). Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of a given pathogen on e.g. a selected outer membrane protein at the bacterial host membrane (Georgiou et al., 1997). Apart from displaying peptide or protein sequences in an outer membrane protein, other bacterial display techniques, such as bacteriophage display technologies and expression via exported proteins are also preferred as bacterial surface expression library (Forrer et al., 1999; Rodi and Makowski, 1993; Georgiou et al., 1997).

The antigen preparation for the first round of screening in the method according to the present invention may be derived from any source containing antibodies to a given pathogen. Preferably, if a plasma pool is used as a source for the antibody preparation, a human plasma pool is selected which comprises donors which had experienced or are experiencing an infection with the given pathogen. Although such a selection of plasma or plasma pools is in principle standard technology in for example the production of hyperimmunoglobulin preparations, it was surprising that such technologies have these effects as especially shown for the preferred embodiments of the present invention.

Preferably the expression libraries are genomic expression libraries of a given pathogen, or alternatively m-RNA, libraries. It is preferred that these genomic or m-RNA libraries are complete genomic or m-RNA expression libraries which means that they contain at least once all possible proteins, peptides or peptide fragments of the given pathogen are expressable. Preferably the genomic expression libraries exhibit a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.

Preferably, the method according to the present invention comprises screening at least a ribosomal display library, a bacterial surface display library and a proteome with the antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation. Such antigens may then be regarded extremely suited as hyperimmunogenic antigens regardless of their way of expression. Preferably the at least two screenings should at least contain the proteome, since the proteome always represents the antigens as naturally expressed proteins including post-translational modifications, processing, etc. which are not obvious from the DNA sequence.

The method according to the present invention may be applied to any given pathogen. Therefore, preferred pathogens are selected from the group of bacterial, viral, fungal and protozoan pathogens. The method according to the present invention is also applicable to cancer, i.e. for the identification of tumor-associated antigens, and for the identification of allergens or

antigens involved in auto-immune diseases. Of course, especially the recombinant methods are rather simple for pathogens having a small genome or a comparatively small number of expressed proteins (such as bacterial or viral pathogens) and are more complicated for complex (eukaryotic) organisms having large genomes. However, also such large genomic libraries of higher organism pathogens may well be analyzed with the method according to the present invention, at least in a faster and more reliable way than with known methods for identifying suitable antigens.

Preferred pathogens to be analyzed or which antigens are to be extracted, respectively, include human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Rous sarcoma virus (RSV), Epstein-Barr virus (EBV), influenza virus (IV), rotavirus (RV), *Staphylococcus aureus* (*S. aureus*), *Staphylococcus epidermidis* (*S. epidermidis*), *Chlamydia pneumoniae* (*C. pneumoniae*), *Chlamydia trachomatis* (*C. trachomatis*), *Mycobacterium tuberculosis* (*M. tuberculosis*), *Mycobacterium leprae* (*M. leprae*), *Streptococcus pneumoniae* (*S. pneumoniae*), *Streptococcus pyogenes* (*S. pyogenes*), *Streptococcus agalactiae* (*S. agalactiae*), *Enterococcus faecalis* (*E. faecalis*), *Bacillus anthracis* (*B. anthracis*), *Vibrio cholerae* (*V. cholerae*), *Borrelia burgdorferi* (*B. burgdorferi*), *Plasmodium* sp., fungal diseases such as *Pneumocystis carinii*, *Aspergillus* sp., *Cryptococcus* sp., *Candida albicans* or parasitic infections such as *ascariasis* (*Ascaris lumbricoides*) and *taeniasis* (*Taenia saginata*). The method according to the present invention is most applicable for bacteria, worms or candida.

As a model organism for the present application *Staphylococcus aureus* has been chosen to demonstrate the applicability and efficacy of the method according to the present invention. Especially with respect to the examples it is clear that the invention is easily transferable to all potential pathogens, especially the ones listed above.

It was surprising that the method according to the present invention allows an efficient and fast biological screening of a given pathogen, especially in view of the fact that only a small fraction of a patient's antibody repertoire is directed to a given

pathogen, even in a state where this pathogen is effectively defeated. It has been discovered within the course of the present invention, especially during performance of the *S.aureus* example that only 1-2% of the antibody repertoire of a patient having high titers against *S.aureus* are indeed antibodies directed against *S.aureus*. Moreover, over 70% of this specific 1% portion is directed against non-protein antigens, such as teichoic acid, so that only a total of 0.1% or less of the antibodies are directed to proteinaceous antigens.

One of the advantages of using recombinant expression libraries, especially ribosome display libraries and bacterial surface display libraries, is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The hyperimmune serum-reactive antigens obtainable by the method according to the present invention may therefore be immediately finished to a pharmaceutical preparation, preferably by addition of a pharmaceutically acceptable carrier and/or excipient, immediately after its production (in the course of the second selection step), e.g. by expression from the expression library platform.

Preferably, the pharmaceutical preparation containing the hyperimmune serum-reactive antigen is a vaccine for preventing or treating an infection with the specific pathogen for which the antigens have been selected.

The pharmaceutical preparation may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens according to the present invention is a immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen. Pref-



erably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alum, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.

The polycationic compound(s) to be used according to the present invention may be any polycationic compound which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (see: Tufts in as described in Goldman et al. (1983)). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20%, especially more than 50% of basic amino acids in a range of more than 8, especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositions are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti-microbial with properties as reviewed in Ganz et al., 1999; Hancock, 1999. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (Andreu et al., 1998; Ganz et al., 1999; Simmaco et al., 1998). Peptides may also belong to the class of defensins (Ganz, 1999; Ganz et al., 1999). Sequences of such peptides can be, for example, be found in the Antimicrobial Sequences Database under the following internet address:

<http://www.bbcm.univ.trieste.it/~tossi/pag2.html>

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present inven-

tion. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substance in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application PCT/EP01/09529, incorporated herein by reference), especially antimicrobial peptides derived from mammal cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide which has the amino acid sequence  $\text{NH}_2\text{-RLAGLLRKGGEKIGEKLLKKIGOKIKNFFQKLVPQPE-COOH}$ . Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural amino acids by amino acids which are not among the 20 standard amino acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for a antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KKK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application PCT/EP01/12041, incorporated herein by reference).

Immunostimulatory deoxynucleotides are e.g. neutral or artificial

CpG containing DNA, short stretches of DNA derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. Krieg et al., 1995) but also inosine containing ODNs (I-ODNs) as described in WO 01/93905.

Neuroactive compounds, e.g. combined with polycationic substances are described in WO 01/24822.

According to a preferred embodiment the individual antibody preparation for the second round of screening are derived from patients who have suffered from an acute infection with the given pathogen, especially from patients who show an antibody titer to the given pathogen above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or carrier) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens to the given pathogen.

It is important that the second screening with the individual antibody preparations (which may also be the selected serum) allows a selective identification of the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations, however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized in at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with

more than 1000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparation according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigen may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against the specific pathogen (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 4000 U, especially above 6000 U, and/or an IgG titer above 10 000 U, especially above 12 000 U (U = units, calculated from the OD<sub>405nm</sub> reading at a given dilution) when whole organism (total lysate or whole cells) is used as antigen in ELISA. Individual proteins with Ig titers of above 800-1000 U are specifically preferred for selecting the hyperimmune serum-reactive antigens according to the present invention only for total titer. The statement for individual proteins can be derived from Fig. 9.

According to the demonstration example which is also a preferred embodiment of the present invention the given pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus and Staphylococcus epidermidis. Staphylococci are opportunistic pathogens which can cause illnesses which range from minor infections to life threatening diseases. Of the large number of Staphylococci at least 3 are commonly associated with human disease: S. aureus, S. epidermidis and rarely S. saprophyticus (Crossley and Archer, 1997). S. aureus has been used within the course of the present invention as an illustrative example of the way the present invention functions. Besides that, it is also an important organism with respect to its severe pathogenic impacts on humans. Staphylococcal infections are imposing an increasing

threat in hospitals worldwide. The appearance and disease causing capacity of Staphylococci are related to the wide-spread use of antibiotics which induced and continue to induce multi-drug resistance. For that reason medical treatment against Staphylococcal infections cannot rely only on antibiotics anymore. Therefore, a tactic change in the treatment of these diseases is desperately needed which aims to prevent infections. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool for the identification of staphylococcal antigenic proteins.

Every human being is colonized with *S. epidermidis*. The normal habitats of *S. epidermidis* are the skin and the mucous membrane. The major habitats of the most pathogenic species, *S. aureus*, are the anterior nares and perineum. Some individuals become permanent *S. aureus* carriers, often with the same strain. The carrier stage is clinically relevant because carriers undergoing surgery have more infections than noncarriers. Generally, the established flora of the nose prevents acquisition of new strains. However, colonization with other strains may occur when antibiotic treatment is given that leads to elimination of the susceptible carrier strain. Because this situation occurs in the hospitals, patients may become colonized with resistant nosocomial Staphylococci. These bacteria have an innate adaptability which is complemented by the widespread and sometimes inappropriate use of antimicrobial agents. Therefore hospitals provide a fertile environment for drug resistance to develop (close contact among sick patients, extensive use of antimicrobials, nosocomial infections). Both *S. aureus* and *S. epidermidis* have become resistant to many commonly used antibiotics, most importantly to methicillin (MRSA) and vancomycin (VISA). Drug resistance is an increasingly important public health concern, and soon many infections caused by staphylococci may be untreatable by antibiotics. In addition to its adverse effect on public health, antimicrobial resistance contributes to higher health care costs, since treating resistant infections often requires the use of more toxic and more expensive drugs, and can result in longer hospital stays for infected patients..

Moreover, even with the help of effective antibiotics, the most serious staphylococcal infections have 30-50 % mortality.

Staphylococci become potentially pathogenic as soon as the natural balance between microorganisms and the immune system gets disturbed, when natural barriers (skin, mucous membrane) are breached. The coagulase-positive *S. aureus* is the most pathogenic staphylococcal species, feared by surgeons for a long time. Most frequently it causes surgical wound infections, and induces the formation of abscesses. This local infection might become systemic, causing bacteraemia and sepsis. Especially after viral infections and in elderly, it can cause severe pneumonia. *S. aureus* is also a frequent cause of infections related to medical devices, such as intravascular and percutan catheters (endocarditis, sepsis, peritonitis), prosthetic devices (septic arthritis, osteomyelitis). *S. epidermidis* causes diseases mostly related to the presence of foreign body and the use of devices, such as catheter related infections, cerebrospinal fluid shunt infections, peritonitis in dialysed patients (mainly CAPD), endocarditis in individuals with prosthetic valves. This is exemplified in immunocompromised individuals such as oncology patients and premature neonates in whom coagulase-negative staphylococcal infections frequently occur in association with the use of intravascular device. The increase in incidence is related to the increased use of these devices and increasing number of immunocompromised patients.

Much less is known about *S. saprophyticus*, another coagulase-negative staphylococci, which causes acute urinary tract infection in previously healthy people. With a few exceptions these are women aged 16-25 years.

The pathogenesis of staphylococci is multifactorial. In order to initiate infection the pathogen has to gain access to the cells and tissues of the host, that is adhere. *S. aureus* expresses surface proteins that promote attachment to the host proteins such as laminin, fibronectin, elastin, vitronectin, fibrinogen and many other molecules that form part of the extracellular matrix (extracellular matrix binding proteins, ECMBP). *S. epider-*

- 18 -

midis is equipped with cell surface molecules which promote adherence to foreign material and through that mechanism establish infection in the host. The other powerful weapons staphylococci use are the secreted products, such as enterotoxins, exotoxins, and tissue damaging enzymes. The toxins kill or misguide immune cells which are important in the host defence. The several different types of toxins are responsible for most of the symptoms during infections.

Host defence against *S. aureus* relies mainly on innate immunological mechanisms. The skin and mucous membranes are formidable barriers against invasion by Staphylococci. However, once the skin or the mucous membranes are breached (wounds, percutaneous catheters, etc), the first line of nonadaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As Staphylococci are primarily extracellular pathogens, the major anti-staphylococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, staphylococci are phagocytosed and killed. Moreover, *S. aureus* can attach to endothelial cells, and be internalised by a phagocytosis-like process. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization.

There is little clinical evidence that cell mediated immunity has a significant contribution in the defence against Staphylococci, yet one has to admit that the question is not adequately addressed. It is known, however, that *Staphylococcus aureus* utilizes an extensive array of molecular countermeasures to

manipulate the defensive microenvironment of the infected host by secreting polypeptides referred to as superantigens, which target the multireceptor communication between T-cells and antigen-presenting cells that is fundamental to initiating pathogen-specific immune clearance. Superantigens play a critical role in toxic shock syndrome and food poisoning, yet their function in routine infections is not well understood. Moreover, one cannot expect a long lasting antibody (memory) response without the involvement of T-cells. It is also known that the majority of the anti-staphylococcal antibodies are against T-cell independent antigens (capsular polysaccharides, lipoteichoic acid, peptidoglycan) without a memory function. The T-cell dependent proteinaceous antigens can elicit long-term protective antibody responses. These staphylococcal proteins and peptides have not yet been determined.

For all these above mentioned reasons, a tactic change on the war field against staphylococcal infections is badly needed. One way of combating infections is preventing them by active immunisation. Vaccine development against *S. aureus* has been initiated by several research groups and national institutions worldwide, but there is no effective vaccine approved so far. It has been shown that an antibody deficiency state contributes to staphylococcal persistence, suggesting that anti-staphylococcal antibodies are important in host defence. Antibodies - added as passive immunisation or induced by active vaccination - directed towards surface components could both prevent bacterial adherence, neutralize toxins and promote phagocytosis. A vaccine based on fibronectin binding protein induces protective immunity against mastitis in cattle and suggest that this approach is likely to work in humans (refs). Taking all this together it is suggestive that an effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of *S. aureus*. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of *S. aureus* which paralyze TH cells (superantigens) or inhibit opsonization (protein A)



can be eliminated, and the individual proteins inducing protective antibodies can be selected. Identification of the relevant antigens help to generate effective passive immunisation (humanised monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Neonatal staphylococcal infections, severe septicemia and other life-threatening acute conditions are the primary target of passive immunisation. An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Moreover, patients suffering from chronic diseases which decrease immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from such a vaccine.

For the illustrative example concerning *Staphylococcus aureus* three different approaches have been employed in parallel. All three of these methods are based on the interaction of *Staphylococcus* proteins or peptides with the antibodies present in human sera with the method according to the present invention. This interaction relies on the recognition of epitopes within the proteins which can be short peptides (linear epitopes) or polypeptide domains (structural epitopes). The antigenic proteins are identified by the different methods using pools of pre-selected sera and - in the second screening round - by individual selected sera.

Following the high throughput screening, the selected antigenic proteins are expressed as recombinant proteins or in vitro translated products (in case it can not be expressed in prokaryotic expression systems), and tested in a series of ELISA and Western blotting assays for the assessment of immunogenicity with a large human serum collection (> 100 uninfected, > 50 patients sera). The preferred antigens are located on the cell surface or secreted, that is accessible extracellularly. Antibodies against the cell wall proteins (such as the Extracellular matrix binding proteins) are expected to serve double purposes: to inhibit adhesion and promote phagocytosis. The antibodies against the secreted proteins are beneficial in toxin neutralisation. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins

will interrupt growth promoting cross-talk between or within staphylococcal species. Bioinformatics (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and use them as reagents in the following assays: cell surface staining of staphylococci grown under different conditions (FACS, microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (in vitro phagocytosis assay).

The recognition of linear epitopes by antibodies can be based on sequences as short as 4-5 aa. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody. *in vivo*. For that reason the defined epitopes, polypeptides and proteins may further be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins *in vivo*. The antigens with the proven capability to induce antibodies will be tested in animal models for the ability to prevent infections.

The antibodies produced against Staphylococci by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity.

Accordingly, novel hyperimmune serum-reactive antigens from Staphylococcus aureus or Staphylococcus epidermidis have been made available by the method according to the present invention. According to another aspect of the present invention the invention relates to a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof. Accordingly, the present invention also relates to a hyperimmune serum-reactive antigen obtainable by the method according to the present invention

and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.

Antigens from *Staphylococcus aureus* and *Staphylococcus epidermidis* have been extracted by the method according to the present invention which may be used in the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *Staphylococcus aureus* and *Staphylococcus epidermidis* infections. Examples of such hyperimmune serum-reactive antigens of *Staphylococcus aureus* and *Staphylococcus epidermidis* to be used in a pharmaceutical preparation are selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *Staphylococcus aureus* and *Staphylococcus epidermidis* infections.

A hyperimmune fragment is defined as a fragment of the identified antigen which is for itself antigenic or may be made antigenic when provided as a hapten. Therefore, also antigen or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s). i.e. suited for eliciting an appropriate immune response in a individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

Preferred examples of such hyperimmune fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of

peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region" of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas" of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID No. 55,

aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49, 63-77 and 274-334, of Seq.ID No.56,

aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57,

aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59,

aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084,

1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205, 2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 50,

aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq.ID No. 62,

- 24 -

aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632, 651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID No. 66,

aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of Seq.ID No. 67,

aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-715 and 704-760, of Seq.ID No. 70,

aa.6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-287 and 286-314, of Seq.ID No. 71,

aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345, 59-74, of Seq.ID No. 72,

aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-114, of Seq.ID No. 73,

aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264, 137-237 and 250-267, of Seq.ID No. 74,

aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-731, 762-768, 800-805, 672-727, of Seq.ID No. 75,

aa 5-32, 35-48, 55-76, of Seq.ID No. 76,

aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-411, 126-143 and 168-186, of Seq.ID No. 77,

aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No. 78,

aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79,

aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of

Seq.ID No. 80,

aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1785, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq.ID No. 81,

aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, 483-511, of Seq.ID No. 82,

aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83,

aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84,

aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID No. 85,

aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251, 168-181, of Seq.ID No. 87,

aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88,

aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-153, of Seq.ID No. 89,

aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of Seq.ID No. 90;

aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92,

aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159, 165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-115, 233-250 and 245-265, of Seq.ID No. 94,

aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220, 232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324, 332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95,

aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-402, of Seq.ID No. 96,

aa 5-32, 34-49, 1-43, of Seq.ID No. 97,

aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-200, of Seq.ID No. 99,

aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-297, 63-126, of Seq.ID No. 100,

aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308, 1-59, of Seq.ID No. 101,

aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218, 254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414, 431-455, 328-394, of Seq.ID No. 102,

aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-272, 77-128, of Seq.ID No. 103,

aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104,

aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172, 190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293, 299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106,

aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229, 236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346, 348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112,

aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-193, 206-212, 222-229, 235-242 of Seq.ID No. 114,

aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314,

321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116,  
aa 9-33, 56-62, 75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142,  
aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq.ID No. 151,  
aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152,  
aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154,  
aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq.ID No. 155 and  
aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158,  
aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168,  
aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174,  
aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa of said sequences. All these fragments individually and each independently form a preferred selected aspect of the present invention.

Especially suited helper epitopes may also be derived from these



antigens. Especially preferred helper epitopes are peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Tables 4 and 5 and from the group of aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seq.ID.No.70, aa 240-260 of Seq.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.

According to another aspect, the present invention relates to a vaccine comprising such a hyperimmune serum-reactive antigen or a fragment thereof as identified above for *Staphylococcus aureus* and *Staphylococcus epidermidis*. Such a vaccine may comprise one or more antigens against *S. aureus* or *S. epidermidis*. Optionally, such *S. aureus* or *S. epidermidis* antigens may also be combined with antigens against other pathogens in a combination vaccine. Preferably this vaccine further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alum, Freund's complete or incomplete adjuvans or combinations thereof. Such a vaccine may also comprise the antigen displayed on a surface display protein platform on the surface of a genetically engineered microorganism such as *E. coli*.

According to another aspect, the present invention relates to specific preparations comprising antibodies raised against at least one of the *Staphylococcus aureus* and *Staphylococcus epidermidis* antigens or *Staphylococcus aureus* and *Staphylococcus epidermidis* antigen fragments as defined above. These antibodies are preferably monoclonal antibodies.

Methods for producing such antibody preparations, polyclonal or monoclonal, are well available to the man skilled in the art and properly described in the prior art. A preferred method for producing such monoclonal antibody preparation is characterized by the following steps

- initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said antigen and
- producing the antibody preparation by cultivation of said cloned hybridoma cells and optionally further purification steps.

Preferably, removing of the spleen or spleen cells is connected with killing said animal.

Monoclonal antibodies and fragments thereof can be chimerized or humanized (Graziano et al. 1995) to enable repeated administration. Alternatively human monoclonal antibodies and fragments thereof can be obtained from phage-display libraries (McGuinness et al., 1996) or from transgenic animals (Brüggemann et al., 1996).

A preferred method for producing polyclonal antibody preparations to said Staphylococcus aureus or Staphylococcus epidermidis antigens identified with the present invention is characterized by the following steps

- initiating an immune response in a non human animal by administering a Staphylococcus antigen or a fragment thereof, as defined above, to said animal,
- removing an antibody containing body fluid from said animal,
- and
- producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.

These monoclonal or polyclonal antibody preparations may be used for the manufacture of a medicament for treating or preventing diseases due to staphylococcal infection. Moreover, they may be used for the diagnostic and imaging purposes.

The method is further described in the following examples and in the figures, but should not be restricted thereto.

Figure 1 shows the pre-selection of sera based on anti-staphylococcal antibody titers measured by ELISA.

Figure 2 shows the size distribution of DNA fragments in the LSA50/6 library in pMAL4.1.

Figure 3 shows the MACS selection with biotinylated human serum. The LSA50/6 library in pMAL9.1 was screened with 10 µg biotinylated, human serum in the first (A) and with 1 µg in the second selection round (B). P.serum, patient serum; B.serum, infant serum. Number of cells selected after the 2<sup>nd</sup> and 3<sup>rd</sup> elution are shown for each selection round.

Figure 4 shows the serum reactivity with specific clones isolated by bacterial surface display as analyzed by Western blot analysis with patient serum at a dilution of 1 : 5000.

Figure 5 shows peptide ELISA with serum from patients and healthy individuals with an epitope identified by ribosome display.

Figure 6 shows representative 2D Immunoblot of *S. aureus* surface proteins detected with human sera. 800 µg protein from *S. aureus*/COL grown on BHI were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%), and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with sera IC35 (1:20,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

Figure 7 demonstrates a representative 2D gel showing *S. aureus* surface proteins stained by Coomassie Blue. 1 mg protein from *S. aureus*/COL were resolved by IEF (pI 4-7) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked.

Figures 8A and 8B show the structure of LPXTG cell wall proteins.

Figure 9 shows the IgG response in uninfected (N, C) and infected (P) patients to LPXTGV, a novel antigen and probable surface adhesin of *S. aureus*, discovered by both the inventive bacterial

surface-display and proteomics approaches.

Figure 10 shows the surface staining of *S. aureus* with purified anti-LPXTGV IgGs.

Figure 11 shows a 2D gel where *S. aureus* surface proteins are stained by Coomassie Blue (left). 1 mg protein from *S. aureus*/agr grown to early log phase was resolved by IEF (pI 6-11) and SDS-PAGE (9-16%). Spots selected for sequencing after serological proteome analysis are marked. Corresponding 2D-immunoblot (right). 800 µg protein from the same preparation was resolved in parallel by 2DE, and subsequently transferred to PVDF membrane. After blocking, the membrane was incubated with the P-pool (1:10,000). Binding of serum IgG was visualized by an anti-human IgG/HRPO conjugate and ECL development.

## EXAMPLES

Discovery of novel *Staphylococcus aureus* antigens

### Example 1: Preparation of antibodies from human serum

The antibodies produced against staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as the present invention which is based on the interaction of the specific anti-staphylococcal antibodies and the corresponding *S. aureus* peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from I. patients with acute *S. aureus* infections, such as bacteraemia, sepsis, infections of intravascular and percutan catheters and devices, wound infections, and superficial and deep soft tissue infection. *S. aureus* was shown to be the causative agent by medical microbiological tests. II. A collection of serum samples from uninfected adults was also included in the present analysis, since staphylococcal infections are common, and antibodies are present as a consequence of natural immunization from

previous encounters with Staphylococci from skin and soft tissue infections (furunculus, wound infection, periodontitis etc.).

The sera were characterized for *S. aureus* antibodies by a series of ELISA assays. Several staphylococcal antigens have been used to prove that the titer measured was not a result of the sum of cross-reactive antibodies. For that purpose not only whole cell *S. aureus* (protein A deficient) extracts (grown under different conditions) or whole bacteria were used in the ELISA assays, but also individual cell wall components, such as lipoteichoic acid and peptidoglycan isolated from *S. aureus*. More importantly, a recombinant protein collection was established representing known staphylococcal cell surface proteins for the better characterization of the present human sera collections.

Recently it was reported that not only IgG, but also IgA serum antibodies can be recognized by the FcRIII receptors of PMNs and promote opsonization (Phillips-Quagliata et al., 2000; Shibuya et al., 2000). The primary role of IgA antibodies is neutralization, mainly at the mucosal surface. The level of serum IgA reflects the quality, quantity and specificity of the dimeric secretory IgA. For that reason the serum collection was not only analyzed for anti-staphylococcal IgG, but also for IgA levels. In the ELISA assays highly specific secondary reagents were used to detect antibodies from the high affinity types, such as IgG and IgA, and avoided IgM. Production of IgM antibodies occurs during the primary adaptive humoral response, and results in low affinity antibodies, while IgG and IgA antibodies had already undergone affinity maturation, and are more valuable in fighting or preventing disease

### Experimental procedures

Enzyme linked immune assay (ELISA). ELISA plates were coated with 2-10 µg/ml of the different antigens in coating buffer (sodium carbonate pH 9.2). Serial dilutions of sera (100-100.000) were made in TBS-BSA. Highly specific (cross-adsorbed) HRP (Horse Radish Peroxidase)-labeled anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (~ 2.000x). Antigen-antibody complexes were quantified by measuring the conversion of the sub-

strate (ABTS) to colored product based on OD<sub>405nm</sub> readings in an automated ELISA reader (Wallace Victor 1420). The titers were compared at given dilution where the dilution response was linear (Table 1). The ~ 100 sera were ranked based on the reactivity against multiple staphylococcal components, and the highest ones (above 90 percentile) were selected for further analysis in antigen identification. Importantly, the anti-staphylococcal antibodies from sera of clinically healthy individuals proved to be very stable, giving the same high ELISA titers against all the staphylococcal antigens measured after 3, 6 and 9 months (data not shown). In contrast, anti-S. aureus antibodies in patients decrease, then disappear after a couple of weeks following the infection (Coloque-Navarro et al, 1998). However, antibodies from patients are very important, since these are direct proof of the in vivo expression of the bacterial antigens tested in or ELISAs or identified as immunogenic during the screens according to the present invention.

This comprehensive approach followed during antibody characterization is unique, and led to unambiguous identification of anti-staphylococcal hyperimmune sera.

Purification of antibodies for genomic screening. Five sera from both the patient and the noninfected group were selected based on the overall anti-staphylococcal titers. Antibodies against E. coli proteins were removed by either incubating the heat inactivated sera with whole cell E. coli (DH5a, transformed with pHIE11, grown under the same condition as used for bacterial display) or with E. coli lysate affinity chromatography for ribosome display. Highly enriched preparations of IgG from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA, and protein concentration measurements. For proteomics, the depletion the IgG and IgA preparation was not necessary, since the secondary reagent ensured the specificity.

**Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of *Staphylococcus aureus***

**Experimental procedures**

Preparation of staphylococcal genomic DNA. This method was developed as a modification of two previously published protocols (So-hail, 1998, Betley et al., 1984) and originally specifically adapted for the methicillin resistant *Staphylococcus aureus* strain COL to obtain genomic DNA in high quality and large scale. 500 ml BHI (Brain Heart Infusion) medium supplemented with 5 µg/ml Tetracycline was inoculated with bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°. The culture was then harvested in two aliquots of 250 ml each, centrifuged with 1600 x g for 15 min and the supernatant was removed. Bacterial pellets were carefully re-suspended in 26 ml of 0.1 mM Tris-HCl, pH 7.6 and centrifuged again with 1600 x g for 15 min. Pellets were re-suspended in 20 ml of 1 mM Tris-HCl, pH 7.6, 0.1 mM EDTA and transferred into sterile 50 ml polypropylene tubes. 1 ml of 10 mg/ml heat treated RNase A and 200 U of RNase T1 were added to each tube and the solution mixed carefully. 250 µl of Lysostaphin (10 mg/ml stock, freshly prepared in ddH<sub>2</sub>O) was then added to the tubes, mixed thoroughly and incubated at 40°C for 10 min in a shaking water bath under continuous agitation. After the addition of 1 ml 10 % SDS, 40 µl of Proteinase K (25 mg/ml stock) and 100 µl of Pronase (10 mg/ml), tubes were again inverted several times and incubated at 40°C for 5 min in a shaking water bath. 3.75 ml of 5 M NaCl and 2.5 ml of cetyl trimethyl-ammonium bromide solution (CTAB) (10% w/v, 4% w/v NaCl) were then added and tubes were further incubated at 65°C in a shaking water bath for 10 min. Samples were cooled to room temperature and extracted with PhOH/CHCl<sub>3</sub>/IAA (25:24:1) and with CHCl<sub>3</sub>/IAA (24:1). Aqueous phases were carefully collected and transferred to new sterile 50-ml tubes. To each tube 1.5 ml of Strataclean™ Resin was added, mixed gently but thoroughly and incubated for one minute at room temperature. Samples were centrifuged and the upper layers containing the DNA were collected into clean 50ml-tubes. DNA was precipitated at room temperature by adding 0.6 x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes con-

taining 80% ice cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12 000 x g, then dried on air and dissolved in ddH<sub>2</sub>O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl<sub>2</sub> in a 50 µl volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2 µl of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.1 was constructed on a pEH1 backbone (Hashemzadeh-Bonehi et al., 1998) with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The bla gene is preceded by the leader peptide sequence of ompA to ensure efficient secretion across the cytoplasmic membrane. A Sma I restriction site serves for library insertion. The Sma I site is flanked by an upstream FseI site and a downstream NotI site which were used for recovery of the selected fragments. The three restriction sites are inserted after the ompA leader sequence in such a way that the bla gene is transcribed in the -1 reading frame result-



ing in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL4.31 was constructed on a pASK-IBA backbone (Skerra, 1994) with the b-lactamase gene exchanged with the Kanamycin resistance gene. In addition it harbors a b-lactamase (bla) gene cloned into the multiple cloning site. The sequence encoding mature b-lactamase is preceded by the leader peptide sequence of ompA to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature b-lactamase follows the ompA leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane (Kajava et al., 2000). A SmaI restriction site serves for library insertion. The SmaI site is flanked by an upstream FseI site and a downstream NotI site which were used for recovery of the selected fragment. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the bla gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that b-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the lamB gene into the multiple cloning site of pEH1. Subsequently, a sequence was inserted in lamB after amino acid 154, containing the restriction sites FseI, SmaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or pMAL4.31 to plasmid pMAL9.1 will yield a continuous reading frame of lamB and the respective insert.

The vector pHE11 was constructed by cloning the fhuA gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in fhuA after amino acid 405, containing the restriction site FseI, XbaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmids pMAL4.1 or

pMAL4.31 to plasmid pHI11 will yield a continuous reading frame of *fhuA* and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic *S. aureus* DNA fragments were ligated into the *Sma*I site of either the vector pMAL4.1 or pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent *E. coli* cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.1 or pMAL4.31 vector, containing the *S. aureus* library with the restriction enzymes *Fse*I and *Not*I. The entire population of fragments was then transferred into plasmids pMAL9.1 (*Lam*B) or pHI11 (*FhuA*) which have been digested with *Fse*I and *Not*I. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.1 or pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into *E. coli* DH5a cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

## Results

Libraries for frame selection. Two libraries (LSA50/6 and LSA250/1) were generated in the pMAL4.1 vector with sizes of approximately 50 and 250 bp, respectively. For both libraries a total number of clones after frame selection of  $1-2 \times 10^4$  was

received using approximately 1 µg of pMAL4.1 plasmid DNA and 50 ng of fragmented genomic *S. aureus* DNA. To assess the randomness of the LSA50/6 library, 672 randomly chosen clones were sequenced. The bioinformatic analysis showed that of these clones none was present more than once. Furthermore, it was shown that 90% of the clones fell in the size range of 19 to 70 bp with an average size of 25 bp (Figure 2). All 672 sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of *E. coli* required the transfer of the inserts from the LSA50/6 library from the frame selection vector pMAL4.1 to the display plasmids pMAL9.1 (LamB) or pHIE11 (PhuA). Genomic DNA fragments were excised by FseI and NotI restriction and ligation of 5ng inserts with 0.1µg plasmid DNA resulted in 2-5x 10<sup>6</sup> clones. The clones were scraped off the LB plates and frozen without further amplification.

**Example 3: Identification of highly immunogenic peptide sequences from *S. aureus* using bacterial surface displayed genomic libraries and human serum**

#### **Experimental procedures**

MACS screening. Approximately 2.5x 10<sup>8</sup> cells from a given library were grown in 5 ml LB-medium supplemented with 50 µg/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately 2x 10<sup>7</sup> cells re-suspended in 100 µl LB medium and transferred to an Eppendorf tube.

10 µg of biotinylated, human serum was added to the cells and the suspension incubated over night at 4°C with gentle shaking. 900 µl of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6000 rpm at 4°C. Cells were washed once with 1 ml LB and then re-suspended in 100 µl LB medium. 10 µl of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were added and the incubation continued for 20 min at 4°C. Thereafter 900 µl of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Mil-

- 39 -

tenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. The elution was performed by removing the magnet and washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and re-suspended in 1 ml LB medium supplemented with 50 µg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 µl LB medium. Since the volume was reduced, 1 µg of human, biotinylated serum was added and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or in a collaboration with TIGR (U.S.A.).

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of 1:5000 and anti human IgG antibodies coupled to HRP at a dilution of 1:5000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit anti FhuA or mouse anti LamB antibodies were used as primary antibodies in combination with the respective secondary antibodies cou-

pled to HRP for the detection of the fusion proteins.

## Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated human serum. The libraries LSA50/6 in pMAL9.1 and LSA250/1 in pHIE11 were screened with a pool of biotinylated, human patient sera (see Example 1) Preparation of antibodies from human serum). The selection procedure was performed as described under Experimental procedures. As a control, pooled human sera from infants that have most likely not been infected with *S. aureus* was used. Under the described conditions between 10 and 50 fold more cells with the patient compared to the infant serum were routinely selected (Figure 3). To evaluate the performance of the screen, approximately 100 selected clones were picked randomly and subjected to Western blot analysis with the same pooled patient serum. This analysis revealed that 30 to 50% of the selected clones showed reactivity with antibodies present in patient serum whereas the control strain expressing Lamb or PhuA without a *S. aureus* specific insert did not react with the same serum. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (500 to 800 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human patient serum used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. In that regard it is striking that some clones (ORF2264, ORF1951, ORF0222, lipase and IsaA) were picked up to 90 times, indicating their highly immunogenic property. All clones that are presented in Table 2 have been verified by Western blot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the screen.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are ei-

ther attached to the surface of *S. aureus* and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of *S. aureus*.

Assessment of reactivity of highly immunogenic peptide sequences with different human sera. 10 to 30 different human patient sera were subsequently used to evaluate the presence of antibodies against the selected immunogenic peptide sequences that have been discovered in the screen according to the present invention. To eliminate possible cross-reactivity with proteins expressed by *E. coli*, all sera were pre-adsorbed with a total cellular lysate of *E. coli* DHA cells expressing FhuA protein.

This analysis is summarized in Table 2 and as an example shown in Figure 4 and is indicative of the validity of the present screen. It further shows that already short selected epitopes can give rise to the production of antibodies in a large number of patients (ORF1618, ORF1632, IsaA, Empbp, Protein A). Those peptide sequences that are not recognized by a larger set of patient sera may still be part of an highly immunogenic protein, but the recombinant protein itself may be tested for that purpose for each single case.

**Example 4: Identification of highly immunogenic peptide sequences from genomic fragments from *S. aureus* using ribosome display and human serum**

#### **Experimental procedures**

Ribosome display screening: 2.4 ng of the genomic library from *S. aureus* LSA250/1 in pMAL4.1 (described above) was PCR amplified with oligos ICC277 and ICC202 in order to be used for ribosome display.

Oligos	ICC277
(CGAATAATACGACTCACTATAGGGAGACCACAACGGTTTCCCACTAGTAATAATTTTGTTTAAC	
TTTAAGAAGGAGATATCCATGCAGaCCTTGGCCGGCCTCCC)	
and	ICC202
(GGCCCAACCCGTGAAGGTGAGCCGGCGTAAGATGCTTTTCGTGACTGG)	

hybridize 5' and 3' of the Fse I-Not I insertion site of plasmid pMAL4.1, respectively. ICC277 introduces a T7 phage RNA polymerase promoter, a palindromic sequence resulting in a stem-loop structure on the RNA level, a ribosome binding site (RBS) and the translation start of gene 10 of the T7 phage including the ATG start codon.

- 42 -

Oligo ICC202 hybridizes at nucleotide position 668 of the  $\beta$ -lactamase open reading frame and also introduces a stem-loop structure at the 3' end of the resulting RNA. PCR was performed with the High fidelity PCR kit (Roche Diagnostic) for 25 cycles at 50°C hybridization temperature and otherwise standard conditions.

The resulting PCR library was used in 5 consecutive rounds of selection and amplification by ribosome display similar as described previously (Hanes et al., 1997) but with modifications as described below.

One round of ribosome display contained the following steps: In vitro transcription of 2  $\mu$ g PCR product with the RiboMax kit (Promega) resulted in ca. 50  $\mu$ g A. In vitro translation was performed for 9 minutes at 37°C in 22  $\mu$ l volume with 4.4  $\mu$ l Premix Z (250 mM TRIS-acetate pH 7.5, 1.75 mM of each amino acid, 10 mM ATP, 2.5 mM GTP, 5 mM CAMP, 150 mM acetylphosphate, 2.5 mg/ml E. coli tRNA, 0.1 mg/ml folinic acid, 7.5 % PEG 8000, 200 mM potassium glutamate, 13.8 mM Mg(Ac)2, 8  $\mu$ l S30 extract (x mg/ml) and about 2  $\mu$ g in vitro transcribed RNA from the pool. S30 extract was prepared as described (Chen et al, 1983). Next, the sample was transferred to an ice-cold tube containing 35.2  $\mu$ l 10 % milk-WBT (TRIS-acetate pH 7.5, 150 mM NaCl, 50 mM Mg(Ac)2, 0.1 % Tween-20, 10 % milk powder) and 52.8  $\mu$ l WBTH (as before plus 2.5 mg/ml heparin). Subsequently, immuno precipitation was performed by addition of 10  $\mu$ g purified IgGs, incubation for 90 minutes on ice, followed by addition of 30  $\mu$ l MAGmol Protein G beads (Miltenyi Biotec, 90 minutes on ice). The sample was applied to a pre-equilibrated  $\mu$  column (Miltenyi Biotec) and washed 5 times with ice-cold WBT buffer. Next 20  $\mu$ l EB20 elution buffer (50 mM TRIS-acetate, 150 mM NaCl, 20 mM EDTA, 50  $\mu$ g/ml *S. cerevisiae* RNA) was applied to the column, incubated for 5 minutes at 4°C. Elution was completed by adding 2 x 50  $\mu$ l EB20. The mRNA from the elution sample was purified with the High pure RNA isolation kit (Roche Diagnostics). Subsequent reverse transcription was performed with Superscript II reverse transcriptase kit (Roche Diagnostics) according to the instruction of the manufacturer with 60 pmol oligo ICC202 for 1 hour at 50°C in 50  $\mu$ l volume. 5  $\mu$ l of this mix was used for the following PCR reaction with primers ICC202 and ICC277 as described above.

Three rounds of ribosome display were performed and the resulting selected PCR pool subsequently cloned into plasmid pHI11 (described above) by cleavage with restriction endonucleases NotI and FseI.

Evaluation of selected clones by sequencing and peptide-ELISA analysis: Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany) or at the Institute of Genomic Research (TIGR; Rockville, MD, U.S.A.). Peptides corresponding to the inserts were synthesized and coated in 10 mM NaHCO<sub>3</sub> pH 9.3 at a concentration of 10 µg/ml (50 µl) onto 96-well microtiter plates (Nunc). After blocking with 1% BSA in PBS at 37°C, 1:200 and 1:1000 dilutions of the indicated sera were diluted in 1% BSA/PBS and applied to the wells. After washing with PBS/0.1 % Tween-20, biotin-labeled anti-human IgG secondary antibodies (SBA) were added and these were detected by subsequent adding horseradish-peroxidase-coupled streptavidin according to standard procedures.

## Results

The 250-bp genomic library (LSA250/1) as described above was used for screening. Purified IgGs from uninfected adults but with high titer against *S. aureus* as described above were used for selection of antigenic peptides.

Three rounds of ribosome display selection and amplification were performed according to Experimental procedures; finished by cloning and sequencing the resulting PCR pool.

Sequence analyses of a large number of randomly picked clones (700) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the high titer serum used for screening. The frequency with which a specific clone was selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. Remarkably, some clones (ORFs) were picked up to 50 times, indicating their highly immunogenic property. Table 2 shows the ORF name, the Seq.ID No. and the number of times it was identi-



fied by the inventive screen.

For a number of immuno-selected ORFs peptides corresponding to the identified immunogenic region were synthesized and tested in peptide-ELISA for their reactivity towards the sera pool they were identified with and also a number of additional sera from patients who suffered from an infection by *S. aureus*. The two examples in the graphs in figure 5 show the values of peptides from aureolysin and Pls. They are not only hyperimmune reactive against the high titer sera pool but also towards a number of individual patient's sera. All synthesized peptides corresponding to selected immunogenic regions showed reactivity towards the high titer sera pool and Table 2 summarizes the number of times the peptides were reactive towards individual patients sera, similar as described above.

In addition, it is striking that for those ORFs that were also identified by bacterial surface display described above), very often the actual immunogenic region within the ORF was identical or overlapping with the one identified by ribosome display. This comparison can be seen in Table 2.

**Example 5: Identification of highly immunogenic antigens from *S. aureus* using Serological Proteome Analysis.**

#### **Experimental procedures**

Surface protein preparations from *S. aureus* containing highly immunogenic antigens. *S. aureus* strains COL (Shafer and Iandolo, 1979) and agr- (Recsei et al., 1986) were stored as glycerol stocks at -80°C or on BHI (DIFCO) plates at 4°C. Single clones were used for inoculation of overnight cultures in either BHI ("standard conditions") or RPMI 1640 (GibcoBRL), last one depleted from iron ("stress conditions") by treating o/n with iminodiacetic acid (Sigma). Fresh medium was inoculated 1:100 the next day and bacteria were grown to O.D.<sub>600</sub> between 0.3 and 0.7. Bacteria were harvested by centrifugation and washed with ice-cold PBS. Surface proteins were prepared by lysostaphin treatment under isotonic conditions (Lim et al. 1998). Briefly,  $\sim 3 \times 10^9$  bacteria (according to O.D.<sub>600</sub> = 1 are about  $5 \times 10^7$  bacteria) were re-

suspended in 1 ml digestion buffer containing 35% raffinose (Aldrich Chemical Company), protease inhibitors (Roche) and 5 units lysostaphin (Sigma). After incubation at 37°C for 30 min, protoplasts were carefully sedimented by low-speed centrifugation. This treatment releases surface proteins covalently linked to the pentaglycine bridge of the peptidoglycan cell wall to the supernatant (in Crossley, 1997). Cell surface proteins were either precipitated with methanol/chloroform (Wessel, 1984) or concentrated in centrifugal filter-tubes (Millipore). Protein samples were frozen and stored at -80°C or dissolved in sample buffer and used for isoelectric focusing (IEF) immediately (Pasquali et al. 1997).

Serological proteome analysis of surface protein preparations from *S. aureus*. Samples were obtained from a) *S. aureus*/agr grown under "stress conditions", b) *S. aureus*/COL grown under "standard conditions" and c) *S. aureus*/COL "stress conditions". Loading onto 17 cm-strips containing immobilized pH gradients (pH 4-7, BioRad) was done using the "in-gel-reswelling procedure" (Pasquali et al., 1997). The gels for blotting were loaded with 100-800 µg protein, the preparative gels with 400-1,000 µg protein. Isoelectric focusing and SDS-PAGE (9-16% gradient gels) were performed as described (Pasquali et al., 1997). For Western blotting, proteins were transferred onto PVDF-membranes (BioRad) by semi-dry blotting. Transfer-efficiency was checked by amido-black staining. After blocking (PBS/0.1% Tween 20/10% dry milk, 4°C for 16 h), blots were incubated for two hours with serum (1:2,500-1:100,000 in blocking solution, see Table 3). After washing, specific binding of serum IgG was visualized with a goat-anti-human-IgG / peroxidase conjugate (1:25,000, Southern Biotech) as secondary antibody and development with a chemiluminescence substrate (ECL<sup>TM</sup>, Amersham). A representative result is shown in Figure 6. Membranes were stripped by treatment with 2% β-ME/Laemmli buffer for 30 min at 50-65°C, immediately re-probed with a different serum, and developed as described above. This procedure was repeated up to five times. Signals showing up with patient and/or healthy donor control sera but not with the infant pool, were matched to the Coomassie (BioRad) stained preparative gels (example shown in Figure 7). The results of these serological proteome analyses of surface protein preparations from *S. aureus* are summarized in Table 3.

Sequencing of protein spots by peptide-fingerprint MALDI-TOF-MS and tandem MS/MS. Gel pieces were washed alternately three times with 10 µl digestion buffer (10mM  $\text{NH}_4\text{HCO}_3$ /CAN, 1:1). Afterwards the gel pieces were shrunken with 10 µl ACN and reswollen with 2 µl protease solution (0.05 µg/µl trypsin, Promega, Madison, USA). Digestion was performed for 10-12 h at 37°C. For MALDI-TOF-MS peptides were extracted from the gel pieces with 10 µl digestion buffer. The supernatant was concentrated with ZipTip™ (Millipore, Bedford, USA), the peptides were eluted onto the MALDI target with 0.5 µl extraction buffer (0.1% TFA/CAN, 1:1) and 0.5 µl matrix solution (HCCA in ACN/0.1% TFA, 1:1) was added. MALDI-TOF-MS was done using a REFLEX III (Bruker Daltonik, Bremen, Germany) equipped with a SCOUT384 ion source. The acceleration voltage was set to 25 kV, and the reflection voltage to 28.7 kV. The mass range was set from 700 Da to 4000 Da. Data acquisition was done on a SUN Ultra using XACQ software, version 4.0. Post-analysis data processing was done using XMASS software, version 4.02 (Bruker Daltonik, Bremen, Germany). The results are summarized in tables 3 and 4.

**Example 6: Characterisation of highly immunogenic proteins from *S. aureus***

The antigens identified by the different screening methods with the IgG and IgA preparations from pre-selected sera are further characterized, by the following ways:

1. The proteins are purified, most preferably as recombinant proteins expressed in *E. coli* or in a Gram+ expression system or in an in vitro translation system, and evaluated for antigenicity by a series of human sera. The proteins are modified based on bioinformatic analysis: N-terminal sequences representing the signal peptide are removed, C-terminal regions downstream of the cell wall anchor are also removed, and extra amino acids as tags are introduced for the ease of purification (such as Strep-tagII, His-tag, etc.) A large number of sera is then used in ELISA assays to assess the fraction of human sera containing specific antibodies against the given protein (see Fig. 9 as an example). One of the selected antigens is a 895 aa long protein, what was called LPXTGV (see Tables 2 and 4), since it contains the Gram+ cell wall anchor sequence LPXTG. This signature has been shown to

serve as cleavage site for sortase, a trans-peptidase which covalently links LPXTG motif containing proteins to the peptidoglycan cell wall. LPXTGV is also equipped with a typical signal peptide (Fig. 8). ELISA data using this protein as a Strep-tagged recombinant protein demonstrate that this protein is highly immunogenic (high titers relative to other recombinant proteins) in a high percentage of sera (Fig. 9). Importantly, patients with acute *S. aureus* infection produce significantly more of these anti-LPXTGV antibodies, than healthy normals, suggesting that the protein is expressed during *in vivo* infection. The overall ELISA titers of the individual antigenic proteins are compared, and the ones inducing the highest antibody levels (highly immunogenic) in most individuals (protein is expressed by most strains *in vivo*) are favored. Since the antigen specificity and quality (class, subtype, functional, nonfunctional) of the antibodies against *S. aureus* produced in individual patients can vary depending on the site of infection, accompanying chronic diseases (e.g. diabetes) and chronic conditions (e.g. intravascular device), and the individuals' immune response, special attention was paid to the differences detected among the different patient groups, since medical records belonging to each sera were available. In addition, each patient serum is accompanied by the pathogenic strain isolated from the patient at the time of serum sampling.

2. Specific antibodies are purified for functional characterization. The purity and the integrity of the recombinant proteins are checked (e.g. detecting the N-terminal Strep-tag in Western blot analysis in comparison to silver staining in SDS-PAGE). The antigens are immobilized through the tags to create an affinity matrix, and used for the purification of specific antibodies from highly reactive sera. Using as an example strep-tagged LPXTGV as the capture antigen, 20  $\mu$ g of antibody from 125 mg of IgG were purified. Based on the ELISA data a pure preparation was received, not having e.g. anti-LTA and anti-peptidoglycan (both dominant with unfractionated IgG) activity. The antibodies are then used to test cell surface localization by FACS and fluorescent microscopy (Fig. 10).

### 3. Gene occurrence in clinical isolates

An ideal vaccine antigen would be an antigen that is present in all, or the vast majority of, strains of the target organism to

- 48 -

which the vaccine is directed. In order to establish whether the genes encoding the identified *Staphylococcus aureus* antigens occur ubiquitously in *S. aureus* strains, PCR was performed on a series of independent *S. aureus* isolates with primers specific for the gene of interest. *S. aureus* isolates were obtained from patients with various *S. aureus* infections. In addition several nasal isolates from healthy carriers and several lab strains were also collected and analyzed. The strains were typed according to restriction fragment length polymorphism (RFLP) of the *spa* and *coa* genes (Goh et al. 1992, Frénay et al., 1994, vanden Bergh et al. 1999). From these results 30 different strains were identified - 24 patient isolates, 3 nasal isolates and 3 lab strains. To establish the gene distribution of selected antigens, the genomic DNA of these 30 strains was subjected to PCR with gene specific primers that flank the selected epitope (ORF1361: Seq.ID No. 187 and 188; ORF2268: Seq.ID No. 193 and 194; ORF1951: Seq.ID No. 195 and 196; ORF1632: Seq.ID No. 181 and 182; ORF0766: Seq.ID No. 183 and 184; ORF0576: Seq.ID No. 185 and 186; ORF0222: Seq.ID No. 189 and 190; ORF0360: Seq.ID No. 191 and 192). The PCR products were analyzed by gel electrophoresis to identify a product of the correct predicted size. ORFs 1361, 2268, 1951, 1632, 0766 and 0222 are present in 100% of strains tested and ORF0576 in 97%. However ORF0360 occurred in only 71% of the strains. Thus ORFs 1361, 2268, 1951, 1632, 0766, 0576 and 0222 each have the required ubiquitous presence among *S. aureus* isolates.

These antigens (or antigenic fragments thereof, especially the fragments identified) are especially preferred for use in a vaccination project against *S. aureus*.

#### 4. Identification of highly promiscuous HLA-class II helper epitopes within the ORFs of selected antigens

The ORFs corresponding to the antigens identified on the basis of recognition by antibodies in human sera, most likely also contain linear T-cell epitopes. Especially the surprising finding in the course of the invention that even healthy uninfected, non-colonized individuals show extremely high antibody titers (> 100,000 for some antigens, see Example 5) which are stable for >1 year (see Example 1), suggests the existence of T-cell dependent memory most probably mediated by CD4+ helper-T-cells. The molecular

definition of the corresponding HLA class II helper-epitopes is useful for the design of synthetic anti-staphylococcal vaccines, which can induce immunological memory. In this scenario the helper-epitopes derived from the staphylococcal antigens provide "cognate help" to the B-cell response against these antigens or fragments thereof. Moreover it is possible to use these helper-epitopes to induce memory to T-independent antigens like for instance carbohydrates (conjugate vaccines). On the other hand, intracellular occurring staphylococci can be eliminated by CD8+ cytotoxic T-cells, which recognize HLA class I restricted epitopes.

T-cell epitopes can be predicted by various public domain algorithms: [http://bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://bimas.dcrt.nih.gov/molbio/hla_bind/) (Parker et al. 1994), <http://134.2.96.221/scripts/MHCServer.dll/home.htm> (Rammensee et al. 1999), <http://mypage.ihost.com/usinet.hamme76/> (Sturniolo et al. 1999). The latter prediction algorithm offers the possibility to identify promiscuous helper-epitopes, i.e. peptides that bind to several HLA class II molecules. In order to identify highly promiscuous helper-epitopes within staphylococcal antigens the ORFs corresponding to Seq ID 64 (IsaA), Seq ID 114 (POV2), Seq ID 89 (ORF0222), Seq ID 70 (LPXTGIV), Seq ID 56 (LPXTGV), Seq ID 142 (LPXTGVI), Seq ID 81 (ORF3200), Seq ID 74 (ORF1951), Seq ID 94 (Empbp), Seq ID 83 (autolysin) and Seq ID 58 (ORF2498) were analyzed using the TEPITOPE package <http://mypage.ihost.com/usinet.hamme76/> (Sturniolo et al. 1999). The analysis was done for 25 prevalent DR-alleles and peptides were selected if they were predicted to be a) strong binders (1% threshold) for at least 10/25 alleles or b) intermediate (3% threshold) binders for at least 17/25 alleles.

The following peptides containing one or several promiscuous helper-epitopes were selected (and are claimed):

Seq ID 56:	pos. 6-40, 583-598, 620-646, 871-896
Seq ID 58:	no peptide fulfills selection criteria
Seq ID 64:	no peptide fulfills selection criteria
Seq ID 70:	pos. 24-53
Seq ID 74:	pos. 240-260
Seq ID 81:	pos. 1660-1682, 1746-1790
Seq ID 83:	pos. 1-29, 680-709, 878-902

Seq ID 89: pos. 96-136  
Seq ID 94: pos. 1-29, 226-269, 275-326  
Seq ID 114: pos. 23-47, 107-156  
Seq ID 142: pos. 24-53

The corresponding peptides or fragments thereof (for instance overlapping 15-mers) can be synthesized and tested for their ability to bind to various HLA molecules in vitro. Their immunogenicity can be tested by assessing the peptide (antigen)-driven proliferation (BrdU or 3H-thymidine incorporation) or the secretion of cytokines (ELISPOT, intracellular cytokine staining) of T-cells in vitro (Mayer et al. 1996, Schmitt et al. 2000, Sester et al. 2000). In this regard it will be interesting to determine quantitative and qualitative differences in the T-cell response to the staphylococcal antigens or the selected promiscuous peptides or fragments thereof in populations of patients with different staphylococcal infections, or colonization versus healthy individuals neither recently infected nor colonized. Moreover, a correlation between the antibody titers and the quantity and quality of the T-cell response observed in these populations is expected. Alternatively, immunogenicity of the predicted peptides can be tested in HLA-transgenic mice (Sonderstrup et al. 1999).

Similar approaches can be taken for the identification of HLA class I restricted epitopes within staphylococcal antigens.

**Synthetic peptides representing one or more promiscuous T helper epitopes from *S.aureus***

Partially overlapping peptides spanning the indicated regions of Seq ID 56 (LPXTGV), Seq ID 70 (LPXTGIV), Seq ID 74 (ORF1hom1), Seq ID 81 (EM\_BP), Seq ID 83 (Autolysin), Seq ID 89 (ORF1hom2), Seq ID 94 (EMPBP), Seq ID 114 (POV2) and Seq ID 142 (LPXTGVI) were synthesized. Sequences of the individual peptides are given in Table 5. All peptides were synthesized using Fmoc chemistry, HPLC purified and analyzed by mass spectrometry. Lyophilized peptides were dissolved in DMSO and stored at -20°C at a concentration of 5-10 mM.

**Binding of synthetic peptides representing promiscuous T helper**

**epitopes to HLA molecules in vitro**

Binding of peptides to HLA molecules on the surface of antigen-presenting cells is a prerequisite for activation of T cells. Binding was assessed in vitro by two independent biochemical assays using recombinant soluble versions of HLA class II molecules. One assay measures the concentration dependent competitive replacement of a labeled reference peptide by the test peptides. The second assay is based on the formation of SDS-stable complexes upon binding of high- and intermediate affinity ligands. A summary of the results obtained by the two assays is given in Table 5. /

Soluble HLA molecules (DRA1\*0101/DRB1\*0101 and DRA1\*0101/DRB1\*0401) were expressed in SC-2 cells and purified as described in Aichinger et al., 1997. For the competition assay (Hammer et al. 1995) HLA molecules were applied between 50 and 200 ng/well. For DRB1\*0101 biotinilated indicator peptide HA (PKYVKQNTLKLAT, Valli et al. 1993) was used at 0.008  $\mu$ M. For DRB1\*0401 biotinilated indicator peptide UD4 (YPKFVKQNTLKAA, Valli et al. 1993) was used between 0.03 and 0.06  $\mu$ M. Test peptides were used in serial dilutions from 0.02 nM to 200  $\mu$ M. Molecules, indicator and test peptides were incubated overnight at 37°C, pH 7. HLA:peptide complexes obtained after incubation with serial dilutions of test and reference peptides (the known high-affinity binders HA and UD4 were used as positive control) were captured in ELISA plates coated with antibody L243, which is known to recognize a conformational epitope formed only by correctly associated heterodimers. Incorporated biotin was measured by standard colorimetric detection using a streptavidin-alkaline phosphatase conjugate (Dako) with NBT/BCIP tablets (Sigma) as substrate and automated OD reading on a Victor reader (Wallac).

**T cell response against promiscuous T helper epitopes assessed by IFN $\gamma$  ELISpot assay**

Upon antigenic stimulation T cells start to proliferate and to secrete cytokines such as interferon gamma (IFN $\gamma$ ). Human T cells specifically recognizing epitopes within S.aureus antigens were detected by IFN $\gamma$ -ELISpot (Schmittl et al. 2000). PBMCs from healthy individuals with a strong anti-S.aureus IgG response were isolated from 50-100 ml of venous blood by ficoll density gradi-



ent centrifugation and used after freezing and thawing. Cells were seeded at 200,000/well in 96-well plates. Peptides were added as mixtures corresponding to individual antigens, in both cases at 10 µg/ml each. Concanavalin A (Amersham) and PPD (tuberculin purified protein derivate, Statens Serum Institute) served as assay positive controls, assay medium without any peptide as negative control. After overnight incubation in Multi Screen 96-well filtration plates (Millipore) coated with the anti-human IFNγ monoclonal antibody B140 (Bender Med Systems) the ELISPOT was developed using the biotinylated anti-human IFNγ monoclonal antibody B308-BT2 (Bender Med Systems), Streptavidin-alkaline phosphatase (DAKO) and BCIP/NBT alkaline phosphatase substrate (SIGMA). Spots were counted using an automatic plate reader (Bioreader 2000, BIO-SYS). Spots counted in wells with cells stimulated with assay medium only (negative control, generally below 10 spots / 100.000 cells) were regarded as background and subtracted from spot numbers counted in wells with peptides.

Table 5: Promiscuous T helper epitopes contained in S.aureus antigens

Amino acid sequences within S.aureus antigens containing highly promiscuous T helper epitopes	binding <sup>1)</sup>	IFNγ ELISPOT <sup>2)</sup>
Seq ID 56 (LPXTGV): pos. 6-40 p6-28 >PKLRSFYSIRKSTLGVASVIVST// p24-40 >VIVSTLFLISQHQQA//	+ -	44;80;8 ;95;112
Seq ID 56 (LPXTGV): pos. 620-646 p620-646 >FPYIPDKAVYNAIVKVVVANIGYEGQ//	+	
Seq ID 56 (LPXTGV): pos. 871-896 p871-896 >QSWWGLYALLGLALFIPKFRKESK//	-	
Seq ID 70 (LPXTGIV): pos. 24-53 p24-53 >YSIRKFTVTGTASILIGSLMYLGTQQEARA//	nd	34;14;0 ;57;16
Seq ID 74 (ORF1hom1): pos. 240-260 p240-260 >MNYGYGPGVVTSRTISASQA//	+	47;50;0 ;85;92

Seq ID 81 (EM_BP): pos. 1660-1682 p1660-1682 >NEIVLETIRDINNAHTLQQVEA//	nd	2;14;5; 77;26
Seq ID 81 (EM_BP): pos. 1746-1790 p1746-1773 >LHMRHFSNNFGNVIRKNAIGVVGISGLLA// p1753-1779 >NNFGNVIRKNAIGVVGISGLLASFWFFI// p1777-1789 >FFIAKRRRKEDEE/	nd nd nd	
Seq ID 83 (Autolysin) pos. 1-29 p1-29: >MAKKPNYKLPMSVALTLVGSAVTAHQVQA//	nd	6;35;7; 60;49
Seq ID 83 (Autolysin) pos. 878-902 p878-902: >NGLSMVPWGGKKNQVLTGNNTAQQ//	nd	
Seq ID 89 (ORF1hom2): pos. 96-136 p96-121 >GESINIIASRYGVSVDQMAANNLRG// p117-136 >NNLRGYLIMPNTLQIPNG//	- -	0;35;0; 29;104
Seq ID 94 (EMPBP): pos. 1-29 p4-29: >KLVLVTNSTLFATQIMNSNHAASV//	+	
Seq ID 94 (EMPBP): pos. 226-269 p226-251 >IKINHFCVVPQINSFKVIPPYGHNS// p254-270 >KHVPSFQNMVITATHQN//	- +	26;28;1 6;43;97
Seq ID 94 (EMPBP): pos. 275-326 p275-299 >YDYKYFYSYKVVKGVKKYFSFSQS// p284-305 >YKVVKGVKKYFSFSQSNKYKIG// p306-326 >PSLNKKNVYQYAVPSYSPT//	++ ++ +	
Seq ID 114 (POV2): pos. 23-47 p23-47 >AGGIFYNQTNQQLLVLCDDMGSGHK//	-	49;20;4 ;77;25
Seq ID 114 (POV2): pos. 107-156 p107-124 >ALVFEKSVVIANVGDSRA/ p126-146 >RAYVINSRQIBQITSDHSFVN// p142-156 >SFVNHLVLTGQITPER//	- nd nd	
Seq ID 142 (LPXTGVI): pos. 1-42 p6-30 >KEPKSFYSIRKSSLGVASVAISTL// p18-42 >SSLGVASVAISTLLLLIMNGRAQA//	++ nd	0;41;20 ;88;109
Seq ID 142 (LPXTGVI): pos. 209-244 p209-233 >IKLVSYDTVKDYAIRFSVSNCTKA// p218-244 >KDYAIRFSVSNCTKAVKIVSSTHFNN//	++ +	
Seq ID 142 (LPXTGVI): pos. 395-428 p395-418 >FMVEGQVRVITSTYAINNTRCTIF// p416-428 >TIFRVVECKSLYE//	- -	

Seq ID 142 (LPXTGVV): pos. 623-647		
p623-647 >MTPLMLALLSSIVAFVLPKRKN //	-	

<sup>4</sup> binding to soluble DRA1\*0101/DRB1\*0401 molecules was determined using a competition assay (+, ++: binding, -: no competition up to 200 µM test peptide; nd: not done)

<sup>2</sup> results from 5 healthy individuals with strong anti-S.aureus IgG response. Data are represented as spots/200.000 cells (background values are subtracted)

5. Antigens may be injected into mice - and the antibodies against these proteins can be measured.

6. Protective capacity of the antibodies induced by the antigens through vaccination can be assessed in animal models.

Both 5. and 6. are methods well available to the skilled man in the art.

#### Example 7: Applications

A) An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Patients suffering from chronic diseases with decreased immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from a vaccine with *S. aureus* by immunogenic serum-reactive antigens according to the present invention. Identification of the relevant antigens will help to generate effective passive immunization (humanized monoclonal antibody therapy), which can replace human immunoglobulin administration with all its dangerous side-effects. Therefore an effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular.

*S. aureus* can cause many different diseases.

1. Sepsis, bacteraemia
2. Haemodialysed patients - bacteriemia, sepsis
3. Peritoneal dialyses patients - peritonitis
4. Patients with endovascular devices (heart surgery, etc) - endocarditis, bacteriemia, sepsis

5. Orthopedic patients with prosthetic devices - septic arthritis
6. Preventive vaccination of general population

B) Passive and active vaccination, both with special attention to T-cells with the latter one: It is an aim to induce a strong T helper response during vaccination to achieve efficient humoral response and also immunological memory. Up till now, there is no direct evidence that T-cells play an important role in clearing *S. aureus* infections, however, it was not adequately addressed, so far. An effective humoral response against proteinaceous antigens must involve T help, and is essential for developing memory. Naïve CD4+ cells can differentiated into Th1 or Th2 cells. Since, innate immunological responses (cytokines) will influence this decision, the involvement of T-cells might be different during an acute, serious infection relative to immunization of healthy individuals with subunit vaccines, not containing components which impair the immune response during the natural course of the infection. The consequences of inducing Th1 or Th2 responses are profound. Th1 cells lead to cell-mediated immunity, whereas Th2 cells provide humoral immunity.

### C) Preventive and therapeutic vaccines

Preventive: active vaccination/passive immunization of people in high risk groups, before infection

Therapeutic: passive vaccination of the already sick.

Active vaccination to remove nasal carriage

Specific example for an application

Elimination of MRSA carriage and prevention of colonization of the medical staff

Carriage rates of *S. aureus* in the nares of people outside of the hospitals varies from 10 to 40%. Hospital patients and personnel have higher carriage rates. The rates are especially high in patients undergoing hemodialysis and in diabetics, drug addicts and patients with a variety of dermatologic conditions. Patients at highest risk for MRSA infection are those in large tertiary-care hospitals, particularly the elderly and immunocompromised, those

in intensive care units, burn patients, those with surgical wounds, and patients with intravenous catheters.

The ELISA data strongly suggest that there is a pronounced IgA response to *S. aureus*, which is not obvious or known from the literature. Since the predominant mucosal immune response is the production of IgA with neutralizing activity, it is clear that the staphylococcal epitopes and antigens identified with the highly pure IgA preparations lead to an efficient mucosal vaccine.

- Clear indication: Everybody's threat in the departments where they perform operation (esp. orthopedics, traumatology, gen. surgery)
- Well-defined population for vaccination (doctors and nurses)
- Health care workers identified as intranasal carriers of an epidemic strain of *S. aureus* are currently treated with mupirocin and rifampicin until they eliminate the bacteria. Sometimes it is not effective, and takes time.
- Available animal model: There are mice models for intranasal carriage.

**Table 1: ELISA titers of séta from non-infected individuals against multiple staphylococcal proteins.**

[illegible]

Sera ID#	BHI	LTA	PG	CKA	DI+D3	FnBPA	sdrE	sdrC	EBP	Enolase	LP309	LP342	coagul	Fib	SrdA	CMB	Map-w
22	lysate																
23	4,5,6...			5	3	6	2	7	4	6,7	7		6,7		2	2	
24							4		6								8,9
25			5														
26	8													7			
27				5				8			4	4,5	4,5		5		
28																	
29										1							
30																	
31					1	1							1				
32			4														
33			8	4		4	5										
34					7,8					2	2	1	6,7	6	1		
35	4,5,6...	8	2,3						5		3	3				3	4
36		3															
37				7	7,8												
38				8						3,4							
39																	
40		7	6,7			3						4,5				8,9	

**Table I. ELISA titers of sera from non-infected individuals against multiple staphylococcal proteins.**

Anti-staphylococcal antibody levels were measured individually by standard ELISA with total lysate prepared from *S. aureus* grown in BHI medium (BHI), lipoteichoic acid (LTA), peptidoglycan (PG), 13 recombinant proteins, representing cell surface and secreted proteins, such as clumping factor A and B (ClfA, ClfB), Fibronectin-binding protein (FnBPA), SD-repeat proteins (sdrC, sdrE), MHC Class II analogous protein (map-w), Elastin-binding protein (EBP), enolase (reported to be cell surface located and immunogenic), iron transport lipoproteins (LP309, LP342), sortase (srtA), coagulase (coa), extracellular fibrinogen-binding protein (fib). Two short synthetic peptides representing 2 of the five immunodominant D repeat domains from FnBPA was also included (DI+D3) as antigens. The individual sera were ranked based on the IgG titer, and obtained a score from 1-9. Score 1 labels the highest titer serum and score 8 or 9 labels the sera which were 8<sup>th</sup> or 9<sup>th</sup> among all the sera tested for the given antigen. It resulted in the analyses of the top 20 percentile of sera (8-9/40). The five "best sera" meaning the most hyper reactive in terms of anti-staphylococcal antibodies were selected based on the number of scores 1-8. \*\*\*\* means that the antibody reactivity against the particular antigen was exceptionally high (>2x ELISA units relative to the 2<sup>nd</sup> most reactive serum).

**Table 2a: Immunogenic proteins identified by bacterial surface and ribosome display: *S. aureus***

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamB with IC sera 1 (471); H, LSA250/1 library in fhuA with patient sera 1 (IgA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). \*, identified 18 times of 33 screened; was therefore eliminated from screen C. \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990); #, identical sequence present twice in ORF; ##, clone not in database (not sequence by



TIGR).

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Pro)
SaA0003	ORF2963P	repC	5-20, 37-44, 52-59, 87-94, 116-132	C:3	aa 112-189	C:GSBYM94(112-189):26/30	171, 172
SaA0003	ORF2967P	repC	7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363	C:18	aa 9-42 aa 158-174	C:GSBYH53(9-42):1/1	150, 158
0093	ORF1879	SdrC	23-51, 75-80, 90-99, 101-107, 151-157, 173-180, 186-205, 215-226, 239-263, 269-274, 284-304, 317-323, 329-336, 340-347, 360-366, 372-379, 391-397, 399-406, 413-425, 430-436, 444-455, 499-505, 520-529, 553-558, 586-592, 600-617, 631-639, 664-678, 695-701, 891-903, 906-912, 926-940	A:1, D:5, C:1, F:6, G:2	aa 98-182 aa 684-764 aa 836-870	A:GSBXL70(98-182):9/30 D:n.d. C:GSBYH73(815-870):3/16	34, 86
0095	ORF1881	SdrE	25-45, 72-77, 147-155, 198-211, 217-223, 232-238, 246-261, 266-278, 281-294, 299-304, 332-340, 353-360, 367-380, 384-396, 404-409, 418-429, 434-440, 448-460, 465-476, 493-509, 517-523, 531-540, 543-555, 561-566, 576-582, 584-591, 603-617, 633-643, 647-652, 668-674, 677-683, 696-704, 716-728, 744-752, 755-761, 789-796, 809-815, 826-840, 854-862, 887-903, 918-924, 1110-1116, 1125-1131, 1145-1159	C:12, E:2	aa 147-192	C:GSBYH3(147-192):2/14 E:GSBZA27(144-162):23/41	145, 153
0123	ORF1909	unknown	9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251	B:3, E:7, G:1	aa 168-181	B:GSBXP80(168-181):5/27 E:GSBZC17(168-181):25/41	35, 87
0160	ORF1941	unknown	4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244, 246-268, 276-284, 296-329	A:1	aa 112-188	A:GSBXO07(112-188):5/30	36, 88
0222	ORF1988	homology with ORF1	4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-173, 178-184, 218-228, 233-238, 255-262	A:52, C:18*, H:19	aa 45-105 aa 103-166 aa 66-153	A:GSBXM63(65-95):1/1 A:GSBXM82(103-166):14/29 A:GSBXC44-bmd3(65-153):47/51	37, 89
0308	ORF2077	Complement, unknown	13-27, 42-63, 107-191, 198-215, 218-225, 233-250	A:6, B:2, C:47, E:35	complement bp 474-367	A:GSBXX03(bp473-367):28/69 B:GSBXD29(bp465-431):10/27	38, 90

<i>S. aureus</i> antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of se- lected clones per ORF and screen	Location of identified immuno- genic region	Serum reactivity with relevant re- gion (positive/total)	Seq ID no: (DNA +Prot)
0317	ORF2088	preprotein translo- case secA subunit	16-29, 64-77, 87-93, 95-101, 127- 143, 150-161, 204-221, 225-230, 236-249, 263-269, 281-309, 311- 325, 337-343, 411-418, 421-432, 435-448, 461-467, 474-480, 483- 489, 508-516, 542-550, 580-589, 602-611, 630-636, 658-672, 688- 705, 717-723, 738-746, 775-786, 800-805, 812-821, 828-834	A:1	aa 1-19	A:GSBXP37(1- 19):6/29	39, 91
0337	ORF2110	Hypothetical pro- tein	26-33, 95-123, 164-176, 189-199	D:12	aa 8-48	D.n.d.	40, 92
0358	ORF2132	Clumping factor A	8-35, 41-48, 59-66, 87-93, 139-144, 156-163, 198-209, 215-229, 236- 244, 246-273, 276-283, 285-326, 328-342, 349-355, 362-370, 372- 384, 396-402, 405-415, 423-428, 432-452, 458-465, 471-477, 484- 494, 502-515, 540-547, 554-559, 869-875, 893-898, 907-924	C:1, D:2, E:1	aa 706-809	D.n.d.	41, 93
0360	ORF2135 Empbp	extracellular matrix and plasma binding protein	7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159, 165- 172, 177-230, 234-240, 258-278, 295-319	A:46, B:21, C:11, E:2, F:18, G:7, H:12	aa 22-56 aa 23-99 aa 97-115 aa 233-250 aa 245-265	A:GSBXX24(23- 55):1/1 B:GSBXXB43(39- 54):58/71 A:GSBXX02- bmd1(22-99):59/59 B:GSBXXD82- bdb19(97-115):1/1 F:SALAL03(233- 250):15/41	42, 94
0453	ORF2227	comA operon protein 2	17-25, 27-55, 84-90, 95-101, 115- 121	C:3	aa 55-101	C:GSBYG07(55- 101):1/1	146, 154
0569	ORF1640	V8 protease	5-32, 66-72, 87-98, 104-112, 116- 124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312- 331	A:1, F:1	aa 174-249	A:GSBXX51(174- 249):11/30	32, 84

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
0576	ORF1633 Autolysin	autolysin, adhesion	4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242	A:21, B:46, C:55, E:5, F:85, H:19	aa 6-66 aa 65-124 aa 579-592 aa 590-604	A:GSBXN93(6-66):5/16 C:GSBYH05(45-144):7/8 A:GSBXX66-bmd18(65-124):16/30 B:GSBXXB89(108-123):1/1 B:GSBXXB02(590-603):39/71 F:SALAM15(579-592):25/41	31, 83
0657	ORF unknown	LPXTGV1 protein	9-33, 56-62, 75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 541-549, 563-569, 578-584, 624-641	A:2, B:27, F:15	aa 527-544	B:GSBXXE07-bdb1(527-542):1/71 F:SALAX70(526-544):11/41	1, 142
0749	ORF1462	Carbamoyl-phosphate synthase	8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037	C:2	aa 630-700	C:GSBYK17(630-700):5/9	144, 152
944	ORF1414	YnfX	6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837	D:4	aa 483-511	D:n.d.	30, 82
1050	ORF1307	unknown	49-72, 76-83, 95-105, 135-145, 148-164, 183-205	A:1, H:45	aa 57-128	A:GSBXXM26(57-128):7/30	28, 80

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
1209	ORF3006	hemN homolog	12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172, 190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293, 299-306, 340-346, 354-366	B:7, F:8	aa 167-181	B:GSBXB76(167-179):25/71 F:SALBC54(169-183):18/41	54, 106
1344	ORF0212	NifS protein homolog	8-16, 22-35, 49-58, 70-77, 101-121, 123-132, 147-161, 163-192, 203-209, 216-234, 238-249, 268-274, 280-293, 298-318, 328-333, 339-345, 355-361, 372-381	A:11	aa 34-94	A:GSBXC59-bmd21(34-94):6/29	5, 141
1356	ORF0197	Hypothetical protease	28-55, 82-100, 105-111, 125-131, 137-143	D:12	aa 1-49	D:n.d.	4, 57
1361	ORF0190	LPXTGV protein	5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889	A:1, B:23, E:3, F:31	aa 37-49 aa 63-77 aa 274-334	B:GSBXC81(37-49):1/1 B:GSBXC45-bdb4(62-77):12/70 A:GSBXL77(274-334):3/30 F:SALAP81(62-77):10/41	3, 56
1371	ORF0175	YnfT, conserved hypothetical protein	37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269	C:3, E:2, G:1	aa 624-684 aa 891-905	C:GSBYG95(624-684):7/22 E:GSBZB45(891-905):10/41	143, 151
1491	ORF0053	Cmp binding factor I homolog	12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274	A:7, C:2, E:7, F:4	aa 39-94	A:GSBXM13(39-94):10/29 F:SALAY30(39-53):4/41	2, 55
1616	ORF1180	Henkocidin F homolog	16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284	A:10	aa 158-220	A:GSBXC06(158-220):8/29	27, 79
1618	ORF1178	LukM homolog	5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-278, 305-313, 321-327, 334-341	A:13, B:3, C:36, E:4, F:12, G:2, H:10	aa 31-61 aa 58-74	A:GSBXC60(31-61):20/29 B:GSBXC48(58-74):49/71 F:SALAY41(58-74):30/41	26, 78

S. aureus antigenic protein	OM ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immuno-ORF and genic region	Serum reactivity with relevant region (positive/total)	Seq ID nos: (DNA +Prot)
1632	ORF1163	SdrH homolog	7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-411	B:6, E:11, F:34	aa 105-119 aa 126-143 aa 163-186	B:GSBXC63(168-186):39/71 F:SALAP07(105-119):11/41	25, 77
1763	ORF1024	unknown	5-32, 35-48, 55-76	C:3	complement lp 237-170	C:GSBYB30(98aa):1	24, 76
1845	ORF0942	Hyaluronate lyase	10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-383, 396-407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-731, 762-768, 800-805	D:5, F:2	aa208-224 aa 672-727	D:n.d.	23, 75
1951	ORF0831	homology with ORF1	5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-264	A:223, B:56, C:167, E:43, F:100, G:13, H:102	aa 137-237 aa 250-267	B:GSBXC07(180-190):1/1 A:GSBXC29(177-195):15/29 B:GSBXC43(250-267):10/71 F:SALAM13(178-191):20/41	22, 74
1955	ORF0826	homology with ORF1	4-9, 15-26, 65-76, 108-115, 119-128, 144-153	A:1, B:3, E:1, F:8	aa 38-52 aa 65-114	A:GSBXR10(66-114):5/30 F:SALAM67(37-52):16/41	21, 73
2031	ORF0749	unknown	10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126, 128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231, 233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345	B:2, F:2	aa 59-74	B:GSBXC01(59-71):11/26	20, 72
2086	ORF0691 Sbi	IgG binding protein	6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415	A:1, B:8, E:24, F:9, G:137	aa 208-287 aa 261-276 aa 286-314	A:GSBXS55(208-287):38/46 B:GSBXC34(209-314):11/71 F:SALAX32(261-276):21/41	19, 71

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
2180	ORF0594	LPXTGIV protein	11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112	A:3, C:3, E:6, F:2, H:6	aa 493-587 aa 633-715 aa 704-760 <sup>a</sup> aa 760-832 (aa 832-887) <sup>f</sup>	A:GSBX861(493-555):1/1 A:GSBXL64(496-585):1/1 A:GSBX892(760-841):1/1 A:bmd4(704-760):16/30 <sup>g</sup> (A:bmd4(830-885):16/30) <sup>f</sup> F:SALBC43(519-533):4/41	18, 70
2184	ORF0590	FabpB	5-12, 18-37, 104-124, 139-145, 154-166, 175-181, 185-190, 193-199, 203-209, 235-244, 268-274, 278-292, 299-307, 309-320, 356-364, 375-384, 390-404, 430-440, 450-461, 488-495, 505-511, 527-535, 551-556, 567-573, 587-593, 599-609, 624-631, 651-656, 665-671, 714-726, 754-766, 799-804, 818-825, 827-833, 841-847, 855-861, 876-893, 895-903, 927-940	A:2, C:4, G:9	aa 701-777 aa 783-822	A:GSBXM62(702-777):28/28 A:GSBXR22(783-855):1/1	17, 69
2186	ORF0588	Fabp	8-29, 96-105, 114-121, 123-129, 141-147, 151-165, 171-183, 198-206, 222-232, 253-265, 267-277, 294-300, 302-312, 332-338, 362-368, 377-383, 396-402, 410-416, 451-459, 473-489, 497-503, 537-543, 549-559, 581-600, 623-629, 643-649, 655-666, 680-687, 694-700, 707-712, 721-727, 770-782, 810-822, 874-881, 883-889, 897-903, 911-917, 925-931, 933-939, 946-963, 965-973, 997-1010	A:4, C:4, D:5, E:2	aa 710-787 aa 855-975 aa 916-983	C:GSBYN05(710-787):19/25 D:n.d. A:GSBXP01(916-983):17/30	16, 68
2224	ORF0551	unknown	49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-167, 169-175, 177-188, 196-224, 230-243, 246-252	B:2	aa 34-46	B:GSBXR89(34-46):1/1	15, 67

<i>S. aureus</i> antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of se- lected clones per ORF and screen	Location of identified immuno- genic region	Serum reactivity with relevant re- gion (positive/total)	Seq ID no: (DNA +Prot)
2254	ORF0519	Conserved hypo- thetical protein	14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190, 193- 214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355, 357- 362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522, 528- 539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632, 651- 667, 673-689, 694-706, 712-739, 756-790	D:3	aa 403-462	D.n.d.	14, 66
2264	ORF0509	ORF1; homology with putative se- creted antigen precursor from <i>S.</i> <i>epidermidis</i>	5-31, 47-55, 99-104, 133-139, 156- 172, 214-224, 240-247	A:131, B:51, C:13, E:43, F:78, G:2, H:17	aa 7-87 aa 133-242	A:GSBX22(145- 196):1/1 A:GSBXX05- bnd16(178- 218):6/29 B:GSBXXE24- bdb20(167-178):1/1 F:SALAQ91(173- 184):15/41	13, 65
2268	ORF0503	IsaA, possibly ad- hesion/ aggrega- tion	7-19, 26-45, 60-68, 94-100, 111- 119, 126-137, 143-148, 169-181, 217-228	A:7, B:65, C:3, E:2, F:53	aa 67-116 aa 98-184 aa 182-225	A:GSBXX88(67- 116):1/1 A:GSBXN19(98- 184):22/29 A:GSBXN32(182- 225):34/71 B:GSBXXB71(196- 209):16/29 F:SALAL22(196- 210):16/41	12, 64
2344	ORF0426	Clumping factor B	4-10, 17-45, 120-127, 135-141, 168-180, 187-208, 216-224, 244- 254, 256-264, 290-312, 322-330, 356-366, 374-384, 391-414, 421- 428, 430-437, 442-449, 455-461, 464-479, 483-492, 501-512, 548- 555, 862-868, 871-876, 891-904	D:9, E:1, F:3, H:4	aa 706-762 aa 810-852	D.n.d.	11, 63
2351	ORF0418	aureolysin	10-29, 46-56, 63-74, 83-105, 107- 114, 138-145, 170-184, 186-193, 216-221, 242-248, 277-289, 303- 311, 346-360, 379-389, 422-428, 446-453, 459-469, 479-489, 496- 501	A:1, C:6	aa 83-156	A:GSBX046(83- 156):14/29	10, 62

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
2359	ORF0409	ISSP, immunogenic secreted protein precursor, putative	4-29, 92-99, 119-130, 228-236, 264-269, 271-280, 311-317, 321-331, 341-353, 357-363, 366-372, 377-384, 390-396, 409-415, 440-448, 458-470, 504-520, 544-563, 568-581, 584-592, 594-603, 610-616	B:4, F:11	aa 168-184 aa 206-220 aa 297-309	B:GSBXD01(168-184):1/1 B:GSBXD62(205-220):1/1 B:GSBXC17(297-309):6/27 F:SALAL04(205-220):9/41	9, 61
2378	ORF0398	StpA	18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1003, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205, 2232-2243	C:1, D:7, F:4, H:11	aa 198-258 aa 646-727 aa 846-857 aa 2104-2206	C:GSBYI73(646-727):2/9 F:SALAO33(846-857):10/41 D:n.d.	8, 60
2466	ORF0302	YycH protein	16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449	D:14	aa 401-494	D:n.d.	7, 59
2470	ORF0299	Conserved hypothetical protein	4-9, 17-41, 50-56, 63-69, 82-87, 108-115, 145-151, 207-214, 244-249, 284-290, 308-316, 323-338, 348-358, 361-378, 410-419, 445-451, 512-522, 527-533, 540-546, 553-558, 561-575, 601-608, 632-644, 656-667, 701-713, 727-733, 766-780	C:3	aa 414-455	C:GSBYH60(414-455):28/31	169, 170



S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID nos (DNA +Prot)
2498	ORF0267	Conserved hypothetical protein	33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707	D:12	aa 358-411 aa 588-606	D:17/21	6, 58
2548	ORF2711	IgG binding protein A	4-16, 24-37, 65-73, 85-91, 95-102, 125-132, 146-152, 156-163, 184-190, 204-210, 214-221, 242-252, 262-268, 272-279, 300-311, 320-337, 433-440, 472-480, 505-523	A:55, B:54, C:35, F:59, G:56, H:38	aa 1-48 aa 47-143 aa 219-285 aa 345-424	A:GSBXK68(1-73):21/30 A:GSBXK41(47-135):1/1 A:GSBXN38(219-285):19/30 A:GSBXL11(322-375):10/30 B:GSBXK22(406-418):37/71 F:SALAM17(406-418):29/41	53, 105
2577	ORF2683	Hypothetical protein	4-21, 49-56, 65-74, 95-112, 202-208, 214-235	C:6	aa 99-171	C:GSBYL56(99-171):1/1	149, 157
2642	ORF2614	unknown	34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-207, 210-221, 234-249, 252-271	C:1, E:1	aa 5-48	C:bba3(5-48):25/30 <sup>9</sup>	52, 104
2664	ORF2593	Conserved hypothetical protein	7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-272	D:35	aa 77-128	D:n.d.	51, 103
2670	ORF2588	Hexose transporter	18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218, 254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414, 431-455	D:16	aa 328-394	D:n.d.	50, 102
2680	ORF2577	Coagulase	4-18, 25-31, 35-40, 53-69, 89-102, 147-154, 159-165, 185-202, 215-223, 284-289, 315-322, 350-363, 384-392, 447-453, 473-479, 517-523, 544-550, 572-577, 598-604, 617-623	C:26, G:4, H:8	aa 438-516 aa 505-570 aa 569-619	C:GSBYH16(438-516):3/5 C:GSBYG24(505-570):1/7 C:GSBYL82(569-619):2/7	148, 156
2740	ORF2515	Hypothetical protein	5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308	D:4	aa 1-59	D:n.d.	49, 101
2746	ORF2507	homology with ORF1	5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-297	A:1, H:13	aa 63-126	A:GSBXO40(66-123):8/29	48, 100
2797	ORF2470	unknown	10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458	B:3, E:2, F:13, H:3	aa 183-200 aa 349-363	B:GSBXE85(183-200):11/27 F:SALAQ47(183-200):8/41	47, 99

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
2798	ORF2469	Lipase (gch)	12-35, 93-99, 166-179, 217-227, 239-248, 269-276, 288-294, 296-320, 322-327, 334-339, 344-356, 362-371, 375-384, 404-411, 433-438, 443-448, 455-464, 480-486, 497-503, 516-525, 535-541, 561-570, 579-585, 603-622, 633-641	A:41, B:42, C:3, F:35, G:1, H:11	aa 48-136 aa 128-172 aa 201-258	C:GSBYG01(48-136):2/6 A:GSBXM31-bmd12(128-188):11/30 B:GSBXE16(165-177):10/30 A:GSBXN20(201-258):8/30 F:SALAW05(165-177):13/41	46, 98
2815	ORF2451	Conserved hypothetical protein	5-32, 34-49	D:21	aa 1-43	D.n.d.	45, 97
2914	ORF2351	metC	39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-601, 603-620, 627-633, 660-665, 674-687, 698-718, 726-739	A:1, C:14, F:2	aa 386-402	A:GSBXM18(386-402):17/29	44, 96
2960	ORF2298	putative Exotoxin	13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220, 232-241, 245-254, 262-271, 280-285, 295-301, 303-310, 319-324, 332-339	C:101, E:2, H:58	aa 1-85 aa 54-121 aa 103-195	C:GSBYG32(1-85):6/7 C:GSBYG61-bhc2(54-121):26/30 C:GSBYN80(103-195):13/17	43, 95
2963	ORF2295	putative Exotoxin	13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290	C:3, E:3, G:1	aa 22-100	C:GSBYJ58(22-100):9/15	147, 155
3002	ORF1704	homology with ORF1	4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331	A:2, C:1, H:4	aa 21-118	A:GSBXL06(21-118):50/52	33, 85

<i>S. aureus</i> antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of se- lected clones per ORF and screen	Location of identified immuno- genic region	Serum reactivity with relevant re- gion (positive/total)	Seq ID no: (DNA +Prot)
3200	ORF1331	putative extracel- lular matrix bind- ing protein	6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179- 185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368- 381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529- 535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718- 725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916- 921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979	A:11, B:11, C:36	aa 5-134	A:GSBX107(5- 134):6/28	29, 81

**Table 2b: Additional immunogenic proteins identified by bacterial surface and ribosome display: *S. aureus***

Bacterial surface display: A, LSA250/1 library in fhuA with patient sera 1 (655); B, LSA50/6 library in lamB with patient sera 1 (484); C, LSA250/1 library in fhuA with IC sera 1 (571); E, LSA50/6 library in lamB with IC sera 2 (454); F, LSA50/6 library in lamB with patient sera P1 (1105); G, LSA50/6 library in lamB with IC sera 1 (471); H, LSA250/1 library in fhuA with patient sera 1 (IgA, 708). Ribosome display: D, LSA250/1 library with IC sera (1686). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar, 1990). ORF, open reading frame; CRF, reading frame on complementary strand; ARF, alternative reading frame.

S. aureus antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ARF0280	Putative protein	7-14	F:6	aa 25-43	SALAM59(25-43): 1/1	401, 402
CRF0145	Putative protein	18-28, 31-37, 40-47, 51-83, 86-126	F:5	aa 81-90	SALAZ40(81-90): 2/12	403, 404
CRF0250	Putative protein	4-24, 26-46, 49-86	G:8	aa 60-76	SALAJ87(60-76): n.d.	365, 378
CRF0308	Putative protein	40-46	A:6, B:2, C:47, E:35	aa 5-38	A:GSBXK03(7-36):28/69 B:GSBXD29(10-20):10/27	391, 392
CRF0337	Unknown	4-17	D:3	aa 1-20	D.n.d.	469; 486
CRF0497	Putative protein	4-28, 31-53, 58-64	B:13, F:5	aa 18-34	GSBXF31(19-34): 1/7	366, 379
CRF0538	Unknown	4-20	D: 7	aa 1-11	D.n.d.	470; 487
CRF0750	Putative protein	4-11, 18-24, 35-40	G:44	aa 25-39	SALAG92(26-39): n.d.	367, 380
CRF1145	Unknown	4-57	D:28	aa 16-32	D.n.d.	464; 481
CRF1247	Putative protein	4-25, 27-56	F:6	aa 36-46	SALAR23(36-46): n.d.	368, 381
CRF1256	Putative protein	19-25, 38-47, 55-74, 77-87	G:5	aa 54-67	SALAG65(54-67): n.d.	369, 382
CRF1356	Unknown	8-15; 18-24; 27-38	D: 5	aa 5-33	D.n.d.	471; 488
CRF1763	Putative protein	4-9, 23-41, 43-58, 71-85	C:3	aa 1-22	C:GSBVI30(1-22):1/1	407, 408
CRF1783	Unknown	8-161	D: 5	aa 76-127	D.n.d.	468; 482
CRF1845	Unknown	4-28; 30-36	D: 272	aa 1-17	D.n.d.	472; 489
CRF1861	Unknown	6-11, 13-34; 36-50	D:8	aa 4-27	D.n.d.	466; 483
CRF1928	Putative protein	4-9, 17-30	F:9	aa 13-22	SALAR41(13-22): n.d.	370, 383
CRF2004	Putative protein	18-38	F:13	aa 16-32	SALAM75(16-32): n.d.	371, 384
CRF2155	Putative protein	4-15, 30-58	F:9	aa 54-66	SALAQ54(54-66):1/12	372, 385
CRF2180	Putative protein	4-61, 65-72, 79-95, 97-106	B:13	aa 86-99	GSBZE08(86-99): n.d.	373, 386
CRF2207	Unknown	4-13	D: 3	aa 17-39	D.n.d.	473; 490
CRF2305	Putative protein	4-9, 22-33, 44-60	C:5	aa 80-116	GSBYL75(80-116): n.d.	374, 387
CRF2341	Putative protein	4-23, 30-44, 49-70	F:8	aa 46-55	SALAW31(46-55): n.d.	375, 388
CRF2349	Putative protein	4-32, 39-46, 62-69, 77-83	B:10, F:4	aa 46-67	GSBXC92(52-67):2/11	376, 389

S. aureus antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
CRF2356	Unknown	4-18	D: 3	aa 3-18	D.n.d.	475; 492
CRF2452	Unknown	4-31	D: 9	aa 7-21	D.n.d.	476; 493
CRF2498	Putative protein	4-29, 31-41	G: 8	aa 2-15	SALAF30(3-15): n.d.	377, 390
CRF2553	Unknown	4-35; 37-42	D: 4	aa 1-20	D.n.d.	474; 491
CRF2578	Unknown	5-25; 30-39	D: 11	aa 9-30	D.n.d.	467; 484
CRF2664	Unknown	11-21	D: 17	aa 1-14	D.n.d.	477; 494
CRF2729	Putative protein	10-41, 50-57	F: 3	aa 40-56	SALAQ25(40-56): 1/1	405, 406
CRF2863/1	Unknown	4-43	D: 78	aa 17-40	D.n.d.	478; 495
CRF2863/2	Unknown	4-46	D: 78	aa 44-49	D.n.d.	479; 496
CRFA002	Unknown	17-39; 52-59	D: 3	aa 38-55	D.n.d.	463; 480
CRFN1	Unknown	5-20; 37-44; 52-59; 87-94; 116-132	D: 4	aa 94-116	D.n.d.	468; 485
ORF0188	UDP-N-acetyl-D-mannosamine transferase, putative	11-18, 43-56, 58-97, 100-118, 120-148, 152-171, 195-203, 207-214, 220-227, 233-244	B: 4, F: 29	aa 197-210	SALAM14(198-209): n.d.	397, 398
ORF0254	Multidrug efflux transporter	4-33, 35-56, 66-99, 109-124, 136-144, 151-180, 188-198, 201-236, 238-244, 250-260, 265-290, 294-306, 342-377	D: 3	aa 155-175	D. n.d.	297, 325
ORF0307	Conserved hypothetical protein	4-23, 25-67, 76-107, 109-148	D: 3	aa 9-44	D. n.d.	298, 326
ORF0452	Conserved hypothetical protein	4-35, 41-47, 55-75, 77-89, 98-113, 116-140, 144-179, 194-215, 232-254, 260-273, 280-288, 290-302, 315-323, 330-369, 372-385, 413-432	D: 5	aa 105-122	D. n.d.	299, 327
ORF0456	Na+/H+/Antiporter	4-81	D: 66	aa 1-21	D. n.d.	300, 328
ORF0556	Iron(III)dicitrate binding protein	5-23, 50-74, 92-99, 107-122, 126-142, 152-159, 172-179, 188-196, 211-218, 271-282	D: 10	aa 1-18	D. n.d.	301, 329
ORF0629	Hypothetical Protein	9-44, 63-69, 75-82, 86-106, 108-146, 153-161, 166-178, 185-192, 233-239, 258-266, 302-307	D: 313	aa 13-37	D. n.d.	302, 330

S. aureus antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF0637	GTP-binding protein TypA	10-19, 22-32, 95-105, 112-119, 121-133, 140-154, 162-174, 186-200, 207-224, 238-247, 254-266, 274-280, 288-294, 296-305, 343-351, 358-364, 366-373, 382-393, 403-413, 415-422, 440-447, 499-507, 565-575, 578-588	F:3	aa 107-119	F.SALAX70(107-119):10/41	393, 395
ORF0713	Conserved hypothetical transmembrane protein, putative	22-51, 53-71, 80-85, 93-99, 105-112, 123-146, 151-157, 163-222, 226-236, 247-270, 290-296, 301-324, 330-348, 362-382, 384-391, 396-461, 463-482, 490-515	D: 3	aa 487 - 513	D: n.d.	303, 331
ORF0788	Cell division protein	104-111, 158-171, 186-197, 204-209, 230-247, 253-259, 269-277, 290-314, 330-340, 347-367, 378-388	D: 4	aa 152 - 178	D: n.d.	304, 332
ORF0797	Conserved hypothetical protein	11-40, 56-75, 83-102, 112-117, 129-147, 154-168, 174-191, 196-270, 280-344, 354-377, 380-429, 431-450, 458-483, 502-520, 525-532, 595-602, 662-669, 675-686, 696-702, 704-711, 720-735, 739-748, 750-756, 770-779, 793-800, 813-822, 834-862	D:12	aa 196-218	D: n.d.	305, 333
ORF0836	Cell Division Protein	34-91, 100-119, 126-143, 147-185, 187-197, 319-335, 349-355, 363-395, 397-412, 414-422, 424-440, 458-465, 467-475, 480-505, 507-529, 531-542, 548-553, 577-589, 614-632, 640-649, 685-704, 730-741, 744-751, 780-786	D:5	aa 26 - 56	D: n.d.	306, 334
ORF1318	Amino acid permease	11-21, 25-32, 34-54, 81-88, 93-99, 105-117, 122-145, 148-174, 187-193, 203-218, 226-260, 265-298, 306-318, 325-381, 393-399, 402-421, 426-448	D: 8	aa127 - 152	D: n.d.	307, 335
ORF1321	Pyruvate kinase	4-11, 50-67, 89-95, 103-109, 112-135, 139-147, 158-170, 185-204, 213-219, 229-242, 248-277, 294-300, 316-323, 330-335, 339-379, 390-402, 408-422, 431-439, 446-457, 469-474, 484-500, 506-513, 517-530, 538-546, 548-561	E:6	aa 420-432	E.OSBZL16(420-432):5/41	197, 216

<i>S. aureus</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID as: (DNA +Prot)
ORF138 8	LPXTG cell wall anchor motif	11-31, 86-91, 103-111, 175-182, 205-212, 218-226, 242-247, 260-269, 279-288, 304-313, 329-334, 355-360, 378-387, 390-399, 407-435, 468-486, 510-516, 535-547, 574-581, 604-615, 635-646, 653-659, 689-696, 730-737, 802-812, 879-891, 893-906, 922-931, 954-964, 997-1009, 1031-1042, 1089-1096, 1107-1120, 1123-1130, 1149-1162, 1176-1184, 1192-1207, 1209-1215, 1253-1259, 1265-1275, 1282-1295, 1304-1310, 1345-1361, 1382-1388, 1394-1400, 1412-1430, 1457-1462, 1489-1507, 1509-1515, 1535-1540, 1571-1591, 1619-1626, 1635-1641, 1647-1655, 1695-1701, 1726-1748, 1750-1757, 1767-1783, 1802-1807, 1809-1822, 1844-1875, 1883-1889, 1922-1929, 1931-1936, 1951-1967, 1978-1989, 1999-2008, 2023-2042, 2056-2083, 2101-2136, 2161-2177	D: 3	aa 508 - 523	Dr: n.d.	308, 336
ORF140 2	3,4-dihydroxy-2-butanone-4-phosphate synthase	18-23, 32-37, 54-63, 65-74, 83-92, 107-114, 123-139, 144-155, 157-164, 191-198, 232-240, 247-272, 284-290, 295-301, 303-309, 311-321, 328-341, 367-376	E:3	aa 121-137	R:GSBZB68(121-137):7/41	198, 217
ORF147 3	hemolysin II* (LukD-Leukotoxin)	4-36, 39-47, 57-65, 75-82, 108-114, 119-126, 135-143, 189-195, 234-244, 250-257, 266-272, 311-316	F:1	aa 245-256	F:SALAP76(245-256):6/41	199, 218
ORF152 3	Iron uptake regulator	13-27, 29-44, 46-66, 68-81, 97-116, 138-145	D:3	aa 120-135	Dr: n.d.	309, 337
ORF170 7	inner membrane protein, 60 kDa	4-23, 57-77, 89-103, 119-125, 132-172, 179-197, 210-254, 256-265, 281-287	F:1	aa 104-118	F:SALBC82(104-118):7/41	200, 219
ORF175 4	amiB	5-10, 16-24, 62-69, 77-96, 100-115, 117-126, 137-156, 165-183, 202-211, 215-225, 229-241, 250-260, 267-273, 290-300, 302-308, 320-333, 336-342, 348-356, 375-382, 384-389	D: 3	aa 293 - 312	Dr: n.d.	310, 338

S. aureus antigenic protein	Potential function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF178 3	Mrp protein (mrpB)	5-29, 46-52, 70-76, 81-87, 155-170, 192-197, 206-213, 215-220, 225-231, 249-258, 273-279, 281-287, 300-306, 313-319, 323-332, 335-341, 344-351, 360-382, 407-431, 443-448, 459-468, 475-496, 513-520, 522-537, 543-550, 556-565, 567-573, 580-585, 593-615, 619-631, 633-642, 670-686, 688-698, 759-766, 768-782, 799-808, 842-848, 868-877, 879-917, 945-950, 979-988, 996-1002, 1025-1036, 1065-1084, 1101-1107, 1113-1119, 1125-1142, 1163-1169, 1183-1189, 1213-1219, 1289-1301, 1307-1315, 1331-1342, 1369-1378, 1385-1391, 1410-1419, 1421-1427, 1433-1447, 1468-1475, 1487-1494, 1518-1529, 1564-1570, 1592-1609, 1675-1681, 1686-1693, 1714-1725, 1740-1747, 1767-1774, 1793-1807, 1824-1841, 1920-1937, 1953-1958, 1972-1978, 1980-1986, 1997-2011, 2048-2066, 2161-2166, 2219-2224, 2252-2257, 2292-2298, 2375-2380, 2394-2399, 2435-2440, 2449-2468	F:2	aa 850-860	F:SALAQ36(850-860):8/41	201, 220
ORF184 8	Map-ND2C protein	4-27, 42-66, 70-76, 102-107, 113-118, 133-138	E:5	aa 75-90	E:OSBZB15(75-90):6/41	202, 221
ORF189 1	ribosomal protein L2 (rplB)	31-39, 48-54, 61-67, 75-83, 90-98, 103-119, 123-145, 160-167, 169-176, 182-193, 195-206, 267-273	F:4	aa 239-257	F:SALAV36(239-257):19/41	203, 222
ORF201 1	Potative drug transporter	5-27, 79-85, 105-110, 138-165, 183-202, 204-225, 233-259, 272-292, 298-320, 327-336, 338-345, 363-376, 383-398, 400-422, 425-470, 489-495, 506-518, 536-544, 549-554, 562-568, 584-598, 603-623	D:5	aa 205 - 224	D: n.d.	311, 339
ORF202 7	lactase permease, putative	10-33, 38-71, 73-103, 113-125, 132-147, 154-163, 170-216, 222-248, 250-269, 271-278, 287-335, 337-355, 360-374, 384-408, 425-442, 453-465, 468-476, 478-501, 508-529	E:2	aa 422-436	E:GSBZF58(422-436):6/41	204, 223
ORF208 7	Hemolysin II (putative)	8-27, 52-59, 73-80, 90-99, 104-110, 117-124, 131-140, 189-209, 217-232, 265-279, 287-293, 299-306	D: 3	aa 126 - 147	D: n.d.	312, 340



S. aureus antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF2090	preLukS	8-26, 75-82, 118-126, 136-142, 163-177, 182-189, 205-215, 221-236, 239-248, 268-274	F:2	aa 270-284	F:SALAQ77(270-284):23/41	205, 224
ORF2092	Hemolysin II (preLUK-F)	5-22, 30-47, 58-65, 75-81, 87-92, 99-105, 107-113, 119-126, 189-195, 217-223, 234-244, 250-257, 266-272	F:3	aa 238-253	F:SALAQ67(237-252):10/41	206, 225
ORF2107	Multidrug resistance protein (putative)	10-28, 30-43, 50-75, 80-113, 116-125, 136-167, 170-191, 197-245, 253-329, 345-367, 375-396	D: 9	aa 54 - 104	D: n.d.	313, 341
ORF2192	Transcriptional regulator GutR family, putative	20-31, 46-52, 55-69, 74-79, 89-97, 108-113, 120-128, 141-171, 188-214	D: 3	aa 15 - 35	D: n.d.	314, 342
ORF2205	Amino acid permease	25-79, 91-103, 105-127, 132-149, 158-175, 185-221, 231-249, 267-293, 307-329, 336-343, 346-359, 362-405, 415-442, 446-468	D: 53	aa 363 - 393	D: n.d.	315, 343
ORF2324	Citrate transporter	10-77, 85-96, 99-109, 111-138, 144-155, 167-176, 178-205, 225-238, 241-247, 258-280, 282-294, 304-309, 313-327, 333-383, 386-402, 405-422, 429-453	D: 7	aa 37 - 83	D: n.d.	316, 344
ORF2422	Anion transporter family protein	7-26, 28-34, 36-53, 55-73, 75-81, 87-100, 108-117, 121-138, 150-160, 175-181, 184-195, 202-215, 221-247, 265-271, 274-314, 324-337, 341-412, 414-423, 425-440, 447-462, 464-469	D: 16	aa 275 - 295	D: n.d.	317, 345
ORF2553	StrA	5-22, 54-78, 97-103, 113-123, 130-148, 166-171, 173-180, 192-201, 254-261, 266-272, 310-322	D:3	aa 1 - 22	D: n.d.	318, 346
ORF2555	ornithine cyclodeaminase	20-35, 37-50, 96-102, 109-120, 123-137, 141-150, 165-182, 206-224, 237-256, 267-273, 277-291, 300-305, 313-324	E:2	aa 32-48	R:GSBZB37(32-48):11/41	207, 226
ORF2558	Multidrug resistance efflux protein, putative	11-63, 79-129, 136-191, 209-231, 237-250, 254-276, 282-306, 311-345, 352-373, 376-397	D: 8	aa 84 - 100	D: n.d.	319, 347
ORF2610	Cap5M	4-30, 34-40, 79-85, 89-98, 104-118, 124-139, 148-160, 167-178	D: 13	aa 114 - 141	D: n.d.	320, 348
ORF2613	Cap5P (UDP-N-acetylglucosamine 2-epimerase)	4-9, 17-24, 32-38, 44-54, 68-82, 89-95, 101-120, 124-131, 136-142, 145-157, 174-181, 184-191, 196-204, 215-224, 228-236, 243-250, 259-266, 274-281, 293-301, 314-319, 325-331, 355-367, 373-378	B:3, F:11	aa 321-341	F:SALAU27(325-337):9/41	208, 227

Seq ID no: (DNA +Prot)	Serum reactivity with relevant region (positive/total)	Location of identified immuno- genic region	No. of se- lected clones per ORF and screen	predicted immunogenic aa**	Putative function (by homology)	Seq ID no: (DNA +Prot)
209, 228	F:SALBD82(1288-1303):9/41	aa 694-708 aa 790-800 aa 1288-1305	F:6	9-15, 28-36, 44-62, 69-88, 96-104, 111-136, 139-149, 177-186, 195-217, 224-236, 241-257, 260-278, 283-290, 292-373, 395-408, 411-443, 465-472, 475-496, 503-520, 552-559, 569-589, 593-599, 607-613, 615-636, 648-654, 659-687, 689-696, 721-733, 738-759, 783-789, 795-801, 811-823, 827-836, 839-851, 867-875, 877-883, 890-898, 900-908, 912-931, 937-951, 961-992, 994-1002, 1005-1011, 1016-1060, 1062-1074, 1088-1096, 1101-1123, 1137-1153, 1169-1192, 1210-1220, 1228-1239, 1242-1251, 1268-1275, 1299-1311, 1322-1330, 1338-1361, 1378-1384, 1393-1412, 1419-1425, 1439-1459, 1469-1482, 1489-1495, 1502-1519, 1527-1544, 1548-1555, 1600-1607, 1609-1617, 1624-1657, 1667-1691, 1705-1723, 1727-1742, 1749-1770, 1773-1787, 1804-1813, 1829-1837, 1846-1852, 1854-1864, 1869-1879, 1881-1896, 1900-1909, 1922-1927, 1929-1935, 1942-1962, 1972-2005, 2009-2029, 2031-2038, 2055-2076, 2101-2114, 2117-2124, 2147-2178, 2188-2202, 2209-2217, 2224-2230, 2255-2266, 2271-2280, 2282-2302, 2307-2316, 2319-2324, 2379-2387	Hypothetical protein	ORF2628
210, 229	F:SALAW60(106-125):3/41	aa 106-159	F:4	8-15, 24-30, 49-68, 80-93, 102-107, 126-147, 149-168, 170-180, 185-193, 241-305, 307-339, 346-355, 358-372, 382-390, 392-415, 418-425, 427-433, 435-444, 450-472	PTS system, sucrose-specific IIIBC component	ORF2644
321, 349	D: n.d.	aa 182-209	D: 5	5-61, 72-84, 87-99, 104-109, 124-145, 158-170, 180-188, 190-216, 223-264, 270-275, 296-336, 355-372	Oligopeptide ABC transporter, putative	ORF2654
211, 230	F:SALBC05(306-323):2/41	aa 306-323	F:1	4-21, 71-79, 99-105, 110-121, 143-161, 199-205, 219-235, 244-258, 265-270, 285-291, 300-308, 310-318, 322-328, 346-351, 355-361, 409-416	maltose ABC transporter, putative	ORF2662

S. aureus antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF2710	sorbitol dehydrogenase	4-12, 19-40, 61-111, 117-138, 140-153, 161-180, 182-207, 226-235, 237-249, 253-264, 267-274, 277-292, 311-323	B:2, F:4	aa 244-257	F:SALAX93(249-256):6/41	212, 231
ORF2742	Hypothetical protein	4-41, 49-56, 61-67, 75-82, 88-104, 114-125, 129-145, 151-165, 171-178, 187-221, 224-230, 238-250, 252-275, 277-304, 306-385	D: 188, E:4	aa 303 - 323	D: n.d.	322, 350
ORF2780	brnQ	4-29, 41-63, 74-95, 97-103, 107-189, 193-209, 220-248, 260-270, 273-299, 301-326, 328-355, 366-397, 399-428	D: 3	aa 26 - 40	D: n.d.	323, 351
ORF2806	Phage related protein	10-17, 23-29, 31-37, 54-59, 74-81, 102-115, 127-137, 145-152, 158-165, 178-186, 188-196, 203-210, 221-227, 232-237	F:3	aa 104-116	F:SALBC34:1/1	213, 232
ORF2900	Conserved hypothetical protein	4-27, 34-43, 62-73, 81-90, 103-116, 125-136, 180-205, 213-218, 227-235, 238-243, 251-259, 261-269, 275-280, 284-294, 297-308, 312-342, 355-380, 394-408, 433-458, 470-510, 514-536, 542-567	D: 24	aa 360 - 376	D: n.d.	324, 352
ORF2931	conserved hypothetical protein	4-19, 43-54, 56-62, 84-90, 96-102, 127-135, 157-164, 181-187	E:6	aa 22-37	E:GSBZA13(22-37):7/41	214, 233
ORF2958	Exotoxin 2	7-19, 26-39, 44-53, 58-69, 82-88, 91-107, 129-141, 149-155, 165-178, 188-194	F:1	aa 154-168	F:SALBB59(154-168):4/41	215, 234
ORF2970	Surface protein, putative	9-23, 38-43, 55-60, 69-78, 93-101, 103-112, 132-148, 187-195, 201-208, 216-229, 300-312, 327-352, 364-369, 374-383, 390-396, 402-410, 419-426, 463-475, 482-491	H:5	aa 1-70	H:GSBYU66: n.d.	399, 400

**Table 2c: Immunogenic proteins identified by bacterial surface and ribosome display: *S. epidermidis*.**

Bacterial surface display: A, LSE150 library in *fluA* with patient sera 2 (957); B, LSE70 library in *lamB* with patient sera 2 (1420); C, LSE70 library in *lamB* with patient sera 1 (551). Ribosome display: D, LSE150 in pMAL4.31 with P2 (1235). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolaskar and Tongaonkar,

1990). ORF, open reading frame; ARF, alternative reading frame; CRF, reading frame on complementary strand. ORF, open reading frame; CRF, reading frame on complementary strand.

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Pro)
ARF0172	cation-transporting ATPase, E1-E2 family	4-34, 37-43	D:6	aa3-32	D: nd	497, 548
ARF0183	condensing enzyme, putative, FabH-related	4-22, 24-49	D:4	aa1-52	D: nd	498, 549
ARF2455	NADH dehydrogenase, putative	4-29	D:3	aa1-22	D: nd	499, 550
CRF0001	Unknown	4-14, 16-26	D:3	aa5-21	D: nd	500, 551
CRF0002	Unknown	4-13, 15-23, 36-62	D:5	aa21-70	D: nd	501, 552
CRF0003	Unknown	4-12, 14-28	D:3	aa 4-31	D: nd	502, 553
CRF0004	Unknown	5-15, 35-71, 86-94	D:4	aa31-72	D: nd	503, 554
CRF0005	Unknown	8-26, 28-34	D:3	aa:9-33	D: nd	504, 555
CRF0006	Unknown	4-11, 15-28	D:3	aa10-22	D: nd	505, 556
CRF0007	Unknown	4-19, 30-36	D:3	aa 7-44	D: nd	506, 557
CRF0008	Unknown	10-48	D:4	aa:9-44	D: nd	507, 558
CRF0009	Unknown	41883	D:3	aa5-14	D: nd	508, 559
CRF0192	Putative protein	4-23, 25-68	C:4	aa 15-34	C:GSBRM10(15-34): n.d.	445, 446

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
CRF0275	Putative protein	4-40, 49-65	B:5	aa 35-68	B:SELAK28(35-68): n.d.	447, 448
CRF0622	Putative protein	4-12, 17-57, 62-70, 75-84, 86-100	C:4	aa 75-99	C:GSEBBR74(76-99): n.d.	449, 450
CRF0879	Putative protein	4-14, 38-44	A:3, B:10	aa 9-40	B:SELAC39(10-40): n.d.	451, 452
CRF1004	Putative protein	4-40	A:3, B:5	aa 29-65	B:SELA163(35-63): n.d.	453, 454
CRF2248	Putative protein	4-10, 19-40, 53-64, 74-91	C:30	aa 74-111	C:GSEBBN64(16-35): n.d.	455, 456
CRF2307	Putative protein	4-19, 35-41, 80-89	A:19	aa 41-87	A:SEFAL47(41-87): n.d.	457, 458
CRF2309	Putative protein	15-21	B:6	aa 4-16	B:SEFAL02(4-16): n.d.	459, 460
CRF2409	Putative protein	6-25	B:6	aa 2-24	B:SELAB48(5-24): n.d.	461, 462
ORF0005	hypothetical protein	13-27, 33-67, 73-99, 114-129, 132-158, 167-190, 193-234, 237-267, 269-299, 316-330, 339-351, 359-382, 384-423	D:3	aa105-128	D: nd	509, 560
ORF0008	Streptococcal hemagglutinin	9-14, 16-24, 26-32, 41-50, 71-79, 90-96, 177-184, 232-237, 271-278, 293-301, 322-330, 332-339, 349-354, 375-386, 390-396, 403-409, 453-459, 466-472, 478-486, 504-509, 518-525, 530-541, 546-552, 573-586, 595-600, 603-622, 643-660, 668-673, 675-681, 691-697, 699-711, 713-726, 732-749, 753-759, 798-807, 814-826, 831-841, 846-852, 871-878, 897-904, 921-930, 997-1003, 1026-1031, 1033-1039, 1050-1057, 1069-1075, 1097-1103, 1105-1111, 1134-1139, 1141-1147, 1168-1175, 1177-1183, 1205-1211, 1213-1219, 1231-1237, 1241-1247, 1267-1273, 1304-1309, 1311-1317, 1329-1335, 1339-1345, 1347-1353, 1382-1389, 1401-1407, 1411-1417, 1447-1453, 1455-1461, 1483-1489, 1491-1497, 1527-1533, 1545-1551, 1556-1561, 1581-1587, 1591-1597, 1627-1638, 1661-1667, 1684-1689, 1691-1697, 1708-1715, 1719-1725, 1765-1771, 1813-1820, 1823-1830, 1835-1856	B:2	aa 895-926	B:SELA79(895-926): 7/12	239, 268

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Pro)
ORF0038	extracellular elastase precursor	6-25, 29-35, 39-45, 64-71, 82-88, 96-102, 107-113, 119-131, 170-176, 186-192, 196-202, 215-220, 243-248, 302-312, 345-360, 362-371, 378-384, 458-470, 478-489, 495-504	C:6	aa 136-165	C:GSBBN08(136-165):1/1	353,359
ORF0099	hypothetical protein	6-18, 31-37, 42-49, 51-67, 73-85, 87-93, 102-109, 119-126, 150-157, 170-179, 185-191, 204-214, 217-223, 237-248, 269-275, 278-316, 320-340, 359-365	D:5	aa218-265	D: nd	510, 561
ORF0101	hypothetical protein	4-10, 15-27, 67-94, 123-129, 167-173, 179-184, 187-198, 217-222, 229-235, 238-246	D:18	aa26-109	D: nd	511, 562
ORF0121	C4-dicarboxylate transporter, anaerobic, putative	4-20, 24-62, 73-86, 89-106, 110-122, 131-164, 169-193, 204-213, 219-236, 252-259, 263-281, 296-306, 318-324, 328-352, 356-397, 410-429	D:5	aa323-379	D: nd	512, 563
ORF0143	amino acid permease	25-79, 91-103, 105-127, 132-150, 157-174, 184-206, 208-219, 231-249, 267-294, 310-329, 336-343, 346-405, 417-468	D:35	aa247-339	D: nd	513, 564
ORF0162	Immunodominant Antigen A	4-27, 35-45, 52-68, 83-89, 113-119, 133-150, 158-166, 171-176, 198-204, 219-230	A:11; B:11; C:153	aa 90-227	B:SELA19(100-118): 1/1 B:SELA24(170-190): 11/12	240, 269
ORF0201	capa protein, putative	10-17, 27-53, 81-86, 98-105, 126-135, 170-176, 182-188, 203-217, 223-232, 246-252, 254-269, 274-280, 308-314	D:9	aa11-53	D: nd	514, 565
ORF0207	Ribokinase (rbsK)	5-11, 15-23, 47-55, 82-90, 98-103, 108-114, 126-132, 134-156, 161-186, 191-197, 210-224, 228-235, 239-248, 258-264, 275-290	B:10	aa 20-45	B:SELAQ30 (20-45): 12/12	241, 270
ORF0288	LrgB	7-28, 34-56, 68-119, 127-146, 149-180, 182-189, 193-200, 211-230	D:4	aa112-149	D: nd	515, 566

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot).
ORF0304	Herpesvirus saimiri ORF73 homolog, putative	8-16, 30-36, 83-106, 116-122, 135-143, 152-165, 177-188, 216-225	D:8	aa69-117	D: nd	516, 567
ORF0340	nitrate transporter	7-21, 24-93, 101-124, 126-139, 141-156, 163-179, 187-199, 202-242, 244-261, 267-308, 313-322, 340-353, 355-376	D:5	aa238-309	D: nd	517, 595
ORF0346	hypothetical protein	8-27, 65-73, 87-93, 95-105	D:8	aa 1-29	D: nd	518, 568
ORF0355	conserved hypothetical protein	5-30, 37-43, 57-66, 85-94, 103-111, 118-125	C:5	aa 63-86	C:GSBBL39(63-86):1/1	354, 360
ORF0356	conserved hypothetical protein	4-14, 21-53, 60-146, 161-173, 175-182, 190-198, 200-211	D:5	aa51-91	D: nd	519, 569
ORF0406	hypothetical protein	12-32, 35-63, 68-102, 106-137, 139-145, 154-168, 173-185, 203-222, 230-259, 357-364, 366-374	D:19	aa1-48, aa69-102	D: nd	520, 570
ORF0425	amino acid permease	40-58, 75-96, 93-110, 117-144, 150-173, 199-219, 229-260, 264-300, 317-323, 329-356, 360-374, 377-390, 392-398, 408-424, 427-452	D:3	aa401-440	D: nd	521, 571
ORF0442	SocB precursor	7-22, 42-48, 55-66, 83-90, 109-118, 136-141	C:38	aa 60-102	C:GSBBM60(65-84):1/1	355, 361
ORF0448	SaaA precursor	6-25, 39-47, 120-125, 127-135, 140-148, 157-168, 200-208, 210-220, 236-243, 245-254	C:170	aa 15-208	C:GSBBN58(81-105):1/1 C:GSBBL13(167-184):1/1 C:GSBBL25(22-45):1/1	356, 362
ORF0503	Ribosomal protein L2	31-39, 48-54, 61-67, 75-83, 90-98, 103-115, 123-145, 160-167, 169-176, 182-193, 195-206, 267-273	A:1, B:3	aa 212-273	B:SELA47(238-259):12/12	242, 271
ORF0551	Conserved hypothetical protein	5-25, 29-36, 45-53, 62-67, 73-82, 84-91, 99-105, 121-142, 161-177, 187-193, 203-224, 242-251, 256-271, 278-285	A:16, B:9	aa 162-213	B:SELA12(164-197): 8/12	243, 272
ORF0556	hypothetical protein	4-24, 30-41, 43-68, 82-90, 107-114, 123-143, 155-168	D:3	aa 1-26	D: nd	522, 596

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic an**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF0623	Fumble, putative	10-17, 32-38, 55-72, 77-84, 88-96, 126-134, 152-160, 176-185, 190-203, 208-214, 217-225, 233-252, 257-262	A:10, B:12; C:1	aa 95-150	B:SELAB86(95-128): 3/12	244, 273
ORF0740	Hypothetical protein	18-24, 47-61, 69-83, 90-96, 125-132, 140-163, 171-188, 222-249, 281-296, 305-315, 322-330, 335-351, 354-368, 390-397, 411-422, 424-431, 451-469, 479-485, 501-507, 517-524, 539-550, 560-568, 588-599, 619-627, 662-673, 678-689, 735-742, 744-749, 780-786, 797-814, 821-827, 839-847, 857-863, 866-876, 902-911, 919-924, 967-982, 1005-1015, 1020-1026, 1062-1070, 1078-1090, 1125-1131, 1145-1150, 1164-1182, 1208-1213, 1215-1234, 1239-1251, 1256-1270, 1298-1303, 1316-1325, 1339-1349, 1362-1369, 1373-1384, 1418-1427, 1440-1448, 1468-1475, 1523-1532, 1536-1542, 1566-1573, 1575-1593, 1603-1619, 1626-1636, 1657-1667, 1679-1687, 1692-1703, 1711-1718, 1740-1746, 1749-1757, 1760-1769, 1815-1849, 1884-1890, 1905-1914, 1919-1925, 1937-1947, 1955-1963, 1970-1978, 2003-2032, 2075-2089, 2117-2124, 2133-2140, 2146-2151, 2161-2167, 2173-2179, 2184-2196, 2204-2220, 2244-2254, 2259-2264, 2285-2296, 2300-2318, 2328-2334, 2347-2354, 2381-2388, 2396-2408, 2419-2446, 2481-2486, 2493-2500, 2506-2516, 2533-2540, 2555-2567, 2576-2592, 2599-2606, 2615-2639, 2647-2655	B:3	aa 1093-1114	B:SELAB23(1097-1114): 7/12	245, 274
ORF0757	hypothetical protein	13-20, 22-28, 33-40, 60-76, 79-86, 90-102, 112-122, 129-147, 157-170, 178-185, 188-193, 200-205, 218-228, 234-240, 243-250, 265-273, 285-291, 310-316, 330-348, 361-380, 399-405, 427-446, 453-464	C:6	aa 260-284	C:GSBBN01(260-284):1/1	357, 363



S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF0912	DNA mismatch repair protein	9-16, 28-39, 47-56, 69-76, 104-121, 124-130, 137-144, 185-195, 199-214, 238-243, 293-307, 317-337, 351-370, 385-390, 411-428, 472-488, 498-516, 518-525, 528-535, 538-545, 553-559, 563-568, 579-588, 592-607, 615-622, 632-638, 641-648, 658-674, 676-705, 709-720, 727-739, 742-750, 753-760, 768-773, 783-788, 811-819, 827-838	A:25	aa 242-304	SBEAT31(242-290): n.d.	441, 442
ORF0923	GTP-binding protein	4-10, 18-27, 42-55, 64-72, 77-92, 114-126, 132-157, 186-196, 206-217, 236-243, 257-280, 287-300, 306-312, 321-328, 338-351, 360-367, 371-382, 385-399	B:13	aa 144-163	B:SELA55(151-163): 8/12	246, 275
ORF0979	Conserved hypothetical protein	4-28, 44-51, 53-84, 88-107, 113-192	A:9, B:18	aa 12-51	B:SELAH01(26-49):5/12	247, 276
ORF0982	sodium/alanine symporter (alsT)	13-21, 24-50, 73-84, 91-118, 126-133, 142-149, 156-175, 189-249, 251-273, 294-332, 339-347, 358-381, 393-413, 425-448, 458-463	D:3	aa 277-305	D: nd	523, 572
ORF1230	Signal peptidase I	6-33, 44-59, 61-69, 74-82, 92-98, 133-146, 163-175	D:14	aa 1-53	D: nd	524, 573
ORF1232	Exonuclease RcxA	4-12, 16-32, 36-48, 50-65, 97-127, 136-142, 144-165, 176-190, 196-202, 211-222, 231-238, 245-251, 268-274, 280-286, 303-316, 334-356, 368-376, 395-402, 410-417, 426-440, 443-449, 474-486, 499-508, 510-525, 540-549, 568-576, 608-617, 624-639, 646-661, 672-678, 688-703, 706-717, 727-734, 743-755, 767-773, 783-797, 806-814, 830-839, 853-859, 863-871, 877-895, 899-918, 935-948, 976-990, 998-1007, 1020-1030, 1050-1062, 1070-1077, 1111-1125, 1137-1149, 1153-1160, 1195-1211	B:6	aa 188-219	B:SELA13(188-216): n.d.	443, 444
ORF1284	permease PerM, putative	10-60, 72-96, 103-109, 127-133, 146-177, 182-189, 196-271, 277-289, 301-319, 323-344, 347-354	D:27	aa 55-106	D: nd	525, 574

<i>S. epidermidis</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF1319	2-oxoglutarate decarboxylase (menD)	9-31, 36-45, 59-67, 71-81, 86-94, 96-107, 111-122, 127-140, 153-168, 180-211, 218-224, 226-251, 256-270, 272-289, 299-305, 310-323, 334-341, 345-353, 358-364, 369-379, 384-390, 396-410, 417-423, 429-442, 454-464, 470-477, 497-505, 540-554	B:5; C:1	aa 400-413	B:SELAIP54(404-413): 11/12	248, 277
ORF1326	autolysin AtlE (lytD)	6-25, 40-46, 75-81, 150-155, 200-205, 237-243, 288-295, 297-306, 308-320, 341-347, 356-363, 384-391, 417-429, 440-452, 465-473, 481-514, 540-546, 554-560, 565-577, 585-590, 602-609, 611-617, 625-634, 636-643, 661-668, 676-684, 718-724, 734-742, 747-754, 766-773, 775-781, 785-798, 800-807, 825-832, 840-857, 859-879, 886-892, 917-923, 950-956, 972-978, 987-1002, 1028-1035, 1049-1065, 1071-1099, 1111-1124, 1150-1172, 1185-1190, 1196-1207, 1234-1241, 1261-1271, 1276-1281, 1311-1320, 1325-1332	B:7; C:5	aa 1282-1298	B:SELAID20(1282-1298): 10/12	249, 278
ORF1333	quinoxalase polypeptide iv (ex I.9.3.-) (quinoxalase aa3-600, subunit qoxd)	4-27, 33-55, 66-88	D:4	aa 3-93	D: nd	526, 575
ORF1356	hypothetical protein	9-36, 44-67, 74-97, 99-149, 161-181, 189-198, 211-224, 245-253, 267-273, 285-290, 303-324, 342-394, 396-427	D:32	aa54-95	D: nd	527, 597
ORF1373	dihydroliipoamide acetyltransferase	33-39, 42-78, 103-109, 126-136, 184-191, 225-232, 258-279, 287-294, 306-315, 329-334, 362-379, 381-404, 425-430	A:3, B:1	aa 124-188	A:SEFAPS7(124-188): 2/12	250, 279
ORF1381	hypothetical protein	21-45, 62-67, 74-105, 108-142, 154-160, 230-236, 245-251, 298-305	D:5	aa7-44	D: nd	528, 576

S. <i>epidermidis</i> antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF1420	MutS2 protein, putative	8-32, 34-41, 46-55, 70-76, 81-89, 97-115, 140-148, 153-159, 165-171, 175-188, 207-239, 256-276, 280-289, 297-319, 321-335, 341-347, 352-360, 364-371, 384-411, 420-440, 449-460, 495-502, 505-516, 560-566, 573-588, 598-605, 607-614, 616-624, 674-694, 702-717	B:7	aa 581-608	B:SELAM40(581-604): 9/12	251, 280
ORF1443	cell division protein (divIB)	61-66, 111-117, 148-155, 173-182, 194-224, 263-293, 297-303, 313-321, 334-343, 345-356, 375-381, 384-395, 408-429, 448-454	D:4	aa175-229	D: nd	529, 577
ORF1500	Cell division protein FisY	100-107, 154-167, 182-193, 200-206, 223-231, 233-242, 249-257, 265-273, 298-310, 326-336, 343-362, 370-384	A:2, B:3	aa 77-182	B:SELA P37(139-162): 9/12	252, 281
ORF1665	amino acid ABC transporter, permease protein	4-25, 44-55, 66-76, 82-90, 93-99, 104-109, 176-209, 227-242, 276-283, 287-328, 331-345, 347-376, 400-407, 409-416, 418-438, 441-474	D:5	aa 1-52	D: nd	530, 578
ORF1707	putative host cell surface-exposed lipoprotein	12-31, 40-69, 129-137, 140-151, 163-171, 195-202, 213-218	D:4	aa 20-76	D: nd	531, 598
ORF1786	D-3-phosphoglycerate dehydrogenase, putative	4-10, 16-32, 45-55, 66-78, 87-95, 103-115, 118-124, 135-150, 154-161, 166-174, 182-193, 197-207, 225-231, 252-261, 266-304, 310-315, 339-347, 351-359, 387-402, 411-423, 429-436, 439-450, 454-464, 498-505, 508-515	D:5	aa400-442	D: nd	532, 579
ORF1849	yhlN protein	8-51, 53-69, 73-79, 85-132, 139-146, 148-167, 179-205, 212-224, 231-257, 264-293, 298-304, 309-317, 322-351	D:5	aa254-301	D: nd	533, 580

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF1877	protein-export membrane protein SecD (secD-1)	6-19, 26-39, 41-51, 59-67, 72-85, 91-98, 104-111, 120-126, 147-153, 158-164, 171-178, 199-209, 211-218, 233-249, 251-257, 269-329, 362-368, 370-385, 392-420, 424-432, 434-489, 506-523, 534-539, 550-556, 563-573, 576-596, 603-642, 644-651, 655-666, 685-704, 706-733, 747-753	D:7	aa367-409	D: nd	534, 581
ORF1912	unknown conserved protein (conserved)	23-35, 37-70, 75-84, 90-112, 129-135, 137-151, 155-180, 183-209, 211-217, 219-225, 230-248, 250-269, 274-284, 289-320, 325-353, 357-371, 374-380, 384-399, 401-411,	D:4	aa131-187	D: nd	535, 582
ORF2015	Trehalose 6-phosphate hydrolase	8-17, 30-54, 82-89, 94-103, 157-166, 178-183, 196-204, 212-219, 222-227, 282-289, 297-307, 345-364, 380-393, 399-405, 434-439, 443-449, 453-475, 486-492, 498-507, 512-535, 538-548	A:3, B:8	aa 465-498	B:SELAH62(465-498): 5/12	253, 282
ORF2018	Glucose 6-phosphate 1-DH	4-16, 21-27, 39-51, 60-69, 76-83, 97-118, 126-132, 159-167, 171-177, 192-204, 226-240, 247-259, 281-286, 294-305, 314-320, 330-338, 353-361, 367-372, 382-392, 401-413, 427-434, 441-447, 457-463	B:17	aa 250-287	B:SELA119(250-279): 3/12	254, 283
ORF2040	LysM domain protein protein	51-56, 98-108, 128-135, 138-144, 152-158, 177-192, 217-222, 232-251, 283-305, 406-431, 433-439	D:23	aa259-331	D: nd	536, 583
ORF2098	PIIB related protein	13-18, 36-43, 45-50, 73-79, 95-100, 111-126, 133-139	A:60	aa 1-57	A:SEFAQ50X(15-57): 5/12	255, 284
ORF2139	sodium:sulfate symporter family protein, putative	7-12, 22-97, 105-112, 121-128, 130-146, 152-164, 169-189, 192-203, 211-230, 238-246, 260-281, 304-309, 313-325, 327-357, 367-386, 398-444, 447-476, 491-512	D:41	aa42-118	D: nd	537, 584

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF2172	SoeB precursor (lytE)	4-23, 28-34, 38-43, 45-51, 63-71, 85-96, 98-112, 118-126, 167-174, 179-185, 219-228, 234-239, 256-263	A:438, B:40, D:4	aa 6-215	B:SELAH53(188-209): 3/12	256, 285
ORF2200	zinc ABC transporter, permease protein, putative	4-31, 33-40, 48-64, 66-82, 92-114, 118-133, 137-159, 173-246, 248-266	D:19	aa162-225	D: nd	538, 585
ORF2248	membrane protein, MmpL family, putative	4-11, 17-34, 72-78, 127-137, 178-227, 229-255, 262-334, 352-380, 397-405, 413-419, 447-454, 462-467, 478-490, 503-509, 517-558, 560-568, 571-576, 582-609, 623-629, 631-654, 659-710, 741-746, 762-767, 771-777, 788-793, 856-867	D:17	aa1-59, aa159-225, aa634-674	D: nd	539, 586
ORF2260	Unknown conserved protein in others	5-10, 18-29, 31-37, 66-178, 196-204, 206-213	B:4	aa 123-142	B:SELAG77(123-142): 12/12	257, 286
ORF2282	conserved hypothetical protein	16-22, 41-50, 52-64, 66-74, 89-95, 107-114, 123-130, 135-159, 167-181, 193-199, 223-231, 249-264, 279-289	A:4	aa 51-97	A:SEFAR88(51-97): 3/12	258, 287
ORF2376	DivIC homolog, putative	27-56, 102-107, 111-116	D:7	aa15-58	D: nd	540, 587
ORF2439	membrane-bound lytic murein transglycosidase D, putative	4-9, 11-26, 36-56, 59-73, 83-100, 116-130, 148-163, 179-193, 264-270, 277-287, 311-321	A:459, B:2, D:53	aa 10-217	B:SELA31(75-129): 12/12	259, 288
ORF2493	conserved hypothetical protein	4-29, 37-77, 80-119	D:6	aa69-113	D: nd	541, 588
ORF2535	ATP-binding cassette transporter-like protein, putative	5-28, 71-81, 101-107, 128-135, 146-52, 178-188, 209-214, 224-233, 279-294, 300-306, 318-325, 342-347, 351-357	D:8	aa1-65	D: nd	542, 589

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF2627	cation-transporting ATPase, E1-E2 family, putative	8-31, 34-80, 125-132, 143-153, 159-165, 176-189, 193-198, 200-206, 215-242, 244-262, 264-273, 281-289, 292-304, 318-325, 327-338, 347-371, 404-416, 422-429, 432-450, 480-488, 503-508, 517-525, 539-544, 551-562, 574-587, 600-631, 645-670	D:3	aa61-105	D: nd	543, 590
ORF2635	Hypothetical protein	4-10, 17-24, 26-42, 61-71, 90-96, 102-111, 117-125, 158-164, 173-182, 193-201, 241-255, 268-283, 289-298, 305-319, 340-353, 360-376, 384-390, 394-406	A:2, B:2	aa 139-169	B:SELAB63(138-163): 7/12	260, 289
ORF2669	Hypothetical protein	4-21, 35-42, 85-90, 99-105, 120-125, 148-155, 175-185, 190-196, 205-210, 217-225	A:14, B:8	aa 22-81	B:SELAE27(22-51): 5/12	261, 290
ORF2671	Hypothetical protein	4-23, 43-49, 73-84, 93-98, 107-113, 156-163, 179-190, 197-204, 208-218, 225-231, 248-255	A:44, B:14	aa 23-68	B:SELA21(36-61): 5/12	262, 291
ORF2673	Hypothetical protein	4-20, 65-71, 99-105, 148-155, 171-182, 190-196, 204-210, 221-228, 240-246	A:16, B:3	aa 23-68	B:SELAE25(23-54): 2/12	263, 292
ORF2694	Hypothetical protein	4-26, 93-98, 121-132, 156-163, 179-192, 198-204, 212-220, 225-238	A:19, B:30	aa 25-82	B:SELAB26(27-60): 5/12	264, 293
ORF2695	Hypothetical protein	4-26, 43-50, 93-98, 107-113, 156-163, 179-190, 198-204, 212-218, 225-231, 247-254	A:7	aa 22-78	A:SEFAH77(22-66): 6/12	265, 294
ORF2719	two-component sensor histidine kinase, putative	5-52, 60-71, 75-84, 91-109, 127-135, 141-156, 163-177, 185-193, 201-214, 222-243, 256-262, 270-279, 287-293, 298-303, 321-328, 334-384, 390-404, 411-418, 427-435, 438-448, 453-479, 481-498, 503-509	B:4	aa 123-132	B:SELA62(123-132): 6/12	266, 295
ORF2728	Accumulation-associated protein	4-13, 36-44, 76-86, 122-141, 164-172, 204-214, 235-242, 250-269, 291-299, 331-337, 362-369, 377-396, 419-427, 459-469, 505-524, 547-555, 587-597, 618-625, 633-652, 675-683, 715-727, 740-753, 761-780, 803-811, 842-853, 962-968, 1006-1020	A:265, B:448; C:4, D:9	aa 803-1001	B:SELA10(850-878): 11/12	267, 296

- 90 -

S. epidermidis antigenic protein	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Pro0)
ORF2740	lipase precursor	4-21, 190-200, 218-228, 233-241, 243-261, 276-297, 303-312, 316-325, 346-352, 381-387, 436-442, 457-462, 495-505, 518-532, 543-557, 574-593	C:3	aa 110-177	C:GS9BL80(110-177):1/1	538, 564
ORF2764	oligopeptide ABC transporter, permease protein, putative	14-36, 62-131, 137-147, 149-162, 164-174, 181-207, 212-222, 248-268, 279-285	D:4	aa 6-41	D:nd	544, 591
ORF2767	unknown conserved protein in others	7-20, 22-35, 40-50, 52-61, 63-92, 94-101, 103-126, 129-155, 161-178, 192-198, 200-208, 210-229, 232-241, 246-273, 279-332, 338-359, 369-383	D:4	aa276-316	D:nd	545, 592
ORF2809	sodium:sulfate symporter family protein	4-29, 37-53, 56-82, 87-100, 108-117, 121-138, 150-160, 175-180, 189-195, 202-214, 220-247, 269-315, 324-337, 341-355, 361-412, 414-423, 425-440, 447-467	D:9	aa266-317, aa357-401	D:nd	546, 593
ORF2851	putative trans-membrane efflux protein	7-13, 20-32, 37-90, 93-103, 107-126, 129-155, 159-173, 178-189, 195-221, 234-247, 249-255, 268-303, 308-379	D:11	aa137-185	D:nd	547, 594

**Table 2d: Immunogenic proteins identified by bacterial surface and ribosome display: *S. aureus* (new annotation)**

Bacterial surface display: A, LSA250/1 library in *fhuA* with patient sera 1 (655); B, LSA50/6 library in *lamB* with patient sera 1 (484); C, LSA250/1 library in *fhuA* with IC sera 1 (571); E, LSA50/6 library in *lamB* with IC sera 2 (454); F, LSA50/6 library in *lamB* with patient sera P1 (1105); G, LSA50/6 library in *lamB* with IC sera 1 (471). Ribosome display: D, LSA250/1 library with IC sera (1686). \*\*, prediction of antigenic sequences longer than 5 amino acids was performed with the programme ANTIGENIC (Kolarik and Tongaonkar, 1990); #, identical sequence present twice in ORF.

<i>S. aureus</i> antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ScA0003	ORF2967 & ORF2963	repC	7-19, 46-57, 85-91, 110-117, 123-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363	B-3, C:14; P:29	aa 9-42; aa 156-241; aa 300-314; aa 343-420	C:GSBY133(9-42):1/1 C:GSBYG39(156-241):1/1 C:GSBYM94(343-420):26/30	394, 396
ORF0123	ORF1909 - 18 aa at N-terminus	unknown	4-10, 25-30, 38-57, 91-108, 110-123, 125-144, 146-177, 179-198, 216-224, 226-233	B-3, E:7, G:1	aa 145-163	B:GSBXF80(150-163):5/27 E:GSBZC17(150-163):25/41	409, 410
ORF0160	ORF1941 -16 aa at N-terminus	unknown	4-26, 34-70, 72-82, 86-155, 160-166, 173-205, 207-228, 230-252, 260-268, 280-313	A:1	aa 96-172	A:GSBXC007(96-172):5/30	411, 412
ORF0657	ORF unknown	LPXTGV1 protein	9-33, 56-62, 75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 541-549, 563-569, 578-584, 624-641	A:2, B:27, F:15	aa 526-544	B:GSBXC07-bdb1(527-542):11/71 F:SBALAX70(526-544):11/41	413, 414
ORF1050	ORF1307 -4 aa at N-terminus	unknown	45-68, 72-79, 91-101, 131-142, 144-160, 179-201	A:1, H:45	aa 53-124	A:GSBXM26(53-124):7/30	415, 416
ORF1344	ORF0212 -10 aa at N-terminus	NitS protein homolog	13-26, 40-49, 61-68, 92-112, 114-123, 138-152, 154-183, 194-200, 207-225, 229-240, 259-265, 271-284, 289-309, 319-324, 330-336, 346-352, 363-372	A:11	aa 24-84	A:GSBXC59-bmd21(24-84):6/29	417, 418



S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Pro)
ORF1632	ORF1163 -4 aa at N-terminus	Scrt homolog	4-31, 50-55, 243-257, 259-268, 298-316, 326-335, 364-370, 378-407	B.6, E.11, F.34	aa 101-115 aa 115-139 aa 158-186	B:GSBXG53(164-182):39/71 F:SALAP07(101-115):11/41	419, 420
ORF2180	ORF0594 -2 aa at N-terminus	LPXTGIV protein	9-17, 24-45, 67-73, 82-90, 100-107, 117-134, 137-145, 158-168, 176-183, 188-194, 206-213, 223-231, 243-248, 263-270, 275-282, 298-304, 344-355, 371-377, 382-388, 427-433, 469-479, 500-505, 534-559, 597-607, 662-687, 790-815, 918-943, 1032-1037, 1046-1060, 1104-1112, 1128-1137, 1179-1184, 1197-1204, 1209-1214, 1221-1239	A.3, C.3, E.6, F.2, H.6	aa 491-587 aa 633-715 aa 702-757* aa 758-830 (aa 830-885)*	A:GSBXG561(491-555):1/1 A:GSBXL64(494-585):1/1 A:GSBXG92(758-841):1/1 A:bmnd4(702-757):16/30* A:bmnd4(830-885):16/30* F:SALBC43(519-533):4/41	421, 422
ORF2184	ORF0590 -8 aa at N-terminus	FnbpB	10-29, 96-116, 131-137, 146-158, 167-173, 177-182, 185-191, 195-201, 227-236, 260-266, 270-284, 291-299, 301-312, 348-356, 367-376, 382-396, 422-432, 442-453, 480-487, 497-503, 519-527, 543-548, 559-565, 579-585, 591-601, 616-623, 643-648, 657-663, 706-718, 746-758, 791-796, 810-817, 819-825, 833-839, 847-853, 868-885, 887-895, 919-932	A.2, C.4, G.9	aa 694-769 aa 774-847	A:GSBXM62(694-769):28/28 A:GSBXR22(774-847):1/1	423, 424
ORF2470	ORF0299 -14 aa at N-terminus	Conserved by pothetical protein	4-27, 36-42, 49-55, 68-73, 94-101, 131-137, 193-200, 230-235, 270-276, 294-302, 309-324, 334-344, 347-364, 396-405, 431-437, 498-508, 513-519, 526-532, 539-544, 547-561, 587-594, 618-630, 642-653, 687-699, 713-719, 752-766	C.3	aa 400-441	C:GSBYH60(400-441):28/31	425, 426
ORF2498	ORF0267 ORF app. 580 aa longer at N terminus; plus other changes	Conserved by pothetical protein	8-19, 21-44, 63-76, 86-92, 281-286, 303-322, 327-338, 344-354, 364-373, 379-394, 405-412, 453-460, 501-506, 512-518, 526-542, 560-570, 577-583, 585-604, 622-630, 645-673, 677-691, 702-715, 727-741, 748-753, 770-785, 789-796, 851-858, 863-869, 876-881, 898-913, 917-924, 979-986, 991-997, 1004-1009, 1026-1041, 1045-1052, 1107-1114, 1119-1125, 1132-1137, 1154-1169, 1173-1192, 1198-1204, 1240-1254, 1267-1274, 1290-1298, 1612-1627	D.12, F.6	aa 358-411 aa 588-606 aa 895-909	D:17/21 F:SALAT38(895-909):8/41	427, 428

S. aureus antigenic protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF2548	ORF2711 -12 aa at N-terminus	IgG binding protein A	4-37, 44-53, 65-71, 75-82, 105-112, 126-132, 136-143, 164-170, 184-190, 194-201, 222-232, 242-248, 252-259, 280-291, 300-317, 413-420, 452-460, 485-503	A:55, B:54, C:35, F:59, G:56, H:38	aa 1-123 aa 207-273 aa 310-410	A:GSBXX68(1-73):21/30 A:GSBXX41(35-123):1/1 A:GSBXN38(207-273):19/30 A:GSBXL11(310-363):10/30 B:GSBXXB22(394-406):37/71 F:SALAM17(394-406):29/41	429, 430
ORF2746	ORF2507 -3 aa at N-terminus	homology with ORF1	4-9, 12-17, 40-46, 91-103, 106-113, 116-125, 150-160, 172-177, 182-188, 195-206, 241-261, 263-270, 277-285, 287-294	A:1, H:13	aa 63-126	A:GSBXX040(66-123):8/29	431, 432
ORF2797	ORF2470 -24 aa at N-terminus	unknown	13-32, 40-75, 82-95, 97-112, 115-121, 124-154, 166-192, 201-225, 227-252, 268-273, 288-297, 308-375, 379-434	B:3, E:2, F:13, H:3	aa 159-176 aa 325-339	B:GSBXX85(159-176):11/27 F:SALAQ47(159-176):8/41	433, 434
ORF2960	ORF2298 -5 aa at N-terminus	putative Exotoxin	8-31, 35-44, 106-113, 129-135, 154-159, 168-178, 203-215, 227-236, 240-249, 257-266, 275-281, 290-296, 298-305, 314-319, 327-334	C:101, E:2, H:58	aa 1-80 aa 48-121 aa 98-190	C:GSBYG32(1-80):6/7 C:GSBYG61-bba2(48-116):26/30 C:GSBYN80(98-190):13/17	435, 436
ORF2963	ORF2295 -5 aa at N-terminus	putative Exotoxin	8-23, 35-41, 64-70, 81-87, 109-115, 121-132, 150-167, 177-188, 194-201, 208-216, 227-233, 238-248, 265-271, 279-285	C:3, E:3, G:1	aa 17-95	C:GSBY158(17-95):9/15	437, 438

S. aureus flagellin protein	Old ORF number	Putative function (by homology)	predicted immunogenic aa**	No. of selected clones per ORF and screen	Location of identified immunogenic region	Serum reactivity with relevant region (positive/total)	Seq ID no: (DNA +Prot)
ORF3200	ORF1331 +8506 aa at N-terminus	putative extracellular matrix binding protein	8-32, 45-52, 92-103, 154-159, 162-168, 207-214, 232-248, 274-280, 297-303, 343-349, 362-375, 425-442, 477-487, 493-498, 505-512, 522-533, 543-550, 558-564, 568-574, 580-600, 618-630, 647-652, 658-672, 692-705, 711-727, 765-771, 788-798, 812-836, 847-858, 870-898, 903-910, 1005-1015, 1018-1025, 1028-1036, 1058-1069, 1075-1080, 1095-1109, 1111-1117, 1119-1133, 1166-1172, 1183-1194, 1200-1205, 1215-1222, 1248-1254, 1274-1280, 1307-1317, 1334-1340, 1381-1391, 1414-1420, 1429-1439, 1445-1467, 1478-1495, 1499-1505, 1519-1528, 1538-1550, 1557-1562, 1572-1583, 1593-1599, 1654-1662, 1668-1692, 1701-1707, 1718-1724, 1738-1746, 1757-1783, 1786-1793, 1806-1812, 1815-1829, 1838-1848, 1853-1860, 1875-1881, 1887-1893, 1899-1908, 1933-1940, 1952-1961, 1964-1970, 1977-1983, 1990-1996, 2011-2018, 2025-2038, 2086-2101, 2103-2117, 2177-2191, 2195-2213, 2220-2225, 42237-2249, 2273-2279, 2298-2305, 2319-2327, 2349-2354, 2375-2381, 2391-2398, 2426-2433, 2436-2444, 2449-2454, 2463-2469, 2493-2499, 2574-2589, 2593-2599, 2605-2611, 2615-2624, 2670-2684, 2687-2698, 2720-2727, 2734-2754, 2762-2774, 2846-2866, 2903-2923, 2950-2956, 2985-2998, 3011-3031, 3057-3064, 23102-3117, 3137-3143, 3186-3195, 3211-3219, 3255-3270, 3290-3300, 3327-3334, 3337-3343, 3390-3396, 3412-3419, 3439-3446, 3465-3470, 3492-3500, 3504-3510, 3565-3573, 3642-3650, 3691-3698, 3766-3775, 3777-3788, 3822-3828, 3837-3847, 3859-3864, 3868-3879, 3895-3902, 3943-3951, 3963-3971, 3991-3997, 4018-4030, 4054-4060, 4074-4099, 4123-4129, 4147-4153, 4195-4201, 4250-4255, 4262-4267, 4270-4277, 4303-4310,	A:11, B:11, C:36, H:32	aa 8543-8601 aa 8461-8475	A:GSDXL07(8543-8601):6/28	439, 440

4321-4330, 4343-4352, 4396-4408,  
4446-4451, 4471-4481, 4503-4509,  
4516-4534, 4596-4604, 4638-4658,  
4698-4710, 4719-4732, 4776-4783,  
4825-4833, 4851-4862, 4882-4888,  
4894-4909, 4937-4942, 5047-5054,  
5094-5100, 5102-5112, 5120-5125,  
5146-5153, 5155-5164, 5203-5214,  
5226-5236, 5278-5284, 5315-5321,  
5328-5342, 5348-5359, 5410-5420,  
5454-5466, 5481-5489, 5522-5538,  
5597-5602, 5607-5614, 0°5623-  
5629, 5650-5665, 5707-5719, 5734-  
5742, 5772-5778, 5785-5790, 5833-  
5845, 5857-5863, 5899-5904, 5908-  
5921, 5959-5971, 5981-5989, 6010-  
6017, 6034-6043, 6058-6064, 6112-  
6120, 6154-6169, 6210-6217, 6231-  
6240, 6261-6268, 6288-6294, 6318-  
6324, 6340-6349, 6358-6369, 6402-  
6407, 6433-6438, 6483-6493, 6513-  
6519, 6527-6546, 6561-6574, 6599-  
6608, 6610-6616, 6662-6673, 6696-  
6705, 6729-6743, 6769-6775, 6792-  
6801, 6819-6828, 6840-6846, 6860-  
6870, 6915-6928, 6966-6972, 7021-  
7028, 7032-7047, 7096-7101, 7109-  
7117, 7138-7149, 7157-7162, 7201-  
7206, 7238-7253, 7283-7294, 7296-  
7302, 7344-7365, 7367-7376, 7389-  
7404, 7413-7433, 7475-7482, 7493-  
7500, 7535-7549, 7596-7608, 7646-  
7651, 7661-7678, 7722-7731, 7741-  
7754, 7764-7769, 7776-7782, 7791-  
7806, 7825-7837, 7862-7875, 7891-  
7897, 7922-7931, 7974-7981, 7999-  
8005, 8039-8045, 8049-8065, 8070-  
8075, 8099-8112, 8119-8125, 8151-  
8158, 8169-8181, 8226-8232, 8258-  
8264, 8291-8299, 8301-8310, 8325-  
8335, 8375-8389, 8394-8400, 8405-  
8412, 8421-8436, 8478-8485, 8512-  
8521, 8528-8538, 8564-8579, 8587-  
8594, 8603-8615, 8626-8637, 8640-  
8646, 8657-8672, 8684-8691, 8725-  
8736, 8748-8761, 8777-8783, 8794-  
8799, 8810-8825, 8851-8862, 8874-  
8887, 8903-8912, 8914-8926, 8933-  
8943, 8954-8960, 8979-8988, 9004-  
9011, 9035-9041, 9056-9069, 9077-  
9086, 9088-9096, 9106-9111, 9124-  
9133, 9183-9191, 9224-9231, 9235-  
9241, 9250-9265, 9279-9290, 9295-

		9300, 9326-9343, 9408-9414, 9422- 9427, 9435-9441, 9455-9461, 9507- 9517, 9532-9538, 9580-9589, 9594- 9600, 9614-9623, 9643-9648, 9665- 9683, 9688-9700, 9720-9726, 9742- 9758, 9767-9775, 9795-9800, 9817- 9835, 9842-9847, 9912-9919, 9925- 9938, 9943-9963, 9970-10009, 10025-10031, 10037-10043, 10045- 10063, 10066-10073, 10117-10124, 10126-10136, 10203-10210, 10218- 10225, 10232-10242, 10287-10292, 10303-10323, 10352-10360, 10385- 10396, 10425-10431, 10452-10459, 10480-10485				
--	--	--	--	--	--	--

**Table 3. Serological proteome analysis of *S. aureus* surface proteins using human sera**

**a) *S. aureus*/agr "stress conditions"**

Spot ID/sera	IC40 1:20,000	IC35, N26, C4 1:50,000 each	Infant pool C2,5,6,10,12 1:10,000	N22 1:10.000 IC40 1:50,000
PCK2	+	+	-	+
PCK4	+	+++	-	+++
PCK5	-	(+)	-	+
PCK6	+	+	-	+

Spot ID/sera	IC35, 40 1:50,000 N22 1:10,000	P-pool (P6,18,25,28,29) 1:50,000 each	Infant pool C2,5,6,10,12 1:10,000	
PAC1	++	++	-	
PAC2	++	+++	-	
PAC3	-	+	-	
PAC5	-	++	-	

Spot ID/sera	P-pool (P6,18,25,28,29) 1:50,000 each	Infant 14 1:10,000	IC pool / IgG (N26, IC34,35) 1:30,000 each	IC pool / IgA (N26, IC34,35) 1:30,000 each
PAC11	++	-	++	++
PAC12	++	-	++	++
PAC13	-	-	-	++
PAC14	-	-	+	+
PAC15	-	-	+++	+++
PAC16	+	-	+	+
PAC17	+	-	+	+
PAC18	++	-	-	-
PAC19	-	-	++	++
PAC20	++	-	-	-
POV31	+++	-	-	-
POV32	+	-	-	-
POV33	+	-	-	-
POV34	+	-	-	-
POV35	+	-	-	-
P OV36	+	-	-	-
P OV37	++	-	-	-

P OV38	++	-	-	-
P OV39	+++	-	-	-
P OV40	+++	-	-	-

b) *S. aureus*/COL "standard conditions"

Spot ID/sera	IC pool (N26,IC34,35) 1:30,000 each	IC35 1:20,000	P18 1:10,000	P25 1:10,000	P1 1:5,000	P29 1:2,500	Infant 18 1:10,000
POV2	+++	+++	+++	+++	+++	-	-
POV3.1	+++	+++	+++	+++	+++	-	-
POV3.2	+++	+++	+++	+++	+++	-	-
POV4	+	+++	-	-	-	-	-
POV7	-	-	+++	-	-	-	-
POV10	-	++	(+)	(+)	-	(+)	-
POV12	-	-	-	-	-	+++	-
POV13	++	+++	+++	+++	++	++	-
POV14	++	+++	+++	++	++	++	-
POV15	+	+	-	+	(+)	-	-

c) *S. aureus*/COL "stress conditions"

Spot ID/sera	P-pool (P6,18,25,28,29) 1:50,000 each	IC34+IC35 1:20,000 each	P18 1:10,000	P29 1:10,000	Infant 14 1:10,000
POV16	-	+++	-	-	-
POV17	-	+++	(+)	-	-
POV18	+	-	++	-	-
POV19	(+)	-	+++	-	-
POV21	-	-	+	-	-
POV23	-	+	-	-	-
POV24	-	+	-	-	-
POV25	+	-	-	-	-

**Table 4. *S. aureus* antigens identified by MALDI-TOF-MS sequencing (ORFs in bold were also identified by bacterial surface display)**  
**Prediction of antigenic regions in selected antigens identified by serological proteome analysis using human sera**

spot ID	<i>S. aureus</i> protein (ORF no. / abbreviation.)	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative localization
PCK2	ORF0599	Glycinamide-ribosyl synthase	107, 108	cytoplasmic
PCK5	ORF0484 yitU	conserved hypoth. protein (yitU)	109, 110	cytoplasmic
PCK6	ORF2309 mqo	membrane-associated malate-quinone oxidase	111, 112	peripheral membrane
POV2	ORF0766 aux1	protein phosphatase contributing to methicillin resistance	113, 114	trans-membrane
POV4, 17 PAC14, 19	ORF0078 EF-Tu	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116	cytoplasmic/ secreted
POV5 <sup>1)</sup>	ORF0782	3-ketoacyl-acyl carrier protein reductase (fabG)	117, 118	cytoplasmic
POV7	<b>ORF0317 SecA</b>	protein transport across the membrane SecA	39, 91	cytoplasmic
POV10	ORF1252 yrzC	hypothetical BACSU 11.9 kd protein (upf0074 (rfi2) family)	119, 120	cytoplasmic
POV12	ORF0621 pdhB	dihydrodipolamide acetyltransferase (pdhB)	121, 122	cytoplasmic
POV14	ORF0072 rpoB	DNA-directed RNA polymerase B	125, 126	cytoplasmic
POV15	ORF0077 EF-G	85 kD vitronectin binding protein	127, 128	cytoplasmic
POV18	not found YLY1	general stress protein YLY1	129, 130	cytoplasmic
POV30 <sup>1)</sup>	ORF0069 RL7	ribosomal protein L7	131, 132	cytoplasmic
POV21	ORF0103 yckG	probable hexulose-6-phosphate synthase (yckG)	133, 134	cytoplasmic
POV24	ORF0419 yurX	conserved hypothetical protein (yurX)	137, 138	cytoplasmic



spot ID	S. aureus protein (ORF no. / ab- brev.)	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative localization
POV25	ORF2441 gidA	glucose inhibited division protein a (gidA)	139, 140	cytoplasmic
PAC1	ORF1490 prsA	protein export protein prsA precursor (prsA)	173, 174	periplasmic
PAC2	ORF1931 ModA	periplasmic molybdate binding protein (ModA)	175, 176	surface
PAC3	ORF2053	heavy metal dependent transcriptional activator, putative regulator of multidrug resistance efflux pump pmrA	177, 178	cytoplasmic
PAC5	ORF2233 ydaP	pyruvate oxidase (ydaP)	179, 180	cytoplasmic
PAC11	ORF1361	LPXTGV, extracellular matrix-bdg.	3, 56	surface
PAC12	ORF1244 alaS	alanyl-tRNA synthetase	159, 160	cytoplasmic
PAC13	ORF0835 ymtA	RNA processing enzyme/ATP-bdg.	161, 162	cytoplasmic
PAC15	ORF1124 bfmBB	lipamid acyltransferase component of branched-chain alpha-keto acid dehy- drogenase complex	163, 164	cytoplasmic
PAC16	ORF0340 GAPDH	glyceraldehydes-3-phosphate dehydrogenase	165, 166	cytoplasmic
PAC17	not found Contig83	5'-methylthioadenosine nucleosidase / S-adenosylhomo-cysteine nucleosidase		cytoplasmic
PAC20	ORF2711	75% identity to ORF2715 similar to hypothetical proteins	167, 168	unknown
POV31	ORF0659	29 kDa surface protein	236, 238	surface
POV32	ORF0659	29 kDa surface protein	236, 238	surface
POV33	ORF0659	29 kDa surface protein	236, 238	surface
POV34	ORF0659	29 kDa surface protein	236, 238	surface
POV35	ORF0659	29 kDa surface protein	236, 238	surface
P OV36	ORF00661	LPXTG-motif cell wall anchor domain protein	235, 237	surface
P OV37	ORF0659	29 kDa surface protein	236, 238	surface

spot ID	S. aureus protein (ORF no. / ab- brev.)	Putative function (by homology)	Seq ID no: (DNA, Prot)	Putative localization
P OV38	ORF0659	29 kDa surface protein	236, 238	surface
P OV39	ORF0657	LPXTG-anchored surface protein	1, 142	surface
P OV40	not identified			

Seq ID no: (Protein)	spot ID	S. aureus ORF no. / abbrev.	Putative localization	Putative antigenic surface areas (Antigenic package)
112	PCK6	ORF2309 mqo	peripheral membrane	61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229, 236-246, 251-258, 271- 286, 288-294, 301-310, 316-329, 337-346, 348-371, 394-406, 418-435, 440-452
114	POV2	ORF766 aux1	trans-mem- brane	30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-193, 206-212, 222- 229, 235-242
116	POV4	ORF078 EF-Tu	cytoplasmic/ secreted	28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234- 249, 262-269, 276-282, 289-302, 306-314, 321-326, 338-345, 360-369, 385-391
176	PAC2	ORF1931 ModA	periplasmic	29-44, 74-83, 105-113, 119-125, 130-146, 155-175, 182-190, 198-211, 238-245
174	PAC1	ORF1490 prsA	periplasmic	5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266- 286, 292-299
168	PAC20	ORF2711	unknown	7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193- 216, 219-234

spot ID	GI no. or TIGR no.	S. aureus protein (ORF no. / ab- brev.)	Putative function (by homology)	Seq ID no: (DNA, Prot)
PCK2	TIGR1280	ORF0599	Glycinamide-ribosyl synthase	107, 108

PCK4	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
PCK5	TIGR6209	ORF0484 yitU	conserved hypoth. protein (yitU)	109, 110
PCK6	TIGR6182	ORF2309	membrane-associated malate-quinone oxidase	111, 112
POV2	6434044	ORF0766 aux1	protein phosphatase contributing to methicillin resistance	113, 114
POV3.1	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
POV3.2	7672993	ORF2268 IsaA	possibly adhesion/aggregation	12, 64
POV4	TIGR8079	ORF0078 EF-Tu	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116
POV5 <sup>1)</sup>	TIGR8091	ORF0782	3-ketoacyl-acyl carrier protein reductase (fabG)	117, 118
POV7	2500720	ORF0317 SecA	protein transport across the membrane SecA	39, 91
POV10	TIGR8097	ORF1252 yzcC	hypothetical BACSU 11.9 kd protein (upf0074 (rf2) family)	119, 120
POV12	2499415	ORF0621 pdhB	dihydrolipoamide acetyltransferase (pdhB)	121, 122
POV13	7470965	ORF0094 SdrD	fibrinogen-bdg. (LPXTG) protein homolog (SdrD)	123, 124
POV14	1350849	ORF0072 rpoB	DNA-directed RNA polymerase $\beta$	125, 126
POV15	6920067	ORF0077 EF-G	85 kD vitronectin binding protein	127, 128
POV17	TIGR8079	ORF0078	C-terminal part of 44 kDa protein similar to elongation factor Tu	115, 116
POV18	3025223	not found	general stress protein YLY1	129, 130
POV30 <sup>1)</sup>	350771	ORF0069 RL7	ribosomal protein L7	131, 132
POV21		ORF0103	probable hexulose-6-phosphate synthase (yckG)	133, 134
POV23		ORF0182	lipoprotein (S.epidermis)	135, 136

<sup>1)</sup> identified from a total lysate from *S. aureus* 8325-4 spa- grown under standard conditions. Seroreactivity with 1/1 patient and 2/4 normal sera but not with infant serum (C5).

## References

Aichinger G., Karlsson L., Jackson M.R., Vestberg M., Vaughau J.H., Teyton L., Lechler R.I. and Peterson P A. Major Histocompatibility Complex classII-dependent unfolding, transport and degradation of endogenous proteins. *J. Biol. Chem.*, v.272, 1997, pp. 29127-29136

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. Eds. (1994). *Current protocols in molecular biology*. John Wiley & Sons, Inc.

Betley, M.J., Lofdahl, S., Kreiswirth, B.N., Bergdoll, M.S. and Novick, R.P. (1984). Staphylococcal enterotoxin A gene is associated with a variable genetic element. *Proc. Natl. Acad. Sci. U.S.A.* 81:5179-5183.

Bruggemann M, Neuberger MS (1996) *Immunol. Today* 17:391-397

Burnie, J.P., Matthews, R.C., Carter, T., Beaulieu, E., Donohoe, M., Chapman, C., Williamson, P. and Hodgetts, S.J. (2000). Identification of an immunodominant ABC transporter in methicillin-resistant *Staphylococcus aureus* infections. *Infect. Immun.* 68:3200-3209.

Chen, H.Z. and Zubay, G. (1983). *Methods Enzymol.* 101:674-690.

Coloque-Navarro, P., Söderquist, B., Holmberg, H., Blomqvist, L., Olcen, P., and Möllby, R. (1998) Antibody response in *Staphylococcus aureus* septicaemia - a prospective study. *J. Med. Microbiol.* 47, 217-25.

Crossley, K.B. and Archer G.L., eds. (1997). *The Staphylococci in Human Disease*. Churchill Livingston Inc.

Flock, J.-I. (1999). Extracellular-matrix-binding proteins as targets for the prevention of *Staphylococcus aureus* infections. *Molecular Medicine Today* 5:532-537.

Forrer, P., Jung, S. and Plückthun, A. (1999). Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins. *Curr. Opin. Struct. Biol.* 9:514-520.

Foster, T.J. and Hook, M. (1998). Surface protein adhesins of *Staphylococcus aureus*. *Trends Microbiol.* 6:484-488.

Frénay, H. M. E., Theelen, J. P. G., Schouls, L. M., Vandenbroucke-Grauls, C. M. J. E., Vernooij, J., van Leeuwen, W. J., and Mooi, F. R. (1994). Discrimination of epidemic and nonepidemic methicillin-resistant *Staphylococcus aureus* on the basis of protein A gene polymorphism. *J. Clin. Microbiol.* 32:846-847.

Georgiou, G., Stathopoulos, C., Daugherty, P.S., Nayak, A.R., Iverson, B.L. and Curtiss III, R. (1997). Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines. *Nature Biotechnology* 15:29-34.

Goh, S.-H., Byrne, S. K., Zhang, J. L., and Chow, A. W. (1992). Molecular typing of *Staphylococcus aureus* on the basis of coagulase gene polymorphisms. *J. Clin. Microbiol.* 30:1642-1645.

Graziano et al. (1995) *J. Immunol.* 155:4996-5002

Hammer et al. *J. Exp. Med* (1995) 181: 1847-1855

Hanes, J. and Plückthun, A. (1997). In vitro selection and evolution of functional proteins by using ribosome display. *PNAS* 94:4937-4942.

Hashemzadeh-Bonehi, L., Mehraein-Ghomi, F., Mitsopoulos, C., Jacob, J.P., Hennessey, E.S. and Broome-Smith, J.K. (1998). Importance of using lac rather than ara promoter vectors for modulating the levels of toxic gene products in *Escherichia coli*. *Mol. Microbiol.* 30:676-678.

Hryniewicz, W. (1999). Epidemiology of MRSA. *Infection* 27:S13-16.

Immler, D., Gremm, D., Kirsch, D., Spengler, B., Presek, P., Meyer, H.E. (1998). *Electrophoresis* 19:1015-1023.

Kajava, A.V., Zolov, S.N., Kalinin, A.E. and Nesmeyanova, M.A. (2000). The net charge of the first 18 residues of the mature sequence affects protein translocation across the cytoplasmic membrane of Gram-negative bacteria. *J. Bacteriol.* 182:2163-2169.

Kluytmans, J., van Belkum, A. and Verbrugh, H. (1997). Nasal car-

riage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin. Microbiol. Rev.* 10:505-520.

Kolaskar, A.S. and Tongaonkar, P.C. (1990). A semi-empirical method for prediction of antigenic determinants on protein antigens. *FEBS Lett.* 276:172-174.

Lim, Y., Shin, S.H., Jang, I.Y., Rhee, J.H. and Kim, I.S. (1998). Human transferring-binding protein of *Staphylococcus aureus* is immunogenic in vivo and has an epitope in common with human transferrin receptor. *FEMS Microbiol. Letters* 166:225-230.

Lorenz, U., Ohlsen, K., Karch, H., Hecker, M., Thiede, A. and Hacker, J. (2000). Human antibody response during sepsis against targets expressed by methicillin resistant *Staphylococcus aureus*. *FEMS Immunol. Med. Microbiol.* 29:145-153.

Mamo, W., Jonsson, P. and Muller, H.P. (1995). Opsonization of *Staphylococcus aureus* with a fibronectin-binding protein antiserum induces protection in mice. *Microb. Pathog.* 19:49-55

McGuinness ET et al. (1996) *Nature Biotech.* 14:1149

Modun, B., Evans, R.W., Joannou, C.L. and Williams, P. (1998). Receptor-mediated recognition and uptake of iron from human transferrin by *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Infect. Immun.* 66:3591-3596.

Nilsson, I., Patti, J.M., Bremell, T., Höök, M. and Tarkowski, A. (1998). Vaccination with a Recombinant Fragment of Collagen Adhesin provides Protection against *Staphylococcus aureus*-mediated Septic Death. *J. Clin. Invest.* 101:2640-2649.

Parker, K. C., M. A. Bednarek, and J. E. Coligan (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. *J. Immunol.* 152:163.

Pasquali, C., Fialka, I. & Huber, L.A. (1997). *Electrophoresis* 18:2573-2581.

Phillips-Quagliata, J.M., Patel, S., Han, J.K., Arakelov, S., Rao, T.D., Shulman, M.J., Fazel, S., Corley, R.B., Everett, M., Klein, M.H., Underdown, B.J. and Corthesy, B. (2000). The IgA/IgM

- 106 -

receptor expressed on a murine B cell lymphoma is poly-Ig receptor. *J. Immunol.* 165:2544-2555

Rammensee, Hans-Georg, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic (1999) SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics* 50: 213-219

Recsei F., Kreiswirth, B., O'Reilly, M., Schlievert, P., Gruss, A. and Novick, R.P. (1986). Regulation of exoprotein gene expression in *Staphylococcus aureus* by *agr*. *Mol. Gen. Genet.* 202:58-61.

Rodi, D.J. and Makowski, L. (1999). Phage-display technology--finding a needle in a vast molecular haystack. *Curr. Opin. Biotechnol.* 10:87-93.

Schaffitzel et al., Ribosome display: an in vitro method for selection and evolution of antibodies from libraries; *Journal of Immunological Methods* 231, 119-135 (1999).

Sanchez-Campillo, M., Bini, L., Comanducci, M., Raggiaschi, R., Marzocchi, B., Pallini, V. and Ratti, G. (1999). *Electrophoresis* 20:2269-2279.

Schmittl A, Keilholz U, Thiel E, Scheibenbogen C. (2000) Quantification of tumor-specific T lymphocytes with the ELISPOT assay. *J Immunother* 23(3):289-95

Sester M, Sester U, Kohler H, Schneider T, Deml L, Wagner R, Mueller-Lantzsch N, Pees HW, Meyerhans A. (2000) Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. *AIDS* 14(17):2653-60.

Shafer, W.M. and Iandolo, J.J. (1979). Genetics of staphylococcal enterotoxin B in methicillin-resistant isolates of *Staphylococcus aureus*. *Infect. Immun.* 25:902-911.

Shibuya, A., Sakamoto, N., Shimizu, Y., Shibuya, K., Osawa, M., Hiroyama, T., Eyre, H.J., Sutherland, G.R., Endo, Y., Fujita, T., Miyabayashi, T., Sakano, S., Tsuji, T., Nakayama, F., Phillips, J.H., Lanier, L.L. and Nakauchi, H. (2000).  $FC_{\gamma}$  receptor mediates endocytosis of IgM-coated microbes. *Nature Immunology* 1:441-446.)

Skerra, A. (1994). Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in *Escherichia coli*. *Gene* 151:131-135.

Sohail, M. (1998). A simple and rapid method for preparing genomic DNA from Gram-positive bacteria. *Mol. Biotech.* 10:191-193.

Sonderstrup G, Cope AP, Patel S, Congia M, Hain N, Hall FC, Parry SL, Fugger LH, Michie S, McDevitt HO (1999) HLA class II transgenic mice: models of the human CD4+ T-cell immune response. *Immunol Rev* 172:335-43

Sturniolo, T. et al., E Bono, J Ding, L Raddrizzani, O. Tuereci, U Sahin, M Braxenthaler, F Gallazzi, MP Protti, F Sinigaglia, and J Hammer (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA chips and virtual HLA class II matrices. *Nature Biotechnology* 17: 555-562.

Valli et al. *J. Clin. Invest.* (1993) 91: 616-62

VandenBergh M. F. Q., Yzerman E. P. F., van Belkum, A., Boelens, H. A. M., Sijmons, M., and Verbrugh, H. A. (1999). Follow-up of *Staphylococcus aureus* nasal carriage after 8 years: redining the persistent carrier state. *J. Clin. Microbiol.* 37:3133-3140..

Wessel, D. and Fluegge, U.I. (1984). *Anal. Biochem.* 138:141-143.



## C l a i m s :

1. Method for identification, isolation and production of hyperimmune serum-reactive antigens from a pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:

- providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
- providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity
- screening said at least one expression library with said antibody preparation,
- identifying antigens which bind in said screening to antibodies in said antibody preparation,
- screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,
- identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods,

2. Method for identification, isolation and production of a practically complete set of hyperimmune serum-reactive antigens of a specific pathogen, said antigens being suited for use in a vaccine for a given type of animal or for humans, characterized by the following steps:

- providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen,
- providing at least three different expression libraries of said specific pathogen,

- 109 -

- screening said at least three different expression libraries with said antibody preparation,
- identifying antigens which bind in at least one of said at least three screenings to antibodies in said antibody preparation,
- screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen,
- identifying the hyperimmune serum-reactive antigen portion of said identified antigens which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera,
- repeating said screening and identification steps at least once,
- comparing the hyperimmune serum-reactive antigens identified in the repeated screening and identification steps with the hyperimmune serum-reactive antigens identified in the initial screening and identification steps,
- further repeating said screening and identification steps, if at least 5% of the hyperimmune serum-reactive antigens have been identified in the repeated screening and identification steps only, until less than 5 % of the hyperimmune serum-reactive antigens are identified in a further repeating step only to obtain a complete set of hyperimmune serum-reactive antigens of a specific pathogen and
- optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

3. Method according to claim 1 or 2 characterized in that at least one of said expression libraries is selected from a ribosomal display library, a bacterial surface library and a proteome.

4. Method according to claim 2 characterized in that said at least three different expression libraries are at least a ribosomal display library, a bacterial surface library and a proteome.

5. Method according to any one of claims 1 to 4, characterized

in that said plasma pool is a human plasma pool taken from individuals having experienced or are experiencing an infection with said pathogen.

6. Method according to any one of claims 1 to 5, characterized in that said expression libraries are genomic expression libraries of said pathogen.

7. Method according to any one of claims 1 to 6, characterized in that said expression libraries are complete genomic expression libraries, preferably with a redundancy of at least 2x, more preferred at least 5x, especially at least 10x.

8. Method according to any one of claims 1 to 7, characterized in that it comprises the steps of screening at least a ribosomal display library, a bacterial surface display library and a proteome with said antibody preparation and identifying antigens which bind in at least two, preferably which bind to all, of said screenings to antibodies in said antibody preparation.

9. Method according to any one of claims 1 to 8, characterized in that said pathogen is selected from the group of bacterial, viral, fungal and protozoan pathogens.

10. Method according to any one of claims 1 to 9, characterized in that said pathogen is selected from the group of human immunodeficiency virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, Rous sarcoma virus, Epstein-Barr virus, influenza virus, rotavirus, Staphylococcus aureus, Staphylococcus epidermidis, Chlamydia pneumoniae, Chlamydia trachomatis, Mycobacterium tuberculosis, Mycobacterium leprae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, Bacillus anthracis, Vibrio cholerae, Borrelia burgdorferi, Plasmodium sp., Aspergillus sp. or Candida albicans.

11. Method according to any one of claims 1 to 10, characterized in that at least one of said expression libraries is a ribosomal display library or a bacterial surface display library and said hyperimmune serum-reactive antigens are produced by expression of the coding sequences of said hyperimmune serum-reactive antigens

contained in said library.

12. Method according to any one of claims 1 to 11, characterized in that said produced hyperimmune serum-reactive antigens are finished to a pharmaceutical preparation, optionally by addition of a pharmaceutically acceptable carrier and/or excipient.

13. Method according to claim 12, characterized in that said pharmaceutical preparation is a vaccine.

14. Method according to claim 12 or 13, characterized in that said pharmaceutically acceptable carrier and/or excipient is an immunostimulatory compound. [ ]

15. Method according to claim 14, characterized in that said immunostimulatory compound is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory deoxynucleotides, alumna, Freund's complete adjuvans, Freund's incomplete adjuvans, neuroactive compounds, especially human growth hormone, or combinations thereof.

16. Method according to any one of claims 1 to 15, characterized in that said individual antibody preparations are derived from patients with acute infection with said pathogen, especially from patients with an antibody titer to said pathogen being higher than 80%, preferably higher than 90%, especially higher than 95% of human patient or carrier sera tested.

17. Method according to any one of claims 1 to 16, characterized in that at least 10, preferably at least 30, especially at least 50, individual antibody preparations are used in identifying said hyperimmune serum-reactive antigens.

18. Method according to any one of said claims 1 to 17, characterized in that said relevant portion of said individual antibody preparations from said individual sera are at least 10, preferably at least 30, especially at least 50 individual antibody preparations, and/or at least 20 %, preferably at least 30 %, especially at least 40 %, of all individual antibody preparations used in said screening.

19. Method according to any one of claims 1 to 18, characterized in that said individual sera are selected by having an IgA titer against a lysate, cell wall components or recombinant proteins of said pathogen being above 4000 U, especially above 6000 U, and/or by having an IgG titer being above 10000 U, preferably above 12000 U.

20. Method according to any one of claims 1 to 19, characterized in that said pathogen is a Staphylococcus pathogen, especially Staphylococcus aureus. and/or Staphylococcus epidermidis.

21. A hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.

22. A hyperimmune serum-reactive antigen obtainable by a method according to any one of claims 1 to 20 and being selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 56, 57, 59, 60, 67, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 87, 88, 89, 90, 92, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155 and hyperimmune fragments thereof.

23. Use of a hyperimmune serum-reactive antigen selected from the group consisting of the sequences listed in any one of Tables 2a, 2b, 2c, 2d, 3, 4 and 5, especially selected from the group consisting of Seq.ID No. 55, 56, 57, 58, 59, 60, 62, 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 92, 94, 95, 96, 97, 99, 100, 101, 102, 103, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 126, 128, 130, 132, 134, 138, 140, 142, 151, 152, 154, 155, 158 and hyperimmune fragments thereof for the manufacture of a pharmaceutical preparation, es-

pecially for the manufacture of a vaccine against staphylococcal infections or colonization in particular against *Staphylococcus aureus* or *Staphylococcus epidermidis*.

24. Hyperimmune fragment of a hyperimmune serum-reactive antigen selected from the group consisting of peptides comprising the amino acid sequences of column "predicted immunogenic aa", "Location of identified immunogenic region" and "Serum reactivity with relevant region" of Tables 2a, 2b, 2c and 2d and the amino acid sequences of column "Putative antigenic surface areas" of Table 4 and 5, especially peptides comprising amino acid No. aa 12-29, 34-40, 63-71, 101-110, 114-122, 130-138, 140-195, 197-209, 215-229, 239-253, 255-274 and 39-94 of Seq.ID No. 55, aa 5-39, 111-117, 125-132, 134-141, 167-191, 196-202, 214-232, 236-241, 244-249, 292-297, 319-328, 336-341, 365-380, 385-391, 407-416, 420-429, 435-441, 452-461, 477-488, 491-498, 518-532, 545-556, 569-576, 581-587, 595-602, 604-609, 617-640, 643-651, 702-715, 723-731, 786-793, 805-811, 826-839, 874-889, 37-49, 63-77 and 274-334, of Seq.ID No.56, aa 28-55, 82-100, 105-111, 125-131, 137-143, 1-49, of Seq.ID No. 57, aa 33-43, 45-51, 57-63, 65-72, 80-96, 99-110, 123-129, 161-171, 173-179, 185-191, 193-200, 208-224, 227-246, 252-258, 294-308, 321-329, 344-352, 691-707, 358-411 and 588-606, of Seq.ID No. 58, aa 16-38, 71-77, 87-94, 105-112, 124-144, 158-164, 169-177, 180-186, 194-204, 221-228, 236-245, 250-267, 336-343, 363-378, 385-394, 406-412, 423-440, 443-449, 401-494, of Seq.ID No. 59, aa 18-23, 42-55, 69-77, 85-98, 129-136, 182-188, 214-220, 229-235, 242-248, 251-258, 281-292, 309-316, 333-343, 348-354, 361-367, 393-407, 441-447, 481-488, 493-505, 510-515, 517-527, 530-535, 540-549, 564-583, 593-599, 608-621, 636-645, 656-670, 674-687, 697-708, 726-734, 755-760, 765-772, 785-792, 798-815, 819-824, 826-838, 846-852, 889-904, 907-913, 932-939, 956-964, 982-1000, 1008-1015, 1017-1024, 1028-1034, 1059-1065, 1078-1084, 1122-1129, 1134-1143, 1180-1186, 1188-1194, 1205-1215, 1224-1230, 1276-1283, 1333-1339, 1377-1382, 1415-1421, 1448-1459, 1467-1472, 1537-1545, 1556-1566, 1647-1654, 1666-1675, 1683-1689, 1722-1737, 1740-1754, 1756-1762, 1764-1773, 1775-1783, 1800-1809, 1811-1819, 1839-1851, 1859-1866, 1876-1882, 1930-1939, 1947-1954, 1978-1985, 1999-2007, 2015-2029, 2080-2086, 2094-2100, 2112-2118, 2196-2205,

- 114 -

2232-2243, 198-258, 646-727 and 2104-2206, of Seq.ID No. 60,  
aa 10-29, 46-56, 63-74, 83-105, 107-114, 138-145, 170-184, 186-  
193, 216-221, 242-248, 277-289, 303-311, 346-360, 379-389, 422-  
428, 446-453, 459-469, 479-489, 496-501, 83-156, of Seq.ID No.  
62,  
aa 14-22, 32-40, 52-58, 61-77, 81-93, 111-117, 124-138, 151-190,  
193-214, 224-244, 253-277, 287-295, 307-324, 326-332, 348-355,  
357-362, 384-394, 397-434, 437-460, 489-496, 503-510, 516-522,  
528-539, 541-547, 552-558, 563-573, 589-595, 602-624, 626-632,  
651-667, 673-689, 694-706, 712-739, 756-790, 403-462, of Seq.ID  
No. 66,  
aa 49-56, 62-68, 83-89, 92-98, 109-115, 124-131, 142-159, 161-  
167, 169-175, 177-188, 196-224, 230-243, 246-252, 34-46, of  
Seq.ID No. 67,  
aa 11-20, 26-47, 69-75, 84-92, 102-109, 119-136, 139-147, 160-  
170, 178-185, 190-196, 208-215, 225-233, 245-250, 265-272, 277-  
284, 300-306, 346-357, 373-379, 384-390, 429-435, 471-481, 502-  
507, 536-561, 663-688, 791-816, 905-910, 919-933, 977-985, 1001-  
1010, 1052-1057, 1070-1077, 1082-1087, 1094-1112, 493-587, 633-  
715 and 704-760, of Seq.ID No. 70,  
aa.6-20, 53-63, 83-90, 135-146, 195-208, 244-259, 263-314, 319-  
327, 337-349, 353-362, 365-374, 380-390, 397-405, 407-415, 208-  
287 and 286-314, of Seq.ID No. 71,  
aa 10-26, 31-43, 46-58, 61-66, 69-79, 85-92, 100-115, 120-126,  
128-135, 149-155, 167-173, 178-187, 189-196, 202-222, 225-231,  
233-240, 245-251, 257-263, 271-292, 314-322, 325-334, 339-345,  
59-74, of Seq.ID No. 72,  
aa 4-9, 15-26, 65-76, 108-115, 119-128, 144-153, 38-52 and 66-  
114, of Seq.ID No. 73,  
aa 5-22, 42-50, 74-81, 139-145, 167-178, 220-230, 246-253, 255-  
264, 137-237 and 250-267, of Seq.ID No. 74,  
aa 10-26, 31-44, 60-66, 99-104, 146-153, 163-169, 197-205, 216-  
223, 226-238, 241-258, 271-280, 295-315, 346-351, 371-385, 396-  
407, 440-446, 452-457, 460-466, 492-510, 537-543, 546-551, 565-  
582, 590-595, 635-650, 672-678, 686-701, 705-712, 714-721, 725-  
731, 762-768, 800-805, 672-727, of Seq.ID No. 75,  
aa 5-32, 35-48, 55-76, of Seq.ID No. 76,  
aa 7-35, 54-59, 247-261, 263-272, 302-320, 330-339, 368-374, 382-  
411, 126-143 and 168-186, of Seq.ID No. 77,  
aa 5-24, 88-94, 102-113, 132-143, 163-173, 216-224, 254-269, 273-

- 115 -

278, 305-313, 321-327, 334-341, 31-61 and 58-74, of Seq.ID No. 78,

aa 16-24, 32-39, 43-49, 64-71, 93-99, 126-141, 144-156, 210-218, 226-233, 265-273, 276-284, 158-220, of Seq.ID No. 79,

aa 49-72, 76-83, 95-105, 135-146, 148-164, 183-205, 57-128, of Seq.ID No. 80,

aa 6-15, 22-32, 58-73, 82-88, 97-109, 120-131, 134-140, 151-163, 179-185, 219-230, 242-255, 271-277, 288-293, 305-319, 345-356, 368-381, 397-406, 408-420, 427-437, 448-454, 473-482, 498-505, 529-535, 550-563, 573-580, 582-590, 600-605, 618-627, 677-685, 718-725, 729-735, 744-759, 773-784, 789-794, 820-837, 902-908, 916-921, 929-935, 949-955, 1001-1008, 1026-1032, 1074-1083, 1088-1094, 1108-1117, 1137-1142, 1159-1177, 1183-1194, 1214-1220, 1236-1252, 1261-1269, 1289-1294, 1311-1329, 1336-1341, 1406-1413, 1419-1432, 1437-1457, 1464-1503, 1519-1525, 1531-1537, 1539-1557, 1560-1567, 1611-1618, 1620-1629, 1697-1704, 1712-1719, 1726-1736, 1781-1786, 1797-1817, 1848-1854, 1879-1890, 1919-1925, 1946-1953, 1974-1979, 5 to 134, of Seq.ID No. 81,

aa 6-33, 40-46, 51-59, 61-77, 84-104, 112-118, 124-187, 194-248, 252-296, 308-325, 327-361, 367-393, 396-437, 452-479, 484-520, 535-545, 558-574, 582-614, 627-633, 656-663, 671-678, 698-704, 713-722, 725-742, 744-755, 770-784, 786-800, 816-822, 827-837, 483-511, of Seq.ID No. 82,

aa 4-19, 57-70, 79-88, 126-132, 144-159, 161-167, 180-198, 200-212, 233-240, 248-255, 276-286, 298-304, 309-323, 332-346, 357-366, 374-391, 394-406, 450-456, 466-473, 479-487, 498-505, 507-519, 521-530, 532-540, 555-565, 571-581, 600-611, 619-625, 634-642, 650-656, 658-665, 676-682, 690-699, 724-733, 740-771, 774-784, 791-797, 808-815, 821-828, 832-838, 876-881, 893-906, 922-929, 938-943, 948-953, 969-976, 1002-1008, 1015-1035, 1056-1069, 1105-1116, 1124-1135, 1144-1151, 1173-1181, 1186-1191, 1206-1215, 1225-1230, 1235-1242, 6-66, 65-124 and 590-604, of Seq.ID No. 83, aa 5-32, 66-72, 87-98, 104-112, 116-124, 128-137, 162-168, 174-183, 248-254, 261-266, 289-303, 312-331, 174-249, of Seq.ID No. 84,

aa 4-21, 28-40, 45-52, 59-71, 92-107, 123-137, 159-174, 190-202, 220-229, 232-241, 282-296, 302-308, 312-331, 21-118, of Seq.ID No. 85,

aa 9-28, 43-48, 56-75, 109-126, 128-141, 143-162, 164-195, 197-216, 234-242, 244-251, 168-181, of Seq.ID No. 87,



- 116 -

aa 4-10, 20-42, 50-86, 88-98, 102-171, 176-182, 189-221, 223-244,  
246-268, 276-284, 296-329, 112-188, of Seq.ID No. 88,  
aa 4-9, 13-24, 26-34, 37-43, 45-51, 59-73, 90-96, 99-113, 160-  
173, 178-184, 218-228, 233-238, 255-262, 45-105, 103-166 and 66-  
153, of Seq.ID No. 89, [ ]  
aa 13-27, 42-63, 107-191, 198-215, 218-225, 233-250, 474-367, of  
Seq.ID No. 90,  
aa 26-53, 95-123, 164-176, 189-199, 8-48, of Seq.ID No. 92,  
aa 7-13, 15-23, 26-33, 68-81, 84-90, 106-117, 129-137, 140-159,  
165-172, 177-230, 234-240, 258-278, 295-319, 22-56, 23-99, 97-  
115, 233-250 and 245-265, of Seq.ID No. 94,  
aa 13-36, 40-49, 111-118, 134-140, 159-164, 173-183, 208-220,  
232-241, 245-254, 262-271, 280-286, 295-301, 303-310, 319-324,  
332-339, 1-85, 54-121 and 103-185, of Seq.ID No. 95,  
aa 39-44, 46-80, 92-98, 105-113, 118-123, 133-165, 176-208, 226-  
238, 240-255, 279-285, 298-330, 338-345, 350-357, 365-372, 397-  
402, 409-415, 465-473, 488-515, 517-535, 542-550, 554-590, 593-  
601, 603-620, 627-653, 660-665, 674-687, 698-718, 726-739, 386-  
402, of Seq.ID No. 96,  
aa 5-32, 34-49, 1-43, of Seq.ID No. 97, [ ]  
aa 10-27, 37-56, 64-99, 106-119, 121-136, 139-145, 148-178, 190-  
216, 225-249, 251-276, 292-297, 312-321, 332-399, 403-458, 183-  
200, of Seq.ID No. 99,  
aa 5-12, 15-20, 43-49, 94-106, 110-116, 119-128, 153-163, 175-  
180, 185-191, 198-209, 244-252, 254-264, 266-273, 280-288, 290-  
297, 63-126, of Seq.ID No. 100,  
aa 5-44, 47-55, 62-68, 70-78, 93-100, 128-151, 166-171, 176-308,  
1-59, of Seq.ID No. 101,  
aa 18-28, 36-49, 56-62, 67-84, 86-95, 102-153, 180-195, 198-218,  
254-280, 284-296, 301-325, 327-348, 353-390, 397-402, 407-414,  
431-455, 328-394, of Seq.ID No. 102,  
aa 7-37, 56-71, 74-150, 155-162, 183-203, 211-222, 224-234, 242-  
272, 77-128, of Seq.ID No. 103,  
aa 34-58, 63-69, 74-86, 92-101, 130-138, 142-150, 158-191, 199-  
207, 210-221, 234-249, 252-271, 5-48, of Seq.ID No. 104,  
aa 12-36, 43-50, 58-65, 73-78, 80-87, 108-139, 147-153, 159-172,  
190-203, 211-216, 224-232, 234-246, 256-261, 273-279, 286-293,  
299-306, 340-346, 354-366, 167-181, of Seq.ID No. 106,  
aa 61-75, 82-87, 97-104, 113-123, 128-133, 203-216, 224-229,  
236-246, 251-258, 271-286, 288-294, 301-310, 316-329, 337-346,

- 117 -

348-371, 394-406, 418-435, 440-452 of Seq.ID No. 112,  
aa 30-37, 44-55, 83-91, 101-118, 121-128, 136-149, 175-183, 185-193, 206-212, 222-229, 235-242 of Seq.ID No. 114,  
aa 28-38, 76-91, 102-109, 118-141, 146-153, 155-161, 165-179, 186-202, 215-221, 234-249, 262-269, 276-282, 289-302, 306-314, 321-326, 338-345, 360-369, 385-391 of Seq.ID No. 116,  
aa 9-33, 56-62, 75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 541-549, 563-569, 578-584, 624-641, 527-544, of Seq.ID No. 142,  
aa 37-42, 57-62, 121-135, 139-145, 183-190, 204-212, 220-227, 242-248, 278-288, 295-30, 304-309, 335-341, 396-404, 412-433, 443-449, 497-503, 505-513, 539-545, 552-558, 601-617, 629-649, 702-711, 736-745, 793-804, 814-829, 843-858, 864-885, 889-895, 905-913, 919-929, 937-943, 957-965, 970-986, 990-1030, 1038-1049, 1063-1072, 1080-1091, 1093-1116, 1126-1136, 1145-1157, 1163-1171, 1177-1183, 1189-1196, 1211-1218, 1225-1235, 1242-1256, 1261-1269, 624-684, of Seq.ID No. 151,  
aa 8-23, 31-38, 42-49, 61-77, 83-90, 99-108, 110-119, 140-147, 149-155, 159-171, 180-185, 189-209, 228-234, 245-262, 264-275, 280-302, 304-330, 343-360, 391-409, 432-437, 454-463, 467-474, 478-485, 515-528, 532-539, 553-567, 569-581, 586-592, 605-612, 627-635, 639-656, 671-682, 700-714, 731-747, 754-770, 775-791, 797-834, 838-848, 872-891, 927-933, 935-942, 948-968, 976-986, 1000-1007, 1029-1037, 630-700, of Seq.ID No. 152,  
aa 17-25, 27-55, 84-90, 95-101, 115-121, 55-101, of Seq.ID No. 154,  
aa 13-28, 40-46, 69-75, 86-92, 114-120, 126-137, 155-172, 182-193, 199-206, 213-221, 232-238, 243-253, 270-276, 284-290, 22-100, of Seq.ID No. 155 and  
aa 7-19, 46-57, 85-91, 110-117, 125-133, 140-149, 156-163, 198-204, 236-251, 269-275, 283-290, 318-323, 347-363, 9-42 and 158-174, of Seq.ID No. 158,  
aa 7-14, 21-30, 34-50, 52-63, 65-72, 77-84, 109-124, 129-152, 158-163, 175-190, 193-216, 219-234 of Seq.ID.No. 168,  
aa 5-24, 38-44, 100-106, 118-130, 144-154, 204-210, 218-223, 228-243, 257-264, 266-286, 292-299 of Seq.ID.No. 174,  
aa 29-44, 74-83, 105-113, 119-125, 130-148, 155-175, 182-190, 198-211, 238-245 of Seq.ID.No. 176, and fragments as depicted in Tables 2 and 4 and fragments comprising at least 6, preferably

more than 8, especially more than 10 aa. of said sequences.

25. Helper epitopes of an antigen or a fragment, as defined in anyone of claims 21 to 24, especially peptides comprising fragments selected from the peptides mentioned in column "Putative antigenic surface areas" in Table 4 and 5 and from the group aa 6-40, 583-598, 620-646 and 871-896 of Seq.ID.No.56, aa 24-53 of Seq.ID.No.70, aa 240-260 of Seq.ID.No.74, aa 1660-1682 and 1746-1790 of Seq.ID.No. 81, aa 1-29, 680-709, and 878-902 of Seq.ID.No. 83, aa 96-136 of Seq.ID.No. 89, aa 1-29, 226-269 and 275-326 of Seq.ID.No. 94, aa 23-47 and 107-156 of Seq.ID.No. 114 and aa 24-53 of Seq.ID.No. 142 and fragments thereof being T-cell epitopes.

26. Vaccine comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 21 to 25.

27. Vaccine according to claim 25, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), neuroactive compounds, especially human growth hormone, alum, Freund's complete or incomplete adjuvans or combinations thereof.

28. Preparation comprising antibodies against at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.

29. Preparation according to claim 27, characterized in that said antibodies are monoclonal antibodies.

30. Method for producing a preparation according to claim 28, characterized by the following steps:

- initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said anti-

gen and

•producing the antibody preparation by cultivation of said cloned hybridoma cells and optionally further purification steps.

31. Method according to claim 29, characterized in that said removing the spleen or spleen cells is connected with killing said animal.


32. Method for producing a preparation according to claim 27, characterized by the following steps:

- initiating an immune response in a non human animal by administering an antigen or a fragment thereof, as defined in any one of the claims 21 to 25, to said animal,
- removing an antibody containing body fluid from said animal,
- and
- producing the antibody preparation by subjecting said antibody containing body fluid to further purification steps.

33. Use of a preparation according to claim 27 or 28 for the manufacture of a medicament for treating or preventing staphylococcal infections or colonization in particular against Staphylococcus aureus or Staphylococcus epidermidis.

34. A screening method assessing the consequences of functional inhibition of at least one antigen or a fragment thereof, as defined in any one of claims 21 to 25.

1/11

IgA vs. IgG titer against total *S. aureus* lysate

IgA titer 10.000X

Figure 1

2/11




Figure 2

3/11




Figure 3




Figure 4



5/11




Figure 5




Figure 6

7/11



Figure 7

8/11

LPTG

TMD

EXTRACELLULAR DOMAIN

Pla  
 S4C  
 S4D  
 S4E  
 S4F  
 C1A  
 C1B  
 C1C  
 C1D  
 C1E  
 C1F  
 C1G  
 C1H  
 C1I  
 C1J  
 C1K  
 C1L  
 C1M  
 C1N  
 C1O  
 C1P  
 C1Q  
 C1R  
 C1S  
 C1T  
 C1U  
 C1V  
 C1W  
 C1X  
 C1Y  
 C1Z  
 C1AA  
 C1AB  
 C1AC  
 C1AD  
 C1AE  
 C1AF  
 C1AG  
 C1AH  
 C1AI  
 C1AJ  
 C1AK  
 C1AL  
 C1AM  
 C1AN  
 C1AO  
 C1AP  
 C1AQ  
 C1AR  
 C1AS  
 C1AT  
 C1AU  
 C1AV  
 C1AW  
 C1AX  
 C1AY  
 C1AZ  
 C1BA  
 C1BB  
 C1BC  
 C1BD  
 C1BE  
 C1BF  
 C1BG  
 C1BH  
 C1BI  
 C1BJ  
 C1BK  
 C1BL  
 C1BM  
 C1BN  
 C1BO  
 C1BP  
 C1BQ  
 C1BR  
 C1BS  
 C1BT  
 C1BU  
 C1BV  
 C1BW  
 C1BX  
 C1BY  
 C1BZ  
 C1CA  
 C1CB  
 C1CC  
 C1CD  
 C1CE  
 C1CF  
 C1CG  
 C1CH  
 C1CI  
 C1CJ  
 C1CK  
 C1CL  
 C1CM  
 C1CN  
 C1CO  
 C1CP  
 C1CQ  
 C1CR  
 C1CS  
 C1CT  
 C1CU  
 C1CV  
 C1CW  
 C1CX  
 C1CY  
 C1CZ  
 C1DA  
 C1DB  
 C1DC  
 C1DD  
 C1DE  
 C1DF  
 C1DG  
 C1DH  
 C1DI  
 C1DJ  
 C1DK  
 C1DL  
 C1DM  
 C1DN  
 C1DO  
 C1DP  
 C1DQ  
 C1DR  
 C1DS  
 C1DT  
 C1DU  
 C1DV  
 C1DW  
 C1DX  
 C1DY  
 C1DZ  
 C1EA  
 C1EB  
 C1EC  
 C1ED  
 C1EE  
 C1EF  
 C1EG  
 C1EH  
 C1EI  
 C1EJ  
 C1EK  
 C1EL  
 C1EM  
 C1EN  
 C1EO  
 C1EP  
 C1EQ  
 C1ER  
 C1ES  
 C1ET  
 C1EU  
 C1EV  
 C1EW  
 C1EX  
 C1EY  
 C1EZ  
 C1FA  
 C1FB  
 C1FC  
 C1FD  
 C1FE  
 C1FF  
 C1FG  
 C1FH  
 C1FI  
 C1FJ  
 C1FK  
 C1FL  
 C1FM  
 C1FN  
 C1FO  
 C1FP  
 C1FQ  
 C1FR  
 C1FS  
 C1FT  
 C1FU  
 C1FV  
 C1FW  
 C1FX  
 C1FY  
 C1FZ  
 C1GA  
 C1GB  
 C1GC  
 C1GD  
 C1GE  
 C1GF  
 C1GG  
 C1GH  
 C1GI  
 C1GJ  
 C1GK  
 C1GL  
 C1GM  
 C1GN  
 C1GO  
 C1GP  
 C1GQ  
 C1GR  
 C1GS  
 C1GT  
 C1GU  
 C1GV  
 C1GW  
 C1GX  
 C1GY  
 C1GZ  
 C1HA  
 C1HB  
 C1HC  
 C1HD  
 C1HE  
 C1HF  
 C1HG  
 C1HH  
 C1HI  
 C1HJ  
 C1HK  
 C1HL  
 C1HM  
 C1HN  
 C1HO  
 C1HP  
 C1HQ  
 C1HR  
 C1HS  
 C1HT  
 C1HU  
 C1HV  
 C1HW  
 C1HX  
 C1HY  
 C1HZ  
 C1IA  
 C1IB  
 C1IC  
 C1ID  
 C1IE  
 C1IF  
 C1IG  
 C1IH  
 C1II  
 C1IJ  
 C1IK  
 C1IL  
 C1IM  
 C1IN  
 C1IO  
 C1IP  
 C1IQ  
 C1IR  
 C1IS  
 C1IT  
 C1IU  
 C1IV  
 C1IW  
 C1IX  
 C1IY  
 C1IZ  
 C1JA  
 C1JB  
 C1JC  
 C1JD  
 C1JE  
 C1JF  
 C1JG  
 C1JH  
 C1JI  
 C1JJ  
 C1JK  
 C1JL  
 C1JM  
 C1JN  
 C1JO  
 C1JP  
 C1JQ  
 C1JR  
 C1JS  
 C1JT  
 C1JU  
 C1JV  
 C1JW  
 C1JX  
 C1JY  
 C1JZ  
 C1KA  
 C1KB  
 C1KC  
 C1KD  
 C1KE  
 C1KF  
 C1KG  
 C1KH  
 C1KI  
 C1KJ  
 C1KK  
 C1KL  
 C1KM  
 C1KN  
 C1KO  
 C1KP  
 C1KQ  
 C1KR  
 C1KS  
 C1KT  
 C1KU  
 C1KV  
 C1KW  
 C1KX  
 C1KY  
 C1KZ  
 C1LA  
 C1LB  
 C1LC  
 C1LD  
 C1LE  
 C1LF  
 C1LG  
 C1LH  
 C1LI  
 C1LJ  
 C1LK  
 C1LL  
 C1LM  
 C1LN  
 C1LO  
 C1LP  
 C1LQ  
 C1LR  
 C1LS  
 C1LT  
 C1LU  
 C1LV  
 C1LW  
 C1LX  
 C1LY  
 C1LZ  
 C1MA  
 C1MB  
 C1MC  
 C1MD  
 C1ME  
 C1MF  
 C1MG  
 C1MH  
 C1MI  
 C1MJ  
 C1MK  
 C1ML  
 C1MM  
 C1MN  
 C1MO  
 C1MP  
 C1MQ  
 C1MR  
 C1MS  
 C1MT  
 C1MU  
 C1MV  
 C1MW  
 C1MX  
 C1MY  
 C1MZ  
 C1NA  
 C1NB  
 C1NC  
 C1ND  
 C1NE  
 C1NF  
 C1NG  
 C1NH  
 C1NI  
 C1NJ  
 C1NK  
 C1NL  
 C1NM  
 C1NO  
 C1NP  
 C1NQ  
 C1NR  
 C1NS  
 C1NT  
 C1NU  
 C1NV  
 C1NW  
 C1NX  
 C1NY  
 C1NZ  
 C1OA  
 C1OB  
 C1OC  
 C1OD  
 C1OE  
 C1OF  
 C1OG  
 C1OH  
 C1OI  
 C1OJ  
 C1OK  
 C1OL  
 C1OM  
 C1ON  
 C1OO  
 C1OP  
 C1OQ  
 C1OR  
 C1OS  
 C1OT  
 C1OU  
 C1OV  
 C1OW  
 C1OX  
 C1OY  
 C1OZ  
 C1PA  
 C1PB  
 C1PC  
 C1PD  
 C1PE  
 C1PF  
 C1PG  
 C1PH  
 C1PI  
 C1PJ  
 C1PK  
 C1PL  
 C1PM  
 C1PN  
 C1PO  
 C1PP  
 C1PQ  
 C1PR  
 C1PS  
 C1PT  
 C1PU  
 C1PV  
 C1PW  
 C1PX  
 C1PY  
 C1PZ  
 C1QA  
 C1QB  
 C1QC  
 C1QD  
 C1QE  
 C1QF  
 C1QG  
 C1QH  
 C1QI  
 C1QJ  
 C1QK  
 C1QL  
 C1QM  
 C1QN  
 C1QO  
 C1QP  
 C1QQ  
 C1QR  
 C1QS  
 C1QT  
 C1QU  
 C1QV  
 C1QW  
 C1QX  
 C1QY  
 C1QZ  
 C1RA  
 C1RB  
 C1RC  
 C1RD  
 C1RE  
 C1RF  
 C1RG  
 C1RH  
 C1RI  
 C1RJ  
 C1RK  
 C1RL  
 C1RM  
 C1RN  
 C1RO  
 C1RP  
 C1RQ  
 C1RR  
 C1RS  
 C1RT  
 C1RU  
 C1RV  
 C1RW  
 C1RX  
 C1RY  
 C1RZ  
 C1SA  
 C1SB  
 C1SC  
 C1SD  
 C1SE  
 C1SF  
 C1SG  
 C1SH  
 C1SI  
 C1SJ  
 C1SK  
 C1SL  
 C1SM  
 C1SN  
 C1SO  
 C1SP  
 C1SQ  
 C1SR  
 C1SS  
 C1ST  
 C1SU  
 C1SV  
 C1SW  
 C1SX  
 C1SY  
 C1SZ  
 C1TA  
 C1TB  
 C1TC  
 C1TD  
 C1TE  
 C1TF  
 C1TG  
 C1TH  
 C1TI  
 C1TJ  
 C1TK  
 C1TL  
 C1TM  
 C1TN  
 C1TO  
 C1TP  
 C1TQ  
 C1TR  
 C1TS  
 C1TT  
 C1TU  
 C1TV  
 C1TW  
 C1TX  
 C1TY  
 C1TZ  
 C1UA  
 C1UB  
 C1UC  
 C1UD  
 C1UE  
 C1UF  
 C1UG  
 C1UH  
 C1UI  
 C1UJ  
 C1UK  
 C1UL  
 C1UM  
 C1UN  
 C1UO  
 C1UP  
 C1UQ  
 C1UR  
 C1US  
 C1UT  
 C1UU  
 C1UV  
 C1UW  
 C1UX  
 C1UY  
 C1UZ  
 C1VA  
 C1VB  
 C1VC  
 C1VD  
 C1VE  
 C1VF  
 C1VG  
 C1VH  
 C1VI  
 C1VJ  
 C1VK  
 C1VL  
 C1VM  
 C1VN  
 C1VO  
 C1VP  
 C1VQ  
 C1VR  
 C1VS  
 C1VT  
 C1VU  
 C1VV  
 C1VW  
 C1VX  
 C1VY  
 C1VZ  
 C1WA  
 C1WB  
 C1WC  
 C1WD  
 C1WE  
 C1WF  
 C1WG  
 C1WH  
 C1WI  
 C1WJ  
 C1WK  
 C1WL  
 C1WM  
 C1WN  
 C1WO  
 C1WP  
 C1WQ  
 C1WR  
 C1WS  
 C1WT  
 C1WU  
 C1WV  
 C1WW  
 C1WX  
 C1WY  
 C1WZ  
 C1XA  
 C1XB  
 C1XC  
 C1XD  
 C1XE  
 C1XF  
 C1XG  
 C1XH  
 C1XI  
 C1XJ  
 C1XK  
 C1XL  
 C1XM  
 C1XN  
 C1XO  
 C1XP  
 C1XQ  
 C1XR  
 C1XS  
 C1XT  
 C1XU  
 C1XV  
 C1XW  
 C1XX  
 C1XY  
 C1XZ  
 C1YA  
 C1YB  
 C1YC  
 C1YD  
 C1YE  
 C1YF  
 C1YG  
 C1YH  
 C1YI  
 C1YJ  
 C1YK  
 C1YL  
 C1YM  
 C1YN  
 C1YO  
 C1YP  
 C1YQ  
 C1YR  
 C1YS  
 C1YT  
 C1YU  
 C1YV  
 C1YW  
 C1YX  
 C1YY  
 C1YZ  
 C1ZA  
 C1ZB  
 C1ZC  
 C1ZD  
 C1ZE  
 C1ZF  
 C1ZG  
 C1ZH  
 C1ZI  
 C1ZJ  
 C1ZK  
 C1ZL  
 C1ZM  
 C1ZN  
 C1ZO  
 C1ZP  
 C1ZQ  
 C1ZR  
 C1ZS  
 C1ZT  
 C1ZU  
 C1ZV  
 C1ZW  
 C1ZX  
 C1ZY  
 C1ZZ

Figure 8A



10/11




Figure 9

11/11

Surface staining of *S. aureus* (strain 8325-4 spa-) with purified anti-LPXTGV IgGs




Figure 10











aaatcaattgagtagctgcgaaggtatgagtggatcagaatacaagctcaacaaagtgtgpgc  
gattcgcwgtcaagntcaaaagtaatatgctcaatttgacttatatgacatacagtgatca  
gaaagcgactcaattgtctacaagtgattcgttatagctcagtggtatcaattcaacaggt  
acatcaacttcaacatcttgactcaatgagcggagcgtatcagtttcaacatcgcaaaagt  
ttaagtgaactcaatatcaggttcaacaaagtcgaagtgaactcgactcgacatcaacagcaact  
acatcaattaaagtgaattcaagtctcaaaagcgaaagtcacaaagtcacagtgcatctcggttcc  
ttaagtacatcgatatacaacatcaabgtcaatgagtgcttagtacaatgctcatcaaaaagc  
acatcggtgtgcacatcattatcaacatcagaacagtabcagtgattctacttcaataaagt  
atcagtcggttcaaaagtcagtgagatcgaactcacaagtgattcaacttctatcagtg  
gactcagaactcaattgagtaacatcagattcagactcgacatcgacaggtacatcgagctca  
acaagtggttcaacttcaaaagcatatctgaatcattaaagtaogtctgtttosggttca  
acgagcgtatctgactcaacatcaatggtgaattcaattatcctcggtgtttcaatgttca  
caagcaaaaatcgacatcaactcaattatggtgactcagatcaggttcaacaaagcaatca  
aogtcaattgagcacaatcagattcgacaagcacatccgaatcaactgagtaacatctatgtct  
gggttcaaaaagcatttctgactcaacatcaaaacagtatgtccgggtcaacaggtacatct  
gaatcaactcaatgctcgtcagactcaatgagtgatgcatcacttcaacgacagagc  
acatctcggtatcaagtgagcaacaacaggaagtgatctctcactcactcaatgaat  
gcaacatctgaagtgaatcaataatggtgacacacagcaaaaagtgaanaagattgcca  
gatcacggtgactcaataaacaazantggattactagtggtggttatgacattattggtt  
ggtttaggtttatgaagagaaagaaaagaaagtgaaatgatcaagatgatctcaaa  
gca

9.	<p>atgctcaaaataaaattttaatttatttgcatacactacgtctgtattacactacttta  gtttccactaacgccttatgtctgatacccccgaagaatcactacagctaaagcaacatct  catgattcaaaaataatctaatgacgttgatgaacactctcaggtatctacagtaaaagatt  gtaaagcagcgaataaataatgatacagaataacagcagacataaagcgaataatttaaaact  atagacgcagcgccttcagactcttaacaataatcattgattttattataagaatttaaca  caaaccaataataaaccaaatctgatacccaaaataaactacgtgataatttacttaataca  actttaatcaaaaacttatctcaatttaaatctggatattcttgatcacgaacaactcgt  aatggcgaatgctcaaaatgattgattgataaannccgtgatacagatgcataaaatgac  actgatacgcatactcatcaaacagataaagcagcaaatcaaaagccactaaatcaaac  atacaaaacacagtaactatcaataagcaacaatctcgcaaaagccacacacactaat  caatcaaatatgctcaaacacacagcagatcaaaagcaatcaaaaactctcaagaagat  aatcaataaagtctcagattcgtcttagactctattttggatacaaatcagtgaaagtga  aagaaacacacaaaagattatgactctcaatctonaanaagcaaaaatgaaaaatctaat  acaagaattccacagctcaacacacagatgaaatgaaacataaaatccaaacvgtcaaa  taattcaataagcgtctaatcaaaagctacaagctgcaacattcttcgaacacagat  cctagtatctacaacatgatgatacggaacatttaagcttggtgaactcaaaagataca  cgtcaatttgcaaatcaatcgtcaaaagcgaactcgcatttggtcaggtacaagctattct  tatgggtcgtctatgatggccaaagcactctagaactctgacacagctcgtagtgattta  gataagtcacacaacatttaatttctggtatcaacaggtgcttttgaaaggaattctggtt  catttttaacacattagaagctgattggttaactcaattgtatagttaatcgtggaattccga  anaatatacgaacgaagaaatcaactcaaaagattactctgacctatttaaaatggtatt  gatggcaatcgaaacattataaacacactggaatcgtggaagcgtgattctatcaaaagat  gcacactacacattatcaaaaacatactgcacagatccaaactatgctagaanaataaac  agttattataaacactatcaatttaactcagtttgacgatgacgcgtctccagatttagat  aaatatagaagctctctcaaaagattatgattgatctcagatgattcaaaactctccgt  gggtatctgtaagtagtgcacattatccaaatcgcaatgactcgttggaattataaacgt  atgaacaactttggtacactctatctcgaagtgatttagtgatgacaaatgtggaataat  cgagctcaataacgtgattatcaagtagtcaatacaacaaacgtcattcgtcgtgtgta  tttgagctggcaaatctggtgagatcaacattacgctatgagcaattgttgaaaa  gttaacgtgattggtctctcgtatttcaagatacattataaagattaggtatcatt  tctatagaactataaacgongctgcgcctggaagattatcattatcacaggtaaa</p>
10.	<p>gtgaggaaattttconagaatgatttaaaagtatgacagatcaactcgttggtgacact  ctatcacccagcagatctagcgtatgattcaaaaataaaacagcttaactctggaattaaa  tttgaggtgattcnaaaagtgatgggtgaacgaatataaaatctgctaaatctcga  aatgtaaaanaatttatctcaagattacgctggtctaatgatcaaaaactgataaaaagga  ttatagcattatacattgcaacgaggtgtgtgtgtgtctcagtcacctgacaagaagngtg  aaagtacacgcagcaacaaatcagaagaagcgttttaabcaatgggataactgatgggaag  aaagtcaacgcacacattcaagtagcatttaagtaaaagtagcgcgcgaacagattt  aaagcagttaaagtatgataagaaataaagcgaataatcttaagataaaagtcttaaaaga  acaagaagtgaataatcgtgtggaacgaataaatacgtttatatactgttgatttaataca  gtgcacacgaatatttcaatttgaaagttaaaattatgctcaactggcgaaattta  gaaanaatgaacttagttaaagaagctcgaggaactcgttaaggaagaaggtgtactgtgc  gatacaaaagatatcaatcaatgattatgcagcgtgatttagctgaagatttaaacg  cactaaaggtataattacagcatttagcttaagatcaannccgggtcaagcaacattgatt  actaatgagatgaacactctgtaaaaggtgagcaactgctgcgtgaatgaataat  tagcttaaacacactatgattattacaagaacacatttggtcgtgaactcatgatgaacaa  caggggtgtcaattgtttcattaaagcattgtaataactacagcgtgtcagaataacaga  atatacgcagctgagagcgtggaacaaatgctatgtgtgtgtgtgtgtgtgtgtgtgtgt  acaggtttatcgggtgcaaatgacgtgtagacacagattacaacccgtgtgcaacaa  gagacgcggaacttagaatataaagcagctcggcgcttaataaagaagcttttcagat  gtttttggtactttgtgagagagagattcttaaggttgagagctctcaacacact  ggaaaggggggt  catatgaagactatgtatttcaactgaagaagataatggcgtgtgtgtgtgtgtgtgtgtgt  attccaaataaagcgtttataacgtgatttaagcaaatagggaactcaaatcagaacaa  atttactaccagactcaacggaacttaacagaaatttaaacagaaattcaaaagctgtgaa  gatgattatacagaagcgttaagatttatatgcgcgagaacagctgaacaggtgatt  gaagcattgaatgaagtagcgtgtgag</p>





16. gtgaaaaacaattotttaggtacggcattagaaaaacataaattggggcagcattcagtatto  
 tttagaaccaatcgctgttcttgggtagcgaacagcaaaagagctcgagcagatcgacaa  
 aagcaactacagctagagaaacgggaatctcagctactgatatatacaaacaggtgaaaca  
 caaacacactgcaactcaacgttaactatagaaagaaactaatctataacagcagcagta  
 acagacacacactgtcaaacgcacacaaagttaacacttgaaagacacccaagcagtaacaa  
 gcaccaacaactgcacacacacgaataatagaaaactgttaagaagcaggttagttaaagaa  
 gaagcgaaactcaagtttaggaaacacacaaactctcaagcaactggaagagatcaagaa  
 caagttagattcaacacctaaagagctacacaaatcaagtcgtagaancacaaagttagaa  
 gtggcagcagccaaagacggcactcgaagaatgaagccacgtgtgacagatcgagagatgta  
 goggagagctaaaggaagctagtcaacgggaagtggaaacgggtacacagtgtaacagtaaa  
 gttacaggtagaaattgggttctatgtgggggttaacactacaaataaagtagaaactta:  
 gcaggacacagcggcgttactaataatataagttgaatttgagaatgggtttacatcaaggt  
 gacactttgactctcaattatcaaaaataatgttaaatacgcagtcgggtatcaactgctaga  
 naagtaaccgaataccaataatggctcagtgtaagtggaacggcagagaggttttagaaggt  
 ggaagatttagatatacaattcaaaaatgatacttgagataaaggttgtagttaaocgctgaa  
 ctgaaataatatttatttatgtacctaaactgtacaaaactatggaataccaactata  
 aactcaacctaaactgaagacacaaactcaaggaatgtaggtgtaataatcaagatgggt  
 attgggaattattatgcacaaatcaaatgggtatgttagagaaatttaataaagcgaataat  
 agtttttcgactgttgcctttatcaaccttaataatggttaaacacgacaggtgtgactggt  
 actggaactttaatgaaggttagtaatacgaatggaaatcaacccaagaatttagatatttt  
 gaataactgggttaataatgaagacntagcggaagcgttatatgcaaaacagcagagatct  
 tctataaatttaaggaagtcacagtaattatgagtggaattttgaattcaaaaataagcga  
 agctattcaattgnaattagaaaactctagataaaaacttatgtgttcaactatgtagggag  
 tatttaaaagtctacgatgaattgatttttagaacacaaactggttagacatccagacga  
 ctttataagtatattatgtagagggatataacttaacttggglaaattggtttagtttta  
 tncgttaataacgcgaacggaaatgggaaataatggtccgattatccaataatacaattt  
 gaatacaagaagatacaantaaagaaactcttcaaggtcaatatgtagaagatttagta  
 actacgcttggaagaggaattgattcaatcaactcttgacattggtatcacacacagctata  
 gatgtgggtgggtggtatgttgaaggatccttggaacaaatagaaagacggatataca  
 gctattgatatcgtattaccataactgctgtgtagtaggaagcaggtcaagtttagaggtac  
 actcggtctctctgaggaatcaaatcccaatgaacttgagaagattcaactatgaatbca  
 aaacatcacgctgagctgtgttgaaattgaagaagatacaaacccaggtggtgacaggt  
 actactgggacttaacttagtgaaatttgacgaaggtctacaaaaggtattgttaactgac  
 gcagtgagcagatatacaaacgttgaaatgatacgaagaataatacaactgaagtaactcg  
 atgtgaattagttagatgaattacgtgaagagctgctcaagcacaaggaacagctcgagga  
 attactgaanaacabactataattctcatctgtgttaggaactgaaatggttcaggg  
 aattatcgaggtgattgaagaantcgagcaaatctgcacgttgatattangagtgaaata  
 ggttatgaagtggtcccaaatagcgtgaacctgctattcgaggaagacacagagaagacac  
 aaactaaatacgaacaggtgcgaatactcgttagataatgatttttagttagtaactcaa  
 attcaggtcaaaataaaggttaactcgttagcttggaagagatacaactccaagaatgaagc  
 aagttagaatctggcgttaactcatctgatatcgaacttcgcaggttgccacattatcac  
 ggtatcaataagcactgtaaatatttggaagaatcaaatataagataaacacagtttat  
 caattcgggtggaacaaactggttagcttggaagagatacaactccaagaatgaagc  
 caaatggaagttcaaaaagatttagaagaatatacaacacctccatctgtgccacaagc  
 ccacgcacacagaagtagaacaagtgaagcgaagcaacacacagcgaacacacaggaata  
 ccaagtgagccggaacacacacacacacagcagacacaggaagtgccagtgccgaacac  
 ccaacacgcgaacacacacaggttagacactgaactggtgaacacaggaacacacacac  
 gaagaacctaaaagactctcaaacacagtggaacacaggttaagtagtaaacactgtatt  
 gaatacaatgaacaggttcaagcgtggcaccacactaaaanaacacacactctgaagaact  
 gaactacctgaaacaggttggaagaatcaacacacacaggttagtgttcggcggtata  
 ttcagatctcgtggttgcgttatctacgcaaaataaaagatcaacaaaga









25.	<p>gtgtctgtggaatgtcatatcatgtgttttaagaanaatgttaactttcaacagtatattta  atlttaagtagtagtagtttaggtgttgcacgcacacgttgaggaacgaatgttaactta  atctgggaanaacacactactactttagtctaatataacttcaacatcactgaatgaat  gaatgataatataatgagactgtggcacccttcaggaatcaatcaacgggttaatgaagga  acaggttgcgaatctgtgtgtgtataatctgtgttcgaataatgtgagccagactccaaac  aaccaaaaacccagttacagattccaaacagccacccaataatccaaacacacagtggaat  ctcaaacccagatccagatcaccacgaacccaacacccatcccaaacacagccacagat  ccaaagccaaatccggatccaaacacagatccagataccacccgaacccaatccagatccca  aaacccagccacagataaacacacagcccaatccgatacccaaacacagatccagataaacca  agcccaaccccgatccaaacacagcccaatcaaacacacacacacacacacacacacacac  ccggttcaacccgttgatccacataatctgtgtgtgcgaacaaatgggggggaatgggaac  ccaaatgtctcagatggatctaatcaaggtccatggcaacacaaatgggaatccaggaac  cccaaaaacccactactgttgatgttttgatcccaacagatcttttagccttggaacaaatggg  gttcagatgaataactcgttatcttttaataaacttaabagttggggaacggttatgga  gaatttactgctgaggaacatttataataattatccgaacaaatctccggggaatgca  catttaaatggatccacacagcaatgaatccattagattccaaatattccatccatgt  aaatcagaagggtactatgtatcttagatgacagtagtccgattatctactgtgga  atttgatccacgggaatttgaaacacccgaagataagccggatccaaacacacgctca  tttgaaacccatgaaacagcagattttaagtagtttaaaacacaggaatgatatagaa  agtgctcactcgtatagtaaaagttggctagcaattgtatgtctatgtatgtgtgga  tcttccatcatcgtattcttattgttaagcgaaataaaggaacaaataaaacacgata  cagccgga</p>
26.	<p>atgaanaataaanaacgtgttttaabagcgtcatattcatctgtcaattttattgtta  tcagacacacacgactccagcaaatccagctctaaagaactccacagcaacaaataagaa  gaactgtgtgataagttccaaacaaagacacacgttaagttactaaataagataaataat  tcaacagctccggatgatttgggaacacccgttaaaatcccaacacacacacacacacac  tatgtatgagaaacaaatatactccaaatattcaatccgaattatctgatgacacacact  tatgcacagatgattactctgtttaaanaacacgggtccatccatccaaatttaagttt  gaattctcaaaagacaaataaataaataatctgtttaaattccacagtgatccatgga  gaatttcaagtaanaaggaatcgttaaacctggaatattagcccaattggcgaacaaataa  atttccaaactgcacaaagtagacagtaactttccatatagcacaggttggaatccogtcc  aonaaaggtattggaggaactccatccatagctatcccaaacaggttagttatatacag  caaaattatgctccacttcgacgggttaanaataactgtgactgacactgggtgaatt  attgcgaatgacttggaattgtgtgggaacagtaanaataagaaatggaattggaattatcc  catgaatccaggaattgtctactgtagaacacccctgaactgaactgttctgtcccaatatt  agataccacagacttagtgaagaggggttatccacaggaatttttaactatttccatcc  gaaaagtcgaatgggaacacgaatttggaatccatccacacacacacacacacacacac  aaaac  agatttaattgtccattatgaagttgattgggaacaaataaagacgttaaagctgttgataa  tattctgagacataaactccacagga</p>
27.	<p>atgtataacagctacagctacacacagtgatgaanaaataattactcaaacgttaca  tttaatttctactgaacataattatgataaagaacacagattttataagcaaacaggt  acacatgggtgagtggtttgaggaatttcagacacaaatgttatctgggaatgataataga  tggctgggaattctatccgttccatccaaatgttgatgaacacacacacacacacacac  actgattttgacacacaaatacaggaatgaatccaggaacttaataatcagtgatggttat  aaacacagtgaggatatttttgatataatctgtggaggttacttggaatattacacacag  agtaattatccagacacaggttagttatccacacacacacacacacacacacacacacac  ctatcgtccacataaaggttaggttggaatgaaggaacatttgatataatataatgaat  catgaccatacaggaacatttaactaatgtatgataatgaacataaagacataaagatattt  cttttaac  ccgtgaactgtgtcgaaggttataacacacacacacacacacacacacacacacacacac  aaagcaacaggttaatacactttgtgttcttataaagacacacacacacacacacacacac  alagattggaatccac  aaaggaac  gttaaggtacttaataatgaagga</p>
28.	<p>gtgggtgaatttatgataatccaaatgtgaacacacacacacacacacacacacacacac  ggaggggaac  gaanaac  aaagac  aaagac  atccac  tattattattgttttggaac  atccac  tccatgactgtgttttaaac  gatttttggaac  aaaatgggttaccatattccatcagatccacacacacacacacacacacacacacacacac  gataagttatatttagtggaagtgaggcccgga</p>



```
aaagaagatgaagaagatgttactgttgaaagaaaaagattogctaaataatggcagtc  
ctcgatcaggttaaacatagcgcgtctcttaccacaaacgtcgtogtaaggaagatgaa  
gaagatgtggagttacaatatgaacacacagatgaaaaagtggtgaaagataacgaacat  
tcaccactcttattcgcaaacgacgcgaagatanagagggaagatgttgaaacacacact  
agratggaatcaagatgaggagcttcctttatcttggtcnaaggaataatcaaaaa  
gataacccatccaaagacaaaaagtcggatcnaaaaaatctctcaaaagtgagcagct  
aaaaagaagcaaccogaaagctcgguaaaataaaaaa
```

30. atgcatcagggaagtttanaaaacaaaattatttccaatctttaaanaattacgtttgtctacagct  
 tcaattattttttagcaatcacatgtaacggggttatctgtgttcaactttaaagat  
 aagttgttgaatttagtaaatcaacgtagtgccttagtgtacattattttgggtggt  
 ggggcatgctgtttattctatcaatgtatgatgtggtttttctctagagotttaaanaag  
 gatatacctttagcgaagtttttaacggttaagttatctatcatcatgcatgcatgaatgcgatt  
 gtaggtttgtgtggttatgtgtggtggcgttagagcaatggttttataaanaacttaag  
 catgtanaaaagaaattagtttcaatttatatcttcaactattttcaatgttgacagggt  
 ttaagctattatcatgtctaattgtatccaagttttctagatcatcttttaacttttagat  
 aagattacatgggtgaagatgggtgaltatagttagtgcatttttcttccacatttcaatt  
 attattcaagggttagcaacggaataaanaactatggtttgtggaattgtactgcaat  
 ttagtgtctgtgtgtgaatggttagcagctggcagttgtattattttctgtggtgtcaall  
 gttgcgcgtctgttatcatctcatgtcctttatgtcaattattatcatctgtctcatatca  
 gggttagtcaagctttattctctgggtttctggcgcttctgaattagttgtattatcagga  
 tttaaaacttttaggtgtccttgaggaagaaatattatgaagcattctctatcatgctttt  
 ggttaactattttgaccggttaattattgtcaataaattatbatacatttgaatttggtaoa  
 cccgttaagaagacatbgaggggtctcaataactttattctctgtcaagaagtttaagctoa  
 ttcttaagttcttacaanaaggaattattgtcaaaattcaactatcatctcttagaatt  
 ttagtattctttcaagctatgacttttttttgaataaacttaacgattgtttwogattgct  
 ttatatgttggaataacttaacgtattatatactatttggcaattctcatctagtgctgt  
 tctatcaatttactgaattagttagttgtttttaaagaagtagtagtgcaattatcttt  
 gcttgatttcaatttatttaactcccggtgggaactttcttcaacttaagcttcaatttt  
 ttaataaactggttagctattatttttgtctcgtctattgttagctttctgttagagcagct  
 aggttgaanccgccaagtaagaatggaanaatatagttgcaatgcttttatccagttattt  
 ahtttatagtttaacatatatttattgtcgggaagcgttatgtatgatalagattatag  
 attgaanccatcaactgttattgtggtattactttcgttagcaatttcaactatgct  
 atcatcatagttattgattgcatggtgtgttgattatcaatttagcaaatgaactattct  
 tctaaattgagattggaagagattatttatccgtacsgggaattatttgagttac  
 ttgattataggtgtgcgaagagttttctcaatgaanaataaactgaacttttattg  
 tatgcttataaagcaagttcattagtggtcttggagatccgttaggtgatgaanaagc  
 ttgtgaattgttagaagcattctataattacgtgagttattaggcatgattgattata  
 tctcatcaagttcaagattcaacacnccgtttatatacaattttcgttaacaaattttc  
 aacttuggtgaagaaacattattgatttcaacgaattttcaacttgggtgnaanaagc  
 cgttgatttagagcgctttaantaactctgaatgaacttaatttttgggtgaanaattt  
 gaaccacgcttttcaatgaatttataaattgaacttcaacatgtaagttattgtgcta  
 gataatcgtccgggaatgcaattctctgtgtgtgtgaatttaagaaacttatctaa  
 gggaactatgtgtgaatgcgaatgaagaaatgaatgaattgaatttggatgaattga  
 caaactatttgaatgcaattctcgtgatttaattgaattgttgcaatttggatgaattg  
 taacatttaattgattggtctatcttgcataatgttactttggatgaagacaagattat  
 ncaaaatttaattggtatgggaagcgttctgaagcgttggtgaattgcaatttatat  
 ttaagagaacagattcgaagccgtgtctttgaacttcaacggtctatagtttgcnaa  
 ggaattcgtgttaataatataatccgaattgggaacacgctttttagtttat  
 cgttaagataattcgttgggaactcttataaagtaatggttgaactgaacaa

















54.	ttgataaaagctctgagagcggggcattaaatgaagcgtacaaagtcatatatacct atccatttttbtgtgaagatagtcacattatgttgattccaataaatttttatcagcgt caacgttagctggtgacttttagtggaactaaacagagaaatgctacagcaataag acttaaaagcctgtatgtatgtggcgacacacacagcgcctttctatataatcagtbg gaagagattttaaagcnaatagctgactcgtttacatccagcgcgtatatacatttgaa gcaatccctgagtgttaactaaagagaaagtcacactatagggcaatgtaggtcaaa agactttcaagggcgcttaaacactcaagcggcggtcattgtctgtttt agtgaagat cgcatactgnaataktttacacttogggtttaatgctcaaaanagcaggttttaaatca atcagtttagatttaatgtatcatttaacgaaagacagcagtgagagatttgaaacat tttagctagctcttagataggaattatccaactattcogagttacgpgcttaacttga ctaaamaacactattataatagttagaasaaggttgcctaaactcttaakgagat ttacgtgctgacgtgatacagttgctgctgtcttagatagacacatctccttccatcaa tagcaaatatcotaattttgctattgctggcagaatcagacacataataagtttactggt tttaagagagacatttgattcttagacagagctgacgggtcttagagatgtgtgctgt tatcagatatacactcagctgaactttatatacaagcttaaaataaagagaaagca atttttagtatcaataaacactctttgactgagagatgaaagagaaatgtttctctggg ttggctttaaatgaaggttgagtagtagtagttagtgcataaagaggttgcacattctatt gaaggtgcttctgtctcaacataaactatcaaaagagagaaatctatgttagaagag aacgagctgattgcaactacaataagaggaagcattaggcaatgaggtttttagaagt ttcctaataaatgat
55.	MNNLEMLFGDSDVDFFLVREKATCGTTAQQGDYKTLHQDKSREIFAKFWTATKNDNAT KREHIVHWGDIATYKRNQKQVNOIRATTEDLTGTEFVDPAISPAIKQSEBRYILA DIENATQCTRIILKKEYOGEPTTYAASHSHHNFAGLSVNVLMZLXIKSIDCTYFLL NKSLYSGIILHDIGKVELSGPVATSYVEENLGHISIASDEVHAREALINBESRIM LDRINILSHHGKLEYGSKPLPYLKEALTECLYIDNDARMHFKEYKTKDQKQPTLPG LEWRKPTPEBLS
56.	MNKHKIKRISPYIRKQCTLVASVIVSTLFLITGHOQAAKHNITYSOKISENNNNAT TOPPKNTQTPATQPAKNTYPAADSEKDKADPALENKEHIGPREQVNFQLDRN NSTQYTHFESILKUPADVYPTKKARVELDINTASTWKKFEVYNNQKLPVRINVSYPVE DHATIRPVELAGQELVATVSGQLDDEFTWYTKLVAFKPYDSEKMGDFNANVPI NDCSSVASNTQYTHFESILKUPADVYPTKKARVELDINTASTWKKFEVYNNQKLP NSNGNTDKTNSSRQSDVNOQVFPADRESDQAKNPAIDKDHIZALNRPFDQMKNK GERQYTHYASTVEPATVPTIKGPIELGLKATFWKKFVPSGDKKLWFLVSTYDSBRD YATIRVFNQSTVATVKTVESELYGRNHEHYDYLWPAQPIQNDPVDREPTLOKL LAPYHAKTLERQVYLEKLEKLEKPEKYKARYKKLDQTRVELADQVSAVTEPNTPT NQDLTLQEHFVPESESSSESVMDGSEVHPVYATANGQKVVMKTKDSDYMKDLIVE GKRVTVSKEDPNSRILFTPTLQKAVYNAZVVVVAQLGYDQVHRELIJDDITKDD DPSQNTSEFLNAPQSGKQKQVADYVATNSGKNTGDSKZAVTEPESVVDKNNIT DKGVSDVDHLSNDSNNHFKDYDKEMDQTLAKDTDENVDKDAINSVGSNSVDKDS NOKNDVILQNLNADKNNHKKAAKLDVUKQYNTNDEVTXKTRTHRPESDTHCTVCKTV KTKAGAPFSEKBEKLGQSPMLKTCGTTPSSQNMGYALLGMLALIPERIKSK 57. Mndfhtdshthnhtgtpyrcpkfpgfktvialicigallvgikpinstlindk Gatvqtnmmkgqldgqskkfgtvmhekiesvptvgvinnkassvdlilkgksskps Eagvgselycilmnasyivtmhvidganeirvghnkqvaklvgkdavtdlavlki Bntkglkaigfamskvgvgsfagmgplqfagsvsgpikaseartidnetgpnk Vsvlqdaatpgagagwlnonlvgpmskkaetvsgigsaipanevktiedvkl Hgidrpsigilglnkldipeereqlhtdredgyvakdsiddikgdiitiedgkld Riddvrlaylenkkgpgevtvtvirdgktkevkvikkgqekqrsreergqpggdr dff 58. VHQQKERTTTTTINPLGKGVGBGEPTTVTKRVEDHITQPGGSEVPOGHKDSFDNL PIDGTEBVGKFGIKNPTGVRVTPPVDVDTKHQKAGBFEVTKSEIPFKKKRBNPDLK PGEKVTQBGQGEKTTTTINPLGKGVGBGEPTTVTKRVEDHITQPGGSEVPOGH KXGDFPNLPIDGTEBVGKFGIKNPTGVRVTPPVDVDTKHQKAGBFEVTKSEIPFK RVLDPTMEPSFDKVAQNGENGKTTTTTTTTINPLGKGVGBGEPTTVTKSEIPDIWY APEIIPKOTRSRIPNLPEBHTKVIIPKDGKLDKDFTGIIIRFQEDVEIHGAKDSADDS DSADGSD DSADSD DSADSD DSADSD DSADSD DSADSD DADRDNDKTKPKNKLEIDYDNDANQNKLPGLFALACGLFVRGRUKNNKNSK 59. MKSLKTVIGRNNKSHIISVLLALLWMLSVLTYMVNVSPTDANVNTDSKCSKTEPLMT FWTAKMDTTTTTQGLIHSDHNPOTIATVSNVNLKTPILKREKVEHVRDRDMLIP DLBSJLITFTPTDLPASTYLPVLAHNAKVNHPFKRLVILHDAKNTVLKLSAKR DYWKATYTKNDIFDALAKKMPVEDITFKGTLDSHVVPAKPSGLATYKAVP NTIGVEKNALIFLSDSVIRSEKSGVTTYNNNTGVANYNDKREHYTONLSDEASSSKM BETIPGTFDEINHGCPLENDKFLSTNNQSGRTYQFLNGYVPTIKRNGSNQVQVWGE KXGDFRSLRLLPGLVNDKNSKLPKLEVSSELSKNSDINPEVNTIAGTGMKSD BHLTFQNSELVPRVYVYTGKTYVYNDGLE















111.	gtgaaccaaatgggttaagtctaattgtaaaagacatcggttttaattggagocgggtactt agcaacaacatttggcttaattgtctaaagaaatttggccgagactggaattccacgtctaac gaacgcttggtgactccctccatccatgaaagtctgaacgaagaagaaatgtgtggttcggt catcgacatcatgtgcttggaactacacagcttttaacactcgaggtgttatatgacact gaanaagcggaagtgtataacgaagcgttttgagatttcaaaacaaattctgggggtcaacta ctgaaagcgggtagcatctgaagaaacccaagagaatttatacatccattaccacaacacgt tatgttagagtgtaaaacaaagtttaaaactttaaaagcttcactgaagcgtgaagact ttccctatgtctgacaatactgaatataactgaagacatcggaagtatagtaaaaatgtgatt ccattgatgtgaagcggctggaataatacccttggtatcatctggcggaagtaaaatttgc gaaggtacagatgttaaaccttggtgaaattacacactgaagcgtgaatgaagattgaaga catccaaattgttactcgtgaaatttatacatggaagttgtgatttgaacaattatcaaat ggccaattgggaagtctactgttaaaatcgctcaactggtgagaattcaacaacgttaact gaatacgtatcatccggtgtggtggcggtggaacattcccatcatcaaaaacacgggtata cctggaagtaaaatttgggtggaattccctatacagtggtcaactctcttgatgtgtgaaca ccacagttatttgacacacagctgccaagaatttatgtaaaagacacactggtacacca ccaatgactgtaccacttatgatacggcttaccattgatgtgttcaagaacattattatttt ggccactttgctaaattgttggaactcaactcttgaaaaaagttgtcaacttagatttatct aagtcgttaaaactgaacacttaacactttatagcagagcgttaaaaacttaact ttaataaatactcatttgaccacagtaattatgacaaaagaagcgtgttatgacacactta ctgactttctatccagaagacgcaatgaagatgggaattatacaactctgtgaacgt gtccnagttatccagaataacacactggaaacgggtgaaggtatccataactcgttcaaga gtggttaacttcacagaacacacttgtaattgcaactataggtagaatacaccagggcttca aattcagttctcagttcgtgtagaagttatgaacgttaactccgaatacaaaaactgaa tgggcacataaattgaagaatactgctccatccacggcgtgaacacttaattgtgaagaagaa aaataacaggaanaaactcgttaacaaacttcaaaaagcactagaattaggtactataga aac
112.	MKPMKSNKSDIVLIGQVLTSTFGSMLKSEPTWNTHVYRLRDPATGSGNRRNNAQTO HAALCHNTVLPDPGSDIRKARKVINPEPSTKQFQWHLVKGSIENPFEIMPLHLS FYKGRNNTFKYKJAWAPPMWNLITSDIYPMKMLKPLGSCGRKRNIMAAQD EFTWNTFQELTKMNAKISIAHPNMVFNHNVDDFQLSNGQWVYVKNRLTGKTKQV DYVFIAGQGIPLLQKPGTPEKSHLGSGFISGQFLACINQVLEHDKARVYGGEPGTP PMVYHLLDTRVLDGQRLTGGPFANVGRFLKNSLDDFKSVYFYNTITLAAANVNP LTKYFPCDNYGKLVNKLRYEARNRQVYVADTSPKRGKIQGVE VNSQDHYVALLGSPFASSTSVVALEVFERNPPEYKTEWAFRIKMSITVSGSLIDE KLMRKTRCTSKDLELYYEN
113.	atgctagaggacacatttttactgtatccggaacacatcagatagaagaatgaagatcgc gtggacttttttatacaaaaacttaactcaaacctttactgtctgtggtatggtatgggt ggcctaaagcagggaaggtgcgaactaaatttggtaacagttagttgaattcccgcttt gaagcgggaacattctatgaacacacatcaagctgaacatttggctgaataataaana gataaattttcgtcatatccattatgacagaagaanaatgcagaataaaagtttgggt acaaactgtgtttgtggaactgtgttttgaaaaaactgtgtgtgaacaaatcgtgga tctagagccttatgttattatagtgcgaacttgacaacacttactngtgaactcattt gttaactcaacttgtttaaagggtcaaahtacgcgggaagacattatacaatcccaaa cgtacacttatcgaagtgatggcgaacagataaagcgtgtgaactcagatttggattt aagacttaaaattttatgattatttatttaataatcgaatggaataactgatattgtt aaagacaatagaattgaagcttggttgttgtaaaagaggttacaatagaagaatcagttgat caactaaagcaattggcattagataaaccttcgaagaatcagttactttcatcactcgc gctatggaagtgtaaaata
114.	natdthgrdnddagymntnvdcgmghkagvaskvdkeranhawrmkdmnyhaayk qmgttccvavsvvnyvdslayvnrtsdshvnyhtgathrknvkgldcrvslrny dynadtdyvdnkrvkgtdhgmadnhskdnvtaagdky
115.	atggcgaagaagaacattcgtctcttcaagaacatgccaatctcgttactactcgttcac gttgccctgtgtgaacacacttaacgcggaacatctcgtactttatagcaaaaatgyl gactcagttgcaacatcatatgacatgattgacaacgctccagaagaanaagaacgtggt atccaaatcaactctctccacttgatgacaaactgcacaacgctcactacgtccagtt gtccctcaggaacacgctgactcagtttaaaacatgacatccgtcgtcgtccacagc cgggtatcatgtatgactcgtggtgaagcgaacgtcaactcgtgaacacatt ctttatacagtaacgttggtgtaccagcaattagtagattcttataaacaagttgaalig gttgacatagaagattatagaatagtagaattgaagttgaagttgactatattagaagaa tatgaactcccggtgacgtgactgttactgtatgctcgttgacgttaaaagcttga ggcgtgctcatcagagaagaanaacttgaagaattaaaggagctgtagactcactcatt ccactccagaagtgattctgacaacacatcatgtagccagttgaggcgtatctotca ctacactcgtgtgactgtgtgctacagcggctgtggaactgttcaactaaagtttgt gaagaattgaattcatcgttttcaatgaacttcaaaacacgttaccagtgtagaa agtttcgtgaattatagactacgtgtgaagctggtgacacactcgtgcaattatcagc ggtgtctctcgtgagacgtacacacgtgctcagttatagctcgtcgtcgttccatataca cactactgaattcaacgcgaagattactgattatccaaagcagaggtggaagctc actccactctctccaaactatcgtccacacttctatttccgtactactgaagcactcgt gtttctcaactacagagaggtactgaagattggttaagctcgtgtgataacgttgaatgaca ctgaattatagcgtcccaactcgcgttggaagcggcactcgtttctccaaatccgggaaggt gagactgactgatacagcgtgtgttcaaggaactcaata
116.	YAKKFPDRSSZHANIGTHGVHGHKHTTAAATATVLAQNDGSAQSYMDTINAPEKRG ITINTSHIEVCTDKRHYAHVDCPHADYVKNMITEGAQMGQGLIIVAAADGMPQTRHII LSLRNVGVPLVFNKVMDDDELLLELVHVRVRLDLSSTYDFPDQVPLVAGAAKAM GQAYSEYILSLILNLTITTPFERDRMFPFACGQVNFYFTTGRVATGHWAGQIDV ESVRIITGLHDTSKTYVQVMEFKLLDYASQDNGIALRGVARSIEQCVLVAAGSIT NTRFKABVTVLSKDEGGRRHFPFSNTRQPFYFRITDTVTGTVHLEGTGVMVMDQVMT VELLAPLADGTRFSIRRGQTVGGGVVTEIT

117.	atgactaagagtgctgctttatgataacaggtgcaatcaagaggaattggaagtagttattgctgta caattagcagaagaagggtataaattgagcaggaactatgcagcagcagaacaggaagagct gaacagctagctgagaagaatacaaggtcaaggtgtggaaggtttgagatctcaagcaaat gtgcgcagctgcatgaaatgactaaagctgcttttagtaacagagtgcatcaagaggaattg gaagtagtattgctgattacatattgcagcagaagaaggtatataattgtagcagtaaacatgcag gcagcagaagaagaagctggaagcagtgctgcagagaacatcaagcagtaaaaggtgtgaaggt ttgcagattcaagcgaatgtgcccagctgctgtagagttaaagcaatgttaaagaagtagt ttagcccaatttgggtctctttagatggttttagtaaaatgaatgcaggtattactgcgcgaatatt tatataatgcctgagaagaacagaagctgggaatgagttgcttatgncacaaactaaaggtg tatttaacctgcatcaaaacagaccaccaatagtttaagaacaagctagtggtatca tcaattatcaaggtgtgttgcgagcagtagtcaatccgggacagaagaacatattgtgcga caagaagcaggtgttattggttttaactaaatgcgcgcgcgtggaatagcattgcgtggtg tcaactgaaatgcagctgcgcctgggtttattgttctgtatgacagagatgcttttaagtg atgagcttaagagctgctgtgtgctcaactgctgtgctgcaatgctttggtcaagcaacac atattgccttaacagctagcgtcttagnatcagaagaagcaaatatattcacaggtcaaa caatccatgtaaatgggtgggaatgtaactg
118.	MTKSAIVTGAARGIGRIALQLAEBGVINVAINYAGSKKAAVVEBIEKAKVESPATGAN VADAEVKAKHKS/VSGGOSLOLVVWNGGTADTLLAKMKQWDMIDTTLAKGVFWLQ KATVQILKRSKATLINSVVGAGVGNPGQANYVAFKAGVTGKSAARELABRGITVNAV AFGEIVSIVMDALSDELKEVM/QIPLARPGQTDIANTVAFLASDKAKYITQGITVHWG GMYM
119.	agaaaattttctactaaaggaagatgppacttaactttagatgttctcttcttgaataaaa gaggggacaggtgptatcatcaattaaagtcaatttgcctgaagaacataatttgagtgattt tatttagaacaagcttctgtaggtctctttaagaattgcgggggttaattgcgaagcttgcagcgt gctaaagptggatataccaattaaagctgcgcagcgggaagaatactgcagcaggggattattata agacgtgttagaaggtcccaattcaacttctggaagatbtgaaacagaacacactgcgcga aaacaaactatggtatgcgatgagagatgcagtagagagatgcttttagatcatacaaatgt aaatatattagcgaagaattgtgagatacaagtggaagtttagacaggaatacatgttttatatt
120.	MIKIDTKGRYGLTMIILANKKGRDPTSLKSLAQTNILSHVILGVSPTRMAGINMSTR QAVGCVVLGSEFATVAGDILVRLVPGTSLACVWKSILPVVSGGAFAGMG
121.	gtgcgctttgaaattagatttaacagatatacggggaaggtatccacagaaggtgaanaattgta aaatggtttgttaagctggagatcctatgcagaagaagagatgttttagctgaggtacaaa aagcataaactcagtagtagaatacccatccacagctatctgttaactgtagaagaagttatg gcagaagaaggtcacagtagctgtaggttggtagaattattgttaaaactgcgtccagctgat gcagagagatggaattaaaggtcatgagtaggtatcatcaactaaagagaagaactgcga aaagagaagaagcgcagcagagcagaacactgtgctactcaaaactgaagaagtagatga aacagcaactgtttaagcaactgctcagtagtaataccacgcgcgtgaagaaggtgtctaac actaaagcagcttcttgagctggttaaaactggtgattatacaaaagagagtagtagtga tacttaaaatgtgtgtcccaacacagcttcaaaagtaactgcgtctcaactacagtgga gaagttgctgaactcctgcgaacactgcgcagctgaacatagaagggcacttccacaga acaactgaaaaataactcctgctatgcttagagaacttgcgcgaagcgaatgttaactctaa catctgcacactcagctgaactttaaagtagaataattgagtttgaagcaatttgggtatc cgttaagaactttaaagaatactgcagctgacaaaggtactaacttaaacatttactaactat gtgtttaagcaactgttttttgttaataaaaataccacagcaacttaaacattcaatcaaat gaagaagcgtgtgaatactggttcaataaactacggaaatcgggtattgcgcgaagcact gttagagattatttagtactgttttaaacatgctgactgaagctatttttccaatt tcagatgaatttaagtaattgctgtttaaacacagctgtagtgaattaaacagcgaatga atgaagaagtgtcactgcacatacagtaaatctggttcagctgtgcgcgaactggtttcaact ccagttatcaataccacagaagtagaacttttagaatttgccggtattgtctaaacact atgtgttaagattggaagaattgttgcagcaccagatttagcattataaattaaagttgac ccacagcaaatgtggtgtgcacactgcaccaactgaatgaatcccaataagcttttatata aatuuuacgaatatttatataatggagggg
122.	NAFEPFLPDIGRGREGVVWVFKAGDTTDEDVLAVVQNDKSVVLPSPVSGTVEEVM VEEGTVAVGVGVIVKIDAFDAHDMQFGKHDDDSSEKSEPAKEPAPAPAPVATQTESVDM NRTVKAMPVSRKYAREKGVNIRKAVSGSKNGRI/TKEDVDAYLVNGGATSNESGAAMTSE SVASTPAPAPAVLVGDFPEPTPEKIPAMRRAKAMWNSRHTAHPVIMDLIDVQALAKH RKTKTSLAABGPKI/PATATVKAIVSALAKAPLWSPAGBAGELVUKYHWGLGADV DRGLVLPVFIADRKSTFQIODELINEAVKARDKLTADKDEKATCTSMISGAGQGT PVINHPEVATIGRIKAPLIVKGRITVAAPVLSLSFDFHRTDQATQNMAMITIKRLI

123. atgctaaacagagaaaaatannacggcgaataacaaaggaaagggatgggtatccaatcgatba  
 aataaaatttttcgatagaaagttacacggatgggaacagacgatcaatttttggtttacacaa  
 ttaatttttgggtgggaagcagagwgaagaggttcggaaagaaactaaataagatttg  
 aacgaagggaacacttcagaaagcgaatcaatcaatcggtggttaaatggtttgatctgcgaa  
 ctcaatccagaagacaaatactaaaattgatactcaaaagaaagtggtatcattotccaaggt  
 attgaacagacttcaaatgggaactaaatctaaatagaaagaagaaaggtgtcaatccatccacgt  
 ggaaaataagtttgaggtttcaactgcgaatactgataaggaaggttcaacaaactbaag  
 aatgaagatttbaaacactaaacaaactataagtaatacaagaag-ggttacaacactgatttg  
 caagagaataaactcaagttgataatggttcaacaaactaatgggaagaaacaaaggttggat  
 gccaaactgtaacaaactaatctaaatggttcaaggaaggtgaggtatcagaggaatgaagaa  
 actctgtgtgatacaaatgatacttcaaatatacgaataatgtaagaatcaatttgcga  
 aaaaagtcacagacacctaaacgtttgaatacaagaatgggtatagcagaagtcagagacata  
 tcaacagaggttcaaaaagttaagtgaattatacaacaaactaaacaaactaaactgaacttgcgt  
 gattgcagataaaaataaaataaatgataatgtaagccagaagacttatttattcaaatcaaa  
 ctacaggttggtgacagaagtttaaatccaggtgattatttcaaatataactcaagtgatga  
 gtacaagtatatggtgattgaatccggagagatacaaaaatattggtatattcaagaatcca  
 aataatggtgaacaaactgcagactgcgaacactgatactctccaactaaacttaacttaaat  
 acatttaacgttatgtgtgatactgttttaattcttcaacaaactgggaataaattattcaaat  
 tatattggtgtgtcgtacaosattctcgttttagtaaaaagagtggttggttttaattgttaacga  
 ggataactatacaaaaaaacactgctacacttcaatccatccagatttatgtgtgaattgag  
 aaaaaactcaatttgatccgggtttcaatgaaacaggtttcaatgtgtgtgaaagaaact  
 ccaggggtactttcaacaaagatttatgttaaaactccgggaataattttttcaaaaatggcc  
 aaactaaaaggttaacgtttaccactcaactcaagtattatccataataatccggcaaatataa  
 gattgttaacagataaaaaattatccaggttccataaaggtttatcaacttaaaataaggaatc  
 gattgtgaatacaagagcttcacagattgaaacaaactaaacttgcgaataacttcaat  
 ggccgacaaactagcgctggttatgttttgggaabgcagattctggtttatgtgtgtgtgt  
 gtttaatacaaaaattccaaatacaaaataggcgaagccaaactctgttcaaatggctact  
 ctatctctcaacaggttaataaactcgttttactgtgcaagcttcttaggtattactaatca  
 caaagtcggcggtggttcgaaggttatcaaaaattgtgaacactgtatgggaagact  
 aataaaaacggtgttcaaggaattagggaagaaaagggcttggcaatgcaactgttaactgtat  
 ttgtgtcaatacaaaaatacaaaaagtcagggaagcgttactaaagaagatgggttatatac  
 ttgattccaacactaccatactggagattacggttgagattctcaaaccttcaaaaaggt  
 tatgaagttacccttcaaaaacaggttacaacagaagatttgattcaaacaggttatct  
 tcaagttattacagtttaattggcaagataaactctctgcgaacttaggtatttcaaacact  
 aaatacaacttaggtgacttatgtctgggaagatacaaaaataaggtttccaaagaccaa  
 gatgaaaaaggttatattcgggtgaaggttaacattaaaggttgaagaggtgaaggtgtz  
 aaaaacggttacaacagacgctgattggcaataataaatttactgatttagataatggttat  
 tataaagttgaatttaatacaacagaaggtatataccagactacagtaactctggttatc  
 ggaactgaaaaagactataaggttttaacaaacaaaggggttatataaggtgtgataaac  
 slgcaattagattggtattttcaaaaacaaacaaataatttataaacttatgtatgag  
 gaagatacaaaaagaattgtaagcaggatttcaaatgaaaaaggttttccagcgttaaac  
 gttacattgaaaaattgaaaacggttgaagttttcaaaaacaaactaaacagataaaggtgt  
 aaactcaatttactgggtgaagaaatggwcttakaaggtgaattcgaacaaactca  
 gggttaacacaaacaaacaaagttgggttcagggaactgtgaaggtatagattcaaatggtaoa  
 tcaacaaaggtgtcattaaagataaagataaacgtactatttgcactcgtgttttcaaaa  
 ccgacttacaacttagtgacttatgttatgggaagatacaaaaataaaacggtgtccagact  
 aaaggtgaagaggtgactttcaggtttacaggttactgttttaaaaggtgaagaaacaaagt  
 ttaaaaacaggtttacaacagattgaatttgtaaatatccattcaactgatttaaaaacatgga  
 acttataaagttgaatttcgagacactcaggttatcaacaaactcagtaactctgtgga  
 aatgactctgaagaaactctaaaggttttaacaaacaaaggtgtcattaaaggtggaat  
 aactggaacttagcgaaggtgtttctataaaaacaaacaaataatgtttagggtattattgt  
 tggtaagacagttataaagacgggaacaaacagattcaactgaaaaggtatcaaaagattgt  
 aaaggttaatttataaagaaagggcgaaggaatttggacaaactaaacagcgggaat  
 ggttaaatcctgttttgaatttgaatggggtaatacaaaaggtatttttgaagagct  
 gctggcttaacaaacaggttacaataacactgaagattgaagaatgaagaatggaatggtgga  
 gcaattgaggttaacaaatcagattcaatgacatttcaactgttaactgtgaattgactacga  
 gaaagaaacaaacagattacagactcagactcaggaacagactcagattcagacagagactca  
 gactcagattgatttgcagactcagactcagactcagactcagactcagactcagactcagact  
 gatagagattcagactcagactcagactcagactcagactcagactcagactcagactcagact  
 gattcagacagagactcagactcagacagagcactcagactcagattatgattatgaactca  
 gatagacagactcagactcagacagagcactcagactcagactcagactcagactcagactcagact  
 gactcagattcagactcagactcagactcagactcagactcagactcagactcagactcagact  
 gattcagactcagactcagactcagactcagactcagactcagactcagactcagactcagact  
 gatagacagactcagactcagacagagcactcagactcagactcagactcagactcagactcagact  
 gatcagactcagactcagactcagacagagcactcagactcagactcagactcagactcagactcagact  
 gactcagactcagactcagactcagactcagactcagactcagactcagactcagactcagactcagact  
 gaaagacatttaaaacagacttaaggaatgaaggttcaaaaacagcaggttattt  
 ggggaattatgcagacttagagatcattattgttatcgtgttcgttgaaaaacaaat  
 aaaa







133.	gtggaaatccaattagcaattgattattaaacaagaagacggoggtgagttagcaaat aaagtaanaagattatgtagattatcgttagaaattcgttagcgcacattatccacgaaggt ttaccagcagtttaacatatggcgagcacttagtaagttaanaagattatagcgcacgt aaactttatggatgcagctgattatgaagtttagcgaagcaattaaattggcgoggtgta attacaactatagggtgttgcgaagaatgcacatcaataaagcagctattgaagaagctcat aaaaataataaacaattacgtgtgattatgattatcgtgttcagattatgaanaaagcga aaagactagtgcaaggtgtcgtgattatattggaatcacacactggttatgatttcaaa gcagaaggggcattcaccaattagaaggttaagaacggttaaatctgttatataaaattct aaagttgcagtagcgaggtgaatttaaacacagatacaaatgaattgaattatgcgtgaaggt ctcgtattctgttatctgtgtggcggaatcgcgaatgcagatgataccggtagaagcga aaacaaatgcctgcgtcaatcgaagtag
134.	MELOJATDILINKDAELANKVDYVDIVKIGTPIIYNEGLPAVKHMDINISNVKLAM KIMDADYEVQAKFEGADVITLVLWDSASIKRAIIEAHKNNKQLVMDIAVQDLEKRA KELDENAGDYIAVHTDVLQABQDPLSLIATVRSVKNSKRAVAGGKIPDTIDIVAS PLVLYSGELVNDPQALANCRRAITGR
135.	atgaanaaaattagtaaccttattattgaccttattacttctgttctgctgcagtggttaact gctgttaacaaacagcagtgataaagtcasatggccaattaaagtagtaacgaagcaattca abtttatatgatactgcgaataaagttgctggcgagcaacgtgcgtatattcaatagtttgt ctgtttgtgtcaagtaacctatgataatgaagtttaaaccttaagattatataaaagtttaact gaacgtgcagcttattttatcacacaggttaaaatttagagactggtgaacggttgggtttgaa aaagcctttagaacagcgtggttaaatcatataaagtaaaaaagttatcgcagttatccaa gaagtttaacctattattataacggtgaagaagcgaacaaagataaacagatccaa cgtatgttaagttagtaaacggttatataatagtaaaccaattcaacaaacattatc gatacgcgaacaaacataaagcagattatgaagaagcaggttaacaaatcactgctcaaa tgggaanaatttaatacattgcgcgttaagcgaatctaaagacattccaaagaacacagct gctatgtatcaagtcgaagtgcttccaaagttctctcaaaacaaataggttatcacaa ggttatatttgggaanaatttaaacctgaacaaacaggttacacctgaacaaatgcgaacagtt attgagtttgttaaaagaacaaatttaaaacatttattagtagaacaaggttgtgttaag aaagcaaatgggaagtttatctgaaganaagaagagatattcttgcgaagtgtaacaa gattcaaatcgtgttaagaaggaacaaaggtgactcttactatacaaaatgataaatacaaat attgaacattgtaacagggagcagaa
136.	MEKLVPLLLALLLVAACTGKQSSDKSNGKLVVTTNSILYMAKIVGVGVNVDIHSIV PVGQDPRHYVVRPKIKILITADVIVLYGALNLTGNGWFKALGKAGSLCKKVLAVSK DVKIVTANQDPRKQDQPHMLSLONGIVTVVGTQTVFIDNDKRAKADFKQSKIVLQ LEKLNDSKCKFNDIPKFORAMITSGQAFVYSKQVGTGTVYIWTNSKQGTPEQRKA TEFVKKHLKHLVTSVDKKAHESLSSTKODIPGVYVTSIDKRGTKGDSYVTKHNS IEVYHGSNK
137.	atgcacactgataattttgaacctttctgaagaaacacttcttgattattotaanaagccaa aatgtgaaccttcttgatgcagcaattacgtataaaaagctttgaatttaacgaauuactta gaactgccaaacactgataaaaacaaattaaagaanaaggtttgattcttttaacaa cacagatgaanaaggtgattgttacaattttacaacattcaactgaactgagcagtaagaa attatgacgtagatcaattcaaaacacttgtaattcaacaaatcaatgattatgcgaac acacaaagttgatgataactgataagatggcgttatcgttgaaggttttagcagagct cttatgaacctagtgtgatttagtaaaaaagtaactttatgaagaagtcgaacacagtagat gaacactgtatccacagcgtataacacggcattagtttaagtggtggtattgtttatgt ctcaaaactgttagtttagtaaacctcgtcatatcactgtgtgtgcacgcagcgaacaaat gcaagctttataacactgttatcatcgtttactgaagaaagcgcgaactcaacattgtt gaaaatctactatcaaatgcattcgttgaagaanaactcaataaattattttctgaagct attcgtgtgtgcactcaaaatcaacatacgttcagtgatcattatggaanaaggttt acccgtcatctactcgtcagctgattactgaagcgggatgcctcaatttaattggcacta ggtttaatgaatgaggttagcacaattatgataacaaacaaatttttgtgtatgt tcaacagtttacttaacatcagtagtgttaggtacacagggcgaacaaatctaatcaaa ttataaaactgaactatcgttaanaagaaacagctgttatctcaacactcgtgttag aaagaacatgcatcgttgtatttaattggtatcgtcacttaataagcagtgrrggaactaa tcaattgataatcaggaacaaagttatcaagtattctcgaacagcagctcgtgtgacgc aatcctttttatttaattgtaggaagatgtagcaagcgggtgcaatcgtcgtcaggt cgtgttgatccagatcaacttactatttaattagtgctgtgtattcttaagaagaaagc gaactcctgtttatacaggtttcttagatccagtagtactgaattactatcagagac gttaaacgtcaactgagagagattttcaacgcgaagttcttcaa
138.	MFIDILALSRGLVLYSALNRBSWTELAKAIATPWLMEYVKKYKIRKNDGSPKQ HYVKGVCYSLQVPSVRKRIIDVHSEKNAVLQNTIATVQVVDNASKGQIVBGLADA LMNHSILVQKVMKDAVDEHRTALATLVNGGVVYVKNVYVVEHPVQVYVVLIEDRN ASPVNRIIVIPKRSARVTVYVYVLSNAGSGKQLNLSVLAGMNSVTVGVYVAKGCF TSHITRQVYVADAETMVALGLANKSGQITLWPNLGFDRSTSLKSTVYVGGKILN SKIVYVGTGTYDYLKGVKMGHASSVFNISYTYHSGTKSLANGSESVLMSEHARDA NPILLIDEDVQAHASVGRVDDPQLYVMSRQISQRARRIVTHGFDVPRVREPIED VKRLREVIIRKVRK



143. atgagctgggttggataaaattatctggcggaagataatgatctcaatgatgaactggtat  
 agaaagaaadaagcgtcgaagactccacaanaattatagataacagatcatcactactactg  
 actccaaataataatgatttatgatgtgtcggagggaataatccgtttctctggaggtga  
 gtttatgaaatgaanaattggaacaaactcgacatctactattctcagatgaaaagacaa  
 taccatcgagactatcgcaaaaacgcccacgattctcgttccaaaaaacgacatccgcct  
 agaaagaatccaaacactgaagacaaanaattatagtgaaacagctgggtgattctcaaa  
 tcaaggaaagtataaalataaagatcatctcaantacatcagatataacgaggtaca  
 tatgtttctctgcaattantggtatggaaggaanaacgcccacgcccacaaacataatg  
 tatctcaataacacnaatcatcgtgtctaaagaattcaactccaggtatctcaaaaagaagt  
 tccagactctcagcgtccagctcagttatgttctggcaccataagcaaaaaggtgaaga  
 aatggtcgtatccgttgaajaaacattcagaanaaagttaggtcaggtatacaaaaataat  
 gataaatagttagtataagacgcaaacgtctcaaaataaacattagaacagaaaaacaa  
 aatgatagtgtgttccaaacaggaactgattcaaatctctcgtgaaanaattgataatca  
 aacaaaatacaatgatttccaaagctgattcaactgaatgatactcaataaaatgaaata  
 tatgtcttccaaatggttgaagaaatttagacgttaacggtgaagagaaagttaagtctca  
 agctgatttaaaaagcgttggcaaaaagcgtgaagaaactataaaagagagacagat  
 gaaatacaaaagcgaattggaagaaattgtctgaacacagcgggaacgttatgttgggtgt  
 agtcttaataagatgctgtgtgtatccagataatagtagtaagatggtgtgtgtgtat  
 acaaatgtgctgtgagatgaactgtatacaaatgtgaaanaataaaagcgttcaatcaaa  
 aatgaagacactaatgcaactcatgttgatgaaggtccatacaatattcgggggaagtgt  
 tggtaacagatcatcgcaaaaacaaactgttgatgaggtgaaggtacggttctgaaatga  
 acgttccaaatcaatcaggaactcaacataaacgttctgagtaagtgaatgaagatgaact  
 aaaaatcaatccagatttaattgtgtatctcgaagagatggggaacagaaatcaaaagaa  
 taatcagggaactcaatcgtgtgtgtgagaaatttatgaatcaatgatacaggaagtgtat  
 gagggtatccactccaaatccagataatccaaatgaagagcgttggaaatggtgtga  
 gacgtctccaaacgcaagcgtacgcgttaactggtatctccagtaataatactcgtataa  
 accgttggataatgaattgaattagcaccgcgtccataaaaagatgacacaaacaaacta  
 agtgcacactcatggaacgaaggtgtgaatgataatcatgtgttggaagaaatccagc  
 atgtgtgaattagaanaagataacgcaggaatcaggaanaatgtgcaaaacgaacagct  
 gaaggtgaacaaatgtcgaagagaanaactattggaacagcttaactcaaaaacaaacagct  
 gaagaaggttccaaacttaagtaaaagcaacttaattgtctcgtatccagcgtatctgataa  
 aagcgtatcgtgtgaaggtgaagcattccaaagtcgaatgtgctgtgtatlaaagcgtga  
 caaagtcgaagcgtgtgtgtgaagaatgctcctcaggttcaagcccacactccataaag  
 tctgattccaaagcgtccaaatacaatgctatataaaacaaataatgatacaaaact  
 gttgagacaaatcaacttatgtgtgtcgaagaaacagaaatgattatcaantgtccaa  
 caactctcgaagcgaacactctgtgtgatacaactcaaaagaaatattggaagaagt  
 caagatgataatcaattggcaaatgacgaagtgtgtcactcaacttgttgttcaattcc  
 gaagtaacgcacatcctgtgaagaaaggggaagaaacaaacacactccaaacatattgtga  
 caacagaatagatgatactccaaagaatttatcaggtcactatttccaaataaaagga  
 gatacagataatgaataagcctcgtggaacacacagcgtgtgtgcaaaaacacagct  
 gtcaacacactctagcagatgattcgttaagggcccaaatatttaattgcccaaggttcca  
 tactagaagaaacacaaagtatttagtctggaagagagcgtggaatcagataaaagaa  
 gaactgaatgagcattatttacttatactgactcgtcgaaggtacagatgaactga  
 ggtccaaagtgttcaagaagattgaattatcagttgaagaaaggtgttaaggttccaaagt  
 accgcatatacagatgacattaaaatggcctgtggaagcgaanaagatattcgtatagaagc  
 cctattccggcaactgtgtgtgtgtgtgtatgaagtccgaacaaataccaaacagcact  
 acattcgttctatattgaattccaaagtttaaaaatcgtgaatttaaatatacaggt  
 gcgattgggtatagaatttaaatatgaacacactactatggtattgtgtcaaacgccacac  
 gcaataattcgaagtgaactgtgacgggaatcagtttgtatcaatgattatttgatgt  
 tcttaactataaaataacacgtcggaaattgaagattatcaattcgtgacaaanaag  
 gttgaatagcctctataatggttttgccacatttagttgacccgttaattcaagagttc  
 aaagcagctacacagagtttaaatgggcgtgagagaacacgggaacgcgttataagtt  
 ttctgcaattacacgtcagtaataatacaagatttaacaaaanaacacacatgataga  
 agaatgcaaaaattgtctgttaattgtatggtgtgtgttttaagtgatgtgtgtgt  
 caagaagttgacagcttatattgtagaatttgtccaaaagcgtgagagcgtgtgtat  
 atgtttagtgtacgcaaaagacacatcgtctaatgttaattacaggtttaattaaagcaac  
 atccaaacagatgcaatttatgttatccaaaggtgtgattcgaagacgattatgaag  
 agtatgggaacagcgtttgtgaagatacgaalagtatactctgtgtgaggtgtgt  
 aataaaacgattagagttcaaggttaactttgttctgtatgacgaatgtatgtgtgt  
 gattttatcaaaacaaagagacagcagatctatctttggaanaanaagatttgttgaa  
 aaacacaaacacacacaaagataatttgtatgtgtgtgttttgttttgttttgttt  
 gaaggacattatccaaacttaactccaaagacatttccaaagcgtatataagaga  
 cgaagattatgataatgagacactcgtgtatgttcgaagcgttaattgttcaaaa  
 ccaagcgtgtgtgtgttgaagaaagaaatttaataaaga

144. atgcctaaacgtatgatatcgaacaaattttagtaaatagggtctggcccaattatcata  
 ggtcaagcagctgaatttgattatgctggaacacagccgtctcgtcgttttaaagaagag  
 ggtatcaggttatcttgtaattcgaacccgggacacatcagcgtatagaaggaatc  
 cgggtataaggtatatatcggaacgtttaactcatgtatttatagcgggaattatcagtaaa  
 gagcaacccgtcagcttacttccaaactttaggcgtgaacacaggttttaacatcggcgat  
 caactacacgaagaagggtgtgtctcgaagttacaggtccaatlataggaactgggtca  
 acatcacttccacacagcgaacacgggtgaaggttttagaacattaatgatttgaac  
 gttctctgtacacagcaggttgaacttgaataacaggtagcgaacgcttttaactcaaaag  
 caagtggtgatacccgctaaattgttagacacgacgtttacgattgggtgacacggaggggt  
 atttgcataactgaagaaattacgttgaaatgctcgaatggtttcattatagttcca  
 gcaaaagcaatgtttatttagaanaattctatcgaggttttaagaagaatcgatccgaagta  
 atgcgtgataaaaaacgataatgccaatggtgttatgtacatggaaatatttgatccngtt  
 ggtattcaccacagcgattcaattgtgtgtgcttcctagtcacacattctcagaggttgg  
 tatcgaatgttcggcggtgtttcattcaaggtttatcgagtttaggtatcgaaggtgg  
 tgaattgttcgaattagcatttagatcccatcatttgattatttatattatagaagtaaat  
 ccggctgtatcaggttcacacggttagcttcaaaagcacaacgatatccatttgcacaaa  
 ttagctgtctaaatccggttgggtccaaatagatgaanaagttcaaaccaattacggga  
 acattctatgacggtttgaacacaaatttagactatgtgtattcgaataaccagaattt  
 ccttttggataaatttgaanaaggagacagagaggttggcaacaaatgaagacacaggt  
 gaagttatgcgaattggtggaactacgagaatcatgttcaaaagcaatttgatccttt  
 ggtatgggtgtgcatcattagattaccaaatgtggaagcttggtatcttgattatatt  
 aaagaacgtatttccacacacagatgatgaacgttatttttccatcgcggaagcaattaga  
 agagccacacatttagaanaaattcataaatatgactcagattgatacattctctacac  
 aagttcccaaacattatgatatttgagcatcaattcaaaagacatcagggtgatttga  
 tatcttaaatgtgcaaaagattatggtattttagtgataacacatacggtcgtttaat  
 atgacgggaagsgaagtataccaattggtatgggaatgataattaaacgttttaraag  
 atggttgatacttgcgcagctgaatttgaatttcaacacacatttatattggtgaatac  
 gaacttgaatgaatcatttagtactgaacaaagaaanaattttagattaggtcttga  
 ccaattcgaatcggcgaaggttagaatttgaatttgaacttgcgcaggttcaacgcttggca  
 attcaaaagcaggttgcgaagcagataatttgaatacaaatccagaacaggttccacac  
 gacttccattctctgacaaattatatttggaacttlaactggaagagattgaggaat  
 atcatattttggaanaacataagaggtgtgtgttacaatttggaggaacaaacgggtt  
 aatttagcagacaaatttggctaaactgggtttgaataacttggctacttcaatgaanaat  
 ctaaatcgtgctgaagttagaanaaatttgaagcaactartaagaacaaattcaagtgcca  
 cagcccaaggggaacacgtcactcaccctggagagcttagcgaagcgtcgaacac  
 ggataccgggttggtagaagacattttatgatattaggtggtcggcgaatggaaattgta  
 gcaatgacaaagaggttagaanaactatagcaccgggttgaanaagaggttcgggaacat  
 ccggtactgtcgatagatttlaactggtaaaagaaatgaagttgatcggtatttgat  
 ggaagacggctcattctcaggaactcgggaactattgaatcgtcgtgggtgtgtagt  
 ggtactcaattcgtgttatccacacacaaactttgacagaagacaggttagcaacactt  
 gaggtactactataaattagtaaaaggtttaaacacatcatttgcattatcaccattca  
 ttggttatgctcagatgtgtgtgtattttagaagtaaatccagcttctagtagaag  
 gtaacatttaagttaaatatggaattcctaagggacaaattagctatcggaacac  
 attggggaacactacagattatgggttatcaggaaggggttaacaaatagctcggggt  
 gctttgtggaagccaggtatttagtttcaataaattgaaattgaaattgtctattactta  
 ggccttgaaatgaatccacaggtgaaggtatgggaagacattacatttgaanaaggt  
 ttatccaaaggttaacaggttagtggttgaagtttaagacacaggttcaagattaatg  
 aocgtcaagtgcacaaagataaagagggaattgttlaaattggcacaacgcttaaatgaatt  
 ggttatanaattttagcaacgttgggaacgctcaataatttgctgagttgacatacct  
 gaaagagtgagggaacatttgggtgggaaggttatatttcaacgcttcaaatgtgt  
 gatgttcaattgttataaatacaattgaactaaaggttaagaggttagaaggggtggctc  
 caaattagcagttactacagttgaanaattgattatccatttgcactcttttagatacagct  
 aatgctttaaagatgttaattgaanaattgacatttcaacttgaacttgaaggt











162.	MNSRFYGRVTNI.GKILSLIKKKNKDIR.IIPLGGVGEIAKNNYIVB.VDDFMFLDAGLM FPFDEMLGIDIVIPDISVVLBNKKRKGZIEPLMGHEHAIGAVSTVLRQLDAPVYGKRLPI ALIEENKRNKRLIKKIVYTVVNRDSIRKPLNANNISFPIHTHSI.PDSLGVCTHPSVGAIVY TWSYFQDLSLVAIPDKKRAKIGSGVPLVLSSTFRAEPCVYNTVENVIGHMYDAFA KVRGRLIVSCYASNTIATQGVNIAKSLKRNKVSFLGRSLSSSPNIAKRMGYPTDKDLIL PTTSEVNYTPNRYV.IIATCGQGEFVBAISLQNAOHRKIKMINIEGDSVF.IATASAMMYV IANTLAMELRVAGAH.IIPNRKRTHSSSSQMBELKAMIKMRPEPT.PQGGYPMQIAHAK IAASGATPEL.IIYFSGGVINWKDKITLANKVNSNILLIDGIGSGOVNIVLIRRHLL AEDGIP.IAVVTLDPENRRTAANGPIQSRGPTVRESDI.LRAPEKRVREIVRAGLQHRKI EWSIKQMRQISKLL.FESTKRRPMITPVISEI
163.	acggcaataaacatgcctcaagctcaggctggtagagcgttcacgaagccacattgcaacaatg tagcttctgtctgtctgtacatctgtgaataatgacacattatgtgaagtatttacagat aaagctgcacagctgaagctccctccacagatatacgaagaacattacagaataatttagttgaa cgggcgcaacagctagctattgatacaaatctctgttaaaattgaacctcgtgtgtaaaag acaanagaacaacactgagaagatcacagcctaaagtgagtagcaatacctcgaatactact aaaaaagctagtgcaacgctgggaacgcctatctgcgtcaacaaatccacacgttaac aatgtcgtcgttttccctcgttgttatttaactcgtcctcaagcagatgaactgtattatca caagttgttagttagtggaattgcaaggtcgtgttaactagaagagataaactcagttatt gaaatcgtgtgcacacagctcaactggaacacaggttcacaaataatcaactcgtga gtacatcaagtaacccatctcctgagaacaaatcgtgaanaacagcaatacagaataat cgtgtcgtcaagcaattgcgcacaaatctggttaactgtgtcaacagatctccacatgca tggatgtgattggaagttagctgctacaaactcgtgaaacacagcaatacttataaaacac agcttataaataaagaagataaatcctgaagctcttctgtctctgtgtaaagctgtg cgagatgctttaaagcatalccttttataaataagtagctgcaacgaagaaatgaactgtc ttacataaagacattataattctcaattcgtgtgtctgatgaanaataaattatacagtaact glgataagcgtcgacgaacagctcaatcaacaggtatagctagaagaataataaacttta gcacgaaagcgtgataagcaattgcacgctgtcgaagatgtagcaaggggtgacatttag gtaaatatactgtgaactatttggttcagatatacaatgggtattataaatactccacaa gacgcgattttacaagtaaatcaatcgtttaaagacagtagtaattatcgtgtatgatt gcaattcgtgacaaggttaatttatgtatttcaattgctcctcgtattttagatgattta caaacagtaaatctgtaacatataaagcagctatcgaacagctataactttagaataat acaaataataat
164.	MSIIMYLIGRSVHEGT.EQNLVSVGDHIDREYPLCEVITDKVTAPVPSTISGTYTHILAV AGCTVALITFICITETADKNNHETREKQVADHTRQSKKASVAFPGTSPARQVPR NRPFSVPTKLASEEDILSGVSGSGEGRVYEDMSVIMNGGTAQSGKQVGTSTSV DTSSNGSSNNSENSTIPVNGVKAIAQNNVSVTEPHAMNNIEVDANVLKVTANHYKN SFIDKSGVNLFFAPFPRVAVADAKATPLNLSSWCGNEVLVHLDINISIAVADNNKIVP VILKADKESIKLAINETPLAKARAKGLADMGCGPTTVNVPFSGVSSNGTININPQ AAILQVBSIVKPPVINDHIAIRNNVNLCSIDRILDGLQTKFNKIKRIEQTILER TNIIY
165.	
166.	
167.	atggagacacacatgatttatgcaggatttttagcacaggaggtattgttcgcaatgggg aactcgcacatacaaaaacaaattttcgatattgataataaaccogatttatacataca attgagaagtctcatttttagttagtgaaatttaattgagattattatcgacacgcacacag tgcatttccataacacacaggtatttttaaaaaataataaactttagagatccacgctgcdaa gtgtgtcgaagtgtgacaggaataatgaacatttatgacacattatgcacatactgca aetgtaaatgaantaaatgaatgatgatgactgtaactcgtgtgcgttaagaccattt ttacatacagctattataaagagaacattgaaatgacgacgaasaatacgtgtcgttagat acagctcattgagcaattgatacagattgttaagtcataagataaacagpacataccacgt atcctcgttaaggaatgaattgtatcagaagccaaaccccaatcatttatatttaaatata ctaaagatgttatcgcgccttaagttagtgacaaasagaatacttatcagatgaatgt aaatcatttgtgaattgcacatgcagctaaattgtgtacgtgagaaactatacaacatt aagtgacacacactatgatttaaaagtagcaaatgccattatcacaaggtgatattgoc gatgat
168.	MEDKNYAGTLAGGIGSRMNNVPLKQPIIDINEKPIILHETREKPIVWSEFNELIATTAQ WISHTQDILKIKYNI.PQVRVVGSGDTRNSTIMLIDHIRNVNGINDNVIVHDNVKRP LFORIKENIEAMKYGVNDVIEADITVMSKKNLMSIPANSSQGGTTPGSPNLIK LQSVYALSSQKELLEDKXKIVSGGAVLVSGELNIIKVTPPTDKNVANAITYGDTA DD



175.	atgcttttagtatagctgggtgctcttaattcttaacgataaatgaacatcaaaagat gacgcagcaaatgttaagaaacaagaagatctaaagtgcgcggcagcctcttaacagat gtaaccaagaatagctagctcagatctaaagatctaaagatctaaagatctaaat aactatgctgtagctcaggcgcatctaaagaacaanaattgaacgcgcacgtctgagta ttatgctctgaacattcaaaagatgtagatgcattaaagaacaagaatcaagcagctgat acatacaaatatgcgaataatctctgattcaattpgtgataaagatctaaatcaact taagttaaaagcttaaaagaacaatgataatctagcttaagctgaagctgaacactgacca cgaagaaatattgcgaaacagctatttagataacaaataacttatttaagaagatgcgaagat aaatgctttatgtctaaagatgaaacagctataaaatattgttgaaagagctgaagct aaacagctgttgctgatacaaacctgacttatacaacaatacaaaaatgtgactgta aaatgaaataaaagcttagaacttaagaagcactccatcaatgaagctgctgactacata gatgctaaattagcaaaagctgtagtgaaattottaataatcagataaagctaaagaata ctaaagaataccacttttcagca
176.	MLLVAGCSNSINRNESKTDANRQKQITQVAAASLDTVYKLLSEFFK RHEWADIKF NYGSSLRQITGSGAPVIVTNSANIKYDARLKDNRPAHDYTYKXNLSVLIGDKDSMYT SVGLDNDLGLAEVKTVPAGKYKYLNNLNNFKFEVSKIVYAKDQKVLQVLYVKNKA KQGPVYKLDLYKQNKIDTVKVIKVEFLKCPITYEAGTSDSLKASWMLFLSKDRAKEI LKEHYFAA
177.	tgtgctacacatacacttaaaagattatttgaaattacaggtgttaactaaagaact ttacattattacagatgaataggattattagttccagataaaaagataaaaattatgc gtttatacaacagcaagacttagaanaattacaaagactttcaatactcaagctcttttgc tttgcatacogctaaaatacaaaacacactttctgataatgaatacaaatgcggaagtt ttatcagaanaataagcggcttagaataaagcttctgacttaacttaattagacgc ctctgttgtaatttttaaaagcctctcttaataagataccagcattttaaacaagca ctcagatcaacatgtgataaagaagcacttaataaaattgtgtatcagaaagcattcaaa tcattatttgagctgaagcagcttaacatgcaggtatcagacaataaagacact atcttcaataaaatttaatactattgtcttttgagctattatcaatcaacagattgtagtgat ctgctatttgagtgaaagcattatgaacactatgcgtgatttgatgataaactta tgcgtcatctgaacacattcaagagatgaacogctttcaagacttaatttaattat gataaatacaaattagcactacattcaagcagctgttaactcttttgaggaattgt ataaagaagcaacatttt
178.	NAATYTLKDIETGVYKRLTHYDEIGLIVPRKDNKNYVYQDLKRLKILMLSPD FDIAKXTGYSTVNFQIRKLBSQIKSLDKKISLGLIRNSVCSPIKGLGIDPSLANK LQSYKDKETIKYIPKAYSTFTRKLSLQSDQDTRUKLPYIPKSNWLSLWYPTCCSN LDFVFAFMYTADFDDEILCCIAKTYEDTFRFDYFKSTDNQNLASYSEAVNYLWV NKSUNF
179.	atgcgaataataaagaacaagaagcattagcttaaacattacaagcattgggatagat acttatacaaacactcaatcagcgaagcagctgaacagtttaagtaacogt agagatacaataaatttttaactagctagctgaagaagtagaagcttagcgcctct ggtttacaacaataactcgttaaaatgggtggcgaattaaatcgttgccctggttta atcattatttaacgtggtatgtagtgccaaatggaatcgtacgcgaacttaattat tctgacaaagcttagctgtagtggaagaagcattccagaacaattttaca aaattatgtgaagctgtagcgcgtttataataccaaattgaasaaggtgacaattggttt gaaatgtctaacgaagcaactcgttaagcattatgaacaagaaggctgagcttggtatt tgcctcaagcatttataactgaanaaatttaagaatcacaaagcaaacacagctgata cgaagcacaacattatcacaacaatttaaaagcattcaaaagcagcttaactctta aataaagataaaagcctgctcgttgaatttggttgagtggaagctggaagagtag ctacgtgaattattgaattgctcaaaattcctgtaattcaatcaatcagcttaaaaca atctgcgcgaatgatacaatcaatagatagctgaacttagtgaatagctgaacaaca tcttacaacaatgcaggaagcggatttataatactggttgcacaaattatcattat gttgattattcaatagaagaataataaagcattcaaatgaacaacaattcaataaact atcggactatggtttcaatttaactgtaggaattgtgggaagcttagtgaattggtgcat cngttactgaaataattaaactgttggaagcatttttaaaacaacgttgatga cgttaagcgtgttggtgaataatggtgaagcaagataaaataataatgaataacata cgtccgaagaatataaggaatcaatacaataattttaagaatgagtgagtgatcca gtagagtaggtacagaacagcttggtcaactcgaacttaacacttggtgtaataac aagttaactattcaagttggttagtacaactgggttggtgcttcccaagtgcaatgca tcaaaaattgctatacaaatgcaacagcactgcgaattgctggtgaagctgcatccaa atggttaaggaagacttcgcacagcagtcacaaatgattacatttaactgtattgta cttaacacaaacgttgagcttattaaatagcaacaagcagctggtgattgata tatgcagctgatttttctgattatggtgactgcaaaattgctgagcagcaggtgtaaa ggttatacaataaagctgtgcgaagtagatgctatgttcgaagaagcattagacaaa gattgcacagacttgtagtlatgctttagtcccaatgctgagctatcacaggtaata attgtaataagagcgttggttatgtagtaagtggtggtgatttagtcaataactgaat aaacttttagatttagatacaattcaacaaatttcagtggaagcaaaagctttotta
180.	MARTKANRALVKALQANDIHLVYIGPDSIVAVDSLKVTDQFPFVIRIEVASLAAA GVYIKRQIGVALSTGQPLIRLILNMGYDARDNRVQLILSGTWSTLAKIAKVEHLQ ELCRVAVYHIGLIGDLPFLVNLKFLVNLKFLVNLKFLVNLKFLVNLKFLVNLKFLV SRFVYVSPKQD IKRIVKILNLSKSPVLMVLCVQAKAKDELSFLEMNAPVHS.PAKT ILEDPDYSYIGNGCIGCTKTSYGYMADLLDWGNNYFVVDYLRKXIKAIQIYHFN TSKPFINDVYVSKSLALGMLFENIKVHPTFAKTRUKAVNMDQKRNKNS RPRRIASRNKTHODDAVSDVQYDITWSTRYLNLGVNKFISLSGLVNGGCLPGLIA SKIAVFNROIAIATGGGAPQVMDPATAVQYDIFLIVFVNLNKLAFIKYQKGAAGS YAVDFSLMDKAFKFAAGGQGTGKTSASEVDAIVEALADVPVTIVYVYDPAALPFG LVFRLALGVNAPKSTIDKULDLVITGIVSAAKFL
181.	gtatgcttttaggctctgaacgac
182.	caccataatgaacatacnaattgtagc
183.	ctgatactggacaacatagaga
184.	aagtaacgttatcttctgaatggt
185.	attctggacatacagtatcaaac
186.	tggcttaggtgttggttaggc
187.	ataatacaactcaactcagcc
188.	tsnactcgtgagctatttttagat
189.	ctcaacatacaacacattaca
190.	gttaatgaattataccgcag
191.	cagcttaacgcaatcagtagca
192.	agcatttgatgttttctgttatgtt





gaccagtttaactggtgaagaasaaactgagcatttagcattgatttaacaaattacagat  
 caagctaaacaggttattctgtagcacaacacactgctgaagttgaaaaagcgaagct  
 caaggacttgaagcatttggatcacattcaaatcgactcaacgaaanaaacaanaagctatc  
 gaaggaattgaaaactgacctagacagattgaagcaggtgttaattgcaacagctgagct  
 acactggaagaaanaagaggtttacgaattgctttagaasaaatttatcaaaagcagct  
 gaagattttctgatacaactacaatgcagaatcgctactgtcaaaaagtgtgagct  
 gaacactttaagcacaagctattaatcctgaagttagaanaattgcttgggaagcattc  
 agagaagtggttcaacagcnaatgaatanttaaaaatgcagattgcagtgcatggg  
 aaagaattgtcagctacggatttaggtagatattttgacagatttggatgaatttagat  
 aaaaacacaaacaaatgcagaagtttctgtaattcaaaaatgtacgatacctgcaattgaa  
 gctattgtgctcaaatgatccagatgcttaattgatacttaataatggtatagatacaaat  
 ggtgcaacagaaattcaaatgctaatgcacacagaaatctggcaacactaacata  
 tctgagacagacagctaatgtgcaaaagcagcgtcttctccgacaacacacaaataatagtgat  
 ggpgcaacaggtgaaacacacgcacacacagcaactgagtgtgcaaatgataaaacgcaa  
 gctaatcaaatctctgagtgatgatacacaacacacgcgaatggataacagatga  
 actagtaacacagagtgagaaactcaataaagggcacacagatgaataactgtacacga  
 actgataatgcaacgcacagagaagacacacacaaataacaaatgatacactacagcaaca  
 aacgagaatgcaacacagagatcaacagcaacgcgtccaaacactgtgagccacagagaa  
 gcaatactgtgtagcgaagatctgactgtgtaactgattcaaaaacaaatggtgaa  
 gtaaaataactgtgtaataactcaactaantgcaaggttgcacaaccaaattctgaa  
 aataagctaaaggcagaaaagatggtgtagtatacaacaaatacaagatggtgtaatca  
 acactgaacactgtctctcgcagacataacagaaaccaaattgacttctaatacatca  
 aaagataaggaataaagtagcaaatcaactgtagtcaggaacatttgcttgaanaat  
 aagcttgcatctaacgaaagcagataaactgcacagcaacagctgatactgaagtttgaat  
 aaacatcaacatctgctctcttctgaagcnaagaaabaaatgacttcaactaactctagc  
 caaaagatgatacgcgaacagcgatactaaatgatacgaanaaatccgttggctcagct  
 gcaacaaataaagctacgaaanaagcagctgccaatgatactcaagctacagtttcaaat  
 ggaagcaatagctgtaataaagatagcttaattgtaactaaactgacagcaacacagct  
 aagacaanaatcagctcaacaggaanaagtttaataagctcaacacacagctaaacttta  
 ccagataactggtatgtaactaatgcaatgtaactaatacgtgaattagctatagtgaa  
 ggtatggcattttaattagaagattcaactaagaagaagcacaacacagaa





207.	<p>atgaatagagagatgttctgatttcaaatagatcagatattgaaacagcgggaggttaactct  tcaacaagtcttatgtggacgattcaacgaagcatlaacagcccatgcgcacaaatgattt  gaaacacggcttaagcgaatttaagacagatctctgaaatggaacacatcgagagcga  attattgcaatgccaaagttaatatcgttggtgaacacgcaatttcaaggtattaaagtga  ggtaglaagcagcagacacatcactgaacagcttaatatggagcgttcacagtgccgtatatt  ttgaatgatccgaagaaagatatacgaattgcggttatgpaagcaggttcaatagtaggt  atcgctactgcggcgggtttcagtgattgcgcgaagcatttgggtaaaaaaggatttaaa  gaacttaacaaatcattggatgcggggttaactgcggagcagcgaatcacaaagtattgttagg  caattcgatcattatgaagcgtgttgggttaagatcaattctctgaagcatgtgcagcgt  ttgttgaagagaggaacaaacgcgctgcgaatataattttatgtgcgaagaaatgct  aaagaagcagatatacaaatggtgaagttagcttacaatgtaacgttaacgatacaacacac  attgaatgatgttgaacaaagggtgcatttattagcaacatttctatcatgtatgtgtg  cataaagaggtctttattaaagctgcgaagctgtgttagatgactgggtgcacatgtgaat  cgagaaagaaactatcaacaaatgggttagaaggttaattcgaagaaagagctctt  catgctgaactaggacaactgtgacaggtgacataccagagcgtgaagacgtagtgag  atcataattacttaactcagatgggtatgggtatcgaagatatttcaagtgctattttatt  tctcaacaggtccagacacaaactattgagcaacaaatgttaggttat</p>
208.	<p>atgaanaaaattatgttatttctggtagagacccgaagcgaataaaaatggcaccntta  gtcaaaagaaatgntcatantgggaactttgaagcgaacnttgggtattacagcaaacat  agagatctgttgaatgtgtgttaagtataattgatattcaagctgatactgatttaaat  atattgcagatcaacaacatattagcaggtcttaccggcgaatgccttgaataacttgat  agctcaattatgaagaaacaaacgggtatgattttagtaactgtgtactacacacgct  tttgttaggaagtttggcgcatttatacatcaaatctcpgtgcgcacatgtggaagctga  cttgagacacatcagaaactactcaacttctcgtgaaggtcaatcagatcattgtgaagt  aaatattgtgtaattgaatttgcgcgaacgaatgtgcagcaaaaattcaacttttgaa  aacaagcgaacagcgcgtctctttattactggaatacagttattgaagcattgttcaaca  acggttcaaatgattttgtttcaacgattataataaacataaagcgaaggtgtgt  ttactaacagcgcagctcgtgtgaataattgggggaacgcatgcatcagatttttaagca  gtaaagattggcgaatgaattaaagaggtgtgtcttacttataccatgcacgtctant  ccaaaggttaagagcagattgcgaaaaaatatattactgcggagcaatcggattgaaatatt  gagccattagatgcgaggttggttccataattttacaacataactcgtactcgtgtgcga  gattcgtgtgtattcagagagaggtctccactttggaacacgtgtgtgtgattcaag  aattcacaagaggtccgcgaaggtttgagcggggaacatcgagatcaattgtgcacat  tatgacaattttgtgaaatgtgaaacaattgtttgagatgagagcgtatcaagct  attagtcgaagcaataaactcattatggtgtaggcgaagctcagcagctattttggaagca  atagaattatttttgattggcgcgaagcgaagcaggtgaattgttactcttaagtcac  aa</p>



gttaagtcacttbgatacgcgatgatatttgaatgcttattatgtcggagagcaacagtg  
gaacaggatttgaagcaatattttaaagatcagctgcttaagtatatgatctcgaagct  
ataacgcatactcgtatgtatgcacttaaccacggaatgacaaagggatgatactacggtttg  
ccaaatccatcactatatacacaagcttaaaatagtggtataggggaacotctaatgaatt  
gggcagacatttgttgatgtatttggcgagggtattgaacaaaaatgatgtcgtgttgac  
gatgtattctttgaacttggttgtaactcaatagaggggcagtggttggtctcgcattta  
aaacgatttggccatcatatttcaatgcagacattataccaatataaaacggtgcgacag  
attgttaattatgtatacaaaatcaacaacatcatttgttgcgttaccggaatactcttcg  
gaattacaaaagtttgttatgtctcgtttataaacttggttattttagaggatagtctaaat  
catcgacctctcggaaatcacactattgactggcgcgacagggtttttcggctcttatctg  
attgaagtaactacaaggatccagtcctcgcatttatgtttccatagtgctgataatggg  
gaattagcttggtatagttgatgcggaatttaaatgatatttttcgagagacagcgtt  
gaataatgtttatcaacaacttgaagtcattgttggtatttcgagtgatatggatgtgtt  
gttttaacgaaaaacatgggtacgattatttcacgtcgtctcgtacagatcaotttgggt  
gatgatgatgaatttgaagaagtaattgttcaaggtactcgttgatgtcagaagttggga  
caacaacatcatgaaaggttaatatatgctctacgataaggtgggaacttatttgat  
atagacacagaagatgtgacattttcagaagcggatgtctataaagggcactactaaca  
tcaccaatacaacggagcgaatttttatagtgaaataaagcatttagagctgttaataat  
gggttagagtggttgatgttaaggttggttaatttgcgatacttaccatggaagtgg  
catatgagcaatataaagctaacgcttttctcatggttaatgaatgattttgtacaaatg  
gattgtatcgggggttagcagtggaatgootgtcagatttttcttttgggtataagact  
gcangacaaattgtgcattagcacagggtcaacacacacacaaatcatttaccatgtgata  
tcacctaataaaatgcggtgaabcttttgttagaatgcgttancgcgaagaatgaa  
ctcgtcagcgtgaatcatttaatgaatttttcgaacacagacatgtacgaacagctt  
gggttaactagtgttgacgtgcaacacaaactgcgatgtatagatacaaatcaaatata  
aaaaaatgctctcactcgttgaaaaaggccaaagataactaaccaattggctgtatcat  
tgggcacatatacaacaacatattcgaatag

210. atgcacaaagacacaaacttgcagagcaatatttgcgcagctagggtgatagbaaact  
atagatagttgcacaaactgtgaacagctgtgcgttatbaaagtattagatgagaaataaa  
gtatgtgacacaaagactaaaggcatatttgcgtgttcgttcgttatatacagatgaagc  
atctaagtctgtgttggaactgttcgaactcaaaatgaatgctcaatcatatgggggaattc  
agtggtgttcaaaatagggtgacccaataacacacatcaaaatgagtgaggaataatgac  
tataaatcatattgcacgtgaataaagcaaggggaataaaggaagcgatacaangcaaaacaa  
aagaattggttaagtgtgaataaagtattgaaatcaattgcocaaatctttataacgttgatt  
ccgtgcattatttgagagctgatatattgtgttgatattgcagagcagctagtgtaacttaag  
cgagcaggttatcttcaggtgtgttgatgcagacctaataacagatttaaatgtatt  
aaagacggttatgtgcacatattgaactatttcaactgttatataatgcgttaaagaatt  
ggtgcgaacacaggaacttgcgcgtgtatttgcgttgcacaaagttataacggttatctggt  
gttaaaattcttttaaggaatgttcgaactgggaacatttgcacacccggagcaaggggt  
atatgttgggttatgttgcgtttgcgttttgaatttgaattgtgaagaaatgaacaa  
atattgcgaatgcgattgatatatttgcgaacgcgcactatgcattgttgatttgagga  
catataacttactttatcttattgcgttagagaggtttgttctgcagacagtttagtttgc  
cgagtttaacggaaatacttagatttcgggtgggttatattaggttatctaatgttgtagc  
ttcttaacgttagttattgttaggcgttaactatatttttaacgcaatctaatgaagaa  
atatacaatcaggtgtacttaacttatgtccaaattgcagagatgcgtgtgctgtgaac  
tagtgtgcgcattgagcaacttcgggaaggttaacgcaacacacacatlaagttactact  
ttaaagagtgatgcgcgtttgttgcgttaggtattgcgaataacacataactatgtgtg  
actttgccattaggtgcactttcttaactgcttgattgtgtgtgtgatttgcgtgcgt  
gtaattgttggaattggaactattggtgcgaaggaatagggccaaaggtgtgtgtgcata  
ttacatatcttcagaataatattagtttatattgcaggaatlaactgtgtgcatt  
gcgttggtattcgtttgtaactatttatttgcgaacaaaggtgcgtgcgcagcagcagc  
tgttgggtgcatt
211. atgtctaaatttttaaaatgtatacagctgagcgggtgaattgttatbaatgttaacgtga  
tgcgcgccbaatgcgttggaagagagatatgtgaatgaattgataaagaattcttga  
gaacagcgtatgcacttgcgtttgcgtgtgtgcgtgcgaacagaaatgcgtgtttataa  
aaattatcgagatcaataactaaanaactggcgtcaaaagtcaggtgttaaatattgtgt  
caaaatgcacatcagaataatttgcgtagagcgtctgcgagcaaaaggttcgaattgt  
ttttttcttgacacatttctgaatgttcgttcgaactgggaacattctacaaaggttagctgtgcgaac  
aaattctcaaaagagcttgatgaaggttgcacatgaacgaacactaaagagcttgattat  
gaacataagcaactagattgcgcagctatggttgaaacaaacgycactttttataataaa  
aaattagtgtaaaatgcacgcgaaggttagaagaggttagaagctaatgcgtgcgaacta  
actgtatgttaaaataaaataacgtgttatatttgaattgaataaattctaktattta  
talcgtttttatgcggaatgattgattatttcaagaaaatagcgcggaatattgat  
attctacagctgcgactaanttaaaacatgtgcgtcaagatgcgtgaacatttacaanaa  
tgytgcgaagaaaggtattcttcttaagagcgaacacacagatgctgatgtgtgttttt  
aaagaggaagaaagtcagacaatttgcgtcgttcgtgcgaactatgattgttgcgtgc  
acgtttggttaagatttagaggttaacacatactctacaggtggtgcgaacacttgaaa  
caattcttagtlaagtygtgtgtgatttatctgcgaatattgaatacaaatattgcggt  
aaagatttgaattgaatttacttcagtaaaatactcaaaaatactgaacacacacacac  
agcgaatttactgcgaaggttgtagcggaaatcatctaatccaaatttaaaagtgttgaa  
aagcgaagcgtcatgctgaacggtgctcaatattctgaattgcgcacagtttgggaa  
cgagtcgggaagtcgaagcatatttatttataatggaagatcttaacaaaggttagat  
guygcgcgaatgatalaagcaaaatataagattcttcatctcaacaaatgtagaa  
aaaggggatt
212. gtgaagcatgtgaattattgcggtggaagatttaccgttagaggataatgaanaagcca  
gtcatgtgaagtgcggaatgatttatataaagtagcgcgcagctggcagatgtgtgtca  
gcacgtgcagctgcacaaanaatggygcaatacaataaagatttgcattgtgtgtga  
ttttcaggtgttagtgatgcaattggaagtgatgttagcgtgttaatgtggygcgaana  
gtgcagaggttgcgaacgaactaacttgcatacaatgcgagatttgcgttaaaaggtgaat  
gcagaggtgcgaaggttatgcgttgcgtctatgaacctgcagctgttgcggaatcat  
gtcaaatgtgcgagcaanaatgttttaaggttgcgcacttgcatttgcattgaagga  
gaaattgtgacatcagcgtgtgtgcgcagtggtttataaagtgaatacaacact  
ggttagctctgtgcagaaatggggtgtgcagctataggtttgttagctattcaatgcga  
cgaatttgcgtgcacatactgcgttatagatagatagtgcgcaacaaatgcagatt  
gcacatacttgcgcgcacatacaacataaactcaaaagaaanaacttgcgaagaaatc  
stcgaataactacgcgcacaaatgcatttagctatagatcatcaggtgcataaggt  
acttagtgcataatttagcgtactcaaaanaaggtgcgaggtgatttagctgcgaatga  
caattatgtgatatagatttagcgtgttcatttgaanaaaatctgcgtgcagattgcgt  
acgtatgtgcgtctgcgaaggtttgttgcagtaatttccgcgcgaaggtgcgga  
acattcaactatattgaaggaagaaatattgaattgcgaactatttataacttttata  
cgttagaanaagcgcggagacattgaataattagttaaaggaagaaagcagattgga  
aaagtcatttagcgttat
213. atgcacagcatcaaaactttaatttttaagagcgtacacagtaagaacagtagaattgaa  
aaagaaactatttttaggaanaagattatgcgtgaatttaggatattgcgaatgcgaac  
aatgcattagaatactagtttagcagaggaacaggtgcagcagcaacttagtgatcat  
gtcaanaacgaatattgattatcatttcaacagatacaagttatgcagctgaattgcgt  
gottctaaacaaagcaaaaacagaaaactgcgaanaactgcgctgcgaattcaaacaggtg  
gtbaacataagattgcotacagctatttgcgaacacaggttatatagcgaacagcaaatgta  
ttatgaacaaacttgcatactgcagacacatactacaggtgtgcgttgatgaatga  
gaanaagagcaaaaacttactttcaacaaagaaatgcggaactaaacaaacagac  
tatgtagatgaatttttaagtaactgcgaacttagcgaacacatacgaatgcgcgaac  
tagctgtatacgcgcgaagatttaacaaactactgcgaagcagtagctatcaagagaaa  
gtaaataacagctgcgtgatttactgcgaacacatgcggaaggttacacgaatgcga  
actatgcgaattgtgcgctgcgaagtagagaaagcaacagttttacaacttagtgcga  
caaaagcgagattggaataactgaatactgactgaattgcgttaggaagatttata  
ggggagagc
214. atgataataaactattagcaggtttatcaactgcagcgggtgttcattgcgtgtgac  
aattgacttccaaagatgaacaaactcaacagcgttcaaatcaactcaacgcactta  
caacaaagaattgttatgtctaaagaggttataacaaacgccacagattgcgtgaaa  
agcgtgcgaagacttcaacaaagcaaggttgaagaggttcttctttaaacttaactta  
gtgaattgggttatgaaggtgcgcgaacaaatctgcgtgaaggtgcagaggtgctgt  
gtgtgaataataaaaaaggttatcaaaaagagctgnaaaagagatcaaaatagatgaa  
aattgaattcttaaatatagcgtatgcataagatttacaanaagagcattcaaaagagca  
gaaggaattgnaaggatattatgaagatgcgataatgcgaagagagagaggaactgtt  
tacaatactgattgaanaaggtatataaaacaaagaaagttacgtgtgcgtgaagac  
gutaagaattatbaagagtgccgcgaatcac





230.	mskilkotclavvnnllivtaocgnpskedidkaikndskdpnqjltmrvdgdkgmafyk kitdqytkktgikvklvniqngdqlenisidapcgkqjclilabndtrasydlglasael klidclvqfinkpakkmaydabqalabvutwllfynkklvknagptleesveanaaki tdskkkqymilfdaknfyfnyplfgmddyilckngseydihqlgnskuvknacrlqk wydkyvlpsaatdhvniqlitkqkvqgfyfvgmilineyqetfplklyvttiptdgagkpk plivrywylasyshkqgkdlmlyltakidclqydimesseltgryvdkamunlvrfc kzashasmpnlpmrcvwpognasilfiangknpkgldestnditcmkilhpagndk kqd
231.	vkalklyvvedivryednekpviesandvikvrattigcsetarykkmqyrikpmpfighe fsgvvdalgsdvthvngdkvtgcpaigcaycayclkgcyarceklfvigypcpfasay vlpagvylkyrdvdyilssawespsavabqfymnigpmvavmgcgsgigilaligwa rifgaahlieididahlkdiatalgahgtinkneekfienhyangidlaesegakv tligplitlkpggervylligipyddieldrvhfekilmelcvcgwvncissnfpkqkwa tlymckedilvngyqghhlyplakpctfdikvnxkqdkvmyfily
232.	mqaetnfikelptvneienepylvkpldasilgynrmdalnrvhdsedkithgfes ggcnmiilnesiglyslifdaskqsknekrretarkfrvrtadvipairkhhgiyatdnv leqtikdpdyiltvitvtyekkeqgnilllqaelgelkpkadydelikstgtlatbqlaad yplsaqklmklhearlgckvnxkqwyvshmgkystesdclalvzadredvltgtrwt qgrrklbelmtefayvswlga
233.	mkklslavlsmaavvltagcndtpkdetkstestngdntntkdviaikdvktpedadv kaeetykqgklqlsfensengwaykvtqdcgeseevsadvnckvinkktekedtme ndnfysdaldyKkaikqgkqEdgdikewslckddklyvniidklkqkqevtvdka qvlkasegdh
234.	mkmnkakislilgiletgvntttekpvbaekbpiviesenskikayvngpsieykmtv yisfiqepkfmilidgnvnnialigkdkghyhtgvhrnlfnfynvedkrfegakysig gttsmdkavdliaearvilkublgueydydfpflidkeamsilkeldfiklidyndyl ygenstgkilyvkkyggyklyfoidklldgnmadvnyrdidreikvrlk
235.	Ttgnaaaattatttaaagtttttaatacaacagatttagcgttaattatcatcatcogcy Accttcagtaattctgcgaatgcgcgagatagtcagcgtactttgcaattagagttacaana taagatcaacaaatgacacgtccacttgtaattgactattttaaataacogpcgaagttacatt Aagpaaaaatggttaattgtatgtbtgowaaseogtgcnaacocagctacttgatctctga Atgagtatgcagagcaataaganaaatattattagtaanaaacctgcgaagatgnaacog Acttctgaattgaaagtaagtaagttgaacgtataatagtggaaseaattraogttat Atogtgtaanaagtaaatggaagcaattcaatatgacacattcaatacaactatcatat Aaatttaaggaacaaatgatgtgagcaaggtgtatgaccagcgaagagtgaaaat Tctgtctcoggtgagtgcgaagaaggtatctgatggaacgactactggtcaagtgnaatcaat Aggttogaataaagacaagtgagaaatcccaacaaacaaatctgtgcacacgtcatata tatcaatacaacgttgcaactcttgagattattatataatgcgaacacattctgttagaana aatctaaagcaatctgga
236.	atgcacaaacattatttaaacngtgaattcaatcagaacaacogtctcatcagctatgnaa aagattacaatgggtacagctatcatctatttggttccctctgtatcatatagcgaagac agccacacagtcgaatgcgcgaacagtgatgcgaacgcaacttaataatcaagcaacaa gtttctcaacgaactcaaaccaatattttcaagtgcaaaaagatggtcttcaagag aagtcaacagtgatgactatgtgcacacacogtggtaagtaattaaacaanaatataaa tattatttcaaacagtglttlaaacatgctcatctctggaagaatacaaatattacaat gcacaaatcaagaattagcaaacactgtgttgaogtatataaaagaaatcaatgaga caatcaatgttgcaattgaacctgtgataaagngcttaaatcaaaagttacatttggc gtgcacaaatattatcaatcatatgataatactacogatttggaattgaaagaacgaatt ctactcttagtgacgcgaagcaaaaacaaacattgttaaacoggtcaacaaacacacagct caactaaacactactatggaacactaaacacoggtcaactgaagltgaaagttataa cctactgttaactcaacaaagcaaggtggaacacactactctactaaagttgtaagttact gacacacaaagatcaacttaanaacacacactgctcatcagcttaaacacogcgaacact gctcaagacaaacacacactgtcaaacacogtgaagagttggaacagpaaatctgaa agcaacacactcaagctgaactgaataaataaatacaacaaacaaagttacaacacat awgacaacogcctaacaacagcatcaagotaaagattacaacacacacaggtttcaactca gttgataactttatagcagcgttgctctgcgaacacttgcccttttaggttcatatct tatctctctctcaagacaaactcaaa
237.	Kknlkvnttllailiilafmenseaadgltlmyevkyntndtsiendynkpekyi Kknklyvqltvnhshwitgasieghkenisektakdrtsefsevklingklgdkdiv ldekvngpkydhyntlykfgngtdvgaanpklidknaagdgsgdgtttgqesaa amkdvmpgplvntgklyvntlyvpranlailiilclvfkzkgvve
238.	mkhbylnskyvsegrsasmkllmgtasiliigelyvlgadsgynaatetnappmgstg vsqatqpinfvqvkqgseksahmdynqhgkvikgmkylygtvlinmasvkeykfyf amngelattvvnndkadtcltnvevopykalttkvhyvppdymnyhrythalefekl plcladekpnrvpvgkpaapktptetgkvgpkyvkvvtrctekvndhatkvrt dttkdgtktathtkvtaqaaqknkvqtpkvkatakssmgagvndksqgtkvtkdh netpkqazekklpklgtlsvdnfistvratiallgsililfrkeek





240.	atgaaaaaaacagttatogcttccacattagcagttatctttaggaattgcaggttaacggt ttatocaggacatgaagcacgcttccgaactccaaacgctgtatgaagcacactagta gatttagcacacataactccgaggaatataagcttaacaggttcacagctgggtctac gatattcttctogtagacaattgataccaaacacttcaatcgaatggtctgaatgg taotggagatagctttagctggtttccagatgctgattacacagatccatcatcaaaacaa gaattgaagtggtacacacactctgtaacaaatgtacaaagctgtttccagctcaaac tctccaaagttogtagctacagcacaactcaactctctatcagcacaagcaatcaac tacagctctccacagtagttccagtaagattacaatggtaactctgctgggtttcttagt tcatctgctgctgtccaaatgctgcaagctggtgattctgtctgctcgaactggaaacac acattgttagagaaacaaatggtccatctctgctgctggttccaggtgtgctggtga ttatccaaactatgcccaggttggggtccaaactggttcagtaaatgctcaaatcaatgct gottataagcatataaagcacaaggtttatctgctgggttctgt
241.	atgaabaaanataaagttatgtatcttgatccaaacagttagttatatttcttatgtt aaaggtttccaaacagcttgagacatcaatattatccaaagcttcaaaaggtgtttgt gggggcacggggccaaactaaacacatagccagtagttagattagcgcagatacaaatct atcagtaagcttggttaagctggcgaactgccactttatttggagacttccaaaaaagca gggtatccacaaatattatcttaactccaaagtggaagaaactgggcaagcattttct actgttgtagaagcaggaacaaatagpctctgtttcaaggtgggtggaattgacat agtgcaactgatgttcagatgaatgtggatgggtttattgtgtgagactttgttctgagcy caggttggaacttccatttggagcgtatgaacaaagcatttaaaattgctggttaacaaat acacactatgtatttaactctgcaacggcnaatggaattgcttcaagctcttaggtta actgatatattttccaaacgaacgggaaggaatatttaacaggtttttccaaactat aatgaaagtgtatgaagaaacagcaaatattttctogatttaggtatactctgcaat tcaattactttggggagagcagcagctattgtgcaatcacagaacatacaaaaagttt tctggtgtgattgtaaagcaatagatagcagcagggcggcgaagcaactattaggtgt tttttaagtgagtttaataaagattttagcaactttagaactgcgtattctgctgcacat acagcgtgctctcacaaggtacacgaanaggacacagctctatatccaaacaggtaaa gggttggagcagataat
242.	atggctcttaaaatatagccaaatcacaaatgtgtctgtatagctacttttagt ttgtgttaattccaaaaacacacactttaaagtctatttccaaacgcttccacgaagaa ggggacgaataacacaggttaattgtactgtctgcctctatggtgtggaacaaacact caatccaggtttatcagattttaacgtcaacacagctggaatcattgtctaaagttgattca attcaatagatccaaacagcttcagcaaaattgtgattgtatgtgtgagatgga aaaagatatattctgcacactaaagattatacaagttagtccaaactgtgaaggtggtgt gaggaatatacaagttgttgaatgctttacatccaaataattctccgctggggaagta attcatcaactagatttcaaaactggttaaggtggcaacttgtctgtctgctggtgtgt ggcttcacagttattgggttaaggggttaattgtatttaactgaattagatctgtgga gtcagctatgattttatctacatgtctgtgcaacattgttccagttgggaacttacaact caattagtaaatgttggtaagcaggaagctctagatggaaagcgtctgcgccactgta cgtgtgtgttaattgacacactaatgataccacacagcgtgggtggaggtgctgctca atcggtagacacattccaaatgcacactgggttaacactcagctgtggtgnaaacctgt cgtgttaaaaatctcttgcaaacacttatgtctgtggagctgaagaaaaa
243.	atgaagtcacaaatccaaatctatttatttcaaatcttttccaaacagatttagttgt gtctattcttlaacaaac aaataaaac acgtttatggtccaaacagcgttaataaaatgtacaaactgaaggtgataacacgctaga cgtgtagtggaaggaagattattttctgataaaaaatgaagtagagctgagcaaaacgt attgtcaagtagaatttaagataatbaaagtgaacttbaaagaaatgattttggt attaaagagttctataccaaacaaaaagcttaattggaattcaacatttaattttgta ggacattcaatgggggaactgtatttctgttttlaactgaaaaattatggggacagatga catttgcacaaatttaaaaggaagctcattataggggggtttatacaaggtatttgaat attgtcaagtagaatttgaagaaatctcgtgttaaaacggggaacacaggtggaat ggcgatctcggcaattgttatcactgataaagattttgtgttaggaataagagatt tcaaatatcctacggagatttagaagatgggtccaaatcgaatgaagctggtgtccaaat acttctcactgctcactcaatttagaggggtgacctcattcttaagaaatgaat tttaacggtgcaagggcacaactagtcaattacatgagaataaagattgtgcaaatgaa atcatacaattcttatgggaact
244.	atgagatgtgaattgtagcggggggactttaataaaattgtacagcagatgacat cgttagatctcagcagctgaatttaacaaactcaataccaaagcttagatttgggttaac attgnaaaatgaaacataaagcttcaaggtggaatgctggttagatgatacgaatgaa attcattcctccctgaaatttttagagattgagatgcatcatcaaaaggtttagaatt tcatgtgtgaacaaaggtcatcaaatggaactcaatttttctgtaagtaggcaagcgt actctctctcatttgaatggaagacacaggaaggttgaaggttaggttaggttaggt ggcggagtagtccaaagtttaagctatttatgttccaaatcaacagatttaaaagatt acgaatttagctcaaaatggagatcgtgtagcacttgttttaaaagtaaaacatatatt aaagatctgaacacacactctcgtgagatttaacagcagcaaattttgaaggtattat cactcactttgataactcagtttaactcagctcaacaaatctccctgaaattggcgtgt gttagagattatacaactatggtatttaacttagcaggtgaatttagactaaagacatt gctatcaggttcaacttatttaatacaactcaattactacgtgaagttgttgaaaatgac actgtcgaagaggttcaaacgctacattatgagaatggtgttttggcgtctta ggcgaacttactcctc



tcttcccagctaaagatagattagatgaatggaaagctacagaatttagtacagactca  
gacggtattattgaagagtagctgctgtgcttaagtttgaactcmaaatgaactgactgttgg  
agaattacagtttaecccgctattcaaccogtggtgaatatacaatgagaggtgaaac  
ctattacttaagtaggaagctgaagtagcgggtgctatacaacogactcaactcttata  
agatactacctgacccgcocttttagaacaacgggaaactctactttaaagactagtgtt  
ttaacaactgatgaagacaaagtggaacaatttagttttatoccatctcccttaacgga  
gcaagagagagacttaaatatlaaagagctgaattacttatacatttactgncaaact  
gaagtaaccaattcttattttaaaggggtggtggtgcaatctgttagacttaaat  
gttaacaactcgaaggctctatttttagtcgaaggaataaagtttaacgggtggttctcagca  
ccagaggagactctctctgctttacagagatataaatctgctatctctcagcagaaca  
ttcatttgagaaadaaganaagatttccaaattgcttaaatctgtgact-gagcgt  
tcaatttagaaagtagctactatgaactcaatataaagtttctaggggaacttaactat  
caaatctctctcagaatacaaatggttctacttcttaacgcgaactcaacttatgaagtt  
gtagctamaaatbaactctttaagttctcaacacogtagcactgctatatttctgaagtaa  
ggctcaacaaaggtttgaatgggtggaattagacaacatgctcaaaactgggtgaac  
cctagatttggtttttagacgttaagcgtgaactctatctctatcttctccctcaact  
actactcaagataattcagttatttaactcaaatatttaggttagtgcctcagcaatcaat  
acaaactaaatctattgatggagcaactgctgattctatgaattacaggttaaggaactt  
aagcgtgagactgaatcaacaacactattttaacttgaactctctctctctgggtggaa  
gggtggaataantgtgactcctcagtagatttgggtgataaanaactttgttatcaact  
ctctcgtacgcaactcaataaanaaagaagataataacanttaaatgaactcaact  
aanaatacaaatcaactctgttatttcaacttacttctgttggaaagctaaaggg  
gtagctatctgtgaacotttbaacactaacttggtagctatataccttcttaataa  
ggtaaatcaactcgttaactataattgaattcgtggttactatgaanaagacccaaca  
tcaaaccccaatgattgctagacatgaatattcaactaaagatttggatataataatggt  
ttcagaatgaacgttagtctgctattctcttatacttaactctgaggttaaaaaactcaat  
tatattagagcttcttactgttatgacgttaaaaactcaagcgttaaatatagtgctata  
ttctattatgcttaactcaactgaagcgttggtatcaaaccaacoggtggtggttatca  
agacttgactgtttagcattgaactattgagctgaaggttgccttcaaccccgaggt  
gggtgattatgcaagaaatattgatttaactgactcaatgaagtttaaatct  
caagctacattaaacatttctggagtaactttaacanttagtaacaacaactgttataat  
gaagtaattataaactcaaaaggttttaactttaaaaaagaagtggtgttagttaagttaaa  
aatggactgaacaaagcgttataggtgctcaagctatgaacccagtttagtctcag  
aatattataaagctactgatcccgctgctaaagctaaagtataattcaacttgcacatt  
gagccggggatgaattggttattacactataaactgggttttaaaatttgagctacaa  
cacaacacactattggaggttaataatacaaaaaatggcgaaggttcaacgctatacaat  
cttcaacaaaaggttataaanaactcaactgctggttctctcaggttaaaagtag  
ctttatataaattcaagacaaaaactggagataactacactccatcaagaaatagttagt  
tctagttcaattggtataccccagatacaaatggttactcagggctaaattagttatccg  
ctcaacaaattgcagactttttgaattcaagctggttagtctatggagaaatatt  
tctatgctggtttctttagaattagaggtatgggaaggtacacacaaatggggag  
gtt

246.	<p>atgtatataacgtgcacagcatgogacttataaacaacaaaataaagcagaactgcgtgtat tcaatcgggtgtacatgtgtcaaacgggttcgtcaatcaatttgaatcatctctggagag ctcgtgtgttatcaccaacttgcacacttastgttaaaaggaacaaactcatcaabaataga gagcaatttgaccataaacttatgtgtgnaaaaggaacaaatcgatgaataaactttct atagatattccatgatatagatgtgtctgtacacacacgatgaatcaagacggcaccgctc aaaaggttaaatgataatttgggtgttaaaatcaatgataagacaaatatttllagag atatctcgtgttgogagogaagtagagaggyaaagctacaagtgaaacttgcacaactc gattatttgttaccacagactacatggtcatgylaaaagcgtgtctcgtcttgggtgtggtc atdgaacacagagggccagggtgaacaaacttgaataatggatgtgtgcataatcagaaca cgtatgagtagatataacataaataaaaacgtcgtgatactgggaagatattga aataaagctgaacaaactcaagtttttcaantgcctttagttgtgttatatacaatgogaga aaatgcgtcaggtttaaagtgttttagtcaatgaggagacacctatgaacaaatatttggttt gtcaacttgcagatcccaacagcagacaatacagatggaatgaagatttaatttaactt ctgatacgttaggatttattcagaaatcaccaacacatgtggcgtcgtgtttaaact acctagaagaagctanaaggtgcagagctacttattgcatgtgtgatcagcagctcatcgt gaatcacgttactcaaatgtgcacgtgataaatacaattattaatgatttagatgatcacat attccacagtagtatttttaaaaaaaagcgtctgtgaacgaagatgtgagtgacact gtatctaaactgcgtcatttggttatctagtgtgatgaataatgataaacaaggtg aaaaatttagtaattcaagaaataaaaaatagttctcagcccaatgaagaagaattgtagat agtgctgattgogagtagcttataatttcttaaaaaaacacacgtgtgtactgaattata tttgcgaacacacaggtcttatcgtatcgaaggttttaaaaaatga</p>
247.	<p>atgatgacatcgtctcgtttaaacttgagttatctgtatgttgcaatcccaacagggtta atattggttaaatatttttataaaaagatataagacaatccggtagtggnaattctgga gaacaaacagttttcgtgtctctggaagaccagctggatttatagattacgtgttttagat atttccaggttttatctacgtgtttttccctatgtgttcccggtctatgogagatgt gttataagccctcttttacaacatggtttaaagttaggtattgttgcacactcgtgtcac ggtatccaaatatattctgaatttaattggcggaagacagtagctacacgtgcagggtt gtattaggtgtcaatctcatttactcttactcttgcacattctatttttagtgatga aaacttttaaatgtgtttctttatcagatcaattgcagacataggtgtgtgtgtgt tcantctcaattcgtatattatttacttgcgtgttagcgaaattgtttcaactcatata ataattgcacacaaactcaataatagttagaatttttaaaaggaagaacotaaactaaa tggatg</p>
248.	<p>atgatgaatcattagtgaaagttttaaactgaacagatttttctttgctcagagctttat gcttatgggttaagagaagtgaattatgtacaggttcaagttcaaacacattagacact ggtttcgaagacacatccaattataaaaacatggattcaccctgatgagcgaagtgctaca tttttgcgtctcgtcttatbaaagtgaggaacaaactgtggaacttttttgcacact ggaacagcgtgtggaacttaacacccgtcttgcgtgaaatgaataatgtctgtgct ctcgtgtttttaacgagcgaacacccgatgaactgcgagtggtgtgcactcaagca ctccacaggtgaatatgttttgtaattatgtgaactttcaattgatttgcgaggtgtg gatggaagtgaacacacactgatacatttaattcaaatgaaatggaagtcacatt ttatatggacacacccaggagacagatttatttaatttaacatttagagaacacctaaca ccagatttagtctgtgtgttttatbascatctgtacataaagcttactcattatcag aaatgcatttgcgttagatgataabaaagacattatcagaacaaaatgggtttcaccatt ctgongatttgcacacccacagctgtgttcaaatatttaacattatcaactatataatg ctgccaactctagacatcccttactcagcttctgttaagagaacacactcaatgata accactatgatttattgtatgagagcagatgaatttagaagatgagatgtatgcacgt gtaggaagcaggttatttctcaaaaattaaataaaggttggaacaaaacagctgggtat caaatattgtgtgcgaataatgataaattgatttattccgacacacccctataatct tatgagatttcagcnaatgattttttctcgtcttataatggagagacacacttgtgnaaga naaaaatggttaccgcaatggcacaactcctgaacaaacagcagcattgaaataatgatt tacttaagcatgagacagatgagagcgcatactgtgggttttaattcaaaaactaca aaagaagatcacatttgttggaaatagatgacaaatagagatgtgataatttactgt ttgtagtgagcgtctgttactacgtcaatcctgggtgacatggaatgagcgggtgatt tcaactcgttaggttggcgccacataagaatgtgaactgtcattgtgtatttactct ttttatcagcatgaacaggttttatgaagcccaaatgaatgaactctatcancatt gtattagttataaacaacaggaaggggtatcttttcaatttactctcaaaaacagcgtg acaaaatttttagagcatatttggnaacacacacaggttbaacttgaattatctgaa cgtttatgtatttcaactttaaagcgttgaatgtgtgtgtgtgtgtgtgtgtgtgtgtgt ttcttcaaatgggtttcactcattgtatgaagtataacaaatgagagacaaattgcat caaccccaaaaatttatcagaaattgagtgagattgttaattgttccatca</p>



251.	<p>atgaatgaagaacagcgaatttccaaatctatacaacagcatogattaccaggttttaagt  gggtctagaagaagtgtctccacttggtttcataggcgacatagagaggggttttaagtgtg  cgagatttcaacgaatttcaaacgcttggttccaaatgcaaatcaatcttcaaacattttac  aatcaatctgctagaagaagctgaagagggttaagtattctctactgcatgataaaaagat  catctccagcatattaccagattatttaagaanaatttaagaacatttgatgacacagat  ttcttgcacatgagatgataactcttcaacagattagaggttaaatctcagaacaaac  caacgattctgtctaaattttagatagatagtgaaactcaaggggatacaaaaaaacta  tctgtgccaatttcaacagtagaagattgacgcaatgttatccgtgtgaagagotgaaat  agcaagattctcaaggttatgttcaatgcatcaatcgcatcagggaacacatataatt  gaacgggtttctgttgaagattgaaatcaatcaatcgtgtgttcgttaagtgaagga  cttgagagtgaaagtattatttgacatttgaagggatttggttlogggagagctgagca  ttactcaatctgtgaatoggtgtatgggttcaaatctgatttttaagtgcataacgctgtat  ggcgacattatcaaggggcaaaaacactcatctcaagaggtgactctatatttact  aaaggttttaccctttcttagcacaagactgattgttgagatcaaatgaaatttgaatttt  gacgtatgtaaacagctcataaattactggacaaacacgggtgtgtgaagcgttaatt  aaaaacccctgagattgacaattgcaatgcaacatcaggattgttaattctcaacaggat  gagagcaattctgttcttagcacaagattatgttatttgaatgtgaggttctcaat  gaacactcaattatcaacattttctctcatcacaatgaaataatagtagaataattacagat  ggaatcaaaaatggtctcaatttttcttgatgaactaggcgaggtgacagatccaaagtga  gtgtggcgctcgtcaagtagtatcttagatttctgtacggcgtttaggtcttttagttatg  gcaacacacatcaactgcaatttcaaaagtatttgttattatgtgaggtgtctcaat  cgaagcgttgaaatttgacgttgaaacacctgagcgcgttataaatttaattgaaggtgt  ccaggagagatcaaaagctttgatatatcgaaaaaacttggtcttaagttctcaaacatatt  ataaaagctaaagacaagtagagggagagagaggaacgaacgaacgttgatgaaat  ttgaacaaatctcaaaacgttgttagcaacacgttaacgaattagtgaggttgtagg  gaagcagcgaacacacacacgtgtgttgtataaacaataccacaggtatcaaaatttag  acatcatctgattgtagaagctcaagaagaagataacagcgtgtgaaattctgagatcaaa  gaaggggcaaaattcttaaggaactgaattataggaataatgaaggtgtgaaggtgaaat  aagaagcagtgatttaattgaaacaaagcaacactgtagtgataatgaggttaaaattca  atttagcaacatctgttcaaaagaaaagatttgatgaactctctactggagattgaagtga  gttctattctaccgctcaaaaaggtaggtgttgtaggtgttggttgtaggaagaaagcgtct  ttacaataatgggaactgttaaaatgaaattcaactttgagatttagaataacagaaag  aacaanaagaaacacttacaataaattgtaacaaagcaaaatagacaacatttcaaacaga  atagattttaagaggtattcttagcaagaagcgtttaaagattcaacttagaatactctgtat  agggcgttttagagatttagcagcaaggttttaattcttcttaggttaaggtacggggca  cttcaaaaggtgttcaacaacatttgaanaacataaaagcgttagacaatttagggga  ggtatgctcattgaggtggaatttggtgtcaatgtgacggacgaacaaag</p>
252.	<p>atgagttttttaaagctctggaagaataatttctctgaataaactgaagatgatataca  aaagccctggatgaatcttgatagctcaaggtttctacaggtctcagattctaaatggt  atgattctgataagaagtttaacccaacaaagaacattcaaaatttgtagagcgtctc  tttagcagaagatggtctgatatcattgaagattttgaagaatatagaagctcaaaaatt  gggcaaaattcaagagcgttttggaataaatacagccaacacttccagaacaggttaaat  aatttaagttctgagagaaaggttagaagaagatttcttgagagcttggaagaagatt  cttattactctggagcgtttggttttaatacgttatgaatttaacgtatgagctacgaca  gaagcaaaagcgttatatacagaagaaacgmgagacttaagacaggttatcgttgagag  atttgaaattcttaccctcaagagagcagatcaattctgagaagaatgaatttagaataat  cgttttaattctactgagatggttgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  aanttagctatcgtttatacaacaaagaggttaaaaagcactgttttagctgtgtgtatct  tttagcgtgtagaattcaaacatttaaaagctgtggggagaaagcgtgtgtgtgtgtgtgt  gtgtgtcaaaaagaggt  aaaaataaagcgtgagatttttaatttgtagactgagcagcgtgtgcaaaataaattct  aatttaagcaggttagataaaaatgaacgtgtgttatatagcgaactacactgtatgcc  cccaagaaatttattagcttagatgagaacacactgtgtcaaaatgcaacttccagaaga  cgtttcttaaggaagtttcaaaattgtctcaggtgtgttttaacaaatttagagcgtgt  cttaaaaggggtttattgtattagcaattcgaattgattcaacattcaagtttaaatgtgt  ggttttaggtgaanaabggtgacttacaacaggttttagtctcgtgaagcgtatgatatga  ttcttctgtgatagttagacaataaagaagattctcctgagaactctctgagaactca  tcctgttaattgagagaggtgac</p>
253.	<p>atgaaagaagaattgggtgaagaagcaggttgctctcaagtatatacccgaggttttaat  gatgctaatgagatggaattaggttatctcctggatcaatganaaatttagattatcta  gaaaatttagaattaggtgtatcttggttagcccaatgattcaatcaacaaagagat  aatgtctatgataattctgaactcaaaagaggttatgtgtgaatttggttaaatgagat  ttgtacaattgttatatacagatacacaagaagggtgaaataaatttagacttagt  gttaatacacaactcagatgataaagattgtttatgaatacaaatctgtaacaaactat  gcaaaaagagatgaatttttggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  tggaagaattcttttaattgttccactgtgggaatttgacagatgactaagcatcaact  ttcatttattagcaaaaagcagaagatttaaaatgggaataacagattgtagagaca  cctgtgtttgaattgatgaattgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  gaaattctcaattcaaaaggaatttgagagagagatttaccgtgtgtgtgtgtgtgtgt  aaatttgcctcagcgaatttgattgagatgataacagccagagatacaagaattggtocaa  gaattgaagatgaattgttaagtgttatgacatgactgactgtagggtgaggtcaatgt  cttactcctaaagacgtggaagaggttgatgagagaagaatgggaatttcaattatgag  tttaggtttgaacactctgtgtttatcagatattggtatagcaatttagatttaaatcc  tataaacttttaaatgttttgccaaagcactagaattttaggttggaattgtgtt  tttatagaacaactgatacacaacgctgtgttttcaacctgggggtgagtagtaaaatt  tprtatgaatcattctgt  atttaccaggtgaagaaataggttagacttaattatcaatttgaagaatttgaaatttcc  aacratgtgtgtgtgtgaacatgaatacaaatgttcaaaaagaggtgtgagtgcaat  caattctcagatgaataaaaatgggaacagcgaactgagaggtgtgtgtgtgtgtgtgtgt  caattctctatctgt  tatagcaaatattgttgaacacacacttaatgtaggttttagatatttttatatt  aaagcgttaattctcaactcaaaaactgatttgaattcaacactcaggtgaatttttagat  gtgagctgtaaaaatagggagattttggtatgataacacacatttaaaaactgaatt  taatttgtagcaattctcaaaatgaagatcaggaactcaaacatttttgaatgagat  atttcaactgtagatataaaattgcatattatctcttaaatgataaatttagacatt  attcaacgtctgaattcaattctcgtgtgaata</p>

254.	<p>ttgagtcacagaaagctatttccctcttatattccatttatatcaacaaagacatttagat  gaacatattgcattatttggctataggagctggcagatcacaaatcaagcaacttccgac  caggtcaagagctcaattcaaaattatgttcaagatcacagatcgaggtgtgagttatg  acgctgctgttttatcaaaaactgacgtgggtgataaagaagattatcgctcaattact  catttttggtggcgcacttcagatccgaacttcaggttagtggggaactcctgttttactta  cggtatgggcacacaaatttttggagtgatctcagatcactcaaatcttcggtctact  caactccacagatctaaagcgttagttatagaagaacactttcgccgacttttaaatct  gctggaactcatataataatcaataaagaagcttctgttaaagaagagaattttatcgata  gatcactactttggcgaagatctggttgcaaaatagaagtttttggatctgcgcacagcg  tactgtgaactttatcgagatataaaacacttcaaaatctcaaaatctcaaaatctcaaa  gactttagtggtagagactcgtgtggtcactatgaatctagttgggtgacttaagaacatg  gtcaaaaatccacatgctcagatgtggtgcttactctgcaactggaagcagcagatagttg  aatgtagaataatcgtgtccgaagaagtcgaaggtacttaactctcttagcaaatcaaaa  ccaggaagaggttaaaagagatttctgtggtgtgctaatgtctcaaggaataatagttgt  aaacaggtctaaatcaatcgagagagagcgtggtgcaagaggtatggttcaacccgaca  tttgtatcgggtcaaatcaaatgttataaactttatagatgggtcggtgacttctctaatct  agacaggttaagcttgaagaatcaaaaacagacagaggtcagtagaatttaagagata  cctatgaattatattgaacactgcaactttactagatctaatcttctgactcttaact  attcaacaaatgaaggaatttcaatgtcacttaaatgtcaaaagacactcgaaggaatt  gatacttagaagatgtcaattatcatcgaactcgaactggtcctcagaataaaatcagtt  gatcctatggaactatcttctggtctgttcaaaagtggtggtgacttaacttaacat  tgggaagaattcaaatctctggaatttctgtagtgcactccaagtctaatgggaacatg  gttgaacactgttctcactatgaagcgggttaagaaaggtacacttgaaggtgactct  ttataggtgtgtgaggaactctgttgggtgatactcacc</p>
255.	<p>Atgatacaaaaacaaagagcagctgacgactgagctgtgacttagtcaactcaagaanaat  ggtactgaacctcogtttcaaaacggtatctggaactcacttgaagaaggaattcagtt  ctgaanaattgtccccaacacactatttacttcagaggaataaatttgaacttaattgoggt  tgccacgatttctcccgacagcatataatgtagatgaagctgtgacactgttgaataaata  tttgttatgattagaaatggaagttcgtgtccgaagaagcaaatgactgacttggggtgtgt  tttaagtagcaggaacttaagaanaaggtggtttaagatagctgtataaactcgtcgtgact  cagttttatcacttctgataactagaagatttaggtatgtggagatttaataaacactttt  aanaaat</p>
256.	<p>tgtgaacaaatagcctttgcaattcaacgcgcttcaggcgcagcagcagttcttatccact  ctggtgctggaagctttctcaacacataaggttcaactctggaagcactcttatgctgactt  gtcaacaaactcaactatcttcgtgaagaacttaagcgaataataatcttgcaacaaact  atggttatcccgagcgaagatttatattttaggtggagagcttccaaataatctagttca  aacacttcttcaactgacttctcactcactcactgacttagtgagagtggaacttaaacat  atagctcaataaatttggttctcagttgtatgcaataatgcaagcaaatcaatcaaatgt  tacttaattatgtccaaacaaataatcaactatccataaggtggttctgtgttcaggtatc  ggtgttcacagacactcaactcagcgtgtaatttacttccacttctcaacacacaaac  tcaactctgaagagagtcgaatgcacatgtagtctgttccgacaaacttcaaacagctgaa  cctatcagtagtctactgtgtctgacaaataactgggctcaaatgcagcgaatgtagt  tatcaagttgataaactcactcacttcttggttgcaacttagcaagaatacactggacatct  ggtcactgtgataactgttgaagctatcaacttctggttaggttttaatttgcgaagt  aattatgcgaattgttccactcaatgaactctgctatctccagcttccagagattct  ctatctgcttatctccactaa</p>
257.	<p>atggcagcatttctcacaanaattgggtcactcctggaagcaatagtttctgtgactcaact  gtaactcgaattgttttccaaacagagcagatctcctgtgtatcaaggttaaaactcga  gtaacgaacttaataaataattctcagctcaatgaactcctcgtcaataatcaaaatgc  aagatgacgcttgaaagagctaaagtcaatagagaataatctgtgtcctaaagagagt  agcagctcaactcctcaaggaatgtgcgaggaactatcgtcagcaggtctcctatctca  caggggggtgtgtgtgtgtatctatccatcgaatctgtagtgcgaagcttggagactt  gtgttagaataatttgatcgaagctcagaacacaaatttatccagacttaaggtctct  ttggttaataggttatattctgttaattggacatgcaattgttctcagcagagatttagct  acactatcaattgcgggtgtcctgctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  cagaatttatccggagcaataatgttaatttcaacaaataactttagaagcttttagtt  actgctcttggattagggcgt</p>
258.	<p>atgacgaagaattgacttatccactagagaggtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  cctgtgcgaaggtacgaanaacactcaataaagtgaatgaacatttaataaagaactcctc  aaaattttcttatgaaatagaagagagagagagagagagagagagagagagagagag  attgactcagatctcaaacagctgtgtttatllagtttttcaacagaglltaanaaaaagaa  aagagcaataatgagtgatatttgaagagcgttggaacaaactatgataatgaggtact  gaacttgnaattcaacacactcaactgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  aatgtgcagctgt  catattaaagcgt  gttaccagtaagaataatcaactatcaagcgaaggaatacaacaaattgtcttctcaca  gaattgt  tataaataatgaattgagcttctcagattataaaaataaatttttagcagctatggaagcg  eaogctgtgtct  gtct  gtct  gtct  cagcagctgt</p>
259.	<p>gtgcacaaaataatatttactgcgaattatgtggaacaaagtcgctctgagcgttgatgaaca  actatgcgaacagctgagcgaactcagacacagcaaaagtggaagattctgtgtgtgtgt  ttcccaaaattatgt  tataatttctcctatctgaatttgaagattcaggtctcctctctctctctctctctctctct  caaatggcgaagtattcagagcttgaagctggagagctctctctctctctctctctctctct  taoggtcacaacttcaaaaactcttggaacttaaggtttcaaaactaatctctctctctct  cctggcacaaggttgaaagtcttctgttaagcgaagcaggttccagctgtgcaaaagcaggt  gggtctctgt  gcttgaagcaatgt  tttattct  ataataactagatcaaacaggt  acttggggcaagtgcaactggcagcttatttataagagctgtggaatgaagaagaagtagt  agtcactactgt  attgattatctgtctgt  gtgagctttgt  agtcagctcctggaagatgcaatagagaacactcgaactcctcagcttctcaggtggaagatc  aacttctctctct</p>



260. gtagcccaaaaagctctttattcttctattctcagaacaagtgatgaacactttaaatgaggtt  
gtgacaggaagaagaactgttgaggtgtgatgaatctgagttcttttagagkgtggtg  
gatctgcaactgagacagctgcttgaaattttttcttgagatctatggttatcagagag  
atagatttttgattctatttaagaagattttcagatttttaataagactaatgatagagaa  
ggggaggtctggaagaagaagaacaataattactctcgaactttatgatgaagcaaaaagat  
atgaagcttatcaactgctcttttagattctcttgatataaggaaacactcatctaacact  
ttttgttaactagatttgcgtattgtatgatgcagacagcaacttatgatatatagagaaata  
gagagatctgcaagaagaataacagctgaacactttatctgcaaaaacagactgctgttaa  
ctaccagattatacaaaaatacaaaatgattgaagaagaacataaaaatactactttta  
tttaaaagttataatgaacatgaaaaattttgagaagagtctagacatttatataaact  
ctagaagaatatagaataatgctgtagaggaatataataaagattgatttaagtactttaaaa  
gaggttttttgactctggaagaatttattacgtatgcgtctgaacaaatgaactttttat  
tttaggaatatacttagagcatataaactggtgcttaagctcttcagaggaagaacttt  
gaaatcccaatgactagatttttaatttatcttcaattttctactagtagaggaactct  
ttctctcaaggagcaaatgaattttgaaagatttatgaagtgaactttcatttttagt  
agaagagaagaacaactctatatatttaagtttatatccccaggtgttatccagaagaat  
tcatattactcaactgctcaaaaagatttgcggaagattttgcgaagaagaaggtata  
aaaaaggttctagagtgccgagtgtaattttatatacagaagaactctgaagaagaaggtta  
cataggtgtatatgaagctggccatggggtttctgttgtatagatagatgctatgctgag  
acaacaacttatataatttttaataataaattttgtagtaaaaaaactctcagacaaacttt  
gactttttatttggaggttccaaagagaagattttgaaactctgatagaagctaaactcc  
acacaagaataactactattctttattttatttgatgaagaagaacttgcgcagctat
261. atgcaactctcaagaagtgactctatacatagaattttataatttttggttggtggtgtg  
ggagacagctcagaagaagcaaaacaaacaaactttanbaantgttaaatgtgtatccca  
actaaactatgagaagctttatgtataaagaggtttatcgttatgaaggtttgataag  
gatgacaagaagaactggattatctagcttgaaatgacaacaaagccaaagaagtaagt  
atgactctcaagaggttatggtgttatcatatgaatagaactctctgaagactcaaatggttat  
targttattagaagaattcttgagaatatancaaggtgaacttgatgtagagaagaagaat  
ttctctataaagaatgataataaaccaactttctctcactcaaaaaattatgacaataa  
ctgaaagatgaagaatagaagaacttaagttctttgtcaataacgaagattctaaaaactca  
gatgatataagagagagggagatttgatacaacactctatgcacaaactattctctgcacaa  
ttcattttaagtagagagacttaatttatcaacaaataagaagaagatgtgactataa  
acgaaaaaaactctcagatttaattatgagagggcgtggagatccaaagaggtctctgtga  
ggtttataaactctgaaattacatttcttgaagatnaggaagaataattattttacac  
catagttataacttttctccagagcaggggttaactctctg
262. gttgaactctgcaagaaggtactttctctgcgaaggttttatataatgaagtttttatt  
ggtgtgtgtgtgatttatgaataaagagaggtgaagaagaagcaaatcaacaaacttt  
atataaactttaaaagctgttatctccactaaaactctagaesacttttatgataaagagggc  
tatcagagtgagaggttttgataaagatgacaaagagacatggaagtctcatctcacaact  
ttctgtgacacagatgataaaaactctggaaatctagaagaggtgtctctctctctctct  
aataatgagaactcaaaaggtcttttatgctcaatgaataagaagaaggtagaagaagga  
agccccattatatacaaaaggaatctctctgtaaaaatgaaataataataaattatccaa  
acaaacccatatacaatgaataatacaaaaagaagaatgaaacacttaaaattttttgtta  
caatctgagcaatttttagatatataaaaattataaaatggtgtgtctttctcaacttt  
atgttcagtggttatctctgcaaaaatacatcatttgatataatgaataaagacatacaaa  
ctagaagaagaatctgcaactccaaactcaaaagatcactcaactttcttgaaaggtgat  
aggggttaaaaggtctcatctggtgtctcaaaatctagaattttactttttagaaat  
nnaagagaatactctattctacagattctgtactatttagccctagcaggtgaatga  
tca
263. atggtgtattctcagaagaagtaagcatatacaatgaattttataattttgttgaggtgtgt  
ggaaaggttgaaagaaggaactcaacaaactttatcgaactgttatagactgttatctgc  
actaaaactctagaagacttttatgataaagaaggtctatcagagtgagaggtttgttaa  
aaggaataagggcactggtgattgtgtatctacactgaacaaatgaaacaaagagcaatc  
atggaaactagaggttatgtttcttatatactcaactcagatagaacaaactcaaggttat  
ttttattgtgggaataacaaagctgtgcagtaaggtgacccaagaatggtgaagaagga  
tatctgttaaaatggaaacaaataaattctccaaagagccaaactctcatgacaaa  
ctaaagaagaagaatagaacaaactcaattttttgttcaaatctgagatttttaaaaactaa  
aaggaatacaaaagtggtgactttatcaacactctatgacacttgattatctgcacaa  
atcaatgtgtatataatgacttaagttataaaaacttgaagaagaaggttatgactctcc  
acaaacaaagccctcaaaattttgttaaaagggatggtgacttaaaaggtctatctata  
gtgtccaaaggtttagaaattacttttatagaataaagaagaagaatctcttttttca  
gtgtgtgtctacttactctctagcagggatgtggtc
264. atgaaacattcagacaaataaattctgttgagtttcttaatttttaagattttttat  
ggagatgtgtgtttttataaataagaagaatgacgaagaagctgaaatcaacaaacacttt  
ataaaacgtcttaagtattgtctccaactcaaaactctagaagacttttatagaagaagggc  
tatctgtgagagaggttgacagagtgatgcagaaggttgatatttataactcaaaatgt  
atgtgtgacagcaagaaggaagaagatggaagaagaaggtatgttttaactgtataataa  
aatgagaagacagctgaaaggttaatttatataaagaagaatcaagcaaaataataaaga  
ncaactgtgtgttgaagaagaataatctcagataaantgaaacaaacaaataattctcca  
craaaacaaattatagatatataaaaataataaagaagaaggtgagacttcaaattttgt  
caatgtgaaatttttaaaacttaaaaggtatatagaagcagagatatactcaactctat  
aatgtgcaagtctacagcgaactctcaatgaaacaaatgtatataaattgaatttaaaaca  
ctagaagaagaagatgactctcagaagcaagctcctaatttatattgaaggttaca  
gagatttaagaagaactctctgtggtttataaacttgaaattttattctgtgagaagaat  
aaaagaagaataatttttttaactgacagtataaacttttaaccaggtacagggggt
265. atggtctatctcagaagaagtaactctatacaatgaattttataatttttaagatttttt  
ggaggt  
aatgaggt  
ttctgagatgagaatttgataaagaggaatgaagaagctgtgatttatggtctgaaagt  
ccaaacagcgaagaagaataaattatgacctgaaggtatggtttctctatatcaaatgt  
aacctagaagacaggaaggt  
agcgcgtgagagatgaagaagaactctctgttaaaatgaagaactaatagaactttcca  
acaaagcaactctctgtgttaatttaaaagaagaatgaaacttcaaatcttttttgt  
caattgaggtttttaaacttaaaaggtatatagaagcagagagatatctcaactccc  
aacgttctctgt  
tgaagaagaagatgattcttttaacaaactcaagcccaatttatgttttaaaaggaat  
ggcgacttaaaaggtatctctgt  
aaagaagaataatttttttaaggtcagactcaactctctctgagagagatgaa  
tca







279.	vafefclpdiqegihgeheivkwifkagdtieeddvlavngnksvveipsvsgtveevl vdegstvavvgvrvikvdpadpdeagkfghgddedskkenegespveeasstqsakte vdegsktvampsvrvkyareenqmkvawgnksnrikedidayingpseegantass easasdvmasatralpadevdeactekipamkalkamvnskthapivlmdedvpl wdhrkfkfkeiaaegqtklflpvyvvalksal kypalntfneeagevvhkhwlgia adtcdglllvppvkhadrksafolsdeinelvkaridgkltseemkgatetienegagq wftvpinhpavalligiracqkplvkdgevaavplalsafchruigdatqgmamkik rlimnpallmes
280.	moctdeisqlynhkrlpelsglakvplvhrasigvynvaeinrikrlvqvvgqkftfy ngmldeeevkvpllbtkmnhplltidfkelnctdahdlfahasytqlsireklsrt qrignldrivkngqgkvklsdaivtrndrnivvpkseyzqfngi vhdgaaqgylly epnsvveomgltkngqklsdaivtrndrnivvpkseyzqfngi vhdgaaqgylly artikgtlptfcderttlylpmathplldktvanti ofiddevvltitgpnatgkvtvl ktlglivmaagslilptlqsgslafenvydcidgdegiogletfssahmknvleigd adgnslllfdelagtpdsegaalamsllqvyrrigsmatthypelkayoyatvsgma asvafsvotagtyklmvgpggsnfidkklglsintekmktldegealmxmas legnskrvdggrleldrlvreaqgthdalskqvyymyetslmdesekangrvksat eadeileklnlrdhkeevkeheildkkglddgyevkslkghvqkkydltihydeq vlsgydgvevlvdeevavvgqslmekpjldektkklkkgkqkvtrngqdkte ldrtzyvealelndeyldgavlmvgyvllhngktgalqkvqgklkkksvqrtrg gmpseggfgytvaelk
281.	msffkrlkdkfsaknoddigkldosdevmnsndedmdpndedevqkpkkkcklseed fdeedglisiedfseleagkigakfagklszgnfgeqimllaryrvkvdfealeem ltsadqfntwklldelrtseagrnlgelodfsewkwkewlyhnpndhesumiedg zinvlmvgvngvgttttkllyrygqekdkvlaagdtfragaqlnvvgvrvpvev vsgnqgsaavvydaiaakukdwilidctagrlgknleagqldemkrvlnrapda pamlacldeatymalmslkskewnvavltklldgskgplvlalnelhplkvly gigedndgltgpcporyvrylfadiegndpdelearnsveseem
282.	mknmweavevgyvprsndnagdgldplgilekdylenlgldivivispepnnd nyydidyqginselntmfdglisslhrqmkllidvmtsdengpwlfeesktk ekrwyvwdgkpgdsepmuvslelfgstweiddeekqyrlhifdcpdlnmvgdyv vrfommuwteklgdfvdaitchknagadplpmsasfddmnappligewig emdkeslerydmtvgengvtpndaeewgeengtnmlfqtelhlwstgdkfklv ykvqlnrvwklglenvvnailehndgprvrvtpgdiknyvysststafatqagtpf lyvgqegmnyrvldedvavtkdygidvdegnmklldgyenarndnrtpep naslnagttgkpgvfhvfnvntenvqkgnkfsllsykalligedldlytyqkfm vdaenkvfaytrtfomtvilvanntevselnplfdlsesvdklmhlndlnldh lkpyesfsvetl
283.	lshrkldshlyqgdndehaiaiggrdnnyegfrdgkiasqiyvktfdrtdom thvryktdvdsesayqllgferldpafalgmriflyanpgffvayadlykmsgit qttgkrlvrlckpfgsdlksaelangzrsdkeeyridhyldkmvmyevlrfema wefpdlmnylianiytsvsevlvwdgpryessgldkmvghmqlgavallawapall nsedraekvkvkslrvydeevknfkmqgmldgkvgrvdeevvoldvdevt fvsqkltidfravagvpyrlrtgkmsktigvrvfkevpmllyvctnldnlln lqgnepelinhnaknqigdtogvlyiasagdeemavdayonllfdclkgdnatn weelstkwfvdalagdtomvpcfpvysseegndpseadltsardghwddh nlknkeindmoylvpmetepfzngvymhkegilyrkdkgplftedekfseog wpsfsklnndelvelvdkesomrtvsekanshghvndgpkkgvlycinsaal qtipydkieelgvvdlidhkk
285.	lklafafatasaagavvshhdseastghkvgeesvltiaegnytsveisikqnmam nyvpgvlnvysseegntasessashtvsgslnlanbyyvsvedlmgagshg ytlmpcrltllpvgssaggtatqsgnytspeahnyltceqctvyvfrkseqak pistywskvysanaandgyvndtpsvgaissgpggyghvayvaringdgsilise nyvngpvmnyvtytsaasvysafih
286.	narlakkygnesstvatvlefvhnesyprlyrktkntalkkiaseneisratng taklneaklyseelyvntkdeslptklsaalctatylagprvlditvatagtyl vveidrlkhagtipelgslvgislvghafpagdlatiiasaavpvgvltlntal odfggmnlntkkslealtvatfsgavssllily
287.	ntedfslreagrvkhfsvdvpgtktpctknteddgshknlfzeisevkaltpvyl ldgvtagltfetselnkeektmasllesvkhngpdeletlbelrltqfssm naagvdegwkdffdyrvpvlkhavhadvtyplaienhtvctkeltigakvltcepsk eysesahmgrrvtvkvayldkmndvidyldnkildaneasallpylkrpketrvt fayenprfwelldelafvdekrerdlmceesghpdafrakkyk
288.	vekpyitaiigtutalealnthagaatthvkgeevvseishkypgieakksingltn lfpnqvlykvgssrsratstngvtykvagdsissiaakotykyqkinglgnlylf pgcklvsgkatssrksagssgrtatvtykvgsdelsaakotykyqkinglgnltnf fhyppgklykvgssasessntrngsyptbnhlybwqgwtvfnrznalngt tytsaeanmdnasasadytlydyppvsaletdgyvlyvafvrvndgdsiveem saapgmnytytspagvrvykh
289.	vtckafisyrtsehlrvrvrvgeslrvdhgdvildvdcdegdllfmesvndet idvillsdqyvrfrandceovvoksttiegidykpkdkfipvldilldnkpslpt fntfralddetldeidqicpalekdhkldlctatylagprvlditvatagtyl skenyetnrfaalidlyktleniensvevnddntkvevdkwzelyalndnfy frelliehnroklteesfepatrtfnyfslilvsessegamellklldnakfhse reanyylselypvlkkyseyntvknalaeqfagelkxvkgadviytelakkl hsyvetwgrlyvsgvleqptlnllnkfrakbyldqtdfsgsgevranyvklks tqelptlntidkeesiegy
290.	mhyklkvtylslilvsgcdgdeketeikgnfnklnvypthkledfydkuzydeefk dyhndnlyentkypkntekmshvmmnttrattyvyrklndeksdksdeek vplamnkltptkldnkldknelenckfvyvgefnadgkesdlysyngvsgvna ylshndnlyktrkrydklktktpvlrlnmgadpksavgyknlteffkneemylyft vshnfpkexkl
291.	dkhscklllclaflltfrfgcgtwkdkgdeketeikgnfnklnvypthkledfydkuzy vryadefdkvdrlyvswvldvdpkgsmeagvmlfntvrtkgylyvaelkdqk rplnnkkkypvkmunknltptkpsndkklleinfkfyvqyngfdkinykxdgdsyp nvpsakvyglennayvqgkrydptkvpklklkdgdkgssavsgnlefften keenyfddsvlfspdesnes

292.	mrylkkvtyiaililivsgogngketeikgnfnkmlmvytpknledfydkgyrdeefdk kdygtvigtatitopkgykysargpfllyinnrtttkgyvyrkrttdsgr:kkdkdekr ypvpmekhnkltptkpinaklikkelenkflfyvgydfknlkdykdsgisypvnpvpyasg yolamndyrvyol:kyrdyptnqapklilkqgdplkgsanlgekzeftrienkcomiffe dgvqfptpsedes
293.	mksheklivfvallitilfiggcgfinkekskaolknfnkntslmvytpknledfydkgyr ydeefdkdkdygtwinksmkvpkgyemeargvwirnmrttagnfnlilkriltennk ipdrickkypvisehmkilptkqkdkdklikelentkrvtygmfnlkdykdsgisyp nvpyasagylmndvnykqlrkrydipntnqapklilkqgdplkgsavgykloftfven kkeniyftdsinfpsgrn
294.	mrylkkvtyiailililfiggcgfinkeksketeikgnfnkmlmvytpknledfydkgyr ydeefdkdkdygtwinksmkvpkgyemeargvwirnmrttagnfnlilkriltennk ipdrickkypvisehmkilptkqkdkdklikelentkrvtygmfnlkdykdsgisyp nvpyasagylmndvnykqlrkrydipntnqapklilkqgdplkgsavgykloftfven kkeniffddevqfptpsedes
295.	nkryvtyghlrralfastilpyfvmnailisfayliyvshrtinhtygtatgclgri dkhfhtrvgogkqghvshpdtlcnkrqllkqvhggpallydydkgsesqfnnmye qltdtkmlyliskrydfdkdtylikymssptllmknkmsagssalldsvdytvlvtndd rfslgkgyppgymnesiklnshablilykdhietiedgiallvvgvillivfig yriandmekrgpkealvzckldakrhlgyepklkhesoolmnydydlfsmegcl qssieterrirdqlkieergpghflfntnqglvliipkspkvgvtyqglasmlrysl rtashtvklaelvgyqyvalgmirdmqlivdapedvghgtlqgmlopivensak hgyspiklitrilrirkkthilvhdnglmspsהלארsvrghhvdftcthlgluhh nralisgtyvrylhfiermhgtlmycglv
296.	vddvtykypvddgdpitsteelpfdkkrefdpnlapgtekvvgkgeptktlttpttknpl tgekvgegeptekitkqpvdeivhyggeeikghkdefdpnapkgsattapnkvgnkpd tgevrvppvddvtykypvddgdpitsteelpfdkkrefdpnlapgtekvvgkgeptktlt tpttknpltgekvgegeptekitkqpvdeivhyggeeikghkdefdpnapkgsattapnkv kpgvknptdtegevtppvddvtykypvddgdpitsteelpfdkkrefdpnlapgtekvvgk geptktlttpttknpltgekvgegeptekitkqpvdeivhyggeeikghkdefdpnapk gsedvpskvgvknptdtegevtppvddvtykypvddgdpitsteelpfdkkrefdpnlap tekvvgkgeptekitkqpvdeivhyggeeikghkdefdpnapkgsattapnkvknptdte efdpnapkgsattapnkvknptdtegevtppvddvtykypvddgdpitsteelpfdkkref dpnlapgtekvvgkgeptktlttpttknpltgekvgegeptekitkqpvdeivhyggee elkpgkkskdefdpnapkgsedvpskvgvknptdtegevtppvddvtykypvddgdpitste elpfdkkrefdpnlapgtekvvgkgeptktlttpttknpltgekvgegeptekitkqpvde elivhyggeeikghkdefdpnapkgsedvpskvgvknptdtegevtppvddvtykypvddg dsiltsteelpfdkkrefdpnlapgtekvvgkgeptktlttpttknpltgekvgegeptek krtkgyvdeivhyggeeikghkdefdpnapkgsedvpskvgvknptdtegevtppvddvty epgkpaepgkpaepgkpaepgkpaepgkpaepgkpaepgkpaepgkpaepgkpaepgkpa esgkpvpgtpagsgapegnrmshdtnklpdtgmrmqaneq:lvgsilaivyslfi fgrckgnk
297.	atgaacaaacagatttttgtttatatttttaabattttcttgatttttttaggtatcoggt ttagtaataacagattcgtcgtgtttatttaaaagatttgggtatbaactgtatgattta ggattactagtctcgtcttttgcgttatctcaaatgatatatocgcttttgttgttaagc ctagcgcacaaataggaggaacaaatatttatcatagattatatttttgttttaggt tcagattttatgttgtcagttgacacaaatttttgttatgaglgltakcagagtgatt tgtgtatgtgtgtgtgtatggttaatgcctgggtgacaggttttaatagctgaenttca ccaagcgcacaaagcaaaaaactttggctacatgtcagcagattatcaatttcgysabtc attttaggaacagagtttgtgtgtatttatggcaagatttcaacagtgatgcaacttca tttgcagagagcattaggtattatagcattttataattgcaattgtattgattcaacagatcg aanaagtcacagagtggttttccaaaagttagagccaaattgtcaacgaaaattcaac tggaaagtgatttatcaacagatttatttcaactgttatatcogtttgttttatcogca tttgaaacattgttttcaacttcaacagctgncgaaggttaatttatcaactagaattt togatgtcattacaggtgcaggtatattttggggcaacttttcaaatatttttctogatt aaatttatgaagtatttctcagagtttaacatttatagcttgttcatttatattatcaggt gttgttttaataataagatttttgttcaatgagctatagctaaatgtatcaggtttt gttgttctcaagttttgtatgatatacagcagcagcatttatcaaatatttttctcaatt gtcggagagagcagcaggtttgcagcggattgactgcagcattcattcatttggtgtaatt tctatagttcatttatcgcaggttggtttttgtatgacacattgaagcacaatttat atggtataggttttcaatacagaggttgtttattgttttaattgaagaagcaactaga gcaaatgtgaagacaaaattatg
298.	atgcatttttatatttttcaattcagcttatatatcaacagacttttctctatc atttctcaatgaacccaagcgccttagtagcatgtgggatttgggtgcactgcagag agatttcaacattgaagcagatttagatttggagatttggagctgtgacttttggga agcttaatttttaggttttaatggtatcatttagtgcagatataaacagcagcttaatt atatcttagtgccagcattatcaacatttagtaacogtgggtgcagcttatcaagcagact agtttttttagtatacaatgattatacaagcgtctgaacacattttttagaagttacaatg atttcogttcogatttcttctgtattattttgttgaatttatatttactatcaaca cgtatcaaacacactgtattggttaaatccaaaggttaagcattataaaactttcaacatg aataatagattt



304.	<p>atgagcttttttaaacggttaaaagataagttttgcacaaataaagaaaatgaagagtt  aaatccttaaacgaagaacaaggttcagacaaatagaagaatacacattctgaaggttc  acggagacgacatgatttagcggaaaacgctgaagtgaaaagaagccacgcgaagttg  agtgaagcggattttgcgcagcgtggcttaatacaattgaaagttagaaataga  gctcnaaaaatgggttgctaaatttaaaagcagcagctcgaanaattctgcataaattccaaa  gaacnaattcaataatttgatagcggatcatcgtanaagtagatgaagcatttttgaagcgt  tagaagaatggttaaaagcgtcagcagcgtctgtatcaacaggtgtagcgttaawtga  gaattacgtatgggaagccaaagcgcataatatacaagatactcgaagatttgcgtgaagtc  attgttgaaaatactgtagagattttacacaaagaagatgataatcagaagcattgaac  tagaagaatgctgcttttaaatgctcttttaattggtttggttgcaattggtgtgcaaaac  acacaaattggaaaattagcgttcggatataaaatggaaggttaaaaggttaattggt  gcggcggaatacttttagcggggtgtatgtgataaattgaaagtttgggcggaacggtt  ggttgtagagcttaattagccaaagtgaaaggttgtatgcagctgtgtcttatgtatgctg  attaaacggcgttaaaaacaagaaggtgtgataattttatctgtgatacggcgtgaagctta  caaatataaaacaaatctaatgcggatagaanaaattgaagcgttatataacgcgga  gtgcagatgctgctcgaagacataaattatattgttagatgctacacattggtagaagtg  ttgacaaagctagaacattaaagagacaaacaaatgttcaagcgttatgtatgaacgaat  tagagctgtagcccaagcgggtgtagctgttagccttaagtaagatgcgaacccaa  gttaaatatattagtttttagtgagcaatagatgacttaacacaaatttaaacctgaaggt  tatgtctagcgttatctgctgatactgattgaacaaatgagaataacacagattgaa  aatgatcaaatgttaacgaagaagaagggcgtataacatcgtggccaata</p>
305.	<p>gtgtataaaaggggtcaaatcaaaagctcaaaacattttgttatcaattttatagtt  gtaatttaaacgcttatctattttctactcaattctgtatattgtgaagcgtgaat  gttttttagcggcgtggagatggatctcgcnaaagtgcctttcaaatgtattgtat  gaacatctacagtgattttcttagtttataagatgctgctgttgaatgaggtggcattat  atggaaggactctcaabttatctctgcgtgcacattctaatggtgaattttctatct  atlaaaataggaagaacgggttggttatatttaactcgcagacatacatttttggcgga  aaccaactattatgctgataagcagctatacaacatttgtcgtacattctactta  tttaaaactcaacatttaaacgctcagcaaatatagatcgtatgaattttatcagggatg  tcacgtgctgttatctctttaaattactgtgtcttttaggaatttatataattta  ttgcctatcgtattctgtgtttggaagaatattttcaaacagcaaaatcgtgtattct  attgttgctagagcattcaacatttagcaattttttattctcaattatatacaagcatt  attataggtgtgctactattatatacgaactattttcaactcaaaaatggaactgtct  agaacacaaaataattttgctcatatctgcgcacgtttttgagtggttatcaaggtta  tttggtttatctcgtggaattttgtggtttttggaatgacgaagaacaaaacccaat  gttgatactcgtttttggaacacattgctatctatttttttttagagagggattt  tatattcagatttttaatttcttaactcgttgctattgtgtctcaacgtgtagctgtt  taactttatagacttttgcgaatagtaaacatggtattattattatgctctatcaacag  tatttgcagcgtgcttttaattggttttttccatccagaagcgttggtgttatatttta  gcaatatactcagtgctcttttgagcgtgttttttcaaatatatacaacataaataag  aaatattatttaacgacaaatcccggtttggaatctgcgaactattatgatactta  tccgcgaacacacacacttgcaattatagtaggtattatctgataatagtgctgctgtt  attttaaatttagtttatggcgttatataaaatataacgctgcgaatttagtatctc  gtttatgattcaacaaatcgttaatttagatcaacaaacaaatcgtgcgaacaaactat  caacaaactatatacagcttgaaacacatgattacatagtaaatatgtaaacacagctt  ataaaagaataaatacaaatgcacacagctgcatttaactcgtattgattatgctgac  tatgcatttaattccacatttatatacatataagatgcaattttcatatctagatt  tttaagtggaacatttaaaattatgacaaacacacacacacattatgacaaatggt  aaaacacgcaattatagattacttggcaatcgtcaaaatttaacttaactttggatgtt  aatgactgaattagagtgaaatgaatgacaaactacacatagtaggttttaaaataagctt  gaacaaagaacaaacaaaggtgtgtggtctcttcaaaataacacacacacacacag  gcacatatatacaaataggtcttttcaaaagaatttaaaatctcaattatgaataaaga  caagcattgttgcaaggaattgtttcaacaaataaaagatttaacacacacacacacac  gcacataaaatttactatcagattcaacaaataaatttaaatgtagcagcgtggcaatct  cctcaaaacatttttaagatgatacaaaaataaggtgtgtcaactgtaaggtgga  aaatcagtttctatacaatttaaaattttgattttgaatggatttgaatttaacttctg  cgggttaagcgtcctgatttgaagtgaaatgaatatacacaagaagaataaactcaat  tataatactgacgggtgtgaacacagctatcgtatcgtatgaatgaagctcagagctgaat  aatatatactgctgaaggttaagttcgttaatttgaaggttatcgtggaaggt  tatcaacgcgtttaaagaacgttcaaaattttagaagcgtgaaggttagtagaagaacag  catggttatactattactaataaaataaaatacaactcgtgttatatttttgcacacga  tataacaggtgtgaaggtgaacacagcgtcgtcgtcgttaaggttatgaacacgaat  gggttttagcggcatttaagcgaacttaaaatacaacaaatctaatgagctataac  ccacatactattttactatacaactatactatttggcaattatgtagattattt  ttccggagatgggcgaacaaaa</p>



306. gtgggtcaattggcaagcaaaaagcaatgcacgctaagaaaaaaacaacatacaaa  
 aaaaagacaacattgcaggaagaaagaaagatgatacccgatacgttatgctatgctatt  
 taagttagtgttatatacgtgtgtgtgtgtttcccaatagggaataataggtgtccaaat  
 gacagctctttaaatttttattgttgcacgttgcataatttcaacataattttagtact  
 cttagcaactgtgttttatatactatcaaacgtattcctaaaactgcagacgtgtgt  
 tggattgtatgcaaatbgcaatgctattgtgtatcacagctagtgttttcaatttaataatg  
 gttatacaagctgaaagaaagcaactgacttttatgtgtgtatgaagtatacaaacag  
 cacttcccaaattttggctggcgtgtattataggttttattattatagatttaagcgtac  
 ttaatttcattatttgggtgtattattatctaattttattattatgtctcaagtgtatt  
 ttatttaacaancccaacattgcgaagtgcgaaggtgcacgtgaaataataaagct  
 tggctgtgttcaataagtgaaatgtgcgaataaaacccaagaaacaaactgtgaaggt  
 gaagaaagacagactttaaagaagaaacaaaagtcacgtcaaatgaacgcacaaata  
 aagaatgtgagtgattttacggaggtgcctcaagaagagatattccaatttatgggca  
 actgaaagaaagaaagaaagctagactcaacagctgcgaaaaagacgtgtgtgtgtga  
 gaaatagttgcgaataactgtcaactgcatacaagagatgcagaaacaaacttaaca  
 gaacaactctataacgtgttgaaggtgaaaacactattgaaagagctgggtgaagtacg  
 aatgtatgtatgtgtgttcaacgttcaacttacttaactaactcaacactgcacaaacaaagca  
 aactcaagctgaggtgcgaactgaaggaacgactactacagatacattcaagaatttt  
 ggggttaaatgcaaaagtgacacaacataaaatttggctgcgtgaactcaattatgaatt  
 caaacgcctcaagggtttaaagtggttaaatgttanaacttcataatgattgtgcata  
 gctttagcagcaaaaagctgttagaactgcgaagcccaactaccgtgtgtctgcagtaggt  
 attgaagtcacaaatgcgaanatttcaatcgtttcaataaaggaattttagatgaanaa  
 ttcccgcttaataataaactagaagttggaattaggaagagataatcaggtgatccaatt  
 actgttcccaataatgaatgcacactattgtggcaggaatgcacaggttagtgtgaa  
 tctgtgttatcaaatgttatatacaggtatitlataaagctgaagcgcaggaagtt  
 aaacttatgttaatgcataccgaaatgtgtgaacaaagtgttataaggaattccccc  
 ttattaatccggtgtgttccaaatcctctaaagctgtcctcaagctttagaanaaaattgta  
 gctgaatgaagaaagcttatgatttattccaaactcctcaactagaacaactaaagct  
 tatcaagatttaactcgttaagcaaaatcaagaaatagagtgagaaagcaacagcaatcct  
 tatactgttgttatgttagatgaactgcagatttaagtctgtgtgctggtaagaagtt  
 gaaattcgtatccacgtattacaacaaatgcacgtgcagcaggttatacatttatgt  
 ggaacaaagacacctctgtgtgaatgtaactacaggtatcatataaacaatattccact  
 agaaatagcttttgcgtgcgttccaaacagatcagaacactatttgtactgtgggc  
 gcaagaaagtacttggttaaaggtgacatgttatagcttggaatgtgtaactcaacaa  
 aacagctattcaaggggtgttttaagtgacacagaggtgcagagatgtgtcaattatgt  
 ttagaacaacacagggcaaatatgttaaaagaaatggaaacagagacacaggtgtataa  
 tcgggaatgaagaaagtgaggtgttttatatgatgaagcttatgtttgtgtgtgaacaa  
 caaagggcaggtacacatctgtttacaagccaatttgaatttggtttatataagacatc  
 aggtgtgaggtatgtttagaagcaatcaggtatcgtgtccacaaaggaagcaagct  
 agcaaggttataatgtcttaataatgaagaggtg

307. atggctgaanaattcaaaaggaactgacgaatgcacacatacaatttaattgcaattgpc  
 ggtgcaattgtgacagcttatcttagtgctgtgcgaacagattgcaataacggccct  
 tcaattctattacaatacctattatagatttatgtattatgtttatgcagaggttata  
 ggaagaaactattatccgaatcaggaatttaattcttgcagaggtgaacaaacaaat  
 attgggaccttttcaggaatttggcttcaggtatgacactgtgtctgtggtattaca  
 ggtatgctgaagtacaggtgtgtgcgaattatgttagcttttgggttcccgaaatcca  
 actgtgaatagtgactatttgcgtgtgttatatagtgcttcaacacttaggtga  
 agacttttcgggaattagaatttgggtttctatcaataatagagaactatttgggt  
 tcaatagtagttgtttcgtcatgttatatttgcatttaaaactcaattcgggtcagtc  
 agtttcaacaatctatgaagcaaggaattcgtcaaggtgtcttggatctttatgt  
 tcttcccaatggcactcttcaactgtgagaaatgaaatgattgtgttccaggtggg  
 gaacaaagagtcaggttaaaacacttccaaagcaatttaacagcttcccaattagaatt  
 ttaatttttaagttgggggttaggggttatcgtctatctattatctcttggcagcaagtt  
 gctcctgaatacaggtccactgtgaataattatgcactgtatgcgaattcgggttgcgg  
 ggtgtgaktantttgtattataacagctgtgtgtcttcaatgatacaggtgtatctc  
 tcaaatagcgtatgtctttcgttttatcaagtcacaaacaaagcaactccgaactttat  
 aagaagataaataatgggttcccaactgtgtcaatcttgcgttcaatccgaatattact  
 tgcgcagcttatacaacataattttcccaagtcgaacaaagattattcagcagtgact  
 acaactctcaagtgatttttaggtgtatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  
 tatagtgttaaaacccagatatacataaaatgtcagctacgtacaaactattaggtgcnaa  
 tataaggtacttaatttgtattctcaatttttgggttgggttatattattattact  
 gtgtatacaaggtgcaatttatcttcaagtttatcttcaacttttagcattatgt  
 tecttaagataaagctatcgtgtcaatcaataaa



gctagtgcagtgactaatgcagatgtggcatatttattgcattgatgagaaaaacgaatt  
cylgaatcgaacctgllattacagaaagggctctgctcgagacacattgcaacctta  
ttcaacgataaaaaacaaagcaattggaagcaatttcacgacacgttagaagaagaacat  
agtatattagcacagttacaaaaatatttatgacactgctattggacacattgatomaagat  
cgtagcaatgcacagttgataaaacagcatcattaaattcaaaaacatatcatgattta  
gatgtaactctctataaaaagccagatgctgaaaaaacgattaatgatcttgcaacg  
gtcaactgcttagtgcaaaattatcgaaaagttaagtaactgtaataaggctgatgcat  
aaagctataactgctttaaaattacaaatggatgagaattaaaaacgcacgcaactaat  
gctgagtgtgagcggtttaaaacgatttaagtgtgcttaagcgattagaaagcaata  
attactgaaaagaaaaatgcttactcggaattgataacattgctcaacaacataggg  
aaattcaaaagcgatcgaaacacacgaacaaattagctaaagttaaagtattaattgataaa  
tatgttcagatgagcaatgaaatgatttgatgaagatgcacatttaattgacatcaaa  
cacacgcaattcatgttgatgaaatttagcaattaaattacacgctgaagcgcaaaa  
gtatcccaaaagaaatttcagcagctccaaaagtttgtagcctattaaaaagagag  
acacatgaatcgcgcaagttgaaaaagaactccaattacaggtctotgagggaatggt  
ttacattgaaagaattgcactgattacaggtgaggcttctgttagctagagagcgtact  
aaaaacgaaaaaatca

309.	atgaggtgttgaataagaatcaattgaaacatgaaatgagaatcaattgacatttgcga caagcaggcgttaagaattacacotcaagacgaagaatattacgttatttaatttcttca catctcaacacagctgtagaattattcaagacatttcaacgtatttccaaatata aggttgccacataataaacttaacttaaggtgttaagaattatggaattgtaaaaga ttacatatacgagacatcaatcaagtcgattgcatttaacacataatcatatcatatt atatgtgaacaatgttggaatattgtgattttcaataatcccaagtttaaatgaattgaa agatagcttcagcatatgactgactttgcgttaacacatcatcgaaatggaatttatgaa gtttcaagaatttccaaatgaaa
310.	atggtgtgaaaacaacaatctcgtattatatagaacaatataatagtattatctoga atcagtcataagatttcatgaagtcctgaacttggtaatgaagaatatttgcgtctoga actttcaatagatcgttgaagaagcattgatttgaatgaagaacgagatttgcgtgaat gaaatcgggtttataggaataatagatccagagtcgaagcgcagatagatttttba cgagaatacagatgcttgcgcaggatgttgctcatgctcttggtcataatcatatggaact cgaagtgcttcttgggtgaatttgggttgaagcagtgattgacaaatttgggtgttaagta gtcgttcttogaatccagctcgaaagagtggaagaaaggtagcgttaagacttcttat glaaggtgtgtgtgtgtgtatcaatagaacttgcatttgaatgattccgggaagatgaa acttataaaagattgtatatttggcagtggaattgttttagattttaaattttcaaggaaa agtgctcactgctctgaaatcgagatgaagcttgaatgcattagagcgtatgctatgt tatcttaatgtgtgtagccaaactcgaacatatttaaaagacacagctgtcgtgaatgt gtgattttgaatgcgggaagacgctaatattatccagctatatacagatgctgtttt tatactagaagcatagcgttaagaagatttggaatatttaacgaagaagtaatcatcaatc gcacgtggaactcgatcaacagctgtgtgtgattatgatttggctgaattcaaaacggt gtgaatgaaattataaaacgggaanaatttgatgattttgtgtgaattgtcgaagaa gttggtgaagcatttatgtgatgatttttggttatggtctacagatcagaggaacgta atgcatgtgtgccaacaatacactcatatataataggatcagctaatattagtagga catagcgtagatttagagaagcgcgtgcggtgtgaaaggatgagacatttaataaa ggcgtcaaatatgtgtgtatcgggttaggttaatttaaatatcagaagattttatcaa gacattatgaagagcgtcgtcatttgaaggaatggaag
311.	atgctacagactcttatttattgacatattttatagcgtcattatgttgggggttctc aatttatttttatagctogaagaagaagcgcacacgaagaagaacacaaatttt acgcgcgtacacaaatcaacttaatttaattgaagctagatttagcaaacacacgtat caatcgcccaacagctatagcgtcgaagaggtgcgtgtgacaaatcagatgatcctagc caggttagctataaattgttaacaaaggggtctcgaagaagatcagaagcatctcaaat aattagaatgaggaagcgttcgctgcataaatctgtaactcagaagatataaagaat gaataataaaagaacataaaactttatttttgggaagtggttcaacgggtgaat atattagcggcatattatctcgtgtatgtttatgcgattttaaaccaaatatttaaat gttgctttacaaataatcaatcgaagattcaattttctgcgtcaacggggcaatggttt atgcgcattctattgttgtaaaaggtattttaaatacaatcaggcgatcattatcaat aaatattcatatogaataatttttttagtgcgttagtactcttcaacttggtctcat atctgtgcgatttcaaggaatttcccaatctgttggttggtgcgttatcaacgcatt gtgtgcgtgtactaaagcgaattggttcaattgttatatttcaacttatcaacgtga aaactgtgtgtgcaatcgttaacatggttatgcaatgatttttagcaactgcaattgtg ccaacatattcaggttatattgtacaaatataccactggaattgtgattttacagtagt tcaatcagcgattctcgtatttttaattgtgtttgtatggttttagtatacatcaat aacaacaacacttaagtgatctcccggttatcaattctagtagcatattcaactgaat tgtttattgtgtttctcgaagcgtgcgaacaaggttgggttcaatgagatagaaaca atgttgtcaatttgttatattcttattatcttctgttatagagaattagaatgaatga tcaacatgtgaatttagaagatagaatttcccaacttatcaattcaacaacattatt aattgtgtgtatgtttatgtttatgtgtgtattgtttattatgcgaatttatcaaa aatlacgcggattctcagcatagatccgaatgtttattattaccttggtctctcaatt atgggtctactgagacacttgcgggttaaatgttgatcaactatttggttttaaaacatga gatacttttgggttatgtgtgaattgactatgcaacaggaattcaacttaataatgt gatcaacactatgcgaactatgggtatctatgttctgttcaatttggtatagcatatt ataatgatccaaatggtaactgcagcatattatggttaccgggaacgattgcctctaat gtatgactttcttaataacgaatgcgtcaatcagcgtctatagtagcagaatctta gttctgttaatgagcaacaaactacaaacacattatcaggttttgggaagagttagat aaaacgattctgttgtaacagatcatatgctgaattagcatcaacatagcgggaca gaagcgcaatgaagaggttactcaatttgaataactgaacacggttgaaggtatt aatgagcatctatagttgcaacgatttatgagcatctgcgttaattttatgttatct ttacaaagttatataaaagcaaaaggtacgcctcaaaagttagatgcgttaattgatt tatactgaa
312.	atgataaaataaaataataaacagcaactttagcagttgtttantagccctttgac aatcaattctagaattttcaagacgaagaatagatagattatcggccaaggttga gaaatataaaagacacaaagcattcttagcaaaagtttagtataactcaaaacatt caattgtattttgtaaaaggttannaaatacaacaagatgccttagtttgaatgacga ggctctatagctctcgaacacatctctcagacttaaaataatcatctataaaga agattatggcaattcaataataaatcaggttgaacaggaagcttcaattgtgattta attantattcttcaaaaataaataatcgaatctcgaatgatttcaaaatagattat aattcggcggaacttccaatcagcgcaatcgaatggaagcagtgctctcaactac ctcaaaacacttagtataatacaaaaactatgttactgaagtagaagcgaagcactc aaaggttgaataggtgttgaagaaatatttgttcaacagatgttgaaggtcgaagtct gaattatgtaactgaattattgcaagaagacacactggtccagcgcgcgcgactatct gtcccgataatacaactacactcttcaatcaaaagtggttatactcaatcttatataca actgttctcagcaagaggttgaaggtgataaagaggttgaatcattctagcgaaga acatggttgttcatatgtattgttcgaagaacatgtgttagcgtgttgcgaagaacat gatgtctttcaacacggcaacgttacaagtttaaatgaagtgaacttggaacaacatgaa gtaaaataataaagcatcaacactag



317.	atggaaacacgggttaaatatcgttaagtttatactccatcgtctgttagtctccttatt tgggcaacttacaacttttaaacccgagtcgttggatccacacgcatgtatgatgttcgca atattcgtcgcgcacaaatcgttcgtgtatctaacacacgagtcgcaatttggcgccgtct ataattggatttacaacacatgctcgtctggcatttggcagtgaacacacgctgcgct ggttttggtaataatagcatttggtaactgcgtatggcattttccatttggagaggattt ggaaacacaggtcttggtagcgtatgcgcattcatttgcgaatttcttggcaaaa scattggagctagcatatctatcgtcgttggagatttaatttagcgcgtccaccca agtaataccgcgctgctgtcgtgggaacatgttcccaattatcaaatcaactttctgaacna tttggttcgaaacccgaacgagatcagcagcaaaaatgggtgcatttctgttttccaca gaattccaaagtaatttaattcattcgcgtcgttcttttaactgcgaatggcggttaacccc cttgcacaaaatttaacatctcagcactatcaatrttcaacttaccgtatgaatttggttt ctagctgctttagttctcgtcgtctgttttccatttaattgtcgtacattttattattataa atttccacacacgttgaagaaacacaaatgtctaaagtttggcggtcaaaatgaattta ggcctatacgggttaaaatggcttttagtgcgaaaaatttatgaggttttttgcgtgcgt ttaacactacaggttgcggaaatttccattcattatgatgcgaacttaacagcgtcttatt gcgtatgacttgttattattgacacgcctcttaacatggcgaagcatttttaacgaacaa gggtcttggaaacacattagttatggcttcacgtatctagttaattgcgcgcgaacataaac aagtttggatttattcttggtaacgaataatcttgcgtcaagcttctgttgcgttaaga tgcctatagctcgttgcatttttaataattgttccactcttatccacttacttatttgcga agttctacacacatatacagtgcgatgatgcagcacttactagggttgcacatgcgcgcgc ggtgcacacacattatcgcgtatataatgttggtttcttcggaaacatttatgactta acacacacactatagttatgttgcgcgcgcgtatattatcttccagtttaacgtgcacaa aaagcttgggtgacaaatgaacttaatttgggttcgtctactttattatctggatttgg ttaggataccttggatgaaagtaattgggtatattt
318.	atgaataagatataaaatgctgttctttagcgttgccttccactggtttttagcagga tgtagtgaggatctcaataaacactctcgtgttaacaaaggttaggaacacactctctt aacactgcaattgggttaacactgaatttaaaagggaacacaaagcgttctgtttagctctat caggttgcacactgagctgcgtgtattctttaggtgttaaacctgtaggtgcgtatagaaca tggcacaacaaacacgaattgcgtatcacataaaacgaatttaaaagacttcaagctgtga ggtcagaacacgcgcacctaacttagaagaattctotaatttaaacacgccttaattgtc gcgtcaaaagttagaattgaaatgtttagcatcatttatcaaatgcgcacacagctt tctatgtagtaagttttcaaaatcgaagatacgaactaagtttaattgggaagcgttttagg aaagaaagaaagcgtgagatttactaaagagacgtgataaagtgagctgcgtccaca aaagctgcaaaagcgaagtataaagctgcacgtccattgaaagctcagttgttaacttc cgtcgtgatatacagaactttatgctgtgttgatcgttggtaaaccttaaatgattta ggtctcaaacgttaataagactcaaaaacaggtgataatgttgaagattatatacaaa cttcaactcaaaagcgaatccattatgaagcgtatcttctttagtgaataac gatccaaatgcgaagatgctgcattagtttaaaagactgaagacgatggaactcgaagt aagpatggaaaattttagagcagatttaaaacacacgaatcctgtagatttagatgaag atcctctggaaacttgcgtggcgatataaactcttataaaccttatgacgatttatat gaaagtttaaatattgaaacacatcaaaa
319.	atgataatcagttctatatggcgagtaacttccgaattttaggtcagtcagtttata ggatgctgtcagctgacagtaacttgcacattatgcgaatttatatggcactcaactaca aatctctcagctgcgaacatacagtttgcgagtggtataggagttcgtgtccaggtgta acgacagatgataacttgcgcgatatgggaagcagtagtgcataaagacgcgcgaataatgc atggtgttaagagcgttacttggtttggcggtatgcttatttttaatggcattgtgtgcg acacacattcagctttagtctgtgaggtctatgcagggacttattgcgtgttctgttgaat gcacacagtcgtttagcgtgcagcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc agactgcgaaggttcagtcagc gottcgtatagggttttagtcgttactgtagtagtatbgcgttatctattcttattgtc tgtatttctgttgcataaaattgattgaaagacacatgcgcgaataacacaaacacca aatattataaagattatcgcgcgttcttctcaggtctattatgcacacacacacacac cgattttatctgttggcgttttagcaaattttgcatagtatgcacgtcaactgcgattta tccacacttgctctcagtggaatcaacacgcgtagatgcacgcgttagtgcgttagattt ttcaagtcgcgaatttgcgcgcttgatttatagcgcgcgcgcgcgcgcgcgcgcgcgcgc gataaactatgttttaactcagtatataatttgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc atactgcgaaggtttagcgcgcgaatagatttttaatgcgcgcgaataactcgcgaatga ttcaactatgtcattcttcaatgaagttcagtttctgttgcgtgcgcgcgcgcgcgcgcgcgc caacttaagcgcgcgtttgtgcgaacgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc ggcagctctagttggcgtgc atcgcggtagttatttgcgcgaagtagtttatttttaatttgcgcgcgcgcgcgcgcgcgcgcgc alcaacgtacacataatggaattttaggggttgaacacacacacacacacacacacacacac
320.	atgaagcagattatcgaatgtagtgatttcaataatagttttagtagttttagtcgaatt cgttataatcagcactactaataaattggaatcactgcgcgcgcgcgcgcgcgcgcgcgcgc aaaagacgc gc caacttaagcgcgcgtttgtgcgaacgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc aagtcgtctatggagcctctatgtatgaatgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc gaaatctcaattttaggtcctgcacacgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc cgtcgaacgaacgc gggggc cactctatgctgtttagatgttatataataataaaacatttaaaattctggttacttcc gaaaggtgcgcgcgc







336.	<p> mmlldknkyseirkykvgifstclgtvlllsmnpngacaltldnqvsgdntqatcpvnsqdkd  vannylansagatpugastntqstnqalvnhngnsivmgatpavqspsagunmhtd  gntteteveanndvnmmtalnrvckntnngsgghltaleiqeivzrhnsakpval  aspsanpbrkrzsgpdpnaptadnaasvpspsvsltsyptttdnsmasqpsa  pnevlfdgdngrpstnrsvptvnmvnlpgftlungekvvifshamvrtsmfddsgdnk  yagvgnlslgrlghtdntdnglgnlgekalvmpnseliefnmtntknggqatvilk  nstdndlsaktsaagplrlfkydvnmvnlkngpndaldaqryglpkykyxf  vdsiglihsghsvrvertadptatnktfvtvtslkngnsgaelldndfvyvqvgpvg  eyvmsltdkfpnsngsvvndnmvtydaanrvitlksbggtansarlpmpdkldlry  klmvnyptrptvtmhtlkykytqgdlinsaaeshtvntpytdlkmkdalqaevd  rlqgdytfaelldfoulkrnqatldennrvnlnkrsvsgvdeltnmghlrlsra  aenavnkkyqmdmvmgndeltqgaaqvgiehkneiglndgtdtdvtrikdk  gltlsgdtatpvpvknakkardkatkrqlnatpdytdeqdainglatdetdald  vlnatntadveatknngntingvppvchkaardainagacatkrglinsreataet  maelnttqbtahalsqtdhntnmdvndakngpdlinsimpyvtrvqgaardvstde  qqlaselnampdaqeergaaidkmaavtaantnlmentnadvevktndmgigst  paktvtdaknaldksaeohtntfmdatleeqaaquilqgevatakninaadnq  evagkddggtgmvivpasevktatrvvndkarseltnntetqgtareekgelrvn  tlkxraltdigtvstamvnsirddvnmqigavpvlvkkqatgvindlatakkqgel  ntntateekvqlngvdqelataimmgadnaevdeqagqlgtklnaigpnvktppa  lagnghynakleiatnatpatndekalaalntlndgrqalceikuntnaevdgnatva  anldavpdyvdkparksdtseavkrlsevktpnatdeekqasvnglqkqngl  ingntdngdttngavnaldnvaasvllpkaladiakavkekqgldnsldtnek  evagakekakekaalaiddqngtvsngvqatqvyvslkqetpkykpsarekimgkn  elrakngdtaaseerqaladknefvnqagelttnrtngvkdttqagldnsiaivtp  dhvraardavkyqgekkrelqeahatdeekqvalnglamekralqndqalmd  vkrtvngatltkvgpvlhvkpaagalkasaengveslktphatvdeldaeangld  ltkaggeintngdnavdvnmghlkaiegkpkvvrkrasldnsoomkqldalnt  ldrtqderasldlaktvntlkndiagagvtdetqgdadkvlkpkvvykpa  qsvvykaagpalldqsdltseerleakhlveqalngelqdnhadktagvndinaeq  nliskpattvktalqnglqntnknlnikmaeadeegnialeqekelikequl  aasvndavdytlnkneirelspvnrkasareglrtfndkgeleangiatveern  lnteqvdytqgdlkasaengvddkselgltktdhvdqkkesatindkars  vtaevpkrvsnknadalkaitalklmdseektartnadvdlkrfnvaldsiaev  ltekenslrlidngagtykfkaklatpeqlakvvlldvgvagnmdadeldndkq  kltfvdelalpkpaelkvsptkqepkvctpkseecheekvkeklpdtsgemd  llpklatitqzallavrrtkneks </p>
337.	<p> msviesiehelesiaslrqagvrttqrgallryllshsthtadeivgalspffnl  svatynmlrvfkldigvkltydsasrfdntnhyhikdehgtckvifvfygplneie  rlsoamtdktyhbnmeisvqyqgdkk </p>
338.	<p> msekqllldyrtknykylshrlberpelneefasrtlldrkehdfetelstegh  atgfatydgldpajagflaeydalpglhagchmigtasvgaiglkqvddgqgv  vvgcpaeeegsngakasykvagvldigialmhpgmetvktldlavdlvdkfyk  satssenedalndamlyngvsglrglkkdrvghvldipokkamllpdycharf  vtrantkrlldltknydarsaalgtqdyekgngymelkqldiddlkyee  vyevliddfygystdngvnavvptlphikfgsznlvgbthrfreasaasvbdsealx  guklmelgellitngdyvddiceehalkgmk </p>
339.	<p> mttctfllyillailvvgvnlflirerkkgkrqkeqgfttgmgekfkaslddktdt  qutqmttheelrvdngdngvngnytkngqkqasfntkdeavnanngesseykm  eklkbehnrfiegvrgvllnaalifgmfiainqtlvnlalpkintoflnasgtgw  mgfmlvnglilpitylfnkyevrklfivalvltfipglcaisamfpmwrvigel  gsylvmpgsvlityyektgaangtnglmlnagaglttgyvnykzwvnyfym  mllpdliaigfwkyynttnkdpagltfistigvnyvseamkngvsvafst  mfalgilfllivrlrakexepnlnevixtpftctliimvmlsvgmilplyq  nlrgtsaldegllilpsllnglpgfagcltdigklpalglavmtyabwolkkm  dtpymtnglyrlngfmgflmngvtaalnlpkrlaegnaflnrcqlagistall  vtvmttqrglasegelktngpvvghurelasqyqeggnakvlqfmlnclavegi  ndefivatifaililclflomnkakateqkldeasnhb </p>
340.	<p> mlkmlktatavglaplapfielekaenklldggvaelkrtdgtakratlatqul  qdfvdkdyndalvkeqgflsrtvrytldkkyplkmvnygmialtktdavdl  lfnlphkldasadvqkgyngngfsgasepgsgsfnyaktiynqymvtevesse  kgvkgvknasvtnpogvsvaydyfagdpogparyfvpnglplpingspfit  tlshergkdseseltgymdasyayvtrrlavdrkdxkfnznrvtyevmwtkeha  vkskltqk </p>
341.	<p> mgsbtkbtkhstfllltlcvgmtafgltldmvyvslpvgvqdgfstseigltlftm  glagqflfpldsafgkrlavslilflvsglsmvdqplfltrfgltgsgv  vlakasaqdfsgmalakflslawvgvltlilaplaglalsvatvrlfittlavl  llygvesvlpkbeeklkpovfssvdkdflvklpelflmgllpntymfmsyssp  fltkllynmtpqgfsmfnavgvlilvsgvavllvkhrlhllililqvgvvalil  lrltclplwvlilaflavcpvltgplgtmmaseertgsgnasalilqfrrlgav  apvlgkbeekntvymvifitadilvslgltvltkqkva </p>
342.	<p> mvyceelagntgaglsaelrlvngvshlaseglitengakngvnrspirdafkl  lqnglglamvghvlfpgeqekdeymdrimlestafrvngxerplvkomkqlom  mukvafodesstkhdfornellikasnghlmszwhlpkmvalvltsmrqpmpop  qdferrbnnvgvdevevsgelkkaflnldkdvqkdlsgfwln </p>
343.	<p> mgsfnklskdeavkghkhtlrvnykialsgvtyvrtfllpvglvaaohap  aveislfaavaglvafayemaampfacsavsvnmvngfagvlgavpavlaiza  vafvaegfsanrlgvlkplgtelpaalnsfpntgngfddiaaivilalllrgssea  arantvlrlaillfvlglvntnsvnyplpehkvatgdfpgwglvygvsaf  vylgfdleaanavldgktrngplglasvrvifiaavilvymfhygynasag  vymalrsgshgvseivqasvigaftaligmmagzyllyfgzrdlplwshlnhdk  lpavrlviltlvgvlgsmfpafialqiasltvafntvslamvzrlkregklpaf  klpypvlpaitfvllvfwvgisfeaklytlwifvlgililygvlshskndvayp  pk </p>

344.	msdmmel tveglilililivglilakklnpvvmtiipclgamllysvtdlvqffakgl dqvlvnmvifaliliffigimndaglfkplvkrilintrgnvvi vcamtaligtiaidga gavtflieipallipklnmmkylilililaamnmvpgvgnmarvaavakavne lvglipiligtifilvni favyglfkgkrikkaeruepqtdidvbklyvevyndgi vrvvkgarrkzkd kymtalatlvllsmnlmnapesafm qvslvlnfkswdegm erlrhahapnalmmaaviiaagmflgvlnetgnakiatnlkvpaevgpylhiivglg vpldlittdatdayfaviplvegtagglvpsvstaysmvgmigtvfpstpaialwalg laesmnytykyefsvlbfvaivmialangvvi
345.	mentvkrvfilipvgllilwaltpkdpadvptasymfalfvatiiaic tgmplgave iigtimlvglvdektavagfmmalwilaiafargfvktglgrrialbfvlfgk tligaysivgdilllepatpantaraggimfpikalseesfgskpdkgarkmgafivt etqkmltaamfitaesvplaglamastaymialkmmvialvpglveilvvpfiyky iypvtvktpnakwaenclatwgkialacfmigifvvalvltvlgvghidatitafi alaililvgvtdilnetgaentlvfsvlvmadqinlgfipwiskatslggis wplivvillifvfyshylfaastahlsayvaillgvaiagapglfsealngffgnlas tbyssgagplifasygptqkrwemlilgfyfifwlgjla wmdyif
346.	mnkvikmlvvtlaflilvgacsmankgsedndkkttsikhangttelkgkprvvtly qgavdvslvgkvpgvasevwtgkpkfayikndikdtklvggcpapniseiklpdliv asvkurnkvtyqskilapvtstdvfkdkttklngalkgkceadilkydykvaafg kdkakaykdwaplkasvvnfradchtriyagypageilndlgfkmklqgkyndgkdiq ltskesiplandhifvksdpnakdaalvktsewstskewvndvdknnqvadldde itwnlaggyssakliddiyeklniekgk
347.	mingswrsnfrilwlsqfliaegitlvplipiymslqlsvveivglwsglaiaapov tmdasplwkgidgkarkewrallglawcflmaettpigfvlvrlaglpvpyd asafasaneapodpqlvgrlqssvsgslvmpiloggvtaslgtsallaglavtly cifgalkiiothmpkqgtpninkgrzsqollctqctozfllvgvianfamygital spilasvntaiddevigflqsaftvasiisaplgvfrndkgykvsyvatiaacgosa ilggatnieflaaraalqgltysealqgsmvfvvpsmgklygtfvvtrnmalvpgai gslsgaaittyttbattfivagvfvavasillicititnginditmlkwlwkask
348.	mkrlfdvssyglvlespilitallikmsapgaifkgkprtimnelvnykfrsmki dtpnvatidmsesytikgkvirktsidelpollvnikgemavvppcalynqyveliek rtkanvntirpvgtsiaqvgvrdidtdkdkvaydhyllthgasmilomvlyktiknive eqvhh
349.	maqlnskiaciklfesvialtyilviltaslnfkxyvadtfyiaetllivtillilil tctqgkhndlvrrivevillimlcnvtilmfsvirryrqtsglhyngvswfzrkt trhrailglilivymtlsvsgftidtlackngnalhgplavpfgtdodfardfi trvvvgtktifelsiavviedfyvltglsyfohndlnlwidvfaipalllvm ilafgsipnlilaalsgmipsartmravslakrmeyvdaarigtentmliawyl pnaalavivrfelnlgvvilttseslfiglvapdvavmiltatsnyletnamlavp qvcmlvvaafnfigdvadldprh
350.	mkthlfrfryhesfllkkyliylfiflaallitlttichvtedduhfnigvdkdgsse tklilnsigksgnigkmeikayddkqahllkklklygyfvdkgmkafyqagelpis vtydqgmskvviesqtdsvyqlmrsmgylafedlapkasesdesimvtdllitgn rgafnleapnldvgyaytgefttffifaleflvlykmgdvlkarkkaefskse lilirtltlvtwlvawvgyvavfzspnifelynoptlaahisyvvtillwllil lttgdlnsiskvilevillvsgltiptiflghiangvfnigpfavvtaglleilimny lelhgyryiesfialiilnlagvwyryq
351.	mkxvilegmlalfifpagnlfpelghatagpawgmigfaltgllpifvivaaf adegvsvymrlhpvorfifawlymsigfyfipraanyavpigrhrlphvngwllif faelifaivylslnpaskivndnlgllpelimvallsiavfnpesleapkdxyth pflesglegyftmdlvaelsevvinygkyfkgltbrnklikyvctegfllaillgmlyf alavysastagofkdgtdilttynslrfgsfmlylvgmvlacititgplvnaactf kdkwpkyekfalfalsiagltfittlgemlkiavplltlypvaslvyisfanaafst frfaweyratvitliisilqilnsfllhgvllksmmlpladidlavvpfalfaig fildvfrprkqatt
352.	mkhytkrvsalfatmsvosefllkbaqaesqsladvvsvtdakalnnmsindnkq alsqvyvyyklslednsenavksdvkiedakandgktdlaqtklsiaeskaakl dagexikllqgvvdkdaamtkaikdnkaeslennsqvtsanetviryndanyqy ievallqrlraehkspldakvshwettfksndhvdckantsandvgyvsgindaleka kaladnqslsdasatldfietagvpyegvqkdgakalytkiedkipygyvdehkaah kdglvldmngikervghyevfdvmlifireglvllvmtctatnrvzdkdgasvlg gaaglvlsilalatfvtelgmsgilresaaaglvavilmlfivgvmbkrsnakred mkmymalsmgnlvilatglslwresvveritfygmgielakndfialglatvll lifaelfrvvklpifvifvfwlvtififncmknlgvskqkqlygampchkegtpin wlgfsvpepliaagvilmvvaliiktkk

353.	<p>atgagaaatctttctaaattctgcacttacaagtattgcoogatttaactgtggcagtgctt  ttagtcaatccagagaggttgagctgaagtaagatcatcagcaactcaaaaacatcgatgag  aagtaacccagagactctcaggaacactcaagcattggaagatttcccaaatcttgaaact  ataaaaagactatcaaaagcttataagctactgtactcgtaaaaggtacaagagattt  agcatttcccaattctgaaacagaaagctgggcaacagctatgcacccagcacaagaagataaa  gtctatcagatacaaaagaggttaaggttagtctcttgcaatgtgatactgctgcagaagaa  gttcaactctgtgtcaaaagagagctaaagttaaaagaaaggtgccacagataaagcttgcga  ggcaataaaattgcacgttcaaaaagctcaaaacttaaaaaggtggtctcaaaacaaact  aaagtgcagattgtagtgcgaaaaaataaataattgtttataaactagaataattacaact  tcccaaaaaattctcttggaatgtgaaatgtgagctggaactcggctgaagtggttgatt  aaattaaattgtgtcaaaagagagctactacagattcaagtaaaaggttactggtgtgac  acgaacaaaacttaataaattagtggtacagcgtggtttatacaactcaagatttaactcaa  caaggtacactttcagcttacaattacgatacgtcaatcagctgcgaactactaatgcga  gataaagataaaattgttgatgatacagaaactgcagcgttgatagatcaaaattat  gtcaagaaacagctgatacctataaaatacttttgcgcgaagattcatatgataaa  ggtagcccaattatttcaatgcacatgttaaaataacttccaaaggttaagataaacaagaa  aatgcagctgtggtgataaaatgataatggttgcagcgtgcagcgtgagcgtacatttaca  cgtgtgtctgggtgcgaagctgtgtgtgtacagtaaaattcaacaggtgttaacaggtga  actgttaactctgtttaccggttctcaatcgtgtgattcaaatgaaggtttttcagatgta  tctgtgttaacttaattgatgatgaagatttcttaaggttgaaaggtgttcaacacactggt  ctagggagagatgctctagaagtatgtgtcaatccagagcgtcttggtgnaacactctat  tgaatggttgttttaatacaaaattctgcaacacagcgtgactcaacgaattctgggtatt  cgaacaacagcagcttcaacaacaaattctgtattgttgaacaacagcttctgaacaatt  tattatagagctgaactgttcttaacttcaactcgaactctgattccaagatgccaaagca  tattcaacaagaagcaattgattattatagcgaaggtattgttcaacaaagtgaatca  gctgcgaacagcttctggcgt</p>
354.	<p>atgtctaaacatagtgtacgtttagtattatgttttttaataactttatgtctattttt  caatacaagctgtctgcacatgcagactttgnaaatacaacaacacacagcagagcgtt  attagaggaacacacaggaacacacagctagaattttaaagaactgtgacacacaaactac  cagaggttgacatttgaagatttaaggtcaaaaggttaaggttttaacacttaac  actggtggtctcagacagctgttatttctatctgcgaactttgaagcaattgaatgcagataact  attgaatgcgaactaggtatctgcggatggacatgaagtcgtagacgtttgatttttca  gttgcgaatctgaaggt</p>
355.	<p>atgaaaaaatacaaaactatctgcacattgttagctgtgaactgtgtacagacttcaagt  cacacaacacatcgagatgcgctgtgaataatacaactcaacaaactacataataactat  agtcaactgaagatactatttcttaacttcaggaactttatctattctgtgcgaatgact  tgattgtttatgatacagcgtggaataaaatcogattacacgtgggaatgcgaatga  tggtgaactgcagctcaaaagcagatttcaattcaataatcaactctganaaggtgga  attatgcacatcaactgaaggtgcttctgcagctgttctgttgaaggtgtcaataat  gatgtgtctatctgtctcagaaatgaactatgaggtgtgtcaatgcgtataagaacaa  gcacaaactctctgcagtggaagcaggttcatattactatccacgtggaat</p>
356.	<p>atgaaaaaatacgtctacagctcaactgcacactgcgaagcagactcacttgcgaattgca  caacacagcgcgaacagcagcgaacaaaataatgatggttcaactccaaacagcacttat  ctatctagctcaacttacaacactcagctgtgaaggttaactcaactcaacttgaagaggt  aacgtgggtgcgaacgtgtgttaacttcaatcaactcaataatattataatactacacac  tacttctgttacaacttaactatagcaactcaactcaactcaactcaactcaactcaact  aactcaactcaac  gcaacttcaac  aactggtgattcttatacagcgtgctgcgaactctgtggaacttcaactcactgagtaa  tgcacattattgtatttgcacagctgaggtgcgaacacacacacacacacacacacacac  aicaactgggcaacagctgcagcagcgtctgtgttcaacagctaaacacacacacacacac  gtgcacacttcaac  aacagcagcagctgttcaactgaaggttcaacacacacacacacacacacacacacacac  acttgcagctacaactctctgcgggtcaacagctgtctcaactcaactatttcaac</p>
357.	<p>tgtgagataaaaaagctccagtaaaatgaagactttttaaatttcaactcaaaaactatgcc  gatgtagaacacacttctctccagcgttagagctgctcgtgtgttgaacactcttataa  actgcacatgactgtgtctccaaacaaaactaaacttgtgtgcgaacacacacacacac  tttctagtgaaattatgcagctgttgcgaagacttatactacaagctgtgtgaatcagct  agcttacttaacttacttattgattatgctgtgttctattatgtgtgtgtgacatgtgtt  agcgt  caacttcaaaaaggaatttaaacactgagtttgtgtgtgtgtgtgtgtgtgtgtgtgtgt  gaagataatttctgt  cttccaaagattgt  ctgtctattttgt  gcaattatttagacgctctattgtgtgaacagcgtgtgtgtgtgtgtgtgtgtgtgtgtgt  actcaactagctgt  acaaaggtgtgaagctgt  aaaattcaactcaactcaactcaactcaactcaactcaactcaactcaactcaactcaact  gatlatocagctgataacttgcacactcagctgagcgaatgtgtgtgtgtgtgtgtgtgt  gttcaagcaaaccttaccagtgaaatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt  gt  cttctcaaggtttagattgaagaacacacacacacacacacacacacacacacacacacac  ctgt  gaagcgtctgt  aatctgtgactctagtaattctgcacaaaactctagaaggtgtgtgtgtgtgtgtgtgtgt</p>



369.	cytttgcgatcttcaatcattttctaatatggccaatctgtccacccaagaagtttaatt tttgttcaatgaatcaaacctcaattcttttagctaaatttgacacgttaagcaccacactt tggcgaacgcaatttggtgtgtgtgcacaaacacttaagtcacacgcttcagaccca gttaagtgaaagtaattgttcaacattttctgtttccaagaagctccaattggactgtc aaccaactttccacaaacttttaacccacgcttaactctttagacaa
370.	cytcacagctctgtcctatgtgtttccaacaaataatcaatccacatgggcaataatcaat caatacaacacacactgt atgaagtgaaagctcaatttaacttcaacacgccaaggaatccaagaagccacaa atagacaagaattgaagccgaacactgctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt acg
372.	attctatagccgcatattccacacgagcattttaaacacacacatgattttccacaa tgttccatattgt taccgcttgcgattgtgcacacttacttttaattttatgcagctgtgtgtgtgtgtgt gctatgtctacgcgaatacagacagcacttat
373.	cctgtgcgctattgttttcaggtcogtattctgttaattcaatbaatcgatcttttgttaac ttctcttttgttgcacatttaccataataatccacgttaactgaatttttagtgtgtgt gt aaatcoggtataaattacgtctttcttgaatgaatctcttcaactttttttctaat ctgtgtattgtttctgcgcgtctcgtgtgaagaatgaactctgaaccttcaagtcagtt ctctccacgcaattggattatcact
374.	ttactaacctttatgtctttaaacctacgatgacaataaataatagctataactttt aaaataactaaaatttttccatcagcgctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gaagttaataaataaagatagcagcaataatctgtgtgtgtgtgtgtgtgtgtgtgtgt gpatgtgaataatgcgcaggaataatctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt gctgagagctctgtgtgcacaaagcgtacggtgtgtgtgtgtgtgtgtgtgtgtgtgtgt ccggcaacccatccaaanaattccacaaataatacattgacccaagaa
375.	gatgtgtggaactgagttcaatgaattatattgtttttattatacactttttgtacatat tttttaaatgaagaagcagagatttttaacattctctgtgtgtgtgtgtgtgtgtgtgt tttcaaatgctttatgaataatcaagccgctgtgtgtgtgtgtgtgtgtgtgtgtgtgt ataccatccgaacccgattttgtgtatataattttgaa
376.	tctatcattgaataactgtatcttaagtgcataaaagcttgactgtgtgaattcaatt gtactacttttttaagctgcgctgcggtattttcaaaataatgaatgcgctgaacttttca atagctgtgcaagattgtactgtgtgaacgcctatagccaaacattttagataaaaca agttctatgcgccttcaaatattgaatgggcaatctgtatcaacccatgttggaattct gcatgttttaaatctgga
377.	gaagctgtggcccttccctgtgataaacatgaagcccgacatctgtctgtgtgtatt acctgt atcattatattctaa
378.	sirfllknfshvqskslvknndttllrlrlkpvvsnilaasmgmpvcpshalk sasfcdhfcrylgkwyevsgyvcint
379.	llhllvllhloqlllaqpyqeltlvrkmdshvlglypllyvqfmgfpyhryngqsihr fllhgvh
380.	daqlglipgvtflmdvpmfavnrlrlegqgttppkpaafanla
381.	yklplclpflgssvllgpcagkycdknlkffspikgmpvssfflavtspcaairrt slfmgspignitfecce
382.	rkasenyemngqvthkfnfvssikpslmitrnapklcattfglatnltkpasap vmsvutfevskcpkppkvestltlthgplap
383.	rrpvrhvpkcnphgromhpyghyrtlneaf
384.	maasnlitmpeskaatkikakipitgagqirfkklit
385.	ilsaaltpollntslpnccfmedktctccalaletlyafalaplilliltstvedtas emstontopy
386.	pgalvcpysvnaigefvissfgspililtvngffsvgvivfsgpcslvtfsvpga kzplnlrfsngiselfsnsvvfgasgvnsespikvliqplalp
387.	lltlatkvptacknkiantfkttktslraandiprdmnanvktlaialidkppfvpn gfdnaagmnpigftspkfaempdatkatakyanranragtphknapmptlto
388.	dvklasllklyvfiithfityflnlrmrffltfmlaffffgmlnkikarspfscfhi spitdillilylg
389.	slvntvskcikrvlqvsiattflnvocgfskirranfscadavzsetplaktstldkt ssgppllngcnglgaenlq
390.	evlaplshhsaplnscctllvvrvvmanckvfkilyffiiif
391.	cgtgcacaaagctgaattgtaaaatcgcatcccgccagcaatgactgcaatccacaa ctgtgacgcacacacacacataaataggaagaagccacgtcaatcgagctgcacaaag aaattgttcaaaaagaatattgtaattgcatctgtctataa
392.	rotklnvnaagpamtatgudatppnlrkhphamaaakfkvkkycm8eck



399. atggtggaaaatttttaagttaacctaaatgaagacggtttatgattatggttggaattaca  
atgttatattttatgcagaggaagcaaggaagctgtgaattacaagaagcttaatac  
ttctaataataaagctgagacaactgaggaagaacaggaattatgaataaagctgtgtccgctgc  
caaaatatactactagaagaacataacgaactacgctgtatcaatgaatgaatgaatgat  
aaacagctgtagtacaatgacacagaaggaacaactttacacgaatgaatgaatgaat  
tttgtataaaaagctgtgagcagaacgtagagctttgcagacaggttttttgatcttgat  
aagaatgggaatttttaagtattgacttaattgtctgcgaattgtctaatataagaatt  
gaagtgttatacttcgaatgcatttaagtgcagaggaagagtagaagagtagagga  
acttaactgaattttttgtgtgaggaagaagtagaagtagaagtagaagtagaagtaga  
acaacccgattatgaaaacacgttatgaatactgagcagaagacagctgaagaagaatgaga  
catcaccaagcttttttcagacaaatctgaagacgttcagttatataaaagcgatcac  
tcgttaagaagtaaaagttgtcttactatataaataatttacttaacttcagtcacaat  
tactgtgtgtgtgcacacagagaagaagaatttttgcagtagaagtagatgcagatgc  
attgtgacaaaagagatcaatttaattttgactctaaaagaagaagcttcgtgatttagag  
ctaaagaaaagagtagagattctataactttacgttcacgtgacagagagtagagagctgt  
agctcaatttaatttttgaagtagaagcgttttaaggtgaagtagaagtagaagtaga  
aaatttgatcatcaataaagtgaaaagaataaagatttgaaagattttctagaagattta  
ctgttagatgaataattacaggaagcttatactatagagaagaagaaggaattgtttgat  
aagaagaggtcatcaagtaataatgaaggaagaactaaatcgcaaatcgagttgtgaagta  
gactgtgaactgttttttgcaggaatttttcctgtgttttttgcagtagaagtagaagtaga  
ttcagctttgtgtagtgactgaatgtgtgatttagatatacaaaaggagagaacaaatctc  
acagttattgatcatctaacggtgaattataaagtgaaatttttttctataaaaacaa  
cagattttatgacagtgaggaagaagaagaagtagagtagagtagagtagagtagagtag  
taacgtgtgatatcatcaaaacacagctgtgataaattgttcgctgactgactatcaggttc  
caggttacctgtttttctacattagtggaagaagaagtagtagagtagagtagacaaatc  
gaaaaa

400. aeeniklrmkvlyvmylnvmyntgcgaaseenagllnvndvrgckmuvngavp  
guntnekvypvfyvadijgpydttctgtlpgnfigltdkdvdsveeetkayfvmad  
kdmfigdngrikvhyngelovvssdyigldedveeveteevgaaseentekayft  
tpyrykayvelpeqkdkdnhhyvflpeitlpeyqiklyhgvskvqvalsmikmfntfn  
engpnekaekakvntkdeedkdkyfnfdkdkyfnfdkdkyfnfdkdkyfnfdkdele  
kalfitkervlesekiddkdekvkvvkdvkdvkdvndvlysvylyvtekygild  
kegtkvlygkttkfnvkvdsleqegpdrplgvdbvsgfdvdkvghvgtcgtlmgf  
vlygtptgelnfvkndivseepkedrafderfmentpnyhikngiklyvydngf  
vlytvygldvkvlyvtekygildk

401. gctatagtatatacaagtagcaggtttattgttgatgtgtgcacaatttgtaataatgc  
actaatcatatgaatgaagaacagtagtgcaataaagaacgtggaattccaagtcgt  
tttttaaa

402. vmyisatrlfrywvnmehlniiaeresgsikndnesofxk

403. cttaaaagataaaaacagtagatataatgaatgaagaacataaataatgact  
ataataatacatattaaagataaataaattggaatcattttatacaatacaacaataat  
aagacgcttcctctgcacactgccaacaaagaagattgatttagctgttcttcagattgtt  
aaagtctaaaattcttttgcgtgattttgagatttttttggtagtcagcaactaactc  
attggaagaagaagaagaagaagaagaagaagaagaagaagaagaagaagaagaagaaga  
tattgtgataatatttttttggatttttattattatttttttttccaagaacagcttc  
cagattcttttcattgattttttat

404. kykknkrlpsimsgyikilylylkinkeyllnltgnkvlypvtgokelllvrtmf  
vrvkfzlllyryfgagllgklsanvhtkilykyslyllylgfllfvwvng  
stafgily

405. ggaaggaagatagtcttgattctcagtagaatcaattgattattttgttgatctgtga  
cgggtatgcttttttatttcctctcgaagtattttttgttgatccattctctatac  
ctctagctagaagctcaaaagaagctgtgaagtttttagttagcagtaggtgcagtag  
cga

406. gmkrlisdeinlconcyvcsifssayflwisemvaktelkrkflvrtaxsrlr

407. ttgttagatcataaagtagacagatataatgtagacataatacaaaagcgttaacatt  
aagaagcgtcgtctgtgtgtgtttttaaagcgttagcagtagcagtagatctctcaanta  
gtactatagctgt  
ctgtgtctacacacacacatacgaacataatagaagaattgttcgaatcttaactct  
saattgttatcaactatacaaa

408. feaktyphngslinnlfnfaelisklunialipkistirgimvlygvcloekkpx  
naltgimvlygvcloekkilyly

409. atgctgtgctgtgcgtataatagaattgtgtgcgaaggtcagcgtgtgtagaagatcc  
atgacagctgtatgcgaaaaacttggtttacaggaagtagaagtagatcttaacacatt  
gtacacagcttagtataactatggaagctgttctatagaatatttagaattatcctctgc  
gatacaacaaatctaaaanaattctcagctataaaaatttcgtgcgtatacaatacaaa  
gaattttcttt  
agagctgttcacataaaagctttgtctgcgagaagtagtggaatgagttcttatttata  
caaggtgtgtagattctatgatttttaactgagatattagcagtaggttctgagtaacta  
gtctgtgagttctgagtt  
ttgatttttaggtatttcgtcgttttttgatcatcatctattccaaaggttagcttgga  
actattatcatctggcgcagtaactgtctgtctgtctgtctgtctgtctgtctgtctgtc  
aaagattttttgt  
actgt

410. nlaarillegaggtvvedmtriklohyssnfvntvltvgitlhesefrfrlrat  
tclliksagknkiergttmseleakactgiklyvkrdsilpfkgfaamssflyl  
cggplldvltaleaglylvldlrdkhhgclpiferglvgilvlgilvltlptldla  
lilvayvlyvltlptldla





417.	ttgataatctatagataatgtcgccaaagcagcaagcaagcatttgaagaagtgtagatacttat ttaaagcaataatcaatcaatgtattataatccgagatgtccgcaaaagcttggtttgcag gcaactcaatcaatcaaaagcaaaaacccaactatgaaagatgataatcaatcaaaacaa aattatgatgtgtgtattcaactcgtgtgcgaactgaatccentatcttgcctttaaaggt attgctcatcgttaatttgcacagcgcaaggaataatcacatcccggttagagacatccg tcgcttagagagtgtagatatttggagcancgaagagattcaasgttaaatatggt gatpaaagaaagctgcgcgtattcaacttagaacctcaaaagaaatcaatgtcagcaaaa gtcggttcagtaacatgtatgtatgtaataatgtactgcgaacaaatcacgcttatccca caaatggccaagttataaaaaatatacttaaggcaactttcgtcagtgccgttttaa gcaactcggcgaactttcaatgagatcccaaacctagaagtagattatgtaagtgaaaca aagttcaatggtttaaaggaagcagcgtcttactgttaactcaactcaaaaatgttgaa ccaactgtccgttggtgtgtgcgaataatgcgttagaagtggaacagtttaatttgca aatgatattgcaatcgtttaaagcagatgagatcagctaatgaacacttgaagcattgac gcaattgttctcgtatgaatgaagcgtcgaatttcaatcaatatacctgaggtt tataattaattctcaactcaggtccaccactcgttttaattatagtttctcgtcgta aaaggtgaagtagtagttaacgttttcaaaaatagcaattatgatatatcagcaaaagc gcttggtcaactaaacgtataaaatcaaatgaagtagatttggtgcaaggggattatgac aaatcaattgaagtagtagatagattatcaattggcggtactcaaacactaaagagatata gcggaggtttaaagaaatatttatcaatttatgagaaatgaaggggttgcataaaa
418.	liylidnaattkafeevlditylkvnsgmympnphkagiqmqllgactqinainekt nydvrttsetgsmlialkgiaayrkfdakeiltsvletpvleqvryleahgfkvkv dykdgslnlehsellnedwplvrcmyynvrbgclgipomavlyimpykhhfwddvq afgkismldmidsaiesghkfnglkgqgvlvnhqveptvghggqevyvrsgtvnlp ndicmvmkankianfoaiafvteinnndvrglnkykvvinsbtsgpflvniiefpvg hgevlvnaikydiminatsscsknknknevlaanglsdkiesgslrlsfatttkedi arfkxifiliyskelik
419.	atgctcatatcattggtttgaagaaatgttactttcaacaaagtatttcaattttagtagt agttagtttaggtgtgcgaacgcacacagtggaagcaaggaataacttaactggagaaaa ccacactcaatattgaatcctaatataactccacatccgttaantagtgaaatgaataat aatgtauctcgggaacactcccgatcaatcaaacggttaataaggaacaggttgaat agtcgtgtagtaactcgtgattcgaataatgtgaagcagactcaaacacaaaccca agtcacagttcaaaaacagacccaataaacaacaaacaaacagctcgaatcctaaacagat ccagatcaaccgcgaacccaacccggatccaaacacagacagatcaaaccaagccaaat ccggtatccaaacacagatccagatcaaccgcgaacaaacacacacacacacacacac gatcaacaaagccaactccggatccaaacacagatccagatcaaacacaaagccaacac aatccaaacacagac ggggtatccaaatctctgtgtgcgaataatgggggaatcggaacccaatgtctca gatggatataatcaagttcaatggcacaacaaatggggaatcggaacacacacacacac actggttaagtatttgcac aatcgttatatttcaatcaatlaactaggttgggcaagatatagggaagtagtatcgt gaagacttataatatttgcgaacaaatattcagcggaatagatatttaaatgga ttacaacgcaatcgaattacttttagattcaatatttcaatcaggtgaatcagaag tactatcgttaatttagatgacaaagtagcgtcatttaattactggtgaatggatcaatg ccagattgaaaaagcccgagtagtgcggatccaaacacagctcattttgaacgcct gaaaaagcagcatttaccaggttttaaaacacgaagatataagaaaagctcgtcaact guatagtaaaagtgggtagcaattgtatgtrctatgtagtgggtgattttcaatcag ctattctcttatttgaagcgaaatcaaaagaaaatcaaacagatcaacacagca neyhwdmllatallissalplatchveokhlnkqkptnlhnltsapevneemm netotphesngtngelgsnrldmpdsnvvcdsngqatdskpdpnngnpsmpkpd pfnkpkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkpdkp npkdpknknpdp tmaivgrrialangvknpyldnglnkdpdpdpdpdpdpdpdpdpdpdpdpdpdpdpdpdp lqqenyrfzyfnpkseyryymldqvialtgeigsmpdkkpedpdkrsfep ekddftvkkqndkcaatayskwlaivcmvrvfslmflfvknkkknkmsqrr
420.	



423. gtgaagaagcaactcttagatcagggcataagaaaahacaaanaattgggagoggctcagtatct  
togggaacaatgatcgtgtgtgggaatgggaacagaanaaagaagctgcagcatcggaaacaa  
aacaaactactacgtaggggaagaagtggagtttcgctcactgaagtaagaagaagcgaacaa  
caaacacatcaaatacgttaatacaatagatgaacacaaactatcacggcgaatca  
actgagcancctacacatacaacaagaatgaacacagaagaagcaccgaaactgtgcaa  
gcaacaaagaatganaactctccgagttgatttgcgcatcggaanaaagtctgctgataggga  
ctcagggaactcaagttgacaaagctcgaacaggaagaaacgtctcagaagtaaacacag  
atgaaaagactcaactgcagcttaccagcagttgcagagaagaagtagttgggaagaanaataaa  
gcgaagcaggtacagatgtatacaanaatnaagttggagttagaagaaggttgttgaactgtagga  
cctaaacnephacagaaagttgttgaanccatcactacgcagagaagagtaactgtgaactat  
aaatggaaatttgggaagaagtttaagggaggagatatttgttctcaacttaagaaat  
aatgttgaacatcctgtgtatctcacaactcgtggaatnaagttccggagataaagtgaatcag  
ggtcgaagttatgggagcagggaagaataatgtggagaagaagaagtttagatatcgtgttaaa  
gatatgtacagaagaagaagaagtttaactgctggaatatcttctaaactctattatcgt  
ctcacaacagctgcgaagaagaatgaacaaactgttgagtttaatttgggtggaatcag  
gttagcaaaatatttaattatcnaattatttagttggagttagagataattggggagtaaca  
gctaattggtcgaatbgaactcttaataaagctagatcggaagaatttagctcatttgcgtac  
atgaacacttaacacacagctgttaagctgtgtgcagtaactgtgtcagtaactaaagga  
taaaacacacggggttaattaaatcaacagtttaaggtatataaacacatttggttcnccggt  
ttagctgaaagcgttatatgaagaagcttgatgatgtcagcaaatttgaagatgtgactgat  
aatagatgtttagattttgatacctaatgttggttatctcttaacatttaaatattagac  
caagtaaaatattgtgaataaataatggaaggttatattgtatcaaatgctagcaactta  
gaatttcaaacacacotttttggatattataactattattatacaagtaatttaactllyg  
aaaagtggcgttgcatatttactactaaatcgtcnaagcgaaggaagaagaacaaacaaag  
gaacattattatagaacatagctactctatgacactgaatttaactcagggcggccggtg  
gagaagcgtgatttgatgttaaatcagaagaagaatgaatgattctagcgaactgtgattt  
gaatatcatcacagctgttgaaagctgcgaaggtctatgcgaagaagttatcattgaactga  
gaagattctatctagttagactttggaagatgcacacgtgaanaattcaaaacataatgct  
gatgttgtgaatgtgaagagatgaaacacacagctgggtcaggttaactctgctgtgct  
aacctagttgaatttgacgaagattctcaaaaaggttatgttaactgtgtgctgttagcgt  
catcaacaacttgagatgcgaagaatatacagatgaagtaattgtgattgaactagta  
gatgaactactgcggaacactggtcgaagcgaaggaacactcgggaagaattactggaac  
aatctcaattttctcatttctgtgttgggaactgaaggttcacggttaattgtggtgt  
attgagaagaatgcgaagaanaatgaccaagttggaatttaaggtggaattaggttaagaaagt  
ggcacaatatgcggttaactcgtcatttgaaagacacagcagaagataaacacgaataat  
gaacaggtgtgcaatatcgtagatagattgttgagtagtgttaactcaaatctagtcaaa  
aatsetgttaacatactctcgaagagataacnrogaagaacacactaagttgagaca  
ggtgttaatactaatgatactgacttoganagtgtgcacatactcagcgaattcaataag  
cacactgaataatttggaagagatcaaatatgaatgaacaaacttaataatgtgtgga  
caaataggtgttgcttggaagagatcaacatcccaagtaaggtgtcatatgaaggt  
caacgaagatgtgaagaagataaacacactcgaactgtgcaccaacggcgaacgaacaa  
gaagtaacaggaagcggcgaacacacacacacacacgaacgaacgaagttacnagcggccg  
gaac  
gctaaaggaagac  
gttatgaaacacatgaagaagtttaagcagttggtaccaactcaaaagacacacacacacac  
aaatctgaacttaactgaacaggtgggaagaatcaacaaacacagcgtgtgtgttcggc  
ggtattttagcatttgaatttgcgtgtttagcgttatcagcagaatnaaagatcaacagga
424. vksnlrylrxkklgaavrlgtaflvmgmgekaaaasegnntveesgsaateskaset  
qtttmvntidetgsysatetepagstgtvtteapktvgapkvetsrvdlpsakvdkte  
ttgtvrdlgaapnsvslkpmkratctdvatvnekvveoctkatgtdvtnkveesgeislvg  
lkzdnvynghaavrllykwlkfgpzkagyltdtlatdvvelhgtstlrxpkaletd  
qymatgellkerkrytfkwyvqekdltaelnlfidtvtvtdkgnnvevklgatt  
vskifnlyqvgvrdnvgvtngrldlnkvdkfshfaymkpnngsiesvttgvtgk  
nkpgvmpvtvrykhlgsddlaesvyakldvdkfedvtdmnliditmgaylnfnlnd  
qsmvlykyegvtdnaenlelgtlilgyryyytlnltvkgvaymnaegwdkdlkl  
epihstpllelfekpvpvkheltgtltsmdskpifdfeyntavegaaghaegtlote  
edshvdfesathenskhdvveveednpggqvvtteanlvdfedekitglvgaavd  
httedketytcealldpeebkagpaeliecmhshlshlgtcnghgvyv  
leelssahvldlkeelgvgevgmssseetdeekdkpkyevyldlddsvghlbyq  
mngngseetdkdkpkyevggynliddfsvphingtkhtleiedntkdkpnyqvfg  
hsuvdeedtlpvsgvimegqtleedttppivpctppvpsapottptpvcpsap  
atptptpwpptpoptpkpeakeekhpkpccpccpvtvplvlelnokvkwvptkagk  
kselpctggseetmgalfnlylfcilglaillrnknkha





















gataaantogactggccaasacttaactgcacaacaagcttacaataatgaatgatgcagtc  
 cctgcagctgaagaagcatataactggtagaagaagcctataaactgtaaaagctgaagca  
 ctacaaagcttgggtcaattaaacacactcaacaactgctcaaaagcaattagcaatona  
 caaatataatactgctgaagcgtcaataaagaacatctcgagcaattaatagagcaactaaa  
 ttgagtaatgcgaattgggtgctgcacacaaatattggagcaagcagcacttggtgttatbc  
 tgcagccaactactcaataagtcgagatgcgaacttgcgaagcaacttatgataatgcgaat  
 gogaatgcagacacatgagttagataaagtcgaaggtgaatgcgaatgcgaagcgtgaagca  
 gagcaattgaacaacaaatattatgcagtcgtcaaaactgcataatgggagccaaacactt  
 gcaatgcgaagatanaagcaaatcgttggtttaattcgtttaaaggataaatacaagcag  
 caacagactttgcacataagagcaattcaaatgcgagactgctgtatgaatgcagagat  
 attgttaataatcaaatgtacttaataatgatgcataatggaacacttgaacactttagtggc  
 atggaattcccaatgcagagcaaatgcataattacacaaagctgcagcagataaagtctona  
 acaaacttcgaagctgcaaacgtgtacacaaactcgtctaaactgagtgataacaaact  
 caaatgagttatcaataagcaatccaaagcgtcaaatggtcaattcatttaacttaattgt  
 gatcaagcactcaacagatgctaaagaacaaaggaactcaattctatttaactcaagctttagct  
 aataagctcaaaagaaatgcgaagctcaaatgcgagcgtatcaagcaagcagacttatgcgaaa  
 aataagcgaagaaatgcgcaagcagcttcaacacacattatcaagcaacacagtaact  
 caggtgcttatctcaagttcaaacagcagcagccacgcgattgaacaaagtcagtcgaact  
 gaactccaaagcaacaaatgtatgcacataaagaacttgataaagcaagttcaagcattta  
 attgcgcaactgatgcgaactcaaatccaaactcaacagcaagcaaacagcaagcttaagat  
 cgtattatcccaactttcaacaggtttacagcgtttacacgtgcgtgactcaagaa  
 gaattgaacacgcaaaagcacaacttgcgcagcattacaaagcctcaagaattgaattagt  
 aaagctcaagaagagtcgcgaacacagatgttgataaacaagttcaagcttaatttgaagaa  
 atgcataaaaacccaaacttaacagataaggaacacagcaactcaagactcgtatatt  
 caactacttcaacaaaggtcatatgcgcaatacaaaatgcgtatgaacaaagcaagcaattgaa  
 caagcaaaagcaactttgcgcgaagcattgcgaagcactcaaaagctttgttgaaagctaaa  
 gaagatgcgcaaaatgataatgataaagctgtacaaagcttaattgcgaagatcgttcaaa  
 aatccaaacttcaacagataaggaacaaacagcagcgtcaagatgcgaactcaactgaat  
 caaacaggtcatatacagcacttaaacatgcgtgcgtatgaagaagaaattgcgcagcgaaaa  
 gcaacacttgcgaacgacttgcgaagcactcaaaagctttgtgcgaagctgaagaagatgcg  
 aaaaatgcgaataaagccttagctaaaagtcgaagcgttgatcaactcaactcaaatccagat  
 ttacactcgtgcgaacaaagcagcgttcgaagaaattgcgcgaagcgtgaagaagcgt  
 ctacaacacttgcgaatgcataaactatgatcaatttaaatgcgaagtttaaatctaggt  
 ttatagtcacattagaattacacatgctatggcggttgatgaacaaactcgtctcaantgaa  
 attttgcgaagcctcaactgcgaactcactagtttaagtggaactcaattgtacacgtgat  
 gacactcaacgcgaacagatattcttgcgaactcaaaacttaactgagcagcttcaagca  
 gaagctatgcatacaccatcaactgcaacgattttgtgatgcgtcaacgcgaagcttgaa  
 gttacactgctgtgatgcgacaaagtgatggttaattgttccgtgttaaggttgtgnaaaa  
 gaattgtcagtagtcaaacacagcgtgaattggaactcaatgcgaactgcgcgaacaaag  
 attaatggaattcaataatagttgacattaaactgcgaacaaagaagcgtgcaattgcga  
 gaagttcaatgcgttaaacacaaagcaattgatactgttaacaaatgcacactgatgttcat  
 tcaagtggaagaaatccaacacagcagcagcagcagatgaacaaattcaatccagaaacaa  
 tttaagcttggaacagcaaatcaactgcaatttaactgcgtgaagctgcaattccaaact  
 atgatttgataaataaagctcgtactgatactaaagataaagcgaagaagcagatatt  
 gctgaattcaatcaactaaagaaacaaagcaattcaagcgttatccagctgcgcgaagcagc  
 gattgaaatgcgtgcgaacttggaacaaatttaagctcaaatggaagcagcgttaacaaac  
 gcaaaagcaactgctcaagcgaacgaagaagcattatgtaghattaagcgttttcaaat  
 gaaanaatcaatgcttattgcgaattggaattggcaactggcaacgtgatgaaacacaaagcaga  
 atggaacttaagcaaatcgtgctggaacaaattagagatattcaatgcgataca  
 ttaacgcgaagtggaagctgcttggaacaaagattatgcgaactttcagcgtcaaat  
 gtaactcgtgctgcttaacaaactcgtcaagtcagtggaattgaactcaatgcgactta  
 acacttggttatggaactgcgaactcaactcaactcaagcttgcactattggcactcaaaag  
 aaacttgcgaagtgatgaactgac  
 ggttaattgttatcaaaacgctattggtgttggtggtatctcgtgttactagctagtttcc  
 tggttctcaatggcacaacgtcgtgcgaagaagatgaagaaggaagaaatagaataaaga  
 gataataaagaatcaataaagaagacatttagacgatacaaaacattaccacttttta  
 ttgcgaagcgtgcgcgaagaagaagtaggaagatgctatctgttggaagaagattgc  
 ctcaaatgaatggcgtgcactgcgataaagtttaaacatgcgcgtttcttctacaaacact  
 cgtcgtcaagaagatcaagaagatgcgtgaagcttcaaatgaacaaacagcgtgaanaagctg  
 tgaagaataacacacactcaac  
 gactgtgaacaaacactagatttgaaactcaagatgaagcgtcctcttatcttgcgt  
 aanaagaanaatacaaanagataacaaatccaaagcaaaagctcagcacaanaaact  
 tctaaagcgtgcgcgtcaaaagcgaagaagcaagctaaagcaacacacacacacacacacac



dekvtaaenivsgtpttpttpodvtnaatqvtmaktqlngnhhleavkngmantaadlgtts  
 lsgpcknklskqevqatqtlpvgvtrvdrqgtintamkgrlrsianegatlkagrgvtdsqg  
 pldvdyrvavtaaklsgttdpmmaagelkngndkdvrlakeqnlngnrltagrakoh  
 lnglsllddaqgdakdqlrlegathvmetvgomnadaltantnlkngldqgnltkqgrv  
 ftdadeekrnaytnavtkvqglknkagpnntakdgvetalengvareknngvngvnm  
 tteknalmltalmekalekksgeqetvteagrvysltaseintamnlqngndase  
 tkaaqtytdedrekgatayndeaatklitktagssndkkaevqelgrvrtaktalngde  
 rlineaktakqvavtmshltadkanlatqiesgttvagvgvlganagtldqmmqlrus  
 laakdatksedqgcaadlqamnydaytnvaeqslsatnmpemppdntkngasvnaqsk  
 alngdcklsakdelsedqgltdltnuegrtcaasavdgpnlaavtsakaklsaklam  
 gnlkhalaeokdktrsvytdedqgkqaydvatvgaeoltnangsnmetvgvaalngl  
 ngakndldngvarekasekralasaynlmnaagtaatsqglndatvavrgvtaangtane  
 lntaseqngnglndevtkvqgnlttdaagdkkdaytnvayvqglldkaghpnnkagve  
 aalngvttaknaldngvarekadekanlgtvlthlmnaqkqglvagiagvtevgvgv  
 ktkaqglldqamqrglsaanlkdgktkaseryldadpklktktdmaai tqaesylkndgank  
 dkqevqaelqvstetenalngdanlgraktealqaldnltlntpgtktlkqgvnaagrv  
 svytknastatknmdadglkgsiadddltvsnrgvtnasqdkqevtydymaaklvng  
 sgvntvnaasdvtaatvrvnaasqclngldntalataqkqkdalrqmthtsdaqgslstgdl  
 daatvtrvgvkdnatldnmmqlrnsianekddvkasqpyvddadkrgmayntavtna  
 enllstasptldpavtvgangvaktalngsqulankkqetlaninglshlmnaqgq  
 dltqvtvnapnllstvnytkkagldpmmrlngldkqdykvqgnltfdeqpkgtayv  
 navtaenllingngtnangsqveaalstvttkqalngdrkvtakmnaqntsltdlml  
 mnaqgqvtnmglnqthvsaevtgslgtageintamgnlcnalndkottlsgqntadadpe  
 dknynseavtnaenllnketvrgpdkvdeavmnaaklaagtmleakakbntant  
 dqlshlttnaqkealkqlvgqatvtaeagmgeknannvdaamklrgsadahtkpgpy  
 tdaegnkdaynevmtbaggldgtstpltpvtvngaaqgvttknaingnolaeakq  
 qasqslgldolmnaqkldvtdlgnabhtvdrnaseqngagntamgnlkagldedkat  
 kvtvntfdaagkqgvtevtvnaenllakngnptkagvdkqgvnaakrglngn  
 vghkdeatallngndldngagkdalkqgvvntvsgvnnvktqagelmmamqlkqgl  
 adkqgtkdgntvynadpdkgnyngavakaealstapdvrvvpseltaelnkvtqaknd  
 lngntalatakvgvghadglpnlknagpdeyskltqatlvprvnlqagatladetekt  
 kqglanekkysevytdedaktvayvkaaslkktqnapntadpklktkvtk  
 ntdngalngnqgladkdeqkdtktlgtlchlnagkqalttveqaplatvnnvkaqna  
 lnnamlnnalqdketelnsaintfdaqdkkdaytnvaeqslskangngngvneqve  
 qamrvnkaqglmnaqgvgrakadkayvtnandlnngkldkgyddagvntvnt  
 kgtqgdlnqantqlkqgladkqktangvrvnaadkqnamvnaahaeqslsgtgnav  
 dvgvvaqglqgvneqkldngmlhgvakdanatadglpnlngqktalkdqvsaelv  
 ltpvnlkqadalnmaaglkqkqgvngvsgvvtqgdqdkqgvnnamagpogllng  
 ltpvltptvtrvntvnaakalngelklsagkkaalantldtldngprdlmri  
 nngalrtvteqtkmaamvtnaenllnglndktdvksaryhdadokgtaytnavaga  
 eqllngtuplmpdelatrtatvtdknglngeklatekqnakdavgmthlndaqg  
 alkygdqgselavrvyktkqgdqamqglagelndkagtladqnylnedpdkmayk  
 gavaaeallnksgntsevgqvssltnevaakqalngndhlanakqgkqglamlthl  
 ndaqkgsfseqtqglvtrvttlnqkagtlshamelllnsevdngtltlesodhdatq  
 rqnqyngvtaamllnqctseptmmpdvngatqvmnkvaldypdenlaakqamml  
 dglchlnnaqkqglqgltnesdlvaavpkrasaelnlangl lnaadkqgvnqgr  
 lnadtdqgtayntavnaaamlnkgtqngnagteveqatkvgtlqalngdhlqskt  
 natqelldaltelndqgtalkldvtaatvltavhgepantingemhnglrgsldhaat  
 kanekyrtedqegrvydgvgvnnlengatldtlenlnagatvttkbaahdgvkl  
 qmndkagkvsglalnmaagmmedltlasegtvavkdqlceagldldlndagvsl  
 dkdtraseayvnaemnkqgydeavngaeslaglmpctlnkngvsaatqavlskma  
 dverlsagdkgtagslnhldltpqeqqalngndatltvevvaqglteaglngaen  
 lruelqdygtaseqklnedqgkdqayvgaqndkltngtmpldkagvgdgvn  
 qakndlhgdqkladckqghavtdlninglmpqrgalsesqmaastryevagtklaekal  
 dqemalmsldqgqtegsakfinedkpkdqvayvnaakldngtrpdlksqevq  
 lgevtakndlhqgklardqggvntvnaenllnhaqglatdaanaaptrvevqgv  
 qataldhamekkydyvntdkagvnytaadkksavdgltaeseltkplngnan  
 kdavdglvtlkegonelngntvsaeklqekqldlqthlnadlatatqakldqatklq  
 plaelvdqatqlngmqlkqgvneharvtevgvtdqadekqnakqkdaaenlvkq  
 nakvgvdaqlnglnakqglngdvralaktngldkldltnnaagrdkqglv  
 lnglqglvdeakalnrmadqlsegtntegrtkntvnyndatqgvrvvtdvdkakqal  
 dkstqgltakvqklndeaaklakngveerlmrkoealgrldlthlnaagrglq  
 qnnatlnkasraklnaktakdnagavagvldqglvstnyvndhlnkqaldan  
 aasaeltdvqgvnlakaeasqglkqnlldagalnqglanekdkknefmselngv  
 qgdlahkalmnadvsvtdvtdvngqldlnameltklhvloneipnaagvtrvvgadndk  
 nttdfakalnnllesatvnmvndlgalqayndalnlnngdqldqadkdkalqengla  
 nklkoesanaadqglakabaealennlmakvtnngvsgvtrvtaghalekqgl  
 elpkakldankdvykvgvnlldemrnpntdkakqklkdlnglqgghngmnaetke  
 elqekaqalqalqldkdlvkadeakqdvdkvgvalldeldgmpltdkekqakdrln  
 qlqgghbdnnaamkeseekekelagelqldkdlvkadekndmdkvrqglldelq  
 npltdkqakldkdrlnlqgghbdnnaamkeseekelagelqldkdlvkade  
 knalakanakrqlngmndptpockkaleldeekeskralqnvnaagtdqlnglrlng  
 lldlrmthvsvdeqgvneltsestpegllngvnelvtrndltfvgdlshnlldlsla  
 evddpgetalstetkverldldekvtrvnpkvskelavtkqglaselsanaqgl  
 nelngvntltlqekonealavmkqglvnnvnpkvskelavtkqglaselsanaqgl  
 fcieqaknalkpiedaqlngldkardltdkekqekalnglkeqalqalqagrsi  
 deiselqgkagmkaampakalarkkqals:ldkfeneklnlmselqtadekqaa  
 anglnelvtetldnuehllqgvaealnglarsvsglvtddakqgsagmnaht  
 ltlygtampfnestlghklddeaddlplhmh:amntgvnkalslvgvsglslasf  
 wfllarkrkrkdeeseelelrdmndksikotldcknlplllfaktrkrkdeedvtrveokde  
 lngesldvkvthpflpkrrrkodeedvvevnenckvklkdnepflfakrrkdeee  
 dvtrvtrsekdgvplllakdngkngkdekkasakntekvnekkkalkkklk

441. atgtcttttgatgatgctaaagaagcatcaagagctacttgaataacattgacgaagaaga  
gatgtcaaaaaagaataatcctattorgatgtgtggcgtaacctatcatttctgtcataat  
tactatgaacacatgtgcttaataaagggttatangtgcgtatgatgtgmaacatggaagat  
ccaagcaacacaaaggaagtggttgaagaggaaggttaagaattctctcaacaggaact  
gttatgtgatcaaaatggttatggtgaagaagaanaataattatttttaagttttatcgaa  
aatgaagaatttggattatgtctatttgtatgtttctacaggaagactccaagtaactcat  
tcaaaagatcacagcaaccttgcttaatgagatatacaacatttaattcccaatgaacatgctc  
ataaagcaagcttctatctgaagatataaagaacaaatccatgttaactctgagacaatt  
actgttcgcgaagataatctggaagaagattatgatatagaatcagttgacacacagttta  
atgcatgacacaacactcaatttatgttagatatacattctacacacaaagaagagatttta  
tctcatattgaggaagcaaatgagatgagatgctgagattgattatgagagagattatatt  
gogaagcgaataattagagctgacagagacgcatcagattaaaatcaaaagaagagactttg  
ttatggttgaatggtgagacaaaaaacacgggggtgtagagcgttaaaagcagtggtatt  
gtctgctcatcaatttaataaacaacaactcaacagcagattaaaatattgttgagaggtct  
atgggcgcttttatggaaagagatacatttgcgttaacttaaaatcaaggttatataca  
gaacgactagtaggaagagtgattttaaagaangtaatgcaagagatttaatacaact  
aagcattctatactcgaataactcaactcaagcattactcaatgaatttggcgcaaaa  
actaacgcgaatttcaagaattagaacctttagatgacttgttacaatttttagaagaa  
agtttattgtaggaacccactatttccctcaaaagatggagatttttaaaatgggttca  
aacgcgcaacttgatgaataattagaagcttcaaanagtgttaaaccttgcttgacga  
tcaacagcaaggaacgtgaacgttaacaggttatlaagctaatgaanaattcgttttaataaa  
ggctttgggttattcttggaaattcaagtgcaaaccttaaatattttcaaacctggaagc  
tttggctataatogaacaaacacttatctaatgctgaagcatttataoggaatgaattta  
aaagaaaaagaagataataactttggtgctgaagataaagcagtagagtttagaatgaa  
tattgtttaaattacgagaaacacttaaacactcaactgaaactttacaagaaggaagc  
aaactaatttcagaacgttgattgtttacaagttttgctgaatgtgtcaaaatataat  
tatgtcaaacctcatttagtgatgataaagttttacatttagaanaactcaagacactcct  
tattgtgagagagtggaaggttatataatgatattgtacctaaatgattgcaatttattgat  
gaacgtttattctatcawliwgaggactcaattgtccgtgaagcaataataataga  
caagtctataataatagtatcatggttcaaatggagcaatgttaacctgtgattgaaga  
acattacttatatttgatcaaattttactagatttggtgcagcagatgatctgtatca  
ggtcaaaagctacatttatggtagaatggttagaagctcaaaagacttcaacttatgctact  
gaaaagtttaattatcttctggagaaatggagaggtacacccactatgaggtctct  
gggttagcgcaagcagtgattgaattgttgcataacttccactgctaaagacattttc  
tcaacacattatcatgaattgacatcacttgatcaaatgttaagttgttaaaatgatga  
catgtgctgcaaacagagatcaacgtgaacgtatatttttgcaatgaagcgaagatggc  
gtgtgagtagagtagagtagattcaagtggaacaaatagaggtatttaccaaagagact  
attgtagagcgaagttatatataatgcaattgagcaaaaacacttgctatcaactctct  
catgagatactgacatcaacaaacgggttcogtgcgtatanaagattttggtgacagaga  
gaagaycaatcagttatagaacacactcaacatacatttatgaggaagcgcctttc  
gattttattgtggttacaatacaacaagtggaattgagtgcaaatctcggaattgaat  
ctatccaattgacacacttgaagccttcaacagctgagtgaaattacaagtgcaata  
aag
442. #fddakeasvleiftkrdekempicgvyvhaadryietlinkykvaiocmed  
pkgtkmrvrevvriitpctvmdqgpcdkmnyilfieneefgcydvstgalkvth  
fkdtallneittinpeivikqaiseelqrqinnitctivredisededymqllthql  
nbdttallllydihhkgdrishleevleyaavdyndvaykrlatcesirikskgtrl  
winderktpgagrrlkpfdrlpknkgndrlinvefnfdrfdrldlinhnpdydl  
erlvgrvsvmynvardliqikhwiseiphiikallnelgaatttqfkelpldldlqilee  
slveppisikdggllkmgfnagldeyleaskngktwlaelqakerctgskiskisfnk  
vryfieltanlinfpaefpymrkqtlmaerfidclkekeldlilguedkvelqeyo  
lfvklrhlkkyetckrakliiselclqfaelaforyvgtfddvrvlhnarip  
vvervayndyvndchlddetfiylitgmmsgkstymrvailisimagayvypdaa  
tlpfdgltfrigaadlvsqkstfemvelmekatcyatanaelilfdelgrytstvdyl  
slageniyvvegnshetlferhyweltsldmklcnkvrvaaaygcgailfikhvkdg  
avdyeyqlvakiadlpevidraqvlinafekpysclshentcngctvpeyndforce  
eegsvietatnhyeqatfdldfynggveevccirelinematpieelikinelqgclt









509.	atgaacaacatttttaaacctcactcaacgtaaatttatcgaaatgttgattatctatcc atcttttatgttgcgacttccataaattgacactaatgatctctcgtcttatcttta ttcctctttaaagagggggcggttaggtgtcggttcaatgaataactctttaatgctcga cgcgaattataaccccatatgatgatacaacaggtatggcgatatacgttaagtatgaaa tatatcttgatttgatgatgttgagatttttctatttaaatgtgtaaaacatttgata agaaatgaattgatcatatagatttatcgaagctactctgattctatgctactttatct ataatgtgttttatcctataatgtccgaggaatctatctcaaatggttbaactctc tttataccgtcaattttgtgtgttatgtatgtttgaatttaaaaaagataaagatctc atcaactggttaatacaattatcaacgtatgattgcctttaactttttatttatagtt atagcgccaataatccatatttaattgagaggagacccctcagaaatgttttcgaagatgca cattcaactcggaattctctgtgtatagggttagttctataalaagtaacataatgaaa caacangattatggtgttatcttaattattattataaatatgggaatgatgagccttat ttataoaattctogtccatatttccatctgtttatcttttatgcttatgctcttatccg ttatctccataaaaaagaaatcaaacatcccatattgtgtgtatgatacaaatggca atgtataataaataaccatataatttatctatttttataaactaatctttaaaggg aagaatgccaaaggtctttatgocgagtgatagaatataaagaattgattgattcgg taacgtagcactctcttttttaggaagcggttttgggtataccaatgataaaaagcggttca gaatacaactctctaatgtagccaggtatgactctctgggtgatgactctctact ggataataggacttaactttatgtacgatacactgctctaatggtcaacttttagttact tttccaatcgaattactattttattatttttaatacactatctgtttaatgtgattat attattttacttctcgggtggggtcaggataattgtgttatataattttggggaatatat ttaaaggaggttaltatcactcaacacgcaaatggt
510.	atgacaactcaaaaactgtgggtctagttgcgtccaggtgttactgaaacgcttgc gaaattctcataaagaatgctcaaaatgtcttaccactatgatcatcgaacgaat tggattttttgttttagtttaaggaatccgtctactggttttgcgtaactgtgagatgaatt ttggggagagagcggttatcccgatgaagcaacagtgatgatgtgtagaactacat gatttaccgattgtttgcgacacgaagtcgtggcattagatattaatatggaaatggt cgactatattctcctatcccgcaatttggcggttcgaatataaaaaagcttcaagct ggaattttataatattatccagaattaaatgtgagctgcaacgaagaagtgtaatatgat aataatagcaatcagaatctcagtaaaaaaactctcgtctctctcaaatgatacaaa gaacaactatataatgaaagaacagacgttataccttaagaattttatcaagttccagt ctcggagcgatgtttgcgctgtttagtggaatgacctttgcggaatacctaatgaatgt tgcgaagttaatacattatgacttagacttatgctctacacaggtctattgggtttt tttaacagcgtgtgcgaatggtataaactttcaatgtgcggttactgtggaatttca attattgcgattatggaaatgcataatgataatgatgtccactgattttatgggagcaa gttatcaaaagcaaacataagcatattactgtgtatatacattctacacataaattgaca ttgatttttgcgcatataaattttatatttttttttttttttttttttttttttttt atgctattattgcatcaaggtatttaggtgacgaagtgtgattggaaggtctctcggcgc atgtgattgttatttaagtattccatggtttgcagcttcaattttacagttcgaagtcga atagggttggtttctctaaatgagactcttaagaagaacacatagatatgtctgac cgtgtgaatcagcaacaaacgctcga
511.	atgaattctgcgcctcaattgtgggaatccgataaaaaaggaaagtcattttgtatga ttgtgaaacactttaagaactcagacacaaagaaaagtgaatcaaatgaaactatg cgtgaaacgaactgtatattctgtggaggaagcaaacactatgattcaactatttat aaagacacacacacactactgttgcgtcaattgtattatcaattattttgtctgtgtga gaagcgtatttgatgtgtgtctcactatgctcaactattatattagttgagcaacgt cccaaacacacagagctctcagcaatcaaatgaatggtatcaaaataggggacacacact gttccaaactgtgtgttttagtgatgatttgtctcaaggtatattgaggtcaggtcca acaagtgatataagcgtgtttataatggaatgacacgtgaagaagtgtgaataaatttt ggaactccaatggtctgtgagaagtttgaagtggaattgacgaacattggtttatla cgtgtagcgtacagatgataatgaattgttagcgttaggtgtagcaactaactatctca gaagtcgaatttttaagtatgttatgaaagcgtgtatgaaatatttcagcgaactatt tatgatgatcaacaaatgaatgacttctctgtgttagctaatgtttaaagatggagatt actgtcatttgaanaatgaaataaatt
512.	atgtttatgtttatcatagaactcaataatcatgatctagcgatatttataggataga actgtgtgtgcctcgatgtgtggcctbtttgtatgtagcgagcttatcaatgataatt ggtttccagttactccctcgtttcggacacggtgagcggttttaatacaattatctatt ggtatagcgggtgtgaattgttacaagccactggtgtgtatgactatttgatacactgca taacgtgtgattgacgcttcccaaaactcaattatttatagcggaatgattgtctct ctttttgttttgaaattgtgtatgctgaatattgacttttcaattgaaactatagc aaactgcacaaagccaggaatccagcgttaaacgcgcattaactgtctgtacttaca gccaatttagcttaactttgttagcggcgagctctgtgatacagcttatattatttgtta ttagcgggttatgaattgataaggggaaggaatttaggaatttttaccacagcgttta atgattatgtttaactgattgataatttttgacattttagagagcaaaaagacacgtggt gatggttcgaagcttttagttcagatgccagaagtcgaaatcaaatgacttttcat taaaatgaataatgggttttagttatgctatttatgtgtcattgtgttttaacgttggc ataattcttaactctcgtgcgaactcgaatggaatggagatgagtaaaatgagatg actgaaattgttccagttcttttagttatctcggcgtacacactaatttatataaaaa atcaactctcttgatattctgtctatgaaattatcacaaatctcgaatggggagcatttt cgaatttatggcggcaggttgggttaggtgcaacataatttatgtctcccaataacttaaaa ataattgaaatgataattgtgtgaatattagtgagctactcgtgtttatcaacttt gtttctgttagttgcaatgattgtcaattctcacaacagctcaagcatattatgtgtcgc atagttatcagcttttaggtatcaactccaaactctttgtgtgagattgtcacaacataat tggaatttctgtatcgaactcaacagcaactattttgtgtgtgtatgagatgaata cgtgacaagaagcactagcaggttatatgataccaggaattttttttttatcacagattcgt attacaggtttgtttataaaacatttttaggtat



518.	atgaaaaataaaaaaggattaggcattggtcttctatcaaatattgattatcggttgatt gtactagttaactatgatgttctgggtgggtgaagaagaatcactacggtattatga atagacgcgcactatgataaaatgataaactactaaatgaaaaatgaaaaaacgta gaattacctaaagtgataactgatctgcttaaaaaagaagattctgtgtatgactttaa gatgaaaaaactgcgaaaaattactaaagttaacgaagttatcatcgtgcgtactcat ggtttaatgctcaaaaatcccatgatatgggtaaatgaacaacggaatg
519.	atggctatgtcattactcgtggtcttctgtgtttatatagtacacatcacatctgata cttgaagaattctctatcatttaaatagagagatgaatgcaactctctatatacaag cttatttactcaaaactttgtttataactttcaatttaaaagatatagaaaaatattg tactggtgcatttctaaatagtattgatgtgctgtgataagtattgtctggacacgtgtgt caacaacagtcacctatgtgtcaattatcactaaagaacacatctatctatagggttaag tgtatgggttccgtgttactctcaatttgtatgtcttaagtgaaaaataaactcgtgt acaggtgtaaaagcgtatgcttttaaaagttaaatatcatctgtgtgattatgctcgtttt acagggattttaatggtcatgataaaagaacatactttaaacctttgtaaatatgtgag gctgtgtctatttattctgttataaaaatcgcaggaattatgctatgatgctattagt tctatacaagcgtatgctgtgttggaacacgaacacgacacacacacacacacacac actgaattgtttaatggtatgataataattttcgggtatca
520.	atgaaaaaactatagattttctgggttcaaatgggctatgatggtctttgtattttct atcacaatgggcaattgtccgtgaactcagaagatttcaagcgcactatcgggtgaanct tttgtctttagatttaaaagatttagctctctcaagctgcacattgtgtgcatattgta tttaagcgcagcaagaagacaaattagcaggattgaattttctcatagtttaaaagtga gagcgttacttttagcactcatctatcaccactatcatcttaaatgattggtcgtttaga tttaadactatgctgattttctcatctatcaaaccttcagatttatcagatcatata taactatatttattgtgtcatattttatgggtctttagtgaggtttgtgttctggtct tacttaaaaatttcttgaacacgaagaaacacacattttttgagattttgtcgttgt cttattttacagatttacaagtaacacgcacatgtgttagaataacgcgcgaataccat hctatataacttcaaggtttcaaggtattgtgtgaatttaattagagctactaaagt cgtaacatttatattgcacactgcttttaaacgcctccagacttttgccttgtctttta tttagtgaagaacacagcgcacctttctcaatgaagctcgcgcactttctacaacaa ttgggtgtttcatttattattatagtataactctgtgcctattgtttataaaagcag aaaacaaagttttagcgaaggtgatacctaaatttatctcatcttccagtgaaag ccaagtcagaagacgcgcctctcactcctaactgatgtatcatctaaagatgaana aagcaacagatattgtataatgacaaacatcaacaagaacacataaagcgtgaagat gcacttactacttcaattataaagaagagcgcctctcagctataaagacacggtaca actcaaatgataaatttaaaagcactcaacttatcaggaagtagacactcatcgtgt gtcaacgatttaagattgaattcagcgaagttgaagatcataaagcgcacagataaa tcaact
521.	atcgaaaataatgattgctcaaaagggttgtaatgcaagctcagatgcagatgatgctt ggggaaactatgggtttgtgtctttttatggagacacagcacaattaaatggaacgt ccaactagttattctgtcatatttaattgtgtgtatttttttttaactctgagagcc atgggtgaatgatatataatcaacaacacacgttcttttggcagattttgctaatgac tatattcactcagcagcgtgtgtgaactgcgtggagcagatttcaaaaggtgtg gtccgcattgattgaagtgtatgcagtaggagaataatgaactactggttccaagcct cctaattggtacacagaggtatagcagttcttctttgtgtgcttaactaactgttca gtcaaaagctttggagagcttgaattttgtgtgtccttaattaaagtgtcaactttga tcaaggtattttggaggtataggattttttttttgttataggcaatggaaggaatca atagaggtttctcaactatgtgtcactgtgtgtttatgtcccaatggattcattggt ttcttgcctttatctatgtgtatggatcacaacaggtgtgaattgtgtgcaatcaca gcaggtgaacacaaaatctcaacaacacattgtaagggcagcagaggtgataatg agattttaattttctatattgtgtgcaattttgtatgtatcagatttctgtgaac caattaggtatatttgtatgctctttttgtgaacgtttgtcaaatgtggcactcagtt gctgcgttttaataaactttgtatgttcaacagcagatgtgtgtgttaattcaaggt attttagtgcaagcgaatgtatttactctgtgcaaaaaggaacaaagcgtcaatga tttactaaagttaatgaaaaatggcgtacctttctacactgtatttgcagttatctatgga alattaaattgtgtctttatataaagtttatcactcaatttaattatgtatggcgtatg acctgttatgtatataagtgctctatctacgggaaggtactatctgtttatgatt tattttgtatgtatgtatgaaggttactctgaacgttgaaggttcaactcatctctt aaaatcgggaaggaagcgaattcaactatcttaactcaactgtattttactctatgatta ctgcgtatgttacttaacaagaacatgtgtatcgtgtgttatgtttactcgtgttttta acagctgtgcctttatct gtgaagacattaaagattttatctcgtgttactatctgtgctatgttgccttctcta ttttattgataatagattgattgctcctaagtttatcgaactactctttcaaat aattgtttccaacacactatgtgtgtgtgcaggtactattatataatcaggactata tagtacttagtatttttaaacactgacacgcacacgcacttttaaaattgt tgtgaacattttactatcagcgaacacgtgtgaanaaacattttacgtacacacgt caatatgataaagttagcaaaccaatgtgttaagtaagctttatacaaaaagaatana caattattgacacacagcagatttctctgacacacacacacacacacacacacacacac acagaggtatcctgtgtatcaaaaggaatgtgtgaacacacacacacacacacacacac agaatttagaatttagcgtatgacgaacacacacacacacacacacacacacacacacac
522.	atgaaaaaactatagattttctgggttcaaatgggctatgatggtctttgtattttct atcacaatgggcaattgtccgtgaactcagaagatttcaagcgcactatcgggtgaanct tttgtctttagatttaaaagatttagctctctcaagctgcacattgtgtgcatattgta tttaagcgcagcaagaagacaaattagcaggattgaattttctcatagtttaaaagtga gagcgttacttttagcactcatctatcaccactatcatcttaaatgattggtcgtttaga tttaadactatgctgattttctcatctatcaaaccttcagatttatcagatcatata taactatatttattgtgtcatattttatgggtctttagtgaggtttgtgttctggtct tacttaaaaatttcttgaacacgaagaaacacacattttttgagattttgtcgttgt cttattttacagatttacaagtaacacgcacatgtgttagaataacgcgcgaataccat hctatataacttcaaggtttcaaggtattgtgtgaatttaattagagctactaaagt cgtaacatttatattgcacactgcttttaaacgcctccagacttttgccttgtctttta tttagtgaagaacacagcgcacctttctcaatgaagctcgcgcactttctacaacaa ttgggtgtttcatttattattatagtataactctgtgcctattgtttataaaagcag aaaacaaagttttagcgaaggtgatacctaaatttatctcatcttccagtgaaag ccaagtcagaagacgcgcctctcactcctaactgatgtatcatctaaagatgaana aagcaacagatattgtataatgacaaacatcaacaagaacacataaagcgtgaagat gcacttactacttcaattataaagaagagcgcctctcagctataaagacacggtaca actcaaatgataaatttaaaagcactcaacttatcaggaagtagacactcatcgtgt gtcaacgatttaagattgaattcagcgaagttgaagatcataaagcgcacagataaa tcaact













543. atggctgaacctactaaatatttggatccacttggctaaacagcgctctaaagacagct  
gtattgaagctctatctctgtttatattgatataaaatcccgattatgtttgtgttagaagtg  
ggcagctgctgttgccttaggattaaacatttatccgatttattccacagaagtgta  
tccagctcatatcggttcagattctcttatacattatcactgaacttggttttgcgaac  
tctcttgcagctttagctgaaggtgcggtaaacgctcagcgaagctttacgccaac  
cnaactgnaatgaaggtacgttgtatttaacacagcggcgttatgaaatgatgcagct  
agtgacttgcgaanaagacatatactgtacgtctccgcagcagctgaacaaatcccaatgac  
gttaagctatttaaggctgcgcacagctgatatgaatctggattacaggtgaatctgca  
cctgtatacgaagaaagcgttgagatttctgtaatatggtgaatttgaggaactctgtagct  
tccagcttggttagaagttgagattacttcagaaacagcttacttcttttagataaaatg  
attggtttgggtggaagggctcagaagaaagaaacacctaagataagactgcgttatctact  
ttattgtgacactaaagatctactctgtgtctacttttaagagatgatacattggc  
aaattcctgattttoaatttatcaattgcgcatcgctgattggtttggctgtgttttaatt  
ccacaacacattgggggtattattatgcgtcatagggtatgcagggtgacgtgtgcaca  
cagtttactatcttggctaaagcgcgactgtctgttagagacttcggtgtgagtgaatgta  
tggatttttagataaaagcttaccattactctgcgaacactgtgtggagcgtgttaatt  
ccgtgtgaactcatcagcttttgaacgcttttagtttaaagcggctatgaagtttatctgca  
gatgcacacacagagagcagctgattgtggaattagcttataaacacatatacgtctta  
ccgcaagggtgcggaacttactctgttgaagctgaacagcttgcagcgtgtgzaaa  
tttaccgscgtgaagtataaaaggtgcacccagtgattgattggttaagcgtgtgaaagaa  
gcaaggggacatattccagttgatttagacgtctctgttcaaggggtgtctaaanaaggt  
ggcncacgctgtgtgtgtgtgaagataatggattttaggtgttatctatttgaagatt  
gtactaaagtagctgtgagacgtttccgtgaatttgcgtgagcgggatttgaacg  
gtgagtgtacagagagataaacgaattgcacagctgcgcaaaatagcgaagagcgggtgtg  
gagctgttbtgtgcagagtgtaaacctggaagataaaactaatgtgattagagaagaca  
cgcgaaggtcatattgttgcagtgaggtgtgcgggtacagcagcagcagcagcttgcga  
gaagctaatgtggtttgtgcacagctcaggaacactgtgtgcgaagagcgggmat  
ttaatgtatttagatttatacacaacaaatgatggaagtgttcttcttgggaaca  
tatttaagacagctggctcactcactcaacttactgtatgcggaagacattgcgaatac  
ttgtgagcttatacagacatgtttatgagcgtgtgtgtgtgagatcatcttgaatatt  
atgcatctgcatcactcagtaacagagatttatctgcttaacttttaagtgttgatt  
attgtattatgtatccgatgtgcgaagcgtgaaatttaaggtgtcctcaacgca  
accatttggtagaanaattgttatttgaagcttaggggtatgattcgtgcacattat  
ggatttagcctcaatgattatcatctcaactcttgcg
544. atgatttggttaagctcgtatttacaagtagcgtgcccatttgcataagctattatt  
acacactacgtagtgcttggagtttttagctcctttaaattacattctatgaacccaatcc  
attgatcagcgaataaatttgcgtggttaagttggtctcactcgttgcgggaacagcact  
ttagctgagatttatcaacgggcaaatataccccaataagccattgttttatatgta  
tttgcgacttgatttatttcgtgtgtgtagggcgatacttgggtttatttcagtttat  
ttccaggttatatgatgcaataatattgcgtatgatgcggttgatgttagctttccca  
agctatggtctcaacttggactgtactgttgttgcagtggtgttagaanaattatt  
atgcatattatattgactcagatggcggtgttttgcgtgtgattgcgaacagctgaaatg  
caattatttgaagctgatactgtaaaatttgcacaagtaatttggtatgaatgttbaaca  
atcattgcgaacacattttgcgaataacacttactgcataagcattatgtcagtagt  
tcgattgtgtcatgatttacaattgtcagagcttatcttcccttgcgttaggtttaag  
gcactcagcgcgaatgggggtgagtgcttaaggaacagcaaaagtaatttccacatt  
cctggaatgtagtgacaacaggtgtggtctatgcgtcaatttgcgtggcgttttaacttt  
tatacagaatgtttcaaatgggacttgatcctgttatcgtcgtcaagaaagacgactgt  
cctctcaagaaaggttgcgaacgactgcacattc
545. atgaaggtgcgcagctgtctggccttttttaagattatataatttttcaactgatgtttt  
agtgcgaatgcataactaatggttttcaactccttaagaggaacagtaacttggggggaag  
aatacgtcaattggaattgtcaatggagccttatgctaaagggcaaatgctatgtctgcgcc  
tgggtggctcaaatatttgcgaatgtgtgcgaataaagctatgcgtattatattgt  
attaatgctatggcacttggtattatattgggtttacaggaacttgaaggttattgtatgca  
cgtatcatgcgaaggtgtgtgtgcagcgaattcttctccaaagcttctacacttgggttata  
gatgcttccagtagaanaacagctcagaaggtgtatcttccattcaatttccaaag  
attcccaatttatgcgaacatttaactcaggttgcgaatgggcaaggtgaataatgctcc  
aatttgcatagtttatgattttattgcgaatgaacacaacacttatttgggtatagaact  
acttttgcgaataaccccaaaaagagatttccccaaaaagcaggtgttgccttttaatgca  
atgctgtgatacttccaaatttttaaaaacacagcacttctgcggtgtgagatgtgt  
attctgtcatctatcgtgttttgggtgcgtagtacttttatcaacattatacagcttagg  
gaaggtttgcgaatgaaggtatttctccacaattcaagcaattacagtagtgaatgct  
agattttatttcaagtagtagcaactatgattgtttatgpatccagcttttatagtg  
attgttttaagcttaactgtgtgtgtgttagtcaattgttagtttgcgaacactatag  
agtattttgttatataagtgcaattttatgcgaataaacacaagcgtcgttttatcct  
acattgcgaacatttatgaatttggcttcttccaaagtagagagcgaataattgttatagga  
ttgttatagcgtatgcgatttttaggtatttcaatagagagtgctcaatgggcaata  
tcagtagcgtgtgagtttaaatggctatatttttatgcgaatcttattgtgtactattgca  
atgcactcagtaaaaatttgcgaacagcaaggttttaaaaagctca

546.	gtgggaagtagctgttaaatatogtaagtttatctacattgtgtgtgttttaattatct tgggcattgagcgccttatataacagatgccttaaatgatcaagctgggtttatgttgcct attttttgtgtcaaccatcatgtgtgtgtattacccaacatgatgactagggtcagatca atccattggttttacaacatgatgtttgtgtggaattgtgtatgaataaacctgcgtgtca ggcttcgttaabagatatttgggttatgtgtatgtgaagtggtctttatctcagcgggttt gttaaaacaggggtagggtgcagctattgtctgcattctgttaaaattttgtgaanaaa acgctgtgtttgtgcttattcaactgtgtgtgtgtgtatcttatcttagctcctgtcagccca agtaataacagcagcgtgtgtgtattatgttttccaacatcaagctctgtcagagctca tttgttctatcgcgcagagagtggttctcgcagaaaatgggtgcgttttaactcttacc gtgtctcagaggttaatttaattacttcagctatgtttttaaagcgtatggcgcgtgaacat atagtcgaagaagtttggaataaaacagccagcagctcaaatatcagatagagatgtgttt ttgtgcgtattctgcgcaggttatgtgtgtatctcagatgtgtccctctcatattataaa tttaaccccacacgtgttaaaagaaacgctcaacgctabaaatggcctcgtgaacacta gaagcaatgggacatagtctatagccgaaaatttgatggttggtattcttatcatagca ctggcttcttggtataggaaagctcatttaagtgtgatgcacgctcctgtgatttatt gctttacattgttactataaacagggtgtataggtgtgcagatatttaattgaanaaa ggcagatggaataacacgtgtgtgttctcagttctgtatkaatgacagaaactataaac segttaggtttatcccatggttaagcaaacctatgtcacaaggtttaaatgpgtttatt tggcctatgttttttactcattctgtttttatcttactacatcatttattctgca agtgcaaacgcacatgtcagcgcacagtgtctcaggtttactcgtgttcagctcgttgc ggtgcacggccatttactcagtcatttaagttagggtctttgttaactactcgtgcaaca acaacacatcatagtgtggaacagcccatatatacagcagcgtgctatgtacacaa aacgctgtgtggacatagcatgtgacgtgtgtatatttatttatttggatgtgt gtggtttcatctatggtgaacatcattaggtatgagt
547.	atgaaagataataaaaagtgtgttcattatttttatgtaggaacattacagtagmaag gctgaatagtgctgcacagcttacttacacaatcgtgcagatagtaggaagtttctatt tcagatgcgggttttallaatgggttatgctatttaggttgctatggaagccttta atgcmaatacaacattgaaagtgtacccaacgtgtacacagattttatgagcgatt ttatataatagtaattttagtggaattgttagcacaagattttaaattgtttattatca agaattatgtctgcgaagaaatcagtcgcacattcttcgggtcggtgatagttgtgtgcg cagctgcactcctgcgaataaaacacagcgcaatgcactgttcaggcaggtttaact attggtgttaagtgtagggtacacttcgacattcttttaggtggtttgcgaattggaga gtgtttttggatttatgattgtgtgtgtgcacattactatgttaggaatgattaaatt gttccaagaattcttcttaagtcagagaaacaaattagcaaaagatatacaggttttaag aatccacacatttttaattgtgtatgcaattattgttttggttactcgtgcactcatt acttactacatttatgagcaaatgatacagagattttctccatttaaaattgtaggttta actcttggtttatttagttgtgtgtgcagcgtgtgataggaatttaactacgtgtaat gtacgcagaagatttatgcaaaaacaaataatggttttcttacttatgataaata atccactatttgttactgttacttaaaatccaatattagatcaatccttgcctctta ctcgggtttgtgtacattgtgcacaccccgcttacttaataagaaattctcttaagtga aagaagacacactcttcagatcttaggcagctcttcttcttaagtgtgtaatttt ctgtgtgcacacttcggatctacttatctcaataggtgtacccatcaaaactact ctgatatctgttggaattatagttgtgtgtgtcttcttactctgttatacnaacttat gaagaacacatcatcatttaagtattacca
548.	cvlmlqnilnlilmlkklvlylmltlngfrdmvklrlfnnklwlaen
549.	klvmvgqglfqlpklilmlatklrlslvtqlvfwvllvllkvppvql
550.	lrlrqlclvlmlvalflfslfvlntk
551.	rlrvtyvkliaatdafklitcptgill
552.	sevfairlttiferfenvgckhklgalmkkllewalivlvalvltvklfasyt vkgasvlyh
553.	rsvphlvltmrlasvllvlgfslvsca
554.	temlilfllltllykklmgyfllnlelrmklfrrcwalflslhflseclphlpt npyvzflldeakumyftlnklcrnfrvkhll
555.	ffczlqlmkyhlysvzlvymtislmhlystic
556.	flstcgcattsewkaevlrvfrvpsapf
557.	lknllrvflagltvffscgggtysnaafldvlgtrfwsrtov
558.	rmsngvgttadivlfmflvlgvlvvgvmpilagimvavstlychl
559.	nqrlectispphssal
560.	mkqfmltrgkfllewlililslvslpknltmlslalilllkrqagvvylllylr csltyptdtesahlysmvlllylviovfllkyvkhwrnemdlrlfektmdalllyl lmlvmpdmlslilmlfapllsllyvmlklklmlwngctflvlfatflv laspkyllfdeslrvfkahslavllanglvlymvltlkqgdydvfmlillngmlye lmsxflilslilmlplshikrllkbpilqandlmalclngvlyhflklilkg kasevgmpsdmlalvltahpflrclgplgldemlksaeelgylfasmllfgmlft gligtltcltlylmhvlvtfpasltillfltlfvmaylilfsevglylcyfwly lkegyvzyngw
561.	mtngctvlgvvpvgpvtarlaenlgemphlshydhqgwlfldvtdpltrfaasvdel fgyvadydkrqdyvialtdlpmfadrkvmaldmmegaalfsyvafvgyvkrfkh alynlqkneasegpyvdrnkqslvkgqglfklldltyvktadylpvlaser sxgmfrlvsgatfarpplmmasmlvalatftpgslvlyttmvgaynfmwrlfgis lilgmliwmmshclvpeupsknhkltwlyntlmfllfallyllylillflae vlvlpelgqvrvlqppagldlylslpfaastlvagalgallndelkstygyrr rvryesort
562.	mkcfephgnppikqgsfknckghkltctqrksenqlhmrgqaylrvexqhhdstfy kqgdtvgwlvllslfvlilaaulygyvnyhlydeqshgttscgseadnqrddst gslvdfsdldfckgynkaastgyrvyngatveedkfgtngasvslwsvetycd svyddnsvrvyagchlsedglamypgkdrnasqlydandkndfsvlvagdy twigwngl
563.	mlfllelllmlallglrtagalcgflfalvaglmfgrglpssapvtevlilsl gaagltgctggdyvlyvsnrvlerfklslflapvlvfvigtgtanialolpilia ktaekrlgprklrllagvltamlllcpaastayllsvlgaelylsmgkylslvlpal lasmllstctfgyvkrhvxdeserlvmpaveelkndflkvkglvslfllcmglitfg lfpnlmpgfnrvrvgvkvemteivqffmlysatnlllkntsdlsennitqasagalf avlpgwlgatfapmlklklkldgelslsvpvlvllsvamvilytqasaaiaav lmslgtppelyvsmvqgtlrvnfvipagptllfaveidstgrtrptamipgtvltvsv tgrvltklly

564.	msfnnrntkmpitvgnkdkhkrtrirvrdflalvgvtivstiftlpgvvaahagpp avalsflaavaglavfaytveomestmpfagsayswvnlfgulfgvavagwallsoyfia vtfvvasgzanrlgrlignpilsipkslnpntgngvgtidlaavvlltalallagamea anmvnvlvklwfnanypdiphekvkctgdgfgvgnvayvawad f laylqfdiaaansaaipnqktmorglignlvaivfavalvlgvnmfhyseqvdaep vgvalreaghgliaavqaisvignatallagmalagrsllvsgfrdglpswajuhkh lpralvyltiagvignvampafatlaqlisagtlvaifavfslamvxlkrqgdklpkpf k4pypilpatitvllvfwglisfeakylitwifvgiislylgvkrskndoeavqv pre
565.	mtkkrlspasewllkqekhrkhrntlytaivllvalvllfavksiqvsvksdrdkis frilylgnvlnkhrirgntndvkgidglndadfstgslvndfarnkdndknien anfrkhnvavslvllfagpdlgaamvklvdeagagvylfgngnpsnktvgdglkq kianvstfdesmytnalnkntatlaipdipfllkikennodvvrvvsgipnornvt trqkevalanagadvlihtntvokvsnvkrtpifvylnttdndfnksnqkmavqg dkvgsungfntolqekdkiskdnmmkndhrrknnkdkidksgnsgytfey
566.	nlehlgnatyfgvlvslpflvlatvrykktgfflglpflvsmvavglfklbgysv vkgpdtinfstpatlcfalsplykrcewkkvwdlfgslavgtlailklykvasifq fgnqilaamqpaaattalavsdagvkvkltelavlnavvialgkvikvfkfemp iarglaltoghtlvoaaakelqeteesmgsviuvrvvavvapiaplil
567.	nkrtdvrydekydydqvgnhrkreesemvrdqsesqzanmratsgndirenyhpery ynardvrrnqqlnoemcekskdkwllailvlllilvfitralinnhndkvodpva qnykveangnddinnrqvdsakadknkkdqtsgidqlnqidqlkqnoetnadsktkf vgnqdklknannaelnngqskvnmaleintkfdsikaklenilngnsan
568.	mknkgoligvlltimlvclvlvnmfvvgkkesyngimkdettdkdnknknekknv olpdknavvdkodvmlfkdketgkikvknhdgphjnmkthdnngmghn
569.	manmlvslvrvymatltsdilediafKleavmgqpyllasieilililfllkdkmeki ywlisvniavismaghwesqpyllvsaierthilglitwlgslvlyicakvknig tevrmlkvnidavlnlvfoglmaidntcltmvnrswasvylvklagiamllg fygtmalrgvrggrfalsatelllqmdllq
570.	mknarlegfswamyvffvftlmalvvlrdfgatgvkrvfrfiskdaplfaavclv fkhrkeglqlkfsaiskvierliallilpdlilimilgfesntydsafllqtsdlevel lilghlghlmafvfseefrslvqmlietrmffiasvlgvlysvfntantvgyvveayh lytcfmfaamellaglsesgrtylatafaamfaivllfseagdkfswklsctv vysvllsllilvltvryktkgldvdpvrvshdseegdeasatuhdvskdet kqgdidkdkgskpnksdaltamvkedasvnmkedtchdnkldhstgedrhssv vndvkdlehevdkndaktsh
571.	manmlgrlgrnrmolellogtvgvrlfagatstikvbgpvlavllagfliflilar agunvlyntkgtatfayvldhagapvssnvfvgvvgvsglavvayvayvafsl pmlvpgvialvflmanmlvsvkafgefsfvalikvtilvmliaaglililfgngmgpp lgienlehwgffmgpgfigffalsavlgvsgvveligisagetkmpgtmivknavvlg vlllytvgilvfvvsgpndgsgpvtatckvgyttagilnrvvltalagvngsg ifsaasmvylakkgqgvkvfsvkngvsgvtyvfvamgillgalvnlplidgads ifvrvysaelpgmpvmlfshlrfrllhpkvnhpfpkgpgaianyltilfllilv vmlilketvsvvlgvflavtlyllylvckkqg
572.	ledndilipqwtvwmvmdilwsgvlglllgaaffitackfgrlmpenfralre kootlesqeklspqfalsasvsgvgtngagvatvlgpggsrvfwllafigraesa fmeetlagvkvhdkeggfgrgpgayvyltknglqkglvfvavlitvtfavfntvqnti aasintqynlspvlgilvavlgllilfgvzslatleslvgpmlavlyvgwllililn idqlyvmigtlaaefvgvgtgavgaallgskrplfaesagmgvpaatsevhg vkgglqelgvfddtmvotataimilysglfgdsgpvgvavtgaalehghsaggit ltvavtfafssvvgvnyvggsnefennkmlifrcrvllvfvagvaktetvata dlhglmaivniisliglmlafavakdyqrkqkgrprvkpenlelnifgietwgha kmpk
573.	lkkelvsvlavafalalfktfveksylkadamdptlkdgarrvvnligvkgave kgnvfrhankddvkrvrgtpgdsveykndtlyvngdkqsepylnynekrktyetltg sfktnlpnanpansvnpkgyvlvgdnrevskdsrfgldkdglvkslvrypfsf kntppmtn
574.	mfnkvrtqfflilfilikfmsvhevfpapiatigvflpfliegflfylofpfni lekvgfprvsttiffiglatiaavvfiapiilinnimlktpslkqeaegllnfl rmdkdpdvchrinkavkmgdatslansavvysfietvflvlnmvflfwalkdh ekfagelgkfkpgevgvllkdnflfcklyggvnmilgilygrytldgpyt pvlvifagvmlpflpvlafapaallgdpstfivovvtiaaglaqngvmpnva gntsvhtlilvvliaagdlgftlilvavpilyvktlvsmiPcyrrvdkvdkmnykd mkslvtkvfiasvllilavfvtlytrmtshkvtilfgrfialqalglfmlhbg kdkrlgkvfksailitvrtvgtyvsgngshl
576.	mlgoytqkgsanrlbekilgwefvllililvsmfialvsvfndstiamactlmm elvqglamdlstqfvlvlgngvavliyvfiwllefialismxrlsglflflla vltlplvllvltlilpliffiaamfarrdrietvpsvynvaydpydygtyepesrn elgvndvymtkbedntrrgfarnagqkdyngi dmpdedusdeglydeydrn ekygsptvayvsgvsgkdeapvswagkykndctfdedagsgmngcdvq vvepdlpkelkagrykkelasfrakdkkraynkrmkerrknqpsavnrmyeerrq amnecedtmnngedskken
577.	seemknopnmnmekndtlnhdsgnedlifrnmknarqvrndrldngskedats tselctekwklfikhkbnsgkkeliedvnmddedagymdkndvsgvtse seemseefltdhsgsektdgshskhllkfstkskokekfstsnsektvqkpls loekrairkkqkrgytililililvlllylntplsklsvnmkgnmvatskikke lnvrsarmvPskakelnkkgllkewdhkplactlvntvayvylvtekdryv plidgkltaydeyngshltdgkdkktrilalasesmptnriasevayptnk qsrilktkdkmvgvdtitadmkvypgseqlardegelktrgydlisvgsafpy qasvsgvsgtqgvktsgteendakeelqgvlnknkqskam

578.	<p>             mkel fmlsliifimstftlfiaptyanadanwtkimrgetrvgladyaplefekti              hkyeteyogvdielakktakdhhlikl vnmqfdallgaiktkgldilamgttperkke              vdfkaymimnagkddakdskkagkqgdqgdlactqetedsksiaa              rlpaeliaakqkvagvvevkvpgvyeajkqnseltfakfkneekgtciavknpsvll              dklngtdvkeknldioymtkaaedmdndgnfskygsetfikiikntilievvgvlg              lfigialikliskrlpdlaweslyiof lrgtgmqvivlrvfftgaalgldisallqgti              alvnsuysiaa lrg lnavdggtsearalgnrgtgmvevvgvlgldlpalngd              vtlkessivstlgvseiafnagvvgvlgisfdpftplvaallyflitfartvmfioegr              msaad           </p>
579.	<p>             nehkllvdpdisedglqslkhpfdvdiqtdisendvnmstydalivrsqgvterti              iaactvrlaragvgnvialaestlqkvlvnapgdvdehagvamliaamrnpr              ahgslknemmkafrgvlygkltlvglagriglvakragskfialdpolytedka              keldiatvdaieaksdvntvhtpkltpktrvgvgsfnaknqnlqinvarvgidiet              aliaedonmlkialidvteheppdtdelpdghkldlvtphlgvsevaegeavvswesi              iolitgmvhahnapkldakvdketgsvfistcttgefaelldogaseakvkgvndi              agmdtelitrtitnllkedlqnevalinalnagqvsvtniekqkdhsgfasyilel              vndgdikigatvafagfpvriavndvldfknpyglvtchkkpgvltgvtgnllgshg              imesetlondagddisimlisdgeesevklitnsgfkvllsktli           </p>
580.	<p>             llnatnnllililiaslililkmhvlipfmgpfiialaioevklkrlpwpflegig              lillvgvigtftqgvklidiekmlvtvrtlililialiaffkkliaqvletaliev              lpgalsgmvmaseenkmnilvsltgatrvfvlvplisyffgdnhhmhtlaevp              tlogclnvgvllilfsmvpliyigmekiafpcklapiivllvnmthlilfaldhwl              ataglvnmirdioqlanlmedkgrvialaiafagvltvrlmigtlnlivesneif              lgaagpgmeqlvlnamatgadvamiesvhiifrfiivfapiagiyfivnklmk           </p>
581.	<p>             vkktsriailliliallftmgagetyknvknvngldlqggfevlfgvdpinkgdikdk              alqatgetclenrvnlvgpvepkiqiednprivlqslkgdagerklstqonlitrade              dhlvnegdndkqnsakctkmetagvrtvfwkdelikdkvtekkkxchvvevdlfe              kydyekkaekqgqkpkpfllsaasvdpinssaveisggngkqveanqiaelnaq              silpvdkeleysvgaqvgdaldkmlfasivglialyifmigtvrlpelvaialitvty              lvtvafnflsvrlcpolaaivlvgpmavndmliayevlkdrlrgtgvkqyknks              gvtitfdmrltvvdeavllfifgeesvqfakmlilgdlmftvavlsargllilvsa              fffkqvlfgvkkdrrhdnsegkvdhdktsyevlnrfvklakplisilivlgliis              ieklnldisegvtradiqskmalqavkvkvkvvgvlpodgplinesggnkatvqkkl              lareoedksakvsefagvgnvltvslpdeklavaknvaiaaieglitvylvseer              mglsvlaillhdvfiialfseftrlevdtlfiazvltvvyvndvltvdrvrenhkv              kvitdtdgddivnrsirgvtatrsintvltvvvvailllgeptifnfsolligllag              vfeisfievzvepmlkkrqcfkktmklvvhnekkendeaklv           </p>
582.	<p>             wpenetkqgkpfifkdkhrilvgvflmasiaipagltgavfacyafafafa              lllisilidgaqnlvrlvvtlrgesekvlgpigtllilafggvafnngnaga              gklngsmgfdvdkwgaaitlfaillfversgkmdvsmilgimvlvvyvnmvmp              pygdvlhvtfapuhfklilipiltvgtvvgvgtitagahrlidsgikfeykvyfvmara              vngiltgmrlilvavlgvrlvlesngpavvlgvlgpikngimfgvrlfaasms              svigvaylatfkltkhsklknmlvltfivstfvtvfigkpvsliligaingvrl              pitlgailasrkksvgnvghptwmlvrglavivtmtgtfslqdlaslvwg           </p>
583.	<p>             venntfddfekrqslpndcheqtelkddktnemkdenesnlennsqvtpnmaag              rkzrratngsqgqddkqnsakctkgsiddrydeaglgqndkqgqmkckagqd              nmekgdialvngteespehkskctgurgpokaqgkctesstgkxptnkdkkaactga              gigaagvagaatetvrbhndkdkdskhsmbendeakvnddqgskkkaavagaa              agvgaagvnlhmqnkhneeknaagvnmvngdsgeekkgvfwkllpilaallilgala              lfegvnlmbndedddgtitnqgkddedkqagvnekkdkedakdkdtedknaad              dedussmpnatsnmndvannmsvntngnqdnangnsnqatqgqetvvgqanl              vrlaivqvgvgtgvndkikranglssnnhngtvlvg           </p>
584.	<p>             mekgdgvahetevndkdkkkykqvrvllisfiliitilltpagipvmkaaalaf              avnmvtaavvrvstlilgimlilgsvpvdisekqgpagdlikggedlgtgna              lehafgftsaavalaavaalflavagctnblkrallvslvnmktrmivgallvsv              laffpervatagvavpvlipgllamfnvskdrasllitvavagvnmigktaeam              vevintnglghdvswewllayaaaplksialyflimklnpephdaldgepkelike              mlkvplvnevwelivayvllfsewtekyrbolnastvavlgilmgkvgrtwqvg              ekkpvgvltvfgvsgilgmvlktagaagladgtfgimgkhlpiatlaialitfili              hlgaftasalealipvlstetlnlgnahglvlgqvfisfgvlvpsvpmagmav              lgtvfkdlfktkplilvpyvlvifvifvsekvglv           </p>
585.	<p>             mldfirhlsyqvtlnralistailvgvvtvgtvslvrlvgislmgdawahavlpvael              fniparigalvtgmalsiafvgfiftonsktkdpbaagisftaflavagvliislnstdly              hlifgnlaltchqetvitiivtvlililfyzplmstfdatfermsintllithyfv              nllilavtvvseavilvavalllpcasatfakslpymavmsiasvissilgyls              vlyvngpactvictfmyivylsatllmpokkrast           </p>
586.	<p>             lakilykklfiaknklevlgvvlvlgvltlpmlnspkfddlwmqlkeldndkds              kethgasekasmkvfhsbnndgnlnkcltkkledaldnirgnddyqlmsvpydsqvn              degdtalavvrvpvgpghdskhllkdkldvtdmndhvgkltqggamnspeggtse              vglvvefvlitlfgeliasgmplisalgvsgvlliallvgvltlftlamlvgil              avgdyvlililfikelkdkvgvteaatavgtagavifegitvnmavogvslvgdf              lavngtasavlfavlaaallpalieilzhsklikdkpckekpdkhewakfivkvrv              leivslilililialvgvsgvgtgddslpdkdaseykvailachngpogvmlvna              kldgsketktdelxnmv-sdledlndvrvknecltkmnyallfclpekeogestgm              vylrdxygqegekldvgtelagqvsvniomseklnnapvfgavvlelfillmvfrs              llypvkavglislmastglttvlvlgqkewsglsgtgentatvrlfvlvltlgilglai              dylfmlrvhseagtkpndhstirvgltksgvtyvaalllsvfvtatvsgdskakm              glalgfylvfdatvrmaltlpatlkfkgasvlpobkgavlrvnvvdkaleedhbat              seakvndvnsesvrgdkndvnyvqndkrnyrvayndedvursvlnmhgdhgrhgvnd              narkdiayevlqgdghdhderyndvnygdndvndvrbnhdhgdhndvbnadfn              dkttnlykdelnddodrfaalnvareuknpydyvsgvsgvrbdelrd           </p>
587.	<p>             mekchevlgnyctseenkkgqrkmlnmvrrrialfegllailililvllvgrhnd              gdaverveketetqgqdeaelkeklnlnndkdyekarddyvlsnkgevifrlpdk              ksgqktsnekun           </p>
588.	<p>             mklidvllilistigvlvliakvtpapthvnyepvvtiaitviallimalpaligif              nhackrisailqisalmwvgvliisignvlnvgnvmsitallvavltvswagv              edkin           </p>

589.	mndkllwsiigivliivliiaafilkqvnsgsskdenadytyvrtetpfilqeknspes vktynnsgvgnfliswvcdgtvkvqgeriinyptagnkrqgllnkvnqsgqvnddyk vngpnmhqlqvkltdqsalneaqsgleqydrqindemasfdgknlkndedvqogp llilqssngqinatitofidinkikogdevmvtvnsqkqyglkikidelptysdsde lasasagqsgqssesqesstemptingtpyqgksetyqkripdillpyrgfemak iplktkkipnvtikdmwfvvdkmrvkhrkrelkierngeilvkkqksgdkvlksqg nlndgekvevss
590.	msettkifeshlvkqakdsvlkvlypyvknipmfvvegmllalgtlitypdlfhqesv erlyvfeifilililvranfesaesagvqkqanaleqgqenkarlkqgqvemda adlkghivrvratgeqipndykviglatvdeanigtessupkesqgdfdnvigtetva sdwlevoitocpgpsfidkmgilvegatrkktpneialftlmtlitiilvvltnypla kfinfmlisamlalavolipptiggllseigisgmndvctvgnlaksgravetocpvy lildtgtitygmadafigvkseserlyksayesaddeppesrviayegqidl pgevgeyiptaetasmvskvttrevykgapnawkrvkaeghigvdlalvgvskqg qtpvlvlednelgvlyikovikdglverfrelrengletvmtogdelatatiakagv drivasckpckdnvireeqnqghivankpogtindaplasaevlmsngstasakean lildimppklmvevtdkqglmtuqglitfelaadlakyfatpamnasagpambini mhhsposavlsailfmailiivllipiamkvfkqastqtilnkmalvlyggnvvpfi qkliditigltv
591.	nlvtrirfdqralfaisaitiyyvrvlapiitfyepahidcankfagiswawigtch lgrvtrirlyisaprellpyvfvalliservgaiglgisgyfpypidailmriodmnap gyvtlailitfigsgvniilifiltrwawcorvirtsawpiedhvkfakvigmdit ilrkhlipitftidiliasessmcsmilqngsficlglykvkptaesgmmlnearkvatth pnmmtbruvilvimeinfidafagmldgmsakelkalkkykardca
592.	wkgamwpflrilyliltifseanilavfiprlghdgaentvigvmsayiltandorp waqqliarigpikviriillanamalvlyygtiglegylarinmgvctaafnaslqgil dalpekyrsegvalysalfstapnllgpllavglvawemsaifalvmlfivatvtilgyrt tiantqkwpkdevlptnmtvywgflmkalfcsmalissivgmsatfilylcvr egfannqfistiaitvlarvlykyrvodglwbrfemvtilkllmwavwafopvly sifryisalfigitgalvyptlittysfvlpklgmllgifiacodlgislgvynapi sdvqfkwvllcalvltamtlskirkqsgvskas
593.	vptvtyvkrfllipivvgliiwaltpikpdaindqwmfalfvtilacitopetigvse ligfsmilvsgvtdktvqvgfmselwianafisqgvktglgrilalqvklkyk tliglayslvgdillapatpentaraggimfpiklasesfgssprdgserknagalfic efgmiltasmltanegnpiaqslaeaktahvqitmmvfvasilpplisilvvpfilyk lypvtvktvnskktvteglseeghmsiseekhvgifilialvhwsgfivmdatitafi akililicovlasadlnetawentlvrsfivlmaeqlnksgifwckilseghpny wplvllilifryfshylfasatahvasayallqvavagaplfasalglafonilas lthysagpapiyaagvytkrwtamivlgivvliivvsgslvnmklmm
594.	aknoladlilmigtftvymoevyvgtliltqadmkdgsissagllisvayalavolpl mlitckkshabrlplvmlfiamlvmlapuvtilarimesasabtpfvmovaya tvappakktqalavvgagltlavmlgvpfsgfllggfanwrvvgfmlvialitlmglmkf vovviseeaniseltvfknpillivaiolvfgsvgtfyttemepndrfspfkilvg twelfmfylggvignlignvpedkiknlytelfilifvtilfvyvionmlailiefl fgqftgttpllmskllsqkempilastinasifnvnfigeligsililsiglyqigt lseggiivamlilnvlnglyekkhittfneys
595.	MAVTVATNCPQRIGRIAFRRIOEVEGLSVAVNDLTDDDLAHLKUTWQGRFTQEVFV VDESRVNGEVEVSGSPDASKPKNDKNDVILKCTSYTNDKQAGATIEAGAKRVLS VAPKATKAVVWVWVSGEGLVSGSTVSGASCTGNSAAYKAVLNDGQVGLATTHAY TGDQNTQAPHRQGDKRRAKAAJENLIPNSTGAAKAIGKVITZIDGKLDGGQAVPVATG SLTELTVVLEKQDVTTVBQVNEAMQNASNESQYTRDETVSSDFVGTGYSLFDATQVAVM SVGRQJUTVAVWVWVSGSTVSGAVALAESE
596.	vkrknlifllilivaivgfllfmyidderiqegvdytligfmrppliglaglililil lvlsikpdrkpglykndfdghiyvarkvektiydciaqyqzrvpnvsklymnknk sfidkaddfvpnhvqvkalteslradiksnvehfclspvrklemvrvdktsuprvi
597.	msflrkheclifvayilvnlftgillilnplnktdgdkdydvchvnnvwlthafae likvmskldgpltasvifvfglvmllgiltfctikdydsielifvlgisylfilit limgvgyfalfvftlptvniiglyvykdelnqdrnknhymviivtygmsyiltigisly xidanelisdlavntffilimllgpmamfllflrspltkaelgeesepelartnky nvengkvkhlkgntetayarktravvldiklakraokfkgkinalvdiqedimnkk kqvkwqvyvldfgyvillfkdfebnamalfbzuelsetqpyvewvtilililil iyiatlctvyldkyyvldfmgsliffkftetefinimvgvllililfipillimlami vayalslrek
598.	mqgetbwqgwefivalsilifipilgflmkkfsekselartitvavsvilyasitbyy nlqmvyetennssetkettmrvndkndkrtvseektvndvickentkqpkkenasa trlonzalekakasyddfhmakiglydiltisaygekrfkdadqyaidhleadvknalek aknyakdmnmdnsiydlilvnygekrfeseakysaiehidr